Name	MOA	Target	Disease Area	Indication	Phase
(R)-(-)-apomorphine	dopamine receptor agonist	ADRA2A, ADRA2B, ADRA2C, CALY, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A	neurology/psychiatry	Parkinson's Disease	Launched
(R)-(-)-rolipram	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4C, PDE4D, PDE5A			Phase 1
(R)-baclofen	benzodiazepine receptor agonist	GABBR1, GABBR2			Phase 3
(S)-(+)-rolipram	phosphodiesterase inhibitor	PDE4B, PDE4D			Phase 1
[sar9,met(o2)11]-substance-p	tachykinin antagonist	TACR1			Preclinical
A-1070722	glycogen synthase kinase inhibitor	GSK3A, GSK3B			Preclinical
A-1120	retinoid receptor ligand	RBP4			Preclinical
A-317491	purinergic receptor antagonist	P2RX3			Preclinical
A-33903					Phase 2
A-366	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			Preclinical
A-381393	dopamine receptor antagonist				Preclinical
A-412997	dopamine receptor agonist	DRD4			Preclinical
A-438079	purinergic receptor antagonist	P2RX7			Preclinical
A-485	histone acetyltransferase inhibitor				Preclinical
A-582941	nicotinic receptor agonist	CHRNA7			Preclinical
A-61603	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D			Preclinical
A-674563	AKT inhibitor	AKT1, PKIA, PRKACA			Preclinical
A-7	calmodulin antagonist				Preclinical
A-769662	AMPK activator				Preclinical
A-784168	transient receptor potential channel antagonist	TRPV1			Preclinical
A-803467	sodium channel blocker	SCN10A			Preclinical
A-804598	purinergic receptor antagonist	P2RX7			Preclinical
A-839977	purinergic receptor antagonist	P2RX7			Preclinical
A-867744	acetylcholine receptor allosteric modulator	CHRNA3, CHRNA4, CHRNA7			Preclinical
A-887826	sodium channel blocker	SCN10A			Preclinical
A-922500	diacylglycerol O acyltransferase inhibitor	DGAT1			Preclinical
A-939572	stearoyl-CoA desaturase inhibitor	SCD			Preclinical
A-967079	transient receptor potential channel antagonist	TRPA1			Preclinical
A-987306	histamine receptor antagonist	ADORA1, AVPR1A, CCR1, CHRM1, CHRM2, CHRM3, CHRM4, DRD3, HTR1A, HTR1B, HTR2A, HTR2B, HTR3A, TACR2			Preclinical
AA-29504	GABA receptor positive allosteric modulator	GABRA1, GABRA4, GABRB3			Preclinical
AAI101	lactamase inhibitor				Phase 3
AB-423	HBV capsid assembly inhibitor				Preclinical
abacavir	nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	Launched
abafungin	sterol methyltransferase inhibitor				Phase 3
abamectin	benzodiazepine receptor agonist	GABBR1, GABBR2	infectious disease	gastrointestinal parasites	Launched
abametapir	metalloproteinase inhibitor	MMP9			Phase 3
abarelix	gonadotropin releasing factor hormone receptor antagonist	GNRHR			Phase 3
ABBV-744	bromodomain inhibitor				Phase 1
ABC-294640	sphingosine kinase inhibitor	SPHK2			Phase 2
abemaciclib	CDK inhibitor	CDK4, CDK6	oncology	breast cancer	Launched
abiraterone	androgen biosynthesis inhibitor	CYP11B1, CYP17A1	oncology	prostate cancer	Launched
abiraterone-acetate	androgen biosynthesis inhibitor	CYP17A1	oncology	prostate cancer	Launched
ABT-072	RNA polymerase inhibitor				Phase 2
ABT-202	acetylcholine receptor agonist				Phase 1
ABT-239	histamine receptor antagonist	HRH1, HRH2, HRH3			Phase 1
ABT-491	platelet activating factor receptor antagonist	PTAFR			Phase 1
ABT-639	calcium channel blocker	CACNA1G, CACNA1H, CACNA1I			Phase 2
ABT-702	adenosine kinase inhibitor	ADK			Preclinical
ABT-724	dopamine receptor agonist	DRD4			Phase 2
ABT-737	BCL inhibitor	BCL2, BCL2L1, BCL2L2			Phase 1/Phase 2
ABT-751	tubulin polymerization inhibitor	TUBB			Phase 2
ABX-1431	monoacylglycerol lipase inhibitor				Phase 2
ABX464	antiviral				Phase 2
AC-186	estrogen receptor agonist	ESR2			Preclinical
AC-261066	retinoid receptor agonist	RARB			Preclinical
AC-264613	PAR agonist	F2RL1			Preclinical
AC-55541	PARP inhibitor	PARP2			Preclinical
AC-55649	retinoid receptor agonist	RARA, RARB			Preclinical
AC-710	PDGFR tyrosine kinase receptor inhibitor	CSF1R, FLT3, KIT, PDGFRA, PDGFRB			Preclinical
AC-7954-(+/-)	urotensin receptor agonist	UTS2R			Preclinical
acadesine	AMPK activator				Phase 3
acalabrutinib	Bruton's tyrosine kinase (BTK) inhibitor	BTK	hematologic malignancy	mantle cell lymphoma (MCL)	Launched
acalisib	PI3K inhibitor	PIK3CB, PIK3CD			Phase 1
acamprosate	glutamate receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, GRM5	neurology/psychiatry	abstinence from alcohol	Launched
acarbose	glucosidase inhibitor	AMY2A, MGAM	endocrinology	diabetes mellitus	Launched
ACDPP	glutamate receptor antagonist	GRM5			Preclinical
acebilustat	leukotriene inhibitor				Phase 2
acebutolol	adrenergic receptor antagonist	ADRB1	cardiology	hypertension, ventricular arrhythmias	Launched
acecainide	polarization inhibitor	SCN5A			Phase 3
aceclidine	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	ophthalmology	glaucoma	Launched
aceclofenac	prostanoid receptor antagonist	PTGS2	rheumatology	rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, periarthritis, lumbago, ischiadynia	Launched
acedapsone			infectious disease	leprosy	Launched
acedoben					Phase 2
acefylline	adenosine receptor agonist	ADORA1	pulmonary	asthma	Launched
aceglutamide			gastroenterology	peptic ulcer disease (PUD)	Launched
acelarin	anticancer agent				Phase 2/Phase 3
acemetacin	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	osteoarthritis	Launched
aceneuramic-acid		CES1, SELE, SELP			Phase 3
acenocoumarol	vitamin K antagonist	VKORC1	hematology	deep vein thrombosis (DVT)	Launched
acepromazine	dopamine receptor antagonist	ADRA1A, ADRA1B, DRD1, DRD2, HTR1A, HTR2A	neurology/psychiatry	sedative	Launched
acesulfame-potassium					Phase 3
acetanilide	hydrogen peroxide decomposition inhibitor				Preclinical
acetarsol			gastroenterology	diarrhea	Launched
acetazolamide	carbonic anhydrase inhibitor	AQP1, CA1, CA12, CA14, CA2, CA3, CA4, CA7	ophthalmology	glaucoma	Launched
acetohexamide	ATP channel blocker	ABCC8, KCNJ1, KCNJ10, KCNJ11	endocrinology	diabetes mellitus	Launched
acetohydroxamic-acid	urease inhibitor	MMP12	infectious disease	urinary tract infections	Launched
acetophenazine	dopamine receptor antagonist	DRD1, DRD2	neurology/psychiatry	psychosis	Launched
acetriazoic-acid					Preclinical
acetyl-farnesyl-cysteine	methyltransferase inhibitor	PPARG	dermatology	acne vulgaris (AV)	Launched
acetyl-l-leucine			neurology/psychiatry	vertigo	Launched
acetyl-11-keto-beta-boswellic-acid	lipoxygenase inhibitor	HSD11B1, HSD11B2			Phase 2
acetylcholine	acetylcholine receptor agonist	ACHE, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA2	neurology/psychiatry, gastroenterology, pulmonary	drowsiness, fatigue, headache, indigestion, chest congestion	Launched
acetylcysteine	mucolytic agent	ACY1, CHUK, GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3A, GSS, IKBKB, RELA, SLC7A11	gastroenterology	acetaminophen overdose, hepatic injury	Launched
acetylsalicylsalicylic-acid	cyclooxygenase inhibitor				Preclinical
acetylspiramycin	other antibiotic				Preclinical
acexamic-acid	5 alpha reductase inhibitor	GAST	dermatology	wound healing	Launched
acifran	cholesterol inhibitor	HCAR2, HCAR3			Phase 3
acipimox	cholesterol inhibitor	HCAR2	endocrinology	hyperlipidemia	Launched
acitazanolast	mediator release inhibitor		allergy	allergic rhinitis	Launched
acitretin	retinoid receptor agonist	RARA, RARB, RARG, RBP1, RXRA, RXRB, RXRG, STAT3	dermatology	psoriasis	Launched
acivicin	gamma glutamyltransferase inhibitor	CTPS1			Phase 2
aclarubicin	topoisomerase inhibitor	TOP1, TOP2A	hematologic malignancy	acute myeloid leukemia (AML)	Launched
aclidinium	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	pulmonary	bronchitis, emphysema, chronic obstructive pulmonary disease (COPD)	Launched
acolbifene	estrogen receptor antagonist				Phase 3
acoziborole	antitrypanosomal				Preclinical
ACPC	glutamate receptor antagonist				Phase 1
acriflavine	hypoxia inducible factor inhibitor	HIF1A	infectious disease	fungal infection	Launched
acriflavinium	hypoxia inducible factor inhibitor	HIF1A	infectious disease	fungal infection	Launched
acrisorcin	other antifungal		infectious disease	fungal infection	Launched
acrivastine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	Launched
acrylate	mucus protecting agent				Phase 3
ACT-132577	endothelin receptor antagonist	EDNRA, EDNRB	pulmonary	pulmonary arterial hypertension (PAH)	Launched
ACT-462206	orexin receptor antagonist	HCRTR1, HCRTR2			Phase 1
actarit	interleukin receptor agonist		rheumatology	rheumatoid arthritis	Launched
ACTB-1003	FGFR inhibitor, VEGFR inhibitor	KDR, TEK			Phase 1
actinomycin-d	RNA polymerase inhibitor		oncology	Wilm's tumor, Ewing's sarcoma, rhabdomyosarcoma, testicular carcinoma	Launched
actinoquinol					Preclinical
acumapimod	p38 MAPK inhibitor				Phase 1
ACY-1215	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC6, HDAC8			Phase 1/Phase 2
acyclovir	DNA polymerase inhibitor	PNP	infectious disease	genitial herpes, shingles, chicken pox	Launched
AC1NDSS5					Phase 1
AC260584	cholinergic receptor agonist				Preclinical
AD-5467	aldose reductase inhibitor	AKR1B1			Phase 2
adapalene	retinoid receptor agonist	RARA, RARB, RARG, RXRA, RXRB, RXRG	dermatology	acne vulgaris (AV)	Launched
adaprev	TGF beta receptor inhibitor	AKR1B1, GPI, HK1, M6PR, PYGM			Phase 3
adaptavir	CC chemokine receptor antagonist	CCR5			Phase 2
adarotene	retinoid receptor agonist	RARB, RARG			Phase 1
adatanserin	serotonin receptor agonist, serotonin receptor antagonist	HTR1A, HTR2A			Phase 2
adavivint	WNT pathway inhibitor				Phase 1
ADD-233089	benzodiazepine receptor agonist				Phase 1
adefovir	DNA polymerase inhibitor		infectious disease	hepatitis B	Launched
adefovir-dipivoxil	DNA polymerase inhibitor		infectious disease	hepatitis B	Launched
adelmidrol	anti-inflammatory agent		dermatology	dermatitis	Launched
ademetionine	methyltransferase stimulant, phosphodiesterase inhibitor		neurology/psychiatry	depression, attention-deficit/hyperactivity disorder (ADHD)	Launched
adenine	protein synthesis stimulant	ACACB, ACP1, APRT, MTAP, PECR, SRPK2			Preclinical
adenosine	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3, PI4K2A, PI4K2B, TRPM4	cardiology	Wolff-Parkinson-White Syndrome (WPW)	Launched
adenosine-phosphate	adenosine receptor agonist	ACSL1, ACSS1, ACSS2, ADCY1, ADK, CREB1, FBP1, HINT1, PDE4B, PDE4D, PIM1, PRKAA1, PRKAB1, PRKAB2, PYGL, TRPM4			Launched
adenosine-triphosphate	adenosine receptor agonist	ABCA1, ABCB1, ABCB11, ABCC2, ABCC8, ABCC9, ABCG1, ABL1, ABL2, ACSL1, ACSS1, ACSS2, ACVR1, ACVR1B, ACVRL1, ADCY1, ADRBK1, ADRBK2, AFG3L2, AKT1, ALK, AMHR2, APAF1, ARAF, ASNA1, ASNS, ASS1, CDK15, GPR17, ITPR1, NAE1, NT5C2, P2RY1, P2RY11, P2RY13, P2RY2, P2RY4, PRKAA1, RYR1, RYR2, RYR3, SLC25A4, TNK2, TRPM4, TRPM7			Phase 2
adiphenine	acetylcholine receptor antagonist	CHRNA1	neurology/psychiatry	spasms	Launched
adipic-acid	solute carrier family member inhibitor	SLC22A6			Preclinical
adiporon	adiponectin receptor agonist	ADIPOR1, ADIPOR2			Preclinical
ADL5859	opioid receptor agonist	OPRD1			Phase 2
adomeglivant	glucagon receptor antagonist				Preclinical
adoprazine	dopamine receptor antagonist, serotonin receptor agonist	DRD2, HTR1A			Phase 2
adrafinil	adrenergic receptor agonist		neurology/psychiatry	fatigue	Launched
adrenalone	adrenergic receptor agonist	ADRA1A	hematology	hemorrhage	Launched
adrenosterone	11-beta hydroxysteroid dehydrogenase inhibitor	HSD11B1, HSD11B2			Preclinical
ADX-10059	glutamate receptor negative allosteric modulator	GRM5			Phase 2
ADX-47273	glutamate receptor modulator	GRM5			Preclinical
AEE788	EGFR inhibitor, VEGFR inhibitor	EGFR, ERBB2, ERBB4, FGFR2, FGFR3, KDR			Phase 1/Phase 2
AEG3482	HSP inducer				Preclinical
afalanine	dopamine receptor agonist	DRD2			Phase 3
afamelanotide	melanocyte-stimulating hormone mimetic				Launched
afatinib	EGFR inhibitor	EGFR, ERBB2, ERBB4	oncology	non-small cell lung cancer (NSCLC)	Launched
afimoxifene	estrogen receptor antagonist	ESR1, ESR2, ESRRG, PLD1, PRKCD, PRKCE, PRKCQ, PRKCZ			Phase 2
afloqualone	acetylcholine receptor antagonist		neurology/psychiatry	sedative	Launched
AFN-1252	FABI inhibitor				Phase 2
afobazole	anxiolytic		neurology/psychiatry	anxiety	Launched
AF38469	sortilin inhibitor	SORT1			Preclinical
AG-1024	insulin growth factor receptor inhibitor	IGF1R			Preclinical
AG-14361	PARP inhibitor	PARP1			Preclinical
AG-490	EGFR inhibitor, JAK inhibitor	EGFR, JAK2, JAK3			Preclinical
AG-555	tyrosine kinase inhibitor	CDK2			Preclinical
AG-556	tyrosine kinase inhibitor				Preclinical
AGI-5198	isocitrate dehydrogenase inhibitor	IDH1			Preclinical
AGI-6780	isocitrate dehydrogenase inhibitor	IDH2			Preclinical
AGM-1470	cell cycle inhibitor	METAP2			Phase 2
agmatine	nitric oxide synthase inhibitor	ADRA2C, ASIC3, CACNA1B, CHRNA1, GRIN1, KCNJ1, NISCH			Phase 3
AGN-192403	imidazoline receptor ligand	NISCH			Preclinical
AGN-194310	retinoid receptor antagonist	RXRA, RXRB, RXRG			Phase 3
AGN-195183	retinoid receptor agonist	RARA			Phase 1/Phase 2
agomelatine	melatonin receptor agonist, serotonin receptor antagonist	HTR2A, HTR2B, HTR2C, MTNR1A, MTNR1B	neurology/psychiatry	depression	Launched
AGP-103	membrane permeability inhibitor				Launched
AH-7614	free fatty acid receptor antagonist	FFAR4			Preclinical
AH11110	adrenergic receptor ligand	ADRA1B			Preclinical
AH6809	prostanoid receptor antagonist	PTGDR, PTGER1, PTGER2, PTGER3			Preclinical
AI-10-49	core binding factor inhibitor	CBFB			Preclinical
AIM-100	tyrosine kinase inhibitor	TNK2			Preclinical
ajmaline	sodium channel blocker		cardiology	Wolff-Parkinson-White Syndrome (WPW)	Launched
AJ76-(+)	dopamine receptor antagonist	DRD2, DRD3, DRD4			Preclinical
AK-7	SIRT inhibitor	SIRT2			Preclinical
AKBA	lipoxygenase inhibitor	ALOX5			Phase 3
aklomide			infectious disease	coccidiosis	Launched
AL-8697	p38 MAPK inhibitor	MAPK14			Preclinical
alacepril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	Launched
alafosfalin	bacterial cell wall synthesis inhibitor				Phase 1
alagebrium	glycosylation inhibitor				Phase 2/Phase 3
alanine					Launched
alanosine	antimetabolite				Phase 2
alantolactone	apoptosis stimulant, STAT inhibitor	STAT3			Preclinical
alaproclate	serotonin receptor antagonist	SLC6A4			Phase 2
alarelin	gonadotropin releasing factor hormone receptor antagonist	GNRH1			Launched
albendazole	tubulin polymerization inhibitor	TUBA1A, TUBB, TUBB4B	infectious disease	cystic hydatid disease, parenchymal neurocysticercosis	Launched
albendazole-oxide	anthelmintic agent		infectious disease	cystic hydatid disease, parenchymal neurocysticercosis	Launched
albuterol	adrenergic receptor agonist	ADRB2	pulmonary	asthma	Launched
alcaftadine	histamine receptor antagonist	HRH1	allergy	allergic conjunctivitis	Launched
alclofenac	cyclooxygenase inhibitor	PTGS1	rheumatology	rheumatoid arthritis	Launched
alclometasone-dipropionate	glucocorticoid receptor agonist	CYP3A4, NR3C1, SERPINA6	dermatology	corticosteroid-responsive dermatoses	Launched
alcuronium	muscle relaxant	CHRM1, CHRM2, CHRM3, CHRM4, CHRNA7	neurology/psychiatry	muscle relaxant	Launched
alda-1	aldehyde dehydrogenase activator	ALDH2			Preclinical
aldoxorubicin	topoisomerase inhibitor	TOP2A			Phase 3
alectinib	ALK tyrosine kinase receptor inhibitor	ALK, MET	oncology	non-small cell lung cancer (NSCLC)	Launched
alendronate	bone resorption inhibitor	ATP6V1A, FDPS, PTPN4, PTPRE, PTPRS	orthopedics	osteoporosis	Launched
alexidine	phosphatidylglycerophosphatase inhibitor	PTPMT1			Preclinical
alfacalcidol	vitamin D receptor agonist	CYP27B1, VDR	endocrinology	vitamin D deficiency	Launched
alfadolone-acetate	benzodiazepine receptor agonist				Phase 2
alfuzosin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	urology	benign prostatic hyperplasia (BPH)	Launched
algestone-acetophenide			endocrinology	contraceptive	Launched
alibendol	antispasmodic		gastroenterology	bile stimulation	Launched
alimemazine	histamine receptor agonist, histamine receptor antagonist	HRH1	neurology/psychiatry, allergy, pulmonary	sedative, urticaria, itching, cough suppressant	Launched
alinidine	bradycardic effect 				Phase 3
alisertib	Aurora kinase inhibitor	AURKA			Phase 3
aliskiren-hemifumarate	renin inhibitor	REN	cardiology	hypertension	Launched
alisporivir	cyclophilin inhibitor				Phase 3
alizapride	dopamine receptor antagonist		gastroenterology	nausea	Launched
alizarin					Preclinical
allantoin	cosmetic		dermatology	skin protectant	Launched
allicin	cytokine production inhibitor	TRPA1, TRPV1			Phase 2
allopurinol	xanthine oxidase inhibitor	XDH	rheumatology, urology	gout, kidney stones	Launched
allopurinol-riboside	anti-leishmanial agent, phosphorylase inhibitor				Phase 2
allylestrenol	steroidal progestin	ESR1, PGR, SLC6A9	obstetrics/gynecology	premature labor	Launched
allylisothiocyanate	TRPV agonist	TRPA1			Preclinical
allylthiourea	nitrification inhibitor				Preclinical
almitrine	neurotransmitter agonist	ATP1A1	pulmonary	chronic obstructive pulmonary disease (COPD)	Launched
almorexant	orexin receptor antagonist	HCRTR1, HCRTR2			Phase 3
almotriptan	serotonin receptor agonist	HTR1B, HTR1D	neurology/psychiatry	migraine headache	Launched
aloe-emodin	anticancer agent	CASP8			Preclinical
alogliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	Launched
aloin	angiogenesis inhibitor				Preclinical
aloperine					Preclinical
alosetron	serotonin receptor antagonist	HTR3A			Withdrawn
alovudine	DNA synthesis marker				Phase 2
aloxistatin	protease inhibitor	CTSG			Phase 3
alpelisib	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG	oncology	breast cancer	Launched
alpha-asarone	cytochrome P450 inhibitor, HMGCR inhibitor	HMGCR			Preclinical
alpha-D-glucopyranose					Preclinical
alpha-glucosyl-hesperidin	antioxidant				Preclinical
alpha-linolenic-acid	omega 3 fatty acid stimulant	ELOVL4, FADS1, FADS2, FFAR1, FFAR4, PTGS2, SLC8A1, TRPV1			Phase 3
alpha-methylhistamine-dihydrobromide-(R)-(-)	histamine receptor agonist	HRH3			Preclinical
alpha-methylhistamine-dihydrobromide-(S)-(+)	histamine receptor agonist	HRH3			Preclinical
alpha-methylserotonin	serotonin receptor agonist	HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR4			Preclinical
alpha-tochopherol	antioxidant		endocrinology	vitamin E deficiency	Launched
alpha-tochopheryl-acetate	antioxidant		endocrinology	vitamin E deficiency	Launched
alpidem	benzodiazepine receptor agonist	GABRA1			Withdrawn
alprenolol	adrenergic receptor antagonist	ADRB1, ADRB2	cardiology	angina pectoris	Launched
alprostadil	prostanoid receptor agonist	CATSPER1, CATSPER2, CATSPER3, CATSPER4, PTGDR, PTGER1, PTGER2, PTGER4, PTGIR	cardiology	congenital heart defects	Launched
alrestatin	aldose reductase inhibitor	AKR1B1			Preclinical
ALS-8112					Phase 1
ALS-8176	RNA polymerase inhibitor				Phase 1
altanserin	serotonin receptor antagonist	HTR2A			Phase 2
althiazide	diuretic		cardiology	hypertension	Launched
altinicline	nicotinic receptor agonist	CHRNA4, CHRNB2			Phase 2
altiratinib	MET inhibitor, VEGFR inhibitor	KDR, MET, TEK			Phase 1
altrenogest	progestogen hormone	PGR	endocrinology	estrus	Launched
altretamine	DNA synthesis inhibitor		oncology	ovarian cancer	Launched
alverine	muscle relaxant	HTR1A	gastroenterology	irritable bowel syndrome, diverticular disease	Launched
alvespimycin	HSP inhibitor	HSP90AA1			Phase 2
alvimopan	opioid receptor antagonist	OPRD1, OPRK1, OPRM1	gastroenterology	postoperative ileus	Launched
alvocidib	CDK inhibitor	CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM			Phase 2
ALX-40-4C	CC chemokine receptor antagonist				Preclinical
ALX-5407	glycine transporter inhibitor	SLC6A9			Phase 1
AM-1241	cannabinoid receptor agonist	CNR1, CNR2			Preclinical
AM-24	lipoxygenase inhibitor	ALOX5			Phase 2
AM-251	cannabinoid receptor antagonist	CNR1, GPR18, GPR55			Preclinical
AM-281	cannabinoid receptor antagonist	CNR1, CNR2, GPR55			Preclinical
AM-404	cyclooxygenase inhibitor, FAAH inhibitor, TRPV antagonist	CNR1, CNR2, FAAH, TRPV1			Preclinical
AM-580	retinoid receptor agonist	RARA			Preclinical
AM-630	cannabinoid receptor antagonist	CNR1, CNR2			Preclinical
AM-92016	potassium channel blocker	GRIN1			Preclinical
amantadine	glutamate receptor antagonist	DRD2, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A	infectious disease, neurology/psychiatry	influenza A virus infection, Parkinson's Disease	Launched
ambazone	DNA damage inducer				Phase 1
ambenonium	cholinesterase inhibitor	ACHE	neurology/psychiatry	myasthenia gravis	Launched
ambrisentan	endothelin receptor antagonist	EDNRA, EDNRB	pulmonary	pulmonary arterial hypertension (PAH)	Launched
ambroxol	sodium channel blocker	CYP3A4	pulmonary	bronchitis	Launched
amcasertib	kinase inhibitor				Phase 2
amcinonide	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	Launched
AMD-3465	CC chemokine receptor antagonist	CXCR4			Preclinical
amdinocillin	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections, gram-negative bacterial infections	Launched
AMD11070	CC chemokine receptor antagonist	CCR5, CXCR4			Phase 3
ameltolide	anticonvulsant				Preclinical
amenamevir	helicase primase inhibitor				Phase 1
ametantrone	anticancer agent				Preclinical
amezinium	adrenergic receptor agonist	ADRB2	cardiology	hypotension	Launched
amfenac	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	Launched
amflutizole	xanthine oxidase inhibitor	XDH			Phase 2
AMG-PERK-44	PERK inhibitor	EIF2AK4			Preclinical
AMG-176	MCL1 inhibitor				Phase 1
AMG-208	tyrosine kinase inhibitor	MET			Phase 1
AMG-232	MDM inhibitor	MDM2			Phase 2
AMG-319	PI3K inhibitor	PIK3CD			Phase 2
AMG-337	MET inhibitor	MET			Phase 2
AMG-487	CC chemokine receptor antagonist				Phase 2
AMG-487-(+/-)	CC chemokine receptor antagonist	CXCR3			Phase 2
AMG-510	K-Ras inhibitor				Phase 1/Phase 2
AMG-517	TRPV antagonist	TRPV1			Phase 1
AMG-548	MAP kinase inhibitor	MAPK11, MAPK12, MAPK13, MAPK14			Phase 1
AMG-837	free fatty acid receptor agonist	FFAR1			Phase 1
AMG-925	CDK inhibitor, FLT3 inhibitor	CDK4, CDK6, FLT3			Phase 1
AMG-9810	TRPV antagonist	TRPV1			Preclinical
AMG319	PI3K inhibitor	PIK3CD			Phase 2
AMG458	MET inhibitor	MET			Preclinical
AMG900	Aurora kinase inhibitor	AURKA, AURKB, AURKC			Phase 1
AMI-1	protein arginine N-methyltransferase inhibitor	PRMT1			Preclinical
amibegron	adrenergic receptor agonist	ADRB3			Phase 3
amidopyrine	analgesic agent		dermatology	dermatitis herpetiformis (DH)	Launched
amifampridine	potassium channel blocker		neurology/psychiatry	Lambert-Eaton myasthenic syndrome (LEMS)	Launched
amiflamine	monoamine oxidase inhibitor	MAOA, SLC6A2			Phase 1
amifostine	reducing agent	ALPPL2, ENPP1	nephrology	renal toxicity	Launched
amikacin	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	Launched
amiloride	sodium channel blocker	AOC1, ASIC1, ASIC2, ASIC3, PKD2, PKD2L1, PLAU, SCNN1A, SCNN1B, SCNN1D, SCNN1G, SLC9A1, TRPC7, TRPV2	cardiology	hypertension, congestive heart failure	Launched
amineptine	dopamine receptor agonist	SLC6A2, SLC6A4			Withdrawn
aminocaproic-acid	plasminogen activator inhibitor	LPA, PLAT, PLG	hematology	fibrinolytic bleeding	Launched
aminoglutethimide	glucocorticoid receptor antagonist	CYP11A1, CYP19A1	endocrinology, oncology	Cushing's syndrome, breast cancer	Launched
aminoguanidine	nitric oxide synthase inhibitor	AKR1B1, NOS2, TIMP3			Phase 3
aminohydroxybutyric-acid			neurology/psychiatry	epilepsy	Launched
aminolevulinic-acid-benzyl-ester					Phase 1
aminomethyltransferase	nitric oxide synthase inhibitor	NOS2			Preclinical
aminopentamide	acetylcholine receptor antagonist	CHRM1	gastroenterology	acute abdominal visceral spasm, hypertrophic gastritis (GHG), nausea	Launched
aminophylline	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3, HDAC2, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A	pulmonary	asthma, bronchitis, emphysema	Launched
aminopterin	dihydrofolate reductase inhibitor	DHFR, SLC46A1			Phase 3
aminopurvalanol-a	CDK inhibitor, tyrosine kinase inhibitor	CDK1, CDK2, CDK5			Preclinical
aminosalicylate	cyclooxygenase inhibitor	ALOX5, CHUK, PLA2G2E, PTGS1, PTGS2	gastroenterology	inflammatory bowel disease, ulcerative colitis	Launched
aminothiadiazole	inosine monophosphate dehydrogenase inhibitor	ADORA3, IMPDH1			Phase 2
aminothiazole	cyclin D inhibitor	NOS2			Preclinical
amiodarone	potassium channel blocker	ADRB1, CACNA1H, CACNA2D2, KCNA7, KCNH2	cardiology	ventricular arrhythmias	Launched
amiprilose	CD antagonist				Phase 3
amiselimod	sphingosine 1-phosphate receptor modulator				Phase 2
amisulpride	dopamine receptor antagonist	DRD2	neurology/psychiatry	psychosis, bipolar disorder, schizophrenia	Launched
amitifadine	serotonin transporter (SERT) inhibitor	SLC6A2, SLC6A3, SLC6A4			Phase 3
amitraz	adrenergic receptor agonist	ADRA1A, ADRA2A	infectious disease	generalized demodicosis	Launched
amitriptyline	norepinephrine inhibitor, norepinephrine reuptake inhibitor, serotonin receptor antagonist, serotonin–norepinephrine reuptake inhibitor (SNRI)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, HRH2, HRH4, HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6, HTR7, KCNA1, KCND2, KCND3, KCNQ2, KCNQ3, NTRK1, NTRK2, OPRD1, OPRK1, OPRM1, SIGMAR1, SLC6A2, SLC6A4	neurology/psychiatry	depression	Launched
amlexanox	histamine receptor modulator	FGF1, IL3, PDE4A, PDE4B, PDE4C, PDE4D, S100A12, S100A13	dental, pulmonary, ophthalmology, allergy	aphthous ulcers, asthma, conjunctivitis, allergic rhinitis	Launched
amlodipine	calcium channel blocker	CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNA2D1	cardiology	hypertension, chronic stable angina, vasospastic angina, coronary artery disease (CAD)	Launched
ammonium-glycyrrhizinate	thrombin inhibitor	HSD11B1, HSD11B2, SLCO1B1, SLCO1B3	dermatology	cosmetic	Launched
ammonium-lactate		HCAR1	dermatology	xerosis cutis, ichthyosis vulgaris	Launched
ammonium-perfluorocaprylate	Pim kinase inhibitor	PIM1			Phase 1
AMN-082	glutamate receptor modulator	GRM7			Preclinical
amodiaquine	histamine receptor agonist	HNMT	infectious disease	malaria	Launched
amonafide	topoisomerase inhibitor	TOP2A, TOP2B			Phase 3
amorolfine	membrane integrity inhibitor		infectious disease	onychomycosis	Launched
amoxapine	norepinephrine reputake inhibitor	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, HRH1, HRH4, HTR1A, HTR1B, HTR2A, HTR2B, HTR2C, HTR3A, HTR6, HTR7, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	Launched
amoxicillin	penicillin binding protein inhibitor	CYP2C19, SLC15A1, SLC15A2, SLC22A6	infectious disease, gastroenterology	skin infections, duodenal ulcer disease, gonorrhea, ear infections, throat infections, genitourinary tract infections, respiratory tract infections	Launched
AMPA-(RS)	glutamate receptor agonist	GRIN1			Preclinical
AMPA-(S)	glutamate receptor agonist	GRIA2, GRIN1			Preclinical
ampalex	glutamate receptor agonist	GRIA1, GRIA2, GRIA3, GRIA4			Phase 2
amperozide	dopamine receptor antagonist	FAAH, HTR2A	neurology/psychiatry	psychosis	Launched
amphotericin-b	membrane permeability enhancer		infectious disease	fungal infection	Launched
ampicillin	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections, meningitis, bacterial septicemia, endocarditis, urinary tract infections, gastrointestinal infections	Launched
ampiroxicam	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	Launched
amprenavir	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	Launched
amprolium	thiamine uptake blocker		infectious disease	coccidiosis	Launched
ampyrone	cyclooxygenase inhibitor				Preclinical
amrinone	phosphodiesterase inhibitor	PDE3A, PDE3B, PDE4B, TNF	cardiology	congestive heart failure	Launched
amrubicin	topoisomerase inhibitor	TOP2A, TOP2B	oncology	small cell lung cancer	Launched
amsacrine	topoisomerase inhibitor	KCNH2, TOP2A	hematologic malignancy	acute lymphoblastic leukemia (ALL)	Launched
amthamine	histamine receptor agonist	HRH2			Preclinical
amtolmetin-guacil	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	rheumatoid arthritis, osteoarthritis	Launched
amuvatinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAD51 inhibitor, RET tyrosine kinase inhibitor	KIT, MET			Phase 2
amygdalin	caspase activator	CASP3			Phase 2
amyl-nitrite	atrial natriuretic peptide receptor agonist				Preclinical
amyleine	local anesthetic				Preclinical
amylene-hydrate	local anesthetic				Preclinical
AMZ30	protein phosphatase inhibitor				Preclinical
AM095	lysophosphatidic acid receptor antagonist				Preclinical
AM211	prostaglandin inhibitor				Preclinical
AM679	cannabinoid receptor agonist, lipoxygenase inhibitor	ALOX5AP, CNR1, CNR2			Preclinical
ANA-12	tropomyosin receptor kinase inhibitor	NTRK2			Preclinical
anabasine	acetylcholine receptor agonist				Preclinical
anacetrapib	cholesteryl ester transfer protein inhibitor	CETP			Phase 3
anagliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	Launched
anagrelide	phosphodiesterase inhibitor	PDE3A	hematology, hematologic malignancy	thrombocythemia, myeloproliferative neoplasms	Launched
anamorelin	growth hormone secretagogue receptor agonist	GHSR			Phase 3
anandamide	cannabinoid receptor agonist	CACNA1G, CACNA1H, CACNA1I, CNR1, CNR2, GLRA1, GPR18, GPR55, KCNA2, KCNK3, KCNK9, TRPM8, TRPV1			Phase 2
anastrozole	aromatase inhibitor	CYP19A1	oncology	breast cancer	Launched
andarine	androgen receptor modulator	AR			Phase 1
andrographolide	tumor necrosis factor production inhibitor	IL1B, IL6, NFKB1, NFKB2, TNF			Phase 2
androstenone	steroid				Preclinical
androsterone	androgen receptor agonist				Preclinical
anecortave-acetate	angiogenesis inhibitor		ophthalmology	macular degeneration	Launched
anethole	glutathione transferase stimulant				Launched
anethole-trithione	glutathione transferase stimulant		dental	xerostomia	Launched
anguidine	protein synthesis inhibitor	SLC5A1			Phase 2
anidulafungin	fungal 1,3-beta-D-glucan synthase inhibitor		infectious disease	candidemia, fungal infection, esophageal candidiasis	Launched
aniracetam	glutamate receptor agonist	DRD2, GRIA1, GRIA2, GRIA3, GRIA4, HTR2A			Launched
anisindione	vitamin K antagonist	GGCX	hematology	deep vein thrombosis (DVT)	Launched
anisodamine	lipid peroxidase inhibitor	ADRA1A			Phase 3
anisomycin	DNA synthesis inhibitor	NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1			Preclinical
anisotropine	acetylcholine receptor antagonist		gastroenterology	peptic ulcer disease (PUD)	Launched
anlotinib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	KDR, PDGFRB			Launched
anpirtoline	serotonin receptor agonist	HTR1B			Phase 1
ANR-94	adenosine receptor antagonist	ADORA2A			Preclinical
ansamitocin-p-3	apoptosis stimulant				Preclinical
antagonist-g	neuropeptide receptor antagonist	MAPK8			Phase 1
antalarmin	corticotropin releasing factor receptor antagonist	CRHR1			Preclinical
antazoline	antihistamine	HRH1	ophthalmology, otolaryngology	conjunctivitis, nasal congestion	Launched
anthralin	DNA synthesis inhibitor		dermatology	psoriasis	Launched
anthraquinone	CDC inhibitor	CDC25B			Preclinical
antimony-potassium					Phase 2
antimonyl					Phase 1
antimycin-A	ATP synthase inhibitor	CYCS			Preclinical
antioxine					Launched
AN2718	leucyl-tRNA synthetase inhibitor				Phase 1
AP-18	transient receptor potential channel antagonist	TRPA1			Preclinical
apabetalone	apolipoprotein expression enhancer	BRD3			Phase 3
apafant	platelet activating factor receptor antagonist	PTAFR			Phase 3
apalutamide	androgen receptor antagonist		oncology	prostate cancer	Launched
apararenone	mineralocorticoid receptor antagonist				Preclinical
apatinib	RET tyrosine kinase inhibitor	CSK, KDR, KIT, RET			Phase 3
APC-100	androgen receptor antagonist, anti-inflammatory agent	AR			Phase 1/Phase 2
APcK-110	KIT inhibitor	KIT, STAT3			Preclinical
APD597	glucose dependent insulinotropic receptor agonist	GPR119			Phase 1
APD668	glucose dependent insulinotropic receptor agonist	GPR119			Phase 1
aphidicolin	RNA synthesis inhibitor				Phase 1
API-001	sigma receptor antagonist	SIGMAR1			Phase 2
API-1	AKT inhibitor	AKT1, AKT2, AKT3			Preclinical
apigenin	casein kinase inhibitor, cell proliferation inhibitor	AKR1B1, AR, CDK6, CFTR, CYP19A1, CYP1B1, HSD17B1			Preclinical
apixaban	coagulation factor inhibitor	F10	neurology/psychiatry, hematology, cardiology	stroke, systemic embolism, pulmonary embolism (PE), atrial fibrillation (AF), deep vein thrombosis (DVT)	Launched
apocynin	NADPH oxidase inhibitor	NOX4			Phase 1
apoptosis-activator-II	carboxylesterase inhibitor	BCHE, CES1			Preclinical
APR-246	p53 activator	TP53			Phase 3
apraclonidine	adrenergic receptor agonist	ADRA1A, ADRA2A, ADRA2B, ADRA2C	ophthalmology	glaucoma, intraocular pressure	Launched
apramycin	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	Launched
apratastat	matrix metalloprotease inhibitor, tumor necrosis factor production inhibitor	ADAM17, MMP1, MMP13, MMP9			Phase 2
apremilast	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4C, PDE4D	dermatology, rheumatology	psoriasis, psoriatic arthritis	Launched
aprepitant	tachykinin antagonist	TACR1	gastroenterology	nausea, vomiting	Launched
apricitabine	nucleoside reverse transcriptase inhibitor				Phase 3
aprindine	voltage-gated sodium channel blocker	CALM1, SCN5A	cardiology	cardiac arrythmia	Launched
apronal	cytochrome P450 modulator				Preclinical
aptiganel	glutamate receptor antagonist	GRIN1			Phase 3
APTO-253	krüppel-like factor expression enhancer	KLF4			Phase 1
APY-29	serine/threonine kinase inhibitor	ERN1			Preclinical
apyramide	cyclooxygenase inhibitor				Preclinical
APY0201	phosphoinositide dependent kinase inhibitor	IL12A, IL12B, PIKFYVE			Preclinical
AP1903		MTOR			Phase 1/Phase 2
AP26113	ALK tyrosine kinase receptor inhibitor	ALK, EGFR			Phase 2
AQ-RA741	acetylcholine receptor antagonist	CHRM2			Preclinical
AQ-13	antimalarial agent				Phase 2
AQW-051	nicotinic receptor agonist				Preclinical
AR-A014418	glycogen synthase kinase inhibitor	GSK3B			Preclinical
AR-C155858	monocarboxylate transporter inhibitor	SLC16A1, SLC16A7			Preclinical
AR-12	phosphoinositide dependent kinase inhibitor	PDPK1			Phase 1
AR-42	HDAC inhibitor	HDAC1			Phase 1
arachidonic-acid	cytochrome P450 inhibitor	CLCN2, KCNJ4, KCNK10, KCNK18, KCNK2, PRKCZ, PTGS1, TRPC6, TRPM2			Phase 1
aramchol	stearoyl-CoA desaturase inhibitor				Phase 2/Phase 3
arbidol	cytochrome P450 inhibitor	CYP3A4	infectious disease	influenza A virus infection	Launched
arbutin	melanin inhibitor	TYR			Phase 2/Phase 3
ARC-239	adrenergic receptor antagonist	ADRA2A, ADRA2B, ADRA2C			Preclinical
arctigenin	MEK inhibitor	CHUK, MAP2K1			Preclinical
arcyriaflavin-a	CDK inhibitor	CCND1, CDK4			Preclinical
ardeparin	thrombin inhibitor	SERPIND1			Withdrawn
arecaidine-but-2-ynyl-ester	acetylcholine receptor agonist	CHRM2			Preclinical
arecaidine-propargyl-ester	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4			Preclinical
arecoline	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4			Phase 1
argatroban	thrombin inhibitor	F2	hematology	heparin-induced thrombocytopenia (HIT)	Launched
argireline	neurotransmitter release inhibitor				Phase 3
arglabin	farnesyltransferase inhibitor	FNTA, NFKB1			Launched
aripiprazole	serotonin receptor agonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7	neurology/psychiatry	depression, schizophrenia, bipolar disorder	Launched
aripiprazole-lauroxil	serotonin receptor agonist		neurology/psychiatry	schizophrenia	Launched
arofylline	phosphodiesterase inhibitor	PDE4A			Phase 3
arotinolol	adrenergic receptor antagonist	ADRB3	cardiology, neurology/psychiatry	hypertension, tremors	Launched
ARQ-092	AKT inhibitor	AKT2			Phase 1
ARQ-621	kinesin-like spindle protein inhibitor	KIF11			Phase 1
ARRY-334543	EGFR inhibitor	ERBB2			Phase 2/Phase 3
arsanilic-acid		LYZ			Phase 1
arsenic-trioxide	apoptosis stimulant	AKT1, CCND1, IKBKB, JUN, MAPK1, MAPK3, TXNRD1	gastroenterology	diarrhea	Launched
artemether	antimalarial agent	ATP1A1	infectious disease	malaria	Launched
artemisinin	DNA synthesis inhibitor	CYP2B6	infectious disease	malaria	Launched
artemotil			infectious disease	malaria	Launched
artesunate	DNA synthesis inhibitor		infectious disease	malaria	Launched
articaine	local anesthetic		neurology/psychiatry	local anesthetic	Launched
arundic-acid	astrocyte modulating agent	PTGS2, S100B			Phase 2/Phase 3
ARV-825	bromodomain inhibitor	BRD4			Preclinical
AS-1269574	glucose dependent insulinotropic receptor agonist	GPR119			Preclinical
AS-1892802	rho associated kinase inhibitor	ROCK1			Preclinical
AS-1949490	SHIP2 phosphatase inhibitor	INPP5D			Preclinical
AS-2034178	free fatty acid receptor agonist	FFAR1			Preclinical
AS-2444697	interleukin inhibitor	IRAK4			Preclinical
AS-252424	PI3K inhibitor	PIK3CG			Preclinical
AS-604850	PI3K inhibitor	PIK3CA, PIK3CG			Preclinical
AS-703026	MEK inhibitor	MAP2K1, MAP2K2			Phase 2
AS-77	potassium channel blocker	KCNA3, KCNA5, KCNN4			Phase 1
ASA-404	angiogenesis inhibitor				Phase 3
asapiprant	prostaglandin inhibitor				Preclinical
asaraldehyde	cyclooxygenase inhibitor	PTGS2			Preclinical
ASC-J9	androgen receptor enhancer	AR			Phase 2
asciminib	Bcr-Abl kinase inhibitor				Phase 2
ascomycin	calcineurin inhibitor	FKBP1A			Preclinical
ascorbic-acid	antioxidant	SLC23A1, SLC23A2	endocrinology	scurvy	Launched
asenapine	dopamine receptor antagonist, serotonin receptor antagonist	DRD2, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A	neurology/psychiatry	schizophrenia, bipolar disorder	Launched
asiatic-acid	apoptosis stimulant	PYGM			Preclinical
asimadoline	opioid receptor agonist	OPRK1			Phase 3
asivatrep	transient receptor potential channel antagonist				Phase 3
ASP-2535	glycine transporter inhibitor	SLC6A9			Phase 1
ASP-6537	cyclooxygenase inhibitor				Preclinical
ASP-9521	aldo-keto reductase inhibitor				Preclinical
aspartame		TAS1R2, TRPV1			Launched
aspirin	cyclooxygenase inhibitor	AKR1C1, ASIC3, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, PTGS1, PTGS2, RPS6KA3, TP53	neurology/psychiatry, endocrinology, dental	headache, fever, toothache, muscle pain	Launched
ASP3026	ALK tyrosine kinase receptor inhibitor	ALK			Phase 1
AST-1306	EGFR inhibitor	EGFR, ERBB2			Phase 1
astaxanthin	antioxidant				Launched
astemizole	histamine receptor antagonist	HRH1, KCNH1, KCNH2			Withdrawn
astilbin	nuclear factor erythroid derived, like (NRF2) activator				Preclinical
astragaloside-a	anti-inflammatory agent				Preclinical
ASTX660	apoptosis inhibitor				Phase 1/Phase 2
asunaprevir	HCV inhibitor				Phase 3
asymmetrical-dimethylarginine	nitric oxide synthase inhibitor	NOS2, NOS3			Phase 1
AT-1015	serotonin receptor antagonist	HTR2A			Preclinical
AT-406	IAP antagonist 				Phase 1
AT-7519	CDK inhibitor	CDK1, CDK2, CDK4, CDK5, CDK6, CDK9			Phase 2
AT-9283	Aurora kinase inhibitor, JAK inhibitor	AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A			Phase 2
ataluren	CFTR channel agonist, dystrophin stimulant	DMD	genetics, pulmonary	duchenne muscular dystrophy (DMD), cystic fibrosis	Launched
atazanavir	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	Launched
ATB-346	cyclooxygenase inhibitor	PTGER2			Phase 2
atenolol-(+)	adrenergic receptor antagonist				Preclinical
atenolol-(+/-)	adrenergic receptor antagonist	ADRB1, ADRB2, LTF, PLA2G2E	cardiology	hypertension, angina pectoris	Launched
atenolol-(-)	adrenergic receptor antagonist		cardiology	hypertension	Launched
atglistatin	adipose triglyceride lipase inhibitor				Preclinical
aticaprant	opioid receptor antagonist				Phase 2
atipamezole	adrenergic receptor antagonist		neurology/psychiatry	reverse sedative	Launched
atiprimod	JAK inhibitor, STAT inhibitor	JAK2, STAT3			Phase 2
atizoram	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4C, PDE4D			Phase 2
ATN-161	integrin antagonist	ITGA5, ITGAV, ITGB1, ITGB3			Phase 2
atomoxetine	norepinephrine transporter inhibitor	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	attention-deficit/hyperactivity disorder (ADHD)	Launched
atorvastatin	HMGCR inhibitor	AHR, DPP4, HMGCR	neurology/psychiatry, cardiology	stroke, heart attack	Launched
atosiban	oxytocin receptor antagonist	AVPR1A, AVPR1B, AVPR2, OXTR	neurology/psychiatry, cardiology, endocrinology	stroke, angina pectoris, myocardial infarction, hyperlipidemia	Launched
atovaquone	mitochondrial electron transport inhibitor		infectious disease	pneumonia	Launched
ATPA	glutamate receptor agonist	GRIK1			Preclinical
atractylenolide-i	JAK inhibitor				Preclinical
atracurium	acetylcholine receptor antagonist		critical care, neurology/psychiatry	endotracheal intubation, muscle relaxant	Launched
atrasentan	endothelin receptor antagonist	EDNRA			Phase 3
atropine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	ophthalmology	cycloplegia, mydriasis, amblyopia	Launched
atropine-oxide	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5			Preclinical
atuveciclib	CDK9 inhibitor				Phase 1
AT13148	protein kinase inhibitor	AKT1, AKT2, AKT3, ROCK1, ROCK2, SGK3			Phase 1
AT13387	HSP inhibitor	HSP90AA1			Phase 2
AT7867	AKT inhibitor	AKT2, GSK3B, PKIA, PRKACA			Preclinical
auranofin	NFkB pathway inhibitor	IKBKB, PRDX5, TRPA1	rheumatology	rheumatoid arthritis	Launched
aurora-a-inhibitor-i	Aurora kinase inhibitor	AURKA			Preclinical
aurothioglucose	PKC inhibitor	PRKCI	rheumatology	rheumatoid arthritis	Launched
AUT-1	potassium channel activator				Preclinical
autotaxin-modulator-1	autotaxin inhibitor	ENPP2			Preclinical
AV-412	protein tyrosine kinase inhibitor	EGFR, ERBB2			Phase 1
AV-608	tachykinin antagonist	TACR1			Phase 2
avacopan	complement inhibitor				Phase 2
avadomide	antitumor agent				Phase 2
avagacestat	gamma secretase inhibitor	PSEN1			Phase 2
avanafil	phosphodiesterase inhibitor	PDE5A	urology	erectile dysfunction	Launched
avapritinib	KIT inhibitor				Launched
avasimibe	ACAT inhibitor	CES1			Phase 3
avatrombopag	thrombopoietin receptor agonist	MPL	hematology	thrombocytopenia	Launched
AVE-0991	angiotensin receptor agonist	MRGPRX1			Preclinical
AVE-3085	nitric oxide synthase stimulant				Preclinical
AVex-73	sigma receptor agonist				Preclinical
avibactam	beta lactamase inhibitor		infectious disease	intra-abdominal infections, urinary tract infections, pyelonephritis	Launched
avitinib	EGFR inhibitor				Phase 2
AVL-292	Bruton's tyrosine kinase (BTK) inhibitor	BTK, YES1			Phase 2
AVN-492	serotonin receptor antagonist				Preclinical
AVN-944	inosine monophosphate dehydrogenase inhibitor	IMPDH1, IMPDH2			Phase 2
avobenzone	topical sunscreen agent		dermatology	cosmetic, sunscreen lotion	Launched
avoralstat	kallikrein inhibitor				Phase 3
avridine	immunostimulant				Preclinical
AX-024	cytokine production inhibitor				Preclinical
axitinib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	CSF1, FLT1, FLT4, KDR, PLK4	oncology	renal cell carcinoma (RCC)	Launched
AY-9944	hedgehog pathway modulator				Preclinical
AZ-10417808	caspase inhibitor	CASP3			Preclinical
AZ-10606120	purinergic receptor antagonist	P2RX7			Preclinical
AZ-12080282	hedgehog pathway inhibitor	DHH			Preclinical
AZ-628	RAF inhibitor	BRAF, RAF1			Preclinical
AZ-7371	antibacterial 				Preclinical
azacitidine	DNA methyltransferase inhibitor	DNMT1, DNMT3A	hematologic malignancy, hematology	myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)	Launched
azacyclonol	histamine receptor antagonist	HRH1			Preclinical
azaguanine-8	purine antagonist	PNP			Preclinical
azalomycin-B	bacterial 50S ribosomal subunit inhibitor				Preclinical
azaperone	dopamine receptor antagonist	DRD2, DRD3	neurology/psychiatry	sedative	Launched
azapropazone	cyclooxygenase inhibitor	PTGS2			Withdrawn
azaserine	purine antagonist				Preclinical
azasetron	serotonin receptor antagonist	HTR3A, HTR3B	infectious disease	genitial herpes	Launched
azatadine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	Launched
azathioprine	dehydrogenase inhibitor	HPRT1, IMPDH1, PPAT	transplant, rheumatology	renal homotransplantation, rheumatoid arthritis	Launched
AZD0156	ATM kinase inhibitor				Phase 1
AZD1080	glycogen synthase kinase inhibitor	GSK3A, GSK3B			Phase 1
AZD1208	Pim kinase inhibitor	PIM1, PIM2, PIM3			Phase 1
AZD1283	purinergic receptor antagonist	P2RY12			Preclinical
AZD1390	ATM kinase inhibitor				Phase 1
AZD1446	acetylcholine receptor agonist	CHRNA4, CHRNB2			Phase 2
AZD1480	JAK inhibitor	JAK1, JAK2, JAK3			Phase 1
AZD1981	CRTH receptor antagonist	PTGDR2			Phase 2
AZD2014	mTOR inhibitor	MTOR			Phase 2
AZD2461	PARP inhibitor				Phase 1
AZD2858	glycogen synthase kinase inhibitor	GSK3B			Preclinical
AZD3264	IKK inhibitor	IKBKB			Preclinical
AZD3463	ALK tyrosine kinase receptor inhibitor, insulin growth factor receptor inhibitor	ALK, IGF1R			Preclinical
AZD3514	androgen receptor modulator	AR			Phase 1
AZD3759	EGFR inhibitor	EGFR			Phase 2/Phase 3
AZD3839	beta-secretase inhibitor	BACE1			Phase 1
AZD3965	monocarboxylate transporter inhibitor	SLC16A1			Phase 1
AZD3988	diacylglycerol kinase inhibitor	DGAT1			Preclinical
AZD4282	glutamate receptor antagonist	AGXT, AGXT2, ALAS1, ALAS2, BAAT, GARS, GATM, GCAT, GCSH, GLDC, GLRA1, GLRA2, GLRA3, GLRB, GLYAT, GLYATL1, GLYATL2, GNMT, GPR18, GPRC6A, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3B, GSS, PIPOX, SHMT1, SHMT2, SLC32A1, SLC36A1, SLC6A5, SLC6A9			Phase 1
AZD4547	FGFR inhibitor	FGFR1, FGFR2, FGFR3, FGFR4, IGF1R, KDR			Phase 2/Phase 3
AZD4573	CDK9 inhibitor				Phase 1
AZD4635	adenosine receptor antagonist				Phase 1/Phase 2
AZD5069	CC chemokine receptor antagonist	CXCR2			Phase 2
AZD5153	bromodomain inhibitor				Phase 1
AZD5363	AKT inhibitor	AKT1, AKT2, AKT3			Phase 3
AZD5438	CDK inhibitor	KCNH2			Phase 1
AZD5582	XIAP inhibitor	BIRC2, BIRC3, XIAP			Preclinical
AZD5991	MCL1 inhibitor				Phase 1
AZD6482	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			Phase 1
AZD6738	ATR kinase inhibitor	ATR			Phase 2
AZD6765	glutamate receptor antagonist	GRIN1			Phase 2
AZD7545	pyruvate dehydrogenase kinase inhibitor	PDK1			Phase 1
AZD7594	glucocorticoid receptor modulator				Phase 2
AZD7687	diacylglycerol O acyltransferase inhibitor	DGAT1			Phase 1
AZD7762	CHK inhibitor	CHEK1, CHEK2			Phase 1
AZD7986	dipeptidyl peptidase inhibitor				Phase 1
AZD8055	mTOR inhibitor	MTOR			Phase 1
AZD8186	PI3K inhibitor	PIK3CB, PIK3CD			Phase 1
AZD8330	MEK inhibitor	MAP3K1			Phase 1
AZD8797	CC chemokine receptor antagonist				Preclinical
AZD8835	PI3K inhibitor	PIK3CA, PIK3CD			Phase 1
AZD8931	EGFR inhibitor	EGFR, ERBB2, ERBB3			Phase 2
AZD9056	purinergic receptor antagonist				Phase 2
AZD9272	glutamate receptor antagonist	GRM5			Preclinical
AZD9496	estrogen receptor agonist	ESR1			Phase 1
AZD9668	elastase inhibitor	ELANE			Phase 2
azelaic-acid	tyrosinase inhibitor	AKR1D1, SRD5A2, TYR	dermatology	rosacea	Launched
azelastine	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	Launched
azeliragon	RAGE receptor antagonist	AGER			Phase 3
azelnidipine	calcium channel blocker	CACNA1C	cardiology	hypertension	Launched
azilsartan	angiotensin receptor antagonist	AGTR1, AGTR2	cardiology	hypertension	Launched
azilsartan-medoxomil	angiotensin receptor antagonist	AGTR1, AGTR2	cardiology	hypertension	Launched
azimilide	potassium channel blocker	KCNA5			Phase 3
azithromycin	bacterial 50S ribosomal subunit inhibitor	MLNR	infectious disease	pelvic inflammatory disease, pneumonia	Launched
azlocillin	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections, gram-negative bacterial infections	Launched
AZM-475271	SRC inhibitor	SRC			Preclinical
azodicarbonamide	DNA synthesis inhibitor				Phase 2
azomycin-(2-nitroimidazole)	protein synthesis inhibitor				Preclinical
azosemide	electrolyte reabsorption inhibitor	SLC12A1, SLC12A2	cardiology	edema	Launched
aztreonam	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections, respiratory tract infections, bacterial septicemia, skin infections, intra-abdominal infections, gynecologic infections	Launched
AZ191	DYRK inhibitor	DYRK1B			Preclinical
AZ20	ATR kinase inhibitor	ATR, MTOR			Preclinical
AZ3146	monopolar spindle 1 kinase inhibitor				Preclinical
AZ505	histone lysine methyltransferase inhibitor	SMYD2			Preclinical
AZ5104	EGFR inhibitor	EGFR			Preclinical
AZ7550	insulin growth factor receptor inhibitor				Phase 1
AZ960	JAK inhibitor	JAK2			Preclinical
A0001					Phase 2
A12B4C3	polynucleotide kinase/phosphatase inhibitor	PNKP			Preclinical
A205804	ICAM1 expression inhibitor	ICAM1, SELE			Preclinical
A61603	adrenergic receptor agonist	ADRA1A			Preclinical
A66	PI3K inhibitor	PIK3CA			Preclinical
A740003	purinergic receptor antagonist	P2RX7			Preclinical
A77636	dopamine receptor agonist	CALY			Preclinical
A922500	diacylglycerol O acyltransferase inhibitor	DGAT1			Preclinical
bacampicillin	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections, gram-negative bacterial infections	Launched
bacitracin	bacterial cell wall synthesis inhibitor	IDE	infectious disease	first-aid antibiotic	Launched
bacitracin-zinc	bacterial cell wall synthesis inhibitor		infectious disease	first-aid antibiotic	Launched
baclofen	benzodiazepine receptor agonist	GABBR1, GABBR2, KCTD12, KCTD16, KCTD8	neurology/psychiatry	multiple sclerosis, spasms	Launched
BADGE	PPAR receptor antagonist	PPARG			Preclinical
bafetinib	Bcr-Abl kinase inhibitor, LYN tyrosine kinase inhibitor	ABL1, BCR, LYN			Phase 2
bafilomycin-a1	ATPase inhibitor				Preclinical
BAG-956	phosphoinositide dependent kinase inhibitor	PIK3CG			Preclinical
baicalein	lipoxygenase inhibitor	ALOX5, GLO1, PREP, SELL, SELP, TNF, XDH			Preclinical
baicalin	beta glucuronidase inhibitor	PREP	neurology/psychiatry	anxiety	Launched
bakuchiol	DNA polymerase inhibitor	HIF1A			Phase 2
balaglitazone	insulin sensitizer, PPAR receptor partial agonist	PPARG			Phase 3
balapiravir	RNA polymerase inhibitor				Phase 2
balicatib	cathepsin inhibitor	CTSK			Phase 2
balofloxacin	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	Launched
baloxavir	endonuclease inhibitor				Phase 3
baloxavir-marboxil	endonuclease inhibitor		infectious disease	influenza A virus infection	Launched
balsalazide	cyclooxygenase inhibitor	ALOX5, PPARG, PTGS1, PTGS2	gastroenterology	ulcerative colitis	Launched
bamaquimast	proton pump inhibitor				Preclinical
bambuterol	adrenergic receptor agonist	ADRB2, BCHE	pulmonary	asthma	Launched
BAM7	BAX activator	BAX			Preclinical
BAN-ORL-24	nociceptin/orphanin FQ receptor antagonist	OPRL1			Preclinical
banoxantrone	topoisomerase inhibitor	TOP2A			Phase 1/Phase 2
barasertib	Aurora kinase inhibitor	AURKA, AURKB			Phase 2/Phase 3
barasertib-HQPA	Aurora kinase inhibitor	AURKB			Phase 2/Phase 3
bardoxolone	nuclear factor erythroid derived, like (NRF2) activator	NOS2, PPARG			Phase 1
bardoxolone-methyl	nuclear factor erythroid derived, like (NRF2) activator	PPARG, STAT3			Phase 3
baricitinib	JAK inhibitor	JAK1, JAK2	rheumatology	rheumatoid arthritis	Launched
barium-6-O-phosphonato-D-glucose					Preclinical
barnidipine	calcium channel blocker		cardiology	hypertension	Launched
basic-fuchsin					Preclinical
basimglurant	glutamate receptor antagonist	GRM5			Phase 2
basmisanil	GABA receptor inverse agonist				Phase 2
batefenterol	acetylcholine receptor antagonist, adrenergic receptor agonist				Phase 2
batimastat	matrix metalloprotease inhibitor	ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8			Phase 3
bavisant	histamine receptor antagonist	HRH3			Phase 2
BAX-channel-blocker	cytochrome C release inhibitor	BAX			Preclinical
BAY-K-8644-(+/-)	L-type calcium channel blocker				Preclinical
BAY-K-8644-(s)-(-)	L-type calcium channel activator	CACNA1C			Preclinical
BAY-W-9798	antioxidant				Phase 2
BAY-11-7082	NFkB pathway inhibitor	RELA			Preclinical
BAY-11-7085	NFkB pathway inhibitor	NFKBIA			Preclinical
BAY-1251152	CDK9 inhibitor				Phase 1
BAY-1436032	isocitrate dehydrogenase inhibitor				Phase 1
BAY-1895344	ATR kinase inhibitor				Phase 1
BAY-2402234	dihydroorotate dehydrogenase inhibitor				Phase 1
BAY-41-2272	guanylyl cyclase activator	GUCY1A3, GUCY1B3			Preclinical
BAY-60-6583	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Preclinical
BAY-60-7550	phosphodiesterase inhibitor	PDE2A			Preclinical
BAY-61-3606	SYK inhibitor	SYK			Preclinical
BAY-8002	monocarboxylate transporter inhibitor				Preclinical
BAY-85-8050					Phase 1
BAY-87-2243	hypoxia inducible factor inhibitor	HIF1A			Phase 1
BAY1125976	AKT inhibitor				Phase 1
BAY1217389	kinase inhibitor				Phase 1
bazedoxifene	selective estrogen receptor modulator (SERM)	ESR1, ESR2	orthopedics, endocrinology	osteoporosis, menopause	Launched
BAZ2-ICR	bromodomain inhibitor	ZNF215			Preclinical
BC-11	urokinase inhibitor	PLAU			Preclinical
BCI-540	glutamate receptor agonist				Phase 2
BCTC	TRPV antagonist	TRPV1			Preclinical
BCX-1470	complement inhibitor, serine protease inhibitor	CFD			Phase 1
BD-1008	sigma receptor antagonist				Preclinical
BD-1047	adrenergic receptor antagonist	SIGMAR1			Preclinical
BD-1063	sigma receptor antagonist	SIGMAR1			Preclinical
BE-2254	adrenergic receptor antagonist	ADRA1A			Phase 2
BEBT-908	PI3K inhibitor				Preclinical
beclabuvir	antiviral				Phase 2
beclamide	anticonvulsant		neurology/psychiatry	sedative, seizures	Launched
beclomethasone	glucocorticoid receptor agonist	NR3C1, SERPINA6	allergy	allergic rhinitis	Launched
beclomethasone-dipropionate	glucocorticoid receptor agonist	GPR97, NR3C1	allergy	allergic rhinitis	Launched
bedaquiline	ATPase inhibitor		infectious disease	tuberculosis	Launched
befuraline					Phase 2
begacestat	gamma secretase inhibitor	PSEN1			Phase 1
bekanamycin	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	Launched
belinostat	HDAC inhibitor	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	Launched
belizatinib	receptor tyrosine protein kinase inhibitor				Preclinical
belotecan	topoisomerase inhibitor				Phase 3
bemegride	chemoreceptor agonist	GABRA1	critical care	poison antidote	Launched
bemesetron	serotonin receptor antagonist	HTR3A, HTR3B			Phase 3
bemotrizinol			dermatology	sunscreen lotion	Launched
bempedoic-acid	AMPK inhibitor	ACLY			Launched
benactyzine	butyrylcholinesterase inhibitor				Preclinical
benaxibine					Phase 1
benazepril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	Launched
bendamustine	DNA inhibitor		hematologic malignancy	chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL)	Launched
bendazac	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry, rheumatology	muscle pain, joint pain	Launched
bendazol	nitric oxide synthase stimulant				Launched
bendroflumethiazide	sodium/potassium/chloride transporter inhibitor	SLC12A1, SLC12A3	cardiology	hypertension	Launched
benethamine					Preclinical
benfluorex	gluconeogenesis inhibitor	HMGCR			Withdrawn
benfluralin		CYP1A1, CYP1A2, CYP2B6, CYP3A4, ESR1, MMP1, SULT2A1, UGT1A1			Phase 3
benfotiamine	antioxidant	AGER	rheumatology	lumbago	Launched
benidipine	calcium channel blocker	CACNA1C, CACNA1G	cardiology	hypertension	Launched
benperidol	dopamine receptor antagonist	DRD2	neurology/psychiatry	schizophrenia	Launched
benproperine	antitussive	SCN5A	pulmonary	cough suppressant	Launched
benserazide	DOPA decarboxylase inhibitor	DDC	neurology/psychiatry	Parkinson's Disease	Launched
bentiromide		HPN	gastroenterology	pancreas diagnostic agent	Launched
benurestat	urease inhibitor				Phase 1
benzalkonium	cationic surfactant		dermatology	abrasions, superficial cuts	Launched
benzamil	sodium channel blocker	ASIC1, PKD2L1, SCNN1A, SCNN1B, SCNN1D, SCNN1G, SLC8A1			Phase 2
benzbromarone	chloride channel blocker	ABCC1	rheumatology	gout	Launched
benzenemethanol,-2,5-dimethyl-[[(1-methylethyl)amino]methyl]					Preclinical
benzethonium	sodium channel blocker	SCN10A	infectious disease	first-aid antiseptic	Launched
benznidazole	DNA synthesis inhibitor		infectious disease	Chagas disease	Launched
benzo[d]thiazole-2(3H)-thione					Phase 1
benzocaine	sodium channel blocker	SCN10A	infectious disease	first-aid antiseptic	Launched
benzoclidine					Preclinical
benzofenac					Phase 1
benzoic-acid	food preservative	DAO, HRSP12, PRDX5, RAB9A	infectious disease	tinea pedis	Launched
benzoin		CES1			Preclinical
benzonatate	local anesthetic	SCN5A	pulmonary	cough suppressant	Launched
benzoquinonium-dibromide	cholinergic receptor antagonist	CHRNA1			Preclinical
benzotript	CCK receptor antagonist	CCKAR, CCKBR			Phase 1
benzoxiquine	antiinfective drug				Preclinical
benzoyl-peroxide	oxidizing agent		dermatology	acne vulgaris (AV)	Launched
benzoylpas					Preclinical
benzthiazide	carbonic anhydrase inhibitor	CA2	cardiology	hypertension, edema	Launched
benztropine-mesylate	acetylcholine receptor antagonist	CHRM1, HRH1, SLC6A3	neurology/psychiatry	extrapyramidal symptoms (EPS), Parkinson's Disease	Launched
benzydamine	prostanoid receptor antagonist		dental, otolaryngology	mouth inflammation, throat inflammation	Launched
benzyl-alcohol	local anesthetic		infectious disease	virus herpes simplex (HSV)	Launched
benzyl-benzoate	lipase inhibitor	LIPE	allergy	sweet itch	Launched
benzyl-isothiocyanate	methylazoxymethanol acetate inhibitor				Preclinical
benzyldimethylhexadecylammonium	cationic surfactant				Preclinical
benzyldimethyloctylammonium					Preclinical
benzylpenicillin	penicillin binding protein inhibitor		infectious disease	celluitis, meningitis, endocarditis, syphilis, pneumonia, bacterial septicemia	Launched
bephenium-hydroxynaphthoate	anthelmintic agent		infectious disease	ascariasis	Launched
bepotastine	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	Launched
bepridil	calcium channel blocker	KCNQ4	cardiology	angina pectoris	Launched
berberine	LDL receptor activator	LDLR			Launched
bergapten					Phase 3
bergenin	interleukin inhibitor	IL1B, TNF			Preclinical
besifloxacin	bacterial DNA gyrase inhibitor		ophthalmology	conjunctivitis	Launched
BET-BAY-002	bromodomain inhibitor				Preclinical
beta-amyloid-synthesis-inhibitor	beta amyloid synthesis inhibitor	APP			Preclinical
beta-carotene					Launched
beta-CCB	benzodiazepine receptor ligand	GABRA1, GABRG2			Launched
beta-elemene	apoptosis stimulant	MMP2, MMP9			Launched
beta-funaltrexamine	opioid receptor antagonist	OPRD1, OPRK1, OPRM1			Preclinical
beta-glycerophosphoric-acid					Preclinical
beta-hydroxy-beta-methylbutyrate	protein synthesis stimulant	MTOR			Launched
beta-hydroxybutyrate		HCAR2			Phase 1
beta-lapachone	topoisomerase inhibitor	TOP1			Phase 2
beta-naphthol					Preclinical
betahistine	histamine receptor agonist, histamine receptor antagonist	HRH1, HRH3	neurology/psychiatry	Meniere's disease	Launched
betaine	nitric oxide donor		metabolism	homocystinuria	Launched
betamethasone	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	Launched
betamethasone-acetate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	Launched
betamethasone-butyrate-propionate			rheumatology	rheumatoid arthritis	Launched
betamethasone-dipropionate	anti-inflammatory agent	NR3C1	dermatology	corticosteroid-responsive dermatoses	Launched
betamethasone-phosphate			rheumatology	rheumatoid arthritis	Launched
betamethasone-valerate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	Launched
betamipron	panipenem uptake inhibitor		nephrology	renal toxicity	Launched
betaxolol	adrenergic receptor antagonist	ADRB1, ADRB2	ophthalmology	intraocular pressure, glaucoma, ocular hypertension	Launched
betazole	histamine receptor agonist	HRH2	gastroenterology	gastric hypersecretion diagnostic	Launched
bethanechol	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4	urology	urinary retention	Launched
BETP	GLP receptor positive allosteric modulator	GLP1R			Preclinical
betrixaban	coagulation factor inhibitor	KCNH2	hematology	deep vein thrombosis (DVT)	Launched
betulinic-acid	apoptosis stimulant, NFkB pathway inhibitor	GPBAR1			Phase 1/Phase 2
bevantolol	adrenergic receptor antagonist		cardiology	angina pectoris, hypertension	Launched
bevenopran	opioid receptor antagonist				Phase 1
bevirimat-dimeglumine	HIV capsid assembly inhibitor				Phase 2
bexagliflozin	solute carrier family member inhibitor				Phase 3
bexarotene	retinoid receptor agonist	RXRA, RXRB, RXRG	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	Launched
bezafibrate	PPAR receptor agonist	PPARA, PPARD, PPARG	cardiology	cholesterol	Launched
BFH772	VEGFR inhibitor				Phase 2
BGP-15	PARP inhibitor				Phase 2
BGT226	PI3K inhibitor	MTOR, PIK3CA, PIK3CB, PIK3CG			Phase 1/Phase 2
BHQ	ATPase inhibitor	ATP2A1			Preclinical
BI-D1870	ribosomal protein inhibitor	RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA6			Preclinical
BI-224436	HIV integrase inhibitor				Phase 1
BI-2536	PLK inhibitor	BRD4, PLK1, PLK2, PLK3			Phase 2
BI-409306	phosphodiesterase inhibitor				Phase 1
BI-78D3	JNK inhibitor	MAPK8			Preclinical
BI-847325	Aurora kinase inhibitor, MEK inhibitor	AURKA, AURKB, AURKC, MAP2K1, MAP2K2			Phase 1
BIA-10-2474	Fatty acid hydrolase inhibitor				Preclinical
biapenem	bacterial cell wall synthesis inhibitor		infectious disease	bacterial septicemia, pneumonia, urinary tract infections	Launched
BIBN4096	calcitonin antagonist	CALCA, CALCRL, RAMP1			Phase 2
BIBR-1532	telomerase inhibitor	TERT			Preclinical
BIBU-1361	EGFR inhibitor	EGFR			Preclinical
BIBX-1382	EGFR inhibitor	EGFR, ERBB2			Phase 1
bicalutamide	androgen receptor antagonist	AR	oncology	prostate cancer	Launched
bicifadine	dopamine reuptake inhibitor, serotonin receptor antagonist				Phase 3
bictegravir	HIV integrase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	Launched
bicuculline-(+)	GABA receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, KCNN1			Preclinical
bicuculline-methochloride-(-)	GABA receptor antagonist				Preclinical
bicyclol	NFkB pathway inhibitor	HSPA1A, HSPB1	infectious disease	hepatitis B, hepatitis C	Launched
bifemelane	acetylcholine release enhancer	MAOA, MAOB	ophthalmology, neurology/psychiatry	glaucoma, senile dementia	Launched
bifendate			infectious disease	hepatitis B, hepatitis C	Launched
bifonazole	sterol demethylase inhibitor		infectious disease	tinea pedis, tinea cruris	Launched
BIIB021	HSP inhibitor	HSP90AA1			Phase 2
bilastine	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	Launched
bilobalide	GABA receptor modulator	GLRA1, GLRA2, GLRB, HTR3A, HTR3B			Preclinical
bimatoprost	prostanoid receptor agonist	AKR1C3, PTGER1, PTGER3, PTGFR	ophthalmology	intraocular pressure, glaucoma, ocular hypertension	Launched
BIMU-8	serotonin receptor agonist	HTR4			Preclinical
BINA	glutamate receptor positive allosteric modulator	GRM2			Preclinical
bindarit	NFkB pathway inhibitor	CCL2, CCL7, CCL8			Phase 2
binimetinib	MEK inhibitor	MAP2K1, MAP2K2	oncology	melanoma	Launched
BIO-1211	integrin antagonist	ITGA4, ITGB1			Phase 2
BIO-5192	integrin inhibitor	ITGA4, ITGB1			Preclinical
biotin	vitamin B	ACACA, ACACB, HLCS, MCCC1, MCCC2, PC, PCCA, PCCB, SLC5A6			Launched
bipenamol	dipeptidyl peptidase inhibitor	CTSC			Phase 2
biperiden	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	neurology/psychiatry	Parkinson's Disease	Launched
birinapant	XIAP inhibitor	BIRC2, XIAP			Phase 2
BIRT-377	lymphocyte function-associated antigen negative modulator	ICAM1			Preclinical
bis(maltolato)oxovanadium(IV)	tyrosine phosphatase inhibitor	PTPN1			Phase 2
bisacodyl	laxative		gastroenterology	constipation	Launched
bisantrene	topoisomerase inhibitor				Phase 2
bisindolylmaleimide-IX	PKC inhibitor	AKT1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SIRT1			Preclinical
bismuth(III)-trifluoromethanesulfonate	direct substitution catalyst				Preclinical
bismuth-oxalate					Preclinical
bismuth-subcitrate-potassium			gastroenterology	duodenal ulcer disease	Launched
bismuth-subgallate	nitric oxide synthase inhibitor	NOS1	gastroenterology	internal deoderant	Launched
bismuth-subsalicylate	antacid		gastroenterology	diarrhea	Launched
bisoctrizole					Phase 2
bisoprolol	adrenergic receptor antagonist	ADRB1	cardiology	hypertension	Launched
bisphenol-A	synthetic estrogen	AR, ESR1, ESR2, ESRRG, PPARG			Phase 1
bithionol	autotaxin inhibitor	ESR1, ESR2, MCL1			Withdrawn
bitopertin	glycine transporter inhibitor	SLC6A5, SLC6A9			Phase 3
bitoscanate	anthelmintic agent				Preclinical
bivalirudin	thrombin inhibitor	F2	cardiology	angina pectoris	Launched
BIX-01294	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			Preclinical
BIX-02188	MEK inhibitor	MAP2K5			Preclinical
BIX-02189	MEK inhibitor	MAP2K5, MAPK7			Preclinical
BL-5583	hypercalcaemic agent				Preclinical
blebbistatin-(+/-)	ATPase inhibitor	MYH14, MYH2			Preclinical
blebbistatin-(-)	ATPase inhibitor				Preclinical
bleomycetin	EGFR expression inhibitor				Launched
bleomycin	DNA synthesis inhibitor		hematologic malignancy, pulmonary, oncology	non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, pleural effusion, testicular carcinoma, squamous cell carcinoma	Launched
blonanserin	dopamine receptor antagonist, serotonin receptor antagonist	DRD2, HTR2A	neurology/psychiatry	schizophrenia	Launched
BLU9931	FGFR inhibitor	FGFR4			Preclinical
BLZ945	CSF1R inhibitor				Phase 1/Phase 2
BML-190	cannabinoid receptor inverse agonist	CNR2			Preclinical
BML-284	WNT agonist				Preclinical
BMS-CCR2-22	CC chemokine receptor antagonist	CCR2			Preclinical
BMS-182874	endothelin receptor antagonist	EDNRA			Phase 2
BMS-191011	potassium channel activator	KCNMA1			Preclinical
BMS-191095	KATP activator, potassium channel agonist				Phase 1
BMS-207940	endothelin receptor antagonist				Preclinical
BMS-214662	farnesyltransferase inhibitor				Phase 1
BMS-265246	CDK inhibitor	CDK1, CDK2			Preclinical
BMS-299897	gamma secretase inhibitor				Phase 1
BMS-309403	fatty acid binding protein inhibitor	FABP4			Preclinical
BMS-345541	IKK inhibitor	CHUK, IKBKB			Preclinical
BMS-387032	CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor	CDK2, CDK7, CDK9			Phase 1
BMS-470539	melanocortin receptor agonist	MC1R			Preclinical
BMS-536924	IGF-1 inhibitor	AKT1, CCNE1, CDK2, CYP3A4, ERBB2, IGF1R, KDR, LCK, MAPK1, MET, PDGFRA, PDGFRB			Preclinical
BMS-566419	inosine monophosphate dehydrogenase inhibitor	IMPDH1, IMPDH2			Preclinical
BMS-582949	p38 MAPK inhibitor				Phase 2
BMS-587101	integrin antagonist	ITGAL, ITGB2			Phase 2
BMS-599626	EGFR inhibitor, protein tyrosine kinase inhibitor	EGFR, ERBB2, ERBB4			Phase 1
BMS-626529	HIV attachment inhibitor				Phase 3
BMS-626531	p38 MAPK inhibitor				Phase 1
BMS-649	retinoid receptor agonist	RXRA			Preclinical
BMS-688521	ICAM1 antagonist, leukocyte function-associated antigen receptor antagonist	ICAM1			Preclinical
BMS-690514	EGFR inhibitor, VEGFR inhibitor	EGFR, ERBB2, FLT3, KDR			Phase 2
BMS-707035	HIV integrase inhibitor				Phase 2
BMS-754807	IGF-1 inhibitor	AKT1, IGF1R			Phase 2
BMS-770767	11-beta-HSD1 inhibitor				Phase 2
BMS-777607	AXL kinase inhibitor, c-Met inhibitor, FLT3 inhibitor, hepatocyte growth factor receptor inhibitor, macrophage migration inhibiting factor inhibitor, tyrosine kinase inhibitor	AXL, MERTK, MET, MST1R, TYRO3			Phase 1/Phase 2
BMS-779788	LXR agonist				Phase 1
BMS-806	HIV attachment inhibitor				Phase 1
BMS-813160	CC chemokine receptor antagonist				Phase 2
BMS-817378	c-Met inhibitor, VEGFR inhibitor	KDR, MET			Phase 1
BMS-833923	smoothened receptor antagonist	SMO			Phase 2
BMS-863233	CDC inhibitor	CDC7, PIM1			Phase 1/Phase 2
BMS-906024	gamma secretase inhibitor				Phase 1
BMS-911543	JAK inhibitor				Phase 1/Phase 2
BMS-935177	Bruton's tyrosine kinase (BTK) inhibitor				Preclinical
BMS-983970	notch signaling inhibitor				Phase 1
BMS-986020	lysophosphatidic acid receptor antagonist	LPAR1			Phase 2
BMS-986142	Bruton's tyrosine kinase (BTK) inhibitor				Phase 2
BMS-986158	bromodomain inhibitor				Phase 1/Phase 2
BMS-986195	Bruton's tyrosine kinase (BTK) inhibitor				Phase 1
BMS-986205	indoleamine 2,3-dioxygenase inhibitor				Phase 3
BMY-14802	sigma receptor antagonist	HTR1A			Phase 2
BMY-45778	IP1 prostacyclin receptor agonist	PTGIR			Preclinical
BMY-7378	adrenergic receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, HTR1A			Preclinical
BNC105	tubulin polymerization inhibitor				Phase 2
BNTX	opioid receptor antagonist	OPRD1, OPRK1, OPRM1			Preclinical
boceprevir	HCV inhibitor	CMA1, CTSA, CTSF, CTSK, CTSL, CTSS	infectious disease	hepatitis C	Launched
bonaphthone					Phase 3
bopindolol	adrenergic receptor antagonist		cardiology	hypertension, coronary artery disease (CAD)	Launched
bornyl-acetate					Preclinical
boronophenylalanine					Phase 2
bortezomib	NFkB pathway inhibitor, proteasome inhibitor	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA	hematologic malignancy	multiple myeloma, mantle cell lymphoma (MCL)	Launched
BOS-172722	monopolar spindle 1 kinase inhibitor				Phase 1
bosentan	endothelin receptor antagonist	EDNRA, EDNRB	pulmonary	pulmonary arterial hypertension (PAH)	Launched
bosutinib	Abl kinase inhibitor, Bcr-Abl kinase inhibitor, SRC inhibitor	ABL1, BCR, CAMK1D, CAMK2G, CDK2, FRK, FYN, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, MAP4K5, SRC, STK10, STK24, STK4, TNK2, TXK	hematologic malignancy	chronic myeloid leukemia (CML)	Launched
BP-554	serotonin receptor agonist	HTR1A			Preclinical
BP-897	dopamine receptor agonist	ADRA1A, ADRA1D, ADRA2A, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2B			Phase 2
BQ-123	endothelin receptor antagonist	EDNRA			Phase 2
BQ-788	endothelin receptor antagonist	EDNRB			Phase 1
BQU57	Ras GTPase inhibitor	RALA, RALB			Preclinical
BRD4770	histone lysine methyltransferase inhibitor	EHMT2			Preclinical
BRD7389	ribosomal protein inhibitor	RPS6KA1, RPS6KA2, RPS6KA3			Preclinical
BRD9876	kinesin inhibitor	KIF11			Preclinical
brefeldin-A	protein synthesis inhibitor	ARF1, CYTH2			Preclinical
bremelanotide	melanocortin receptor agonist	MC1R, MC2R, MC3R, MC4R, MC5R	neurology/psychiatry	hypoactive sexual desire disorder	Launched
brequinar	dihydroorotate dehydrogenase inhibitor	DHODH			Phase 2
bretazenil	GABA benzodiazepine site receptor partial agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6			Phase 2
bretylium	norepinephrine inhibitor	ATP1A1	cardiology	ventricular arrhythmias, ventricular fibrillation (VF), ventricular tachycardia (VT)	Launched
brexpiprazole	dopamine receptor partial agonist	DRD2	neurology/psychiatry	depression, schizophrenia	Launched
briciclib	cyclin D inhibitor	CCND1			Phase 1
brigatinib	ALK tyrosine kinase receptor inhibitor, EGFR inhibitor	ALK, EGFR	oncology	non-small cell lung cancer (NSCLC)	Launched
brilliant-green			infectious disease	antiseptic	Launched
brimonidine	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C	ophthalmology	intraocular pressure, glaucoma, ocular hypertension	Launched
brincidofovir	antiviral				Phase 3
brinzolamide	carbonic anhydrase inhibitor	CA1, CA12, CA14, CA2, CA4, CA5A, CA7	ophthalmology	intraocular pressure, glaucoma, ocular hypertension	Launched
brivanib	FGFR inhibitor, VEGFR inhibitor	CYP3A4, FGFR1, FLT1, KCNH2, KDR			Phase 3
brivanib-alaninate	FGFR inhibitor, VEGFR inhibitor	FGFR3			Phase 3
brivudine	DNA directed DNA polymerase inhibitor		infectious disease	shingles	Launched
BRL-15572	serotonin receptor antagonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6			Preclinical
BRL-26314	cholesterol inhibitor	LPL			Phase 1
BRL-37344	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3			Phase 2
BRL-44408	adrenergic receptor antagonist	ADRA2A, ADRA2B, ADRA2C			Preclinical
BRL-50481	phosphodiesterase inhibitor	PDE7A, PDE7B			Preclinical
BRL-52537	opioid receptor agonist	OPRK1			Preclinical
BRL-54443	serotonin receptor agonist	HTR1E, HTR1F			Preclinical
brolitene	muscle relaxant	RYR1	rheumatology	lumbago	Launched
bromantan	dopamine reuptake inhibitor, serotonin reuptake inhibitor		neurology/psychiatry	neurasthenia	Launched
bromebric-acid	DNA synthesis inhibitor, purine antagonist				Preclinical
bromfenac	cyclooxygenase inhibitor	PTGS1, PTGS2			Withdrawn
bromhexine	mucolytic agent		pulmonary	chest congestion	Launched
bromindione	anticoagulant				Phase 2
bromisoval	anti-inflammatory agent				Preclinical
bromocriptine	dopamine receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7	endocrinology, neurology/psychiatry	hyperprolactinemia, Parkinson's Disease, acromegaly	Launched
bromopride	dopamine receptor antagonist	DRD2	gastroenterology	nausea, vomiting, gastroesophageal reflux disease (GERD)	Launched
bromosporine	bromodomain inhibitor				Preclinical
bromperidol	dopamine receptor antagonist	DRD2	neurology/psychiatry	schizophrenia	Launched
brompheniramine	histamine receptor antagonist	HRH1	allergy, otolaryngology	allergic rhinitis, common cold	Launched
bronopol			obstetrics/gynecology	mastitis	Launched
bropirimine	interferon inducer				Phase 3
broxaldine					Preclinical
broxaterol	adrenergic receptor agonist	ADRB2			Phase 3
broxuridine	antimetabolite				Phase 2
broxyquinoline	antiprotozoal agent				Phase 1
bruceantin	protein synthesis inhibitor				Phase 2
brucine	glycine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5			Preclinical
BS-181	CDK inhibitor	CDK7			Preclinical
BT-11	cAMP stimulant				Phase 2
BTB06584	ATPase inhibitor	ATP5F1			Preclinical
BTB1	mitotic kinesin inhibitor	KIF18A			Preclinical
BTK-IN-1	Bruton's tyrosine kinase (BTK) inhibitor				Preclinical
BTS					Preclinical
BTS-54505	dopamine reuptake inhibitor	SLC6A2, SLC6A3, SLC6A4			Withdrawn
BTS-71321					Phase 2
BTS-72664	GABA receptor antagonist	GABBR1			Phase 1
BTT-3033	integrin inhibitor	ITGA2, ITGB1			Preclinical
BTZ043-racemate	DPRE1 inhibitor				Phase 1/Phase 2
BU-224	imidazoline receptor ligand	MAOA, MAOB			Preclinical
BU-239	imidazoline receptor agonist, imidazoline receptor ligand				Preclinical
bucetin	analgesic agent				Withdrawn
bucillamine	immunosuppressant		rheumatology	rheumatoid arthritis	Launched
bucladesine	adenosine receptor agonist, cAMP stimulant	PRKACA	dermatology	skin ulcer	Launched
buclizine	histamine receptor antagonist	HRH1	neurology/psychiatry	migraine headache	Launched
budesonide	glucocorticoid receptor agonist	NR3C1	gastroenterology	Crohn's disease	Launched
budipine	glutamate receptor antagonist	GRIN1	neurology/psychiatry	Parkinson's Disease	Launched
bufexamac	cyclooxygenase inhibitor	HDAC10, HDAC6			Withdrawn
buflomedil	adrenergic receptor antagonist, calcium channel blocker	ADRA1A	cardiology	peripheral artery disease (PAD)	Launched
bumetanide	solute carrier family member inhibitor	CFTR, GPR35, SLC12A1, SLC12A2, SLC12A4, SLC12A5	cardiology	edema, congestive heart failure	Launched
bunazosin	adrenergic receptor antagonist	ADRA1A	ophthalmology	glaucoma, intraocular pressure	Launched
buparlisib	PI3K inhibitor	PIK3CA, PIK3CG			Phase 3
buparvaquone	antiprotozoal agent		infectious disease	protozoan infection	Launched
buphenine	adrenergic receptor agonist	ADRB2	rheumatology	Raynaud's disease	Launched
bupicomide	adrenergic receptor antagonist	ADRB1			Phase 1
bupivacaine	sodium channel blocker	KCNA5, SCN10A	neurology/psychiatry	peripheral nerve block, caudal epidural block, lumbar epidural block	Launched
bupranolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	cardiology, ophthalmology	hypertension, glaucoma	Launched
bupropion	dopamine reuptake inhibitor	SLC6A2, SLC6A3	neurology/psychiatry	depression	Launched
buramate	antiepileptic				Preclinical
buserelin	gonadotropin releasing factor hormone receptor agonist		oncology, obstetrics/gynecology	prostate cancer, endometriosis	Launched
buspirone	serotonin receptor agonist	DRD2, HTR1A	neurology/psychiatry	generalized anxiety disorder (GAD)	Launched
busulfan	DNA inhibitor		hematologic malignancy	chronic myeloid leukemia (CML)	Launched
butabindide	tripeptidyl peptidase inhibitor	TPP2			Preclinical
butacaine	local anesthetic		neurology/psychiatry	local anesthetic	Launched
butaclamol	dopamine receptor antagonist	DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A			Phase 2
butalbital	GABA receptor antagonist	CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2	neurology/psychiatry	headache, muscle relaxant	Launched
butamben	sodium channel blocker				Withdrawn
butaprost	prostaglandin receptor agonist				Preclinical
butein	EGFR inhibitor, SRC inhibitor	ACE			Preclinical
butenafine	fungal squalene epoxidase inhibitor	SQLE	infectious disease	tinea pedis, tinea cruris, tinea corporis	Launched
buthionine-sulfoximine	glutathione transferase inhibitor	GCLM			Phase 1
butibufen	cyclooxygenase inhibitor				Withdrawn
butoconazole	bacterial cell wall synthesis inhibitor		infectious disease	vulvovaginal candidiasis	Launched
butofilolol	adrenergic receptor antagonist				Phase 2
butyl-paraben	DNA synthesis inhibitor				Preclinical
butylated-hydroxyanisole	antioxidant				Preclinical
butylated-hydroxytoluene	carbonic anhydrase inhibitor	CA2			Phase 1
butylidenephthalide	cyclooxygenase inhibitor				Phase 1/Phase 2
butylphthalide	potassium channel antagonist	KCNK2	neurology/psychiatry	stroke	Launched
butylscopolamine-bromide	cholinergic receptor antagonist		gastroenterology	abdominal pain	Launched
BU226	imidazoline receptor ligand				Preclinical
BVD-523	MAP kinase inhibitor				Phase 2
BVT-2733	11-beta hydroxysteroid dehydrogenase inhibitor	HSD17B1			Preclinical
BVT-948	tyrosine phosphatase inhibitor	PTPN1, PTPN11, PTPN2			Preclinical
BW-A4C	lipoxygenase inhibitor	ALOX5			Phase 1
BW-B70C	lipoxygenase inhibitor	ALOX5			Preclinical
BW-180C	opioid receptor agonist	OPRD1, OPRM1			Phase 2
BW-348U87	antiviral				Preclinical
BW-373U86	opioid receptor agonist	OPRD1			Preclinical
BW-616U	monoamine oxidase inhibitor	MAOA			Preclinical
BW-723C86	serotonin receptor agonist	HTR2A, HTR2B, HTR2C			Preclinical
BX-795	IKK inhibitor	CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1			Preclinical
BX-912	pyruvate dehydrogenase kinase inhibitor	CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1			Preclinical
BYK-204165	PARP inhibitor	PARP1			Preclinical
C-021	CC chemokine receptor antagonist	CCR4			Preclinical
C-1	protein kinase inhibitor	PRKCA			Preclinical
C-751					Preclinical
CA-4948	kinase inhibitor				Phase 1
cabagin			gastroenterology	dyspepsia	Launched
cabaletta	pharmacological chaperone				Phase 2
cabazitaxel	microtubule inhibitor	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	prostate cancer	Launched
cabergoline	dopamine receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR7	endocrinology	hyperprolactinemia	Launched
cabotegravir	HIV integrase inhibitor				Phase 3
cabozantinib	RET tyrosine kinase inhibitor, VEGFR inhibitor	KDR, MET, RET	oncology	medullary thyroid cancer (MTC)	Launched
CaCCinh-A01	calcium-activated chloride channel inhibitor	CLCA1			Preclinical
cadazolid	antibacterial 				Phase 3
cadralazine	adrenergic receptor antagonist		cardiology	hypertension	Launched
cafestol	pregnane X receptor agonist				Launched
caffeic-acid	HIV integrase inhibitor, lipoxygenase inhibitor, nitric oxide production inhibitor, tumor necrosis factor production inhibitor	ALOX5, MIF			Preclinical
caffeic-acid-phenethyl-ester	HIV integrase inhibitor	RELA			Preclinical
caffeine	adenosine receptor antagonist, phosphodiesterase inhibitor	ADORA1, ADORA2A, ADORA2B, ADORA3, ATM, ITPR1, ITPR2, ITPR3, PDE10A, PDE11A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE6A, PDE6B, PDE6C, PDE7A, PDE7B, PDE8A, PDE8B, PDE9A, PIK3CA, PIK3CB, PIK3CD, PRKDC, RYR1, RYR2, RYR3	neurology/psychiatry	fatigue, drowsiness	Launched
calcifediol	vitamin D receptor agonist	VDR	endocrinology	hyperparathyroidism	Launched
calcipotriol	vitamin D receptor agonist	VDR	dermatology	psoriasis	Launched
calcitonin	calcitonin agonist		orthopedics	osteoporosis	Launched
calcitriol	vitamin D receptor agonist	VDR	endocrinology, orthopedics	hypocalcemia, hypoparathyroidism, osteoporosis	Launched
calcium-gluceptate					Launched
calcium-levofolinate					Launched
Calhex-231	calcium sensing receptor negative allosteric modulator	CASR			Preclinical
calpeptin	calpain inhibitor				Preclinical
camicinal	motilin receptor agonist	MLNR			Phase 2
CaMKII-IN-1	calcium/calmodulin dependent protein kinase inhibitor	AKT1, CAMK2A, CAMK4, MYLK			Preclinical
camobucol	anti-inflammatory agent				Preclinical
camostat-mesilate	protease inhibitor	PRSS1	gastroenterology	pancreatitis	Launched
camphor-(+)					Phase 2
camphor-(1R)	TRPV activator	TRPV1			Phase 1
camptothecin	topoisomerase inhibitor	TOP1			Phase 3
camylofine-chlorhydrate			gastroenterology	abdominal pain	Launched
canagliflozin	sodium/glucose cotransporter inhibitor	SLC5A1, SLC5A2	endocrinology	diabetes mellitus	Launched
candesartan	angiotensin receptor antagonist	AGTR1	cardiology	hypertension, congestive heart failure	Launched
candesartan-cilexetil	angiotensin receptor antagonist		cardiology	hypertension, congestive heart failure, hypertension	Launched
candicidin	fungal ergosterol inhibitor		infectious disease	vulvovaginal candidiasis	Launched
canertinib	EGFR inhibitor	AKT1, EGFR, ERBB2, ERBB4			Phase 3
cangrelor	purinergic receptor antagonist		cardiology	myocardial infarction	Launched
canrenone	mineralocorticoid receptor antagonist	NR3C2			Withdrawn
cantharidin	protein phosphatase inhibitor		dermatology	blisters	Launched
capadenoson	adenosine receptor agonist	ADORA1			Phase 2
capecitabine	DNA synthesis inhibitor, thymidylate synthase inhibitor	TYMS	oncology	breast cancer, colorectal cancer	Launched
capobenic-acid					Preclinical
capreomycin	protein synthesis inhibitor		infectious disease	tuberculosis	Launched
capromorelin	growth hormone secretagogue receptor agonist				Preclinical
caprylic-acid					Launched
capsaicin	TRPV agonist	CFTR, TRPV1	neurology/psychiatry, rheumatology	muscle pain, rheumatoid arthritis	Launched
capsazepine	TRPV agonist	TRPV1, TRPV4			Preclinical
captamine					Preclinical
captan					Phase 1
captopril	angiotensin converting enzyme inhibitor	ACE, LTA4H, MMP2, MMP9	cardiology, endocrinology, nephrology	hypertension, congestive heart failure, myocardial infarction, diabetes mellitus, diabetic nephropathy	Launched
caracemide	ribonucleotide reductase inhibitor	RRM1			Phase 2
caramiphen	cholinergic receptor antagonist	CHRM1, CHRM2	neurology/psychiatry	Parkinson's Disease	Launched
carazolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	cardiology	angina pectoris, cardiac arrythmia, hypertension, myocardial infarction	Launched
carbachol	cholinergic receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA2	ophthalmology	intraocular pressure	Launched
carbadox	other antibiotic		infectious disease, gastroenterology	dysentry, enteritis	Launched
carbamazepine	carboxamide antiepileptic	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	Launched
carbaril	acetylcholinesterase inhibitor				Launched
carbarsone	antiprotozoal agent		infectious disease	amebiasis	Launched
carbazochrome			hematology	hemorrhage	Launched
carbendazim	microtubule inhibitor, tubulin polymerization inhibitor	TP53, TUBB	infectious disease	fungicide	Launched
carbenicillin	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	Launched
carbenoxolone	11-beta hydroxysteroid dehydrogenase inhibitor	GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, HSD11B1, PANX1, PANX2, PANX3	gastroenterology, dental	peptic ulcer disease (PUD), mouth inflammation	Launched
carbetapentane	acetylcholine receptor antagonist	CHRM2	otolaryngology, pulmonary	common cold, nasal congestion, bronchitis	Launched
carbetocin	oxytocin receptor agonist	OXTR	hematology	hemorrhage	Launched
carbidopa	aromatic L-amino acid decarboxylase inhibitor	DDC	neurology/psychiatry	Parkinson's Disease	Launched
carbimazole	antithyroid agent	TPO	endocrinology	hyperthyroidism	Launched
carbinoxamine	histamine receptor antagonist	HRH1	allergy, ophthalmology, otolaryngology, dermatology	allergic rhinitis, conjunctivitis, vasomotor rhinitis, dermatographism	Launched
carboplatin	DNA alkylating agent, DNA inhibitor		oncology	ovarian cancer	Launched
carboxyamidotriazole	calcium channel blocker	CXCL8			Phase 3
carboxylosartan	angiotensin antagonist	AGTR1			Phase 1
carboxypyridine-disulfide					Phase 2
cardiogenol-C	cardiomyogenesis inducer				Preclinical
cardionogen-1	WNT signaling inhibitor	CTNNB1			Preclinical
carebastine	histamine receptor antagonist	HRH1			Phase 1
carfilzomib	proteasome inhibitor	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9	hematologic malignancy	multiple myeloma	Launched
carglumic-acid	carbamoyl phosphate synthase activator	CPS1	metabolism	hyperammonemia	Launched
caricotamide	NADPH quinone oxidoreductase inhibitor	NQO2			Phase 2
cariporide	sodium/hydrogen exchanger inhibitor	SLC9A1			Phase 3
cariprazine	dopamine receptor antagonist	DRD2, DRD3	neurology/psychiatry	schizophrenia	Launched
carmofur	thymidylate synthase inhibitor	TYMS	oncology	breast cancer, colorectal cancer	Launched
carmoterol	adrenergic receptor agonist	ADRB2			Phase 2
carmoxirole	dopamine receptor agonist	DRD2			Phase 2
carmustine	DNA alkylating agent, DNA inhibitor	GSR	hematologic malignancy, oncology	non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, multiple myeloma, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma	Launched
carnitine-(D/L)					Phase 3
carnosine	antiglycating agent				Phase 2
caroverin	cytochrome P450 inhibitor				Phase 3
caroxazone	monoamine oxidase inhibitor	MAOA, MAOB			Withdrawn
carprofen	cyclooxygenase inhibitor	PTGS2	rheumatology	osteoarthritis	Launched
carsalam	analgesic agent				Preclinical
carteolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	ophthalmology	intraocular pressure, glaucoma, ocular hypertension	Launched
carumonam	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections, gram-negative bacterial infections	Launched
carvedilol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	cardiology	myocardial infarction, hypertension	Launched
carzenide		CA1, CA12, CA14, CA2, CA6, CA9			Preclinical
casanthranol-variant			gastroenterology	constipation	Launched
casin	GTPase inhibitor	CDC42			Preclinical
caspofungin	bacterial cell wall synthesis inhibitor, fungal 1,3-beta-D-glucan synthase inhibitor		infectious disease	candidemia, esophageal candidiasis, aspergillosis, peritonitis, fungal infection	Launched
castanospermine	glucosidase inhibitor	GAA, GBA			Phase 2
catharanthine	tubulin polymerization inhibitor				Preclinical
cathepsin-inhibitor-1	cathepsin inhibitor	CTSB, CTSL, CTSV			Preclinical
CAY10505	PI3K inhibitor	PIK3CG			Preclinical
CB-03-01	androgen receptor antagonist	AR			Phase 3
CB-10-277	DNA synthesis inhibitor				Phase 1
CB-5083	valosin-containing protein inhibitor	VCP			Phase 1
CB-839	glutaminase inhibitor	GLS			Phase 2
CBiPES	glutamate receptor positive allosteric modulator	GRM2			Preclinical
cbl0137	histone chaperone inhibitor				Phase 1
CBS-1114	lipoxygenase inhibitor	ALOX5			Phase 1
CC-115	DNA protein kinase inhibitor, mTOR inhibitor	MTOR			Phase 2
CC-223	mTOR inhibitor	MTOR			Phase 2
CC-401	JNK inhibitor	MAPK8			Phase 1
CC-90003	MAP kinase inhibitor				Phase 1
CC-930	JNK inhibitor				Phase 2
CCG-1423	apoptosis stimulant	RHOC, SRF			Preclinical
CCG-50014	G protein signaling inhibitor	RGS4, RGS8			Preclinical
CCG-63802	G protein signaling inhibitor	RGS4			Preclinical
CCG-63808	G protein signaling inhibitor	RGS4			Preclinical
CCMI	acetylcholine receptor allosteric modulator	CHRNA7			Preclinical
CCMQ	homoquinolinic acid binding inhibitor				Preclinical
CCT-031374	WNT signaling inhibitor	CTNNB1			Preclinical
CCT018159	HSP inhibitor	HSP90AA1, HSP90AB1			Preclinical
CCT128930	AKT inhibitor				Preclinical
CCT129202	Aurora kinase inhibitor	AURKA, AURKB, AURKC			Preclinical
CCT137690	Aurora kinase inhibitor	AURKA, AURKB, AURKC			Preclinical
CCT196969	RAF inhibitor				Preclinical
CCT245737	kinase inhibitor				Preclinical
CC4	nicotinic receptor agonist	CHRNB2			Preclinical
CD-1530	retinoid receptor agonist	RARG			Preclinical
CD-437	retinoid receptor agonist	RARG			Preclinical
CDBA					Phase 3
CDK1-5-inhibitor	CDK inhibitor, glycogen synthase kinase inhibitor	CDK1, CDK5, GSK3B			Preclinical
CDK9-IN-6	CDK inhibitor	CDK9			Preclinical
CDPPB	glutamate receptor positive allosteric modulator	GRM5			Preclinical
cebranopadol	opioid receptor agonist	OPRL1, OPRM1			Phase 3
cediranib	KIT inhibitor, VEGFR inhibitor	CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB			Phase 3
cedrol					Phase 2
cedrol-(+)	sedative				Phase 2
cefaclor	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology	pneumonia, skin infections, urinary tract infections, respiratory tract infections, tonsillitis, pharyngitis	Launched
cefadroxil	bacterial cell wall synthesis inhibitor	SLC15A1, SLC15A2, SLC22A6, SLC22A8	infectious disease, otolaryngology	urinary tract infections, skin infections, tonsillitis, pharyngitis	Launched
cefalonium	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	Launched
cefamandole	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, urinary tract infections, respiratory tract infections	Launched
cefamandole-nafate	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, urinary tract infections, respiratory tract infections	Launched
cefathiamidine	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	Launched
cefazolin	bacterial cell wall synthesis inhibitor	PON1	infectious disease	urinary tract infections, skin infections, bacterial septicemia, endocarditis, surgical prophylaxis, bone and joint infections	Launched
cefcapene-pivoxil	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, pneumonia, urinary tract infections	Launched
cefdinir	bacterial cell wall synthesis inhibitor	MPO	infectious disease, otolaryngology, pulmonary	pneumonia, tonsillitis, pharyngitis, bronchitis, skin infections, otitis, sinusitis	Launched
cefditoren-pivoxil	bacterial cell wall synthesis inhibitor		infectious disease, pulmonary, otolaryngology	pneumonia, bronchitis, skin infections, tonsillitis, pharyngitis	Launched
cefepime	bacterial cell wall synthesis inhibitor		infectious disease	pneumonia, urinary tract infections, skin infections, intra-abdominal infections	Launched
cefetamet	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology, pulmonary	ear infections, pneumonia, otitis, sinusitis, bronchitis, urinary tract infections	Launched
cefetamet-pivoxil	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	Launched
cefiderocol	antibacterial 				Launched
cefixime	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology, pulmonary	urinary tract infections, otitis, pharyngitis, tonsillitis, gonorrhea, bronchitis	Launched
cefmenoxime	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	Launched
cefmetazole	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections, skin infections	Launched
cefminox	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	Launched
cefodizime	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections, skin infections, gonorrhea	Launched
cefonicid	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	Launched
cefoperazone	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	Launched
ceforanide	penicillin binding protein inhibitor		infectious disease	gram-negative bacterial infections	Launched
cefoselis	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	Launched
cefotaxime	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections, bone and joint infections, pelvic inflammatory disease, intra-abdominal infections, skin infections, meningitis, urinary tract infections, bacterial septicemia, gynecologic infections	Launched
cefotetan	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections, respiratory tract infections, skin infections, gynecologic infections, chlamydia, intra-abdominal infections, bone and joint infections, surgical prophylaxis	Launched
cefotiam	bacterial cell wall synthesis inhibitor		infectious disease	bacterial septicemia, bone and joint infections, respiratory tract infections, skin infections, urinary tract infections	Launched
cefotiam-cilexetil	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	Launched
cefoxitin	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections, urinary tract infections, intra-abdominal infections, gynecologic infections, bacterial septicemia, bone and joint infections, skin infections	Launched
cefozopran	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	Launched
cefpiramide	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	Launched
cefpirome	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	Launched
cefpodoxime	bacterial cell wall synthesis inhibitor		otolaryngology, infectious disease, pulmonary	pharyngitis, pneumonia, bronchitis, gonorrhea, skin infections, urinary tract infections, sinusitis, tonsillitis	Launched
cefprozil	bacterial cell wall synthesis inhibitor		otolaryngology, infectious disease, pulmonary	pharyngitis, tonsillitis, otitis, sinusitis, respiratory tract infections, skin infections, bronchitis	Launched
cefradine	bacterial cell wall synthesis inhibitor	CYP3A4	infectious disease, otolaryngology	respiratory tract infections, otitis, skin infections, urinary tract infections, tonsillitis, pharyngitis, pneumonia	Launched
cefsulodin	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	Launched
ceftaroline-fosamil	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, pneumonia	Launched
ceftazidime	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections, skin infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra-abdominal infections, meningitis	Launched
ceftibuten	bacterial cell wall synthesis inhibitor		pulmonary, otolaryngology	bronchitis, otitis, pharyngitis, tonsillitis	Launched
ceftiofur	bacterial cell wall synthesis inhibitor		infectious disease	pneumonia, respiratory tract infections	Launched
ceftizoxim	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections, urinary tract infections, gonorrhea, pelvic inflammatory disease, intra-abdominal infections, bacterial septicemia, skin infections, bone and joint infections, meningitis	Launched
ceftobiprole	antiinfective drug				Phase 3
ceftriaxone	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology	gonorrhea, pneumonia, otitis, skin infections, urinary tract infections, pelvic inflammatory disease, bacterial septicemia, bone and joint infections, intra-abdominal infections, meningitis, surgical prophylaxis	Launched
cefuroxime	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	Launched
cefuroxime-axetil	bacterial cell wall synthesis inhibitor		otolaryngology	pharyngitis, tonsillitis, otitis, sinusitis	Launched
celecoxib	cyclooxygenase inhibitor	CA12, PDPK1, PTGS2	rheumatology, endocrinology	osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, primary dysmenorrhea (PD)	Launched
celgosivir	glucosidase inhibitor				Phase 2
celiprolol	adrenergic receptor antagonist	ADRA2A, ADRB1, ADRB2	genetics	Ehlers-Danlos syndrome (EDS)	Launched
cenerimod	sphingosine 1-phosphate receptor modulator				Phase 2
cenicriviroc	CC chemokine receptor antagonist				Phase 3
cenobamate	GABA receptor modulator, voltage-gated sodium channel blocker				Launched
centanafadine	dopamine reuptake inhibitor				Phase 3
centazolone	monoamine oxidase inhibitor				Phase 1
centhaquin	analgesic agent				Phase 1
centpropazine	inositol monophosphatase inhibitor				Phase 3
CEP-32496	RAF inhibitor	BRAF, RAF1			Phase 1/Phase 2
CEP-33779	JAK inhibitor	JAK2			Preclinical
CEP-37440	ALK tyrosine kinase receptor inhibitor	ALK			Phase 1
CEP-40783	AXL kinase inhibitor				Preclinical
cephalexin	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology	respiratory tract infections, otitis, skin infections, bone and joint infections, genitourinary tract infections	Launched
cephalomannine	DNA polymerase inhibitor				Preclinical
cephalosporin-c-zn	bacterial cell wall synthesis inhibitor				Preclinical
cephalothin	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, surgical prophylaxis	Launched
cephapirin	bacterial cell wall synthesis inhibitor		obstetrics/gynecology	mastitis	Launched
cepharanthine	NFkB pathway inhibitor				Phase 2
cephradine	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, respiratory tract infections, urinary tract infections	Launched
ceramide	phosphoenolpyruvate carboxylase activator, serine/threonine protein phosphatase activator		dermatology	cosmetic	Launched
ceritinib	ALK tyrosine kinase receptor inhibitor	ALK, FLT3, IGF1R, INSR, TSSK1B	oncology	non-small cell lung cancer (NSCLC)	Launched
cerulenin	fatty acid synthase inhibitor	FASN	infectious disease	fungal infection	Launched
ceruletide	CCK receptor agonist	CCKAR			Preclinical
cetaben	ACAT inhibitor, cholesterol inhibitor	PPARA			Phase 2
cetilistat	triacylglycerol lipase inhibitor	PNLIP			Phase 3
cetirizine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	Launched
cetrimonium			dermatology	cosmetic	Launched
cetrorelix	gonadotropin releasing factor hormone receptor antagonist	GNRHR, LHCGR	endocrinology	premature luteinizing hormone surges	Launched
cetylpyridinium			dental	gingivitis, mouth inflammation	Launched
cevimeline	acetylcholine receptor agonist	CHRM3	rheumatology	sjogren's syndrome	Launched
cevipabulin	microtubule stimulant, tubulin polymerization inhibitor	TUBB			Phase 1
CE3F4	rap guanine nucleotide exchange factor inhibitor	RAPGEF3			Preclinical
CFI-400945	serine/threonine kinase inhibitor				Phase 2
CFI-402257	dual specificity protein kinase inhibitor				Phase 1/Phase 2
CFM-1571	guanylate cyclase activator				Preclinical
CFM-2	glutamate receptor antagonist				Preclinical
CFTRinh-172	chloride channel blocker	CFTR			Preclinical
CF102	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Phase 2
CG-400549	FABI inhibitor				Phase 2
CGH2466	adenosine receptor antagonist	ADORA1, ADORA2B, ADORA3			Preclinical
CGK-733	ATM kinase inhibitor, ATR kinase inhibitor	ATM, ATR			Preclinical
CGM097	MDM inhibitor	MDM2			Phase 1
CGP-12177	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3			Phase 1
CGP-13501	GABA receptor modulator	GABBR1			Preclinical
CGP-20712A	adrenergic receptor antagonist	ADRB1, ADRB3			Preclinical
CGP-25454A	dopamine receptor antagonist				Preclinical
CGP-37157	mitochondrial Na+/Ca2+ exchanger antagonist, sodium/calcium exchange inhibitor	SLC8A1			Preclinical
CGP-37849	glutamate receptor antagonist	GRIN2A, GRIN2B, GRIN2C, GRIN2D			Phase 1
CGP-39551	NMDA receptor antagonist				Preclinical
CGP-52411	EGFR inhibitor	EGFR			Preclinical
CGP-53353	EGFR inhibitor, PKC inhibitor	EGFR, PRKCB			Preclinical
CGP-54626	GABA receptor antagonist	GABBR1, GABBR2, KCTD12, KCTD16, KCTD8			Preclinical
CGP-55845	GABA receptor antagonist	GABBR1, GABBR2, KCTD12, KCTD16, KCTD8			Preclinical
CGP-57380	MAP kinase inhibitor	AURKB, LCK, MKNK1, MKNK2, SGK1			Preclinical
CGP-60474	CDK inhibitor	CDK1, CDK2			Preclinical
CGP-71683	neuropeptide receptor antagonist	NPY5R			Preclinical
CGP-74514	CDK inhibitor	CDK1			Preclinical
CGP-78608	glutamate receptor antagonist				Preclinical
CGP-7930	GABA receptor modulator	GABBR1			Preclinical
CGS-15943	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Preclinical
CGS-20625	benzodiazepine receptor agonist, GABA benzodiazepine site receptor partial agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6			Phase 1
CGS-21680	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Preclinical
CGS-9896	GABA receptor antagonist	GABRA1, GABRB2, GABRG2			Preclinical
CH-170					Phase 1
CH-5183284	fibroblast growth factor inhibitor	FGFR1, FGFR2, FGFR3			Phase 2
CHC	monocarboxylate transporter inhibitor	SLC16A1			Preclinical
chenodeoxycholic-acid	11-beta hydroxysteroid dehydrogenase inhibitor, FXR agonist	HSD11B1, NR1H4	cardiology, gastroenterology	cerebral cholesterosis, gallstones	Launched
CHF5074	gamma secretase modulator	PSEN1			Phase 2
chicago-sky-blue-6b	glutamate inhibitor, macrophage migration inhibiting factor inhibitor	MIF			Preclinical
chidamide	HDAC inhibitor	HDAC10, HDAC3	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	Launched
chiniofon	antiprotozoal agent		infectious disease	amebiasis	Launched
CHIR-124	CHK inhibitor	CHEK1			Preclinical
CHIR-98014	glycogen synthase kinase inhibitor	GSK3A, GSK3B			Preclinical
CHIR-99021	glycogen synthase kinase inhibitor	CDK1, GSK3A, GSK3B, MAPK1			Preclinical
chloralose					Preclinical
chlorambucil	DNA inhibitor		hematologic malignancy	chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma	Launched
chloramine-T			infectious disease	bacterial gill disease	Launched
chloramphenicol	bacterial 50S ribosomal subunit inhibitor	CD55	infectious disease, endocrinology	meningitis, fever, cholera	Launched
chloramphenicol-palmitate	protein synthesis inhibitor		infectious disease, endocrinology	meningitis, fever, cholera	Launched
chloramphenicol-sodium-succinate	protein synthesis inhibitor		infectious disease	gram-negative bacterial infections	Launched
chlorazanil					Preclinical
chlorcyclizine	histamine receptor antagonist		allergy	allergic rhinitis	Launched
chlorfenson	other antifungal				Phase 2
chlorhexidine	membrane integrity inhibitor		dermatology, infectious disease, dental	cosmetic, skin infections, gingivitis	Launched
chlorindanol					Preclinical
chlorindione					Preclinical
chlorisondamine-diiodide	acetylcholine receptor antagonist	CHRNA1			Preclinical
chlormadinone-acetate	5 alpha reductase inhibitor	PGR	endocrinology	hypermenorrhea, amenorrhea, oligomenorrhea, polymenorrhea	Launched
chlormezanone	GABA receptor modulator	GABRA1			Withdrawn
chlormidazole	fungal lanosterol demethylase inhibitor		infectious disease	fungal infection	Launched
chlorobutanol			neurology/psychiatry	anesthetic, sedative	Launched
chlorocresol	ryanodine receptor activator		infectious disease	first-aid antiseptic	Launched
chlorogenic-acid	antioxidant	SLC37A4	neurology/psychiatry, pulmonary, allergy	headache, chest congestion, allergic rhinitis	Launched
chlorophyllin			urology	urinary incontinence	Preclinical
chlorophyllin-copper	cytochrome P450 inhibitor				Phase 1
chloroprocaine	sodium channel blocker	ATP1A1, CHRNA10, GRIN3A, HTR3A, SCN10A, SLC6A3	neurology/psychiatry	local anesthetic	Launched
chloropyramine	histamine receptor antagonist	HRH1	cardiology, ophthalmology, allergy, pulmonary	edema, conjunctivitis, allergic rhinitis, asthma	Launched
chloroquine	antimalarial agent	MRGPRX1	infectious disease	malaria, amebiasis	Launched
chlorothiazide	diuretic	CA1, CA2, CA4, SLC12A3	cardiology	hypertension	Launched
chlorothymol					Launched
chlorotrianisene	estrogenic hormone	ESR1, ESR2	endocrinology, oncology	menopause, prostate cancer	Launched
chloroxine	opioid receptor antagonist	OPRK1	gastroenterology, infectious disease, dermatology	diarrhea, inflammatory bowel disease, giardiasis, dandruff	Launched
chloroxoquinoline					Launched
chloroxylenol	ATP synthase inhibitor		infectious disease	skin infections	Launched
chlorphenamine	histamine receptor antagonist		allergy	allergic rhinitis, urticaria	Launched
chlorphenesin	muscle relaxant		neurology/psychiatry	muscle relaxant, sedative	Launched
chlorphenoxamine	histamine receptor antagonist				Preclinical
chlorphensin-carbamate	muscle relaxant		neurology/psychiatry	spasms	Launched
chlorproguanil	dihydrofolate reductase inhibitor	DHFR	infectious disease	malaria	Launched
chlorpromazine	dopamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CALM1, CHRM1, CHRM3, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HRH4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7, KCNH2, ORM1, ORM2, SMPD1, TRPC5	neurology/psychiatry, gastroenterology, hematology, infectious disease	schizophrenia, nausea, vomiting, acute intermittent porphyria (AIP), tetanus	Launched
chlorpropamide	ATP channel blocker	ABCC8, KCNJ10	endocrinology	diabetes mellitus	Launched
chlorpropham	antiviral				Phase 1
chlorprothixene	dopamine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, HRH1, HTR2A, HTR2B, HTR2C	neurology/psychiatry	schizophrenia, bipolar disorder	Launched
chlorpyrifos	acetylcholinesterase inhibitor	ACHE			Launched
chlorquinaldol	other antibiotic		infectious disease	fungal infection	Launched
chlortetracycline	protein synthesis inhibitor		ophthalmology	conjunctivitis	Launched
chlorthalidone	carbonic anhydrase inhibitor	CA1, CA12, CA14, CA2, CA4, CA7, SLC12A1	cardiology, gastroenterology, rheumatology, nephrology	hypertension, edema, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis (AGN), chronic renal failure	Launched
chlorzoxazone	bacterial 30S ribosomal subunit inhibitor	KCNMA1, KCNN4	neurology/psychiatry	muscle relaxant	Launched
cholecalciferol		VDR	endocrinology	vitamin D deficiency	Launched
cholesterol		RORA			Preclinical
cholic-acid	bile acid	ADH1C, CES1, COX4I1, COX5A, COX5B, COX6A2, COX6B1, COX6C, COX7A1, COX7B, COX7C, COX8A, ESRRG, FABP6, FECH, GPBAR1, MT-CO1, MT-CO2, MT-CO3, PLA2G1B	gastroenterology, neurology/psychiatry, genetics	bile acid synthesis disorders, peroxisomal disorders, Zellweger syndrome	Launched
choline	acetylcholine precursor	ACHE, BCHE, CHRNA2, PCYT1A, PCYT1B, PHOSPHO1, PLD1, PLD2			Phase 3
choline-alfoscerate	acetylcholine precursor				Launched
CHPG	glutamate receptor agonist	GRM5			Preclinical
CHR-6494	serine/threonine kinase inhibitor	GSG2			Preclinical
chromanol-(+/-)	potassium channel blocker				Preclinical
chromanol-293B-(-)-[3R,4S]	potassium channel blocker				Preclinical
chromium-picolinate	insulin sensitizer		endocrinology	diabetes mellitus	Launched
chromocarb	antispasmodic				Launched
chrysin	breast cancer resistance protein inhibitor	AKR1B1, CDK6, CYP19A1, CYP1B1			Phase 1
chrysophanic-acid	EGFR inhibitor	EGFR, MTOR			Preclinical
chuanxiongzine					Phase 2
CH223191	aryl hydrocarbon receptor antagonist	AHR			Preclinical
CH5132799	PI3K inhibitor	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG			Phase 1
CH55	retinoid receptor binder	RARA, RARB			Preclinical
CI-844					Phase 2
CI-923	acetylcholine receptor antagonist				Phase 1
CI-953	voltage-gated sodium channel blocker				Phase 1
CI-966	GAT inhibitor	SLC6A1			Phase 1
CI-976	ACAT inhibitor	ACAT1, CES1			Phase 1
ciaftalan-zinc	reactive oxygen species stimulant				Phase 1
cianidanol	fatty acid synthase inhibitor	PTGS1			Withdrawn
cibenzoline	sodium channel blocker		cardiology	cardiac arrythmia	Launched
ciclesonide	glucocorticoid receptor agonist	NR3C1, SERPINA6	allergy	allergic rhinitis	Launched
ciclopirox	membrane integrity inhibitor	ATP1A1	infectious disease	onychomycosis	Launched
cicloprofen	cyclooxygenase inhibitor	PTGS1, PTGS2			Preclinical
CID-16020046	G protein-coupled receptor antagonist	GPR55			Preclinical
CID-2011756	protein kinase inhibitor	PKD1			Preclinical
CID-2745687	G protein-coupled receptor antagonist	GPR35			Preclinical
CID-5458317	MAP kinase phosphatase inhibitor	MAPK3			Preclinical
cidofovir	DNA polymerase inhibitor		infectious disease	acquired immunodeficiency syndrome (AIDS), cytomegalovirus retinitis	Launched
ciglitazone	PPAR receptor agonist	PPARG			Phase 2
cilastatin	dehydropeptidase inhibitor	DPEP1			Launched
cilazapril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, congestive heart failure	Launched
cilengitide	integrin antagonist	ITGAV, ITGB3			Phase 3
cilnidipine	calcium channel blocker	CACNA1B	cardiology	hypertension	Launched
cilofexor	FXR agonist				Phase 3
cilomilast	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4D			Phase 3
cilostamide	phosphodiesterase inhibitor	PDE3A, PDE3B			Preclinical
cilostazol	phosphodiesterase inhibitor	PDE3A, PDE3B	cardiology	claudication	Launched
ciluprevir	serine protease inhibitor				Preclinical
CIM-0216	transient receptor potential channel agonist	TRPM3			Preclinical
cimaterol	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3			Preclinical
cimetidine	histamine receptor antagonist	HRH2, SLC29A4, SLC47A1, SLC47A2	gastroenterology, hematologic malignancy, endocrinology	duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma	Launched
cimetropium	acetylcholine receptor antagonist	CHRM1	gastroenterology	irritable bowel syndrome	Launched
cinacalcet	calcium channel activator	CASR	endocrinology, nephrology, oncology	hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia	Launched
cinaciguat	guanylate cyclase activator	GUCY1A3, GUCY1B3			Phase 2
cinalukast	leukotriene receptor antagonist	CYSLTR1			Phase 2
cinanserin	serotonin receptor antagonist	HTR2A			Preclinical
cinchocaine	sodium channel blocker	CALM1, SCN10A, SCN5A	neurology/psychiatry	local anesthetic	Launched
cinchonidine	P glycoprotein inhibitor				Phase 1
cinchonine	P glycoprotein inhibitor	CYP2D6			Preclinical
cinchophen	analgesic agent		rheumatology	gout	Launched
cinepazet	vasodilator				Launched
cinepazide	calcium channel activator				Withdrawn
cinflumide	muscle relaxant				Phase 2
cinnamaldehyde	aldose reductase inhibitor, TRPV agonist	TRPA1			Preclinical
cinnarazine	calcium channel blocker		neurology/psychiatry, gastroenterology, ophthalmology	Meniere's disease, nausea, vomiting, Cogan's syndrome	Launched
cinobufotalin	anticancer agent				Phase 1
cinoctramide					Preclinical
cinoxacin	topoisomerase inhibitor		infectious disease	urinary tract infections	Launched
cinoxate			dermatology	sunscreen lotion	Launched
CINPA-1	CAR antagonist	NR1H4, NR1I3, PPARG			Preclinical
cinromide					Phase 3
cintirorgon	ROR agonist				Phase 1/Phase 2
cintriamide					Preclinical
cipamfylline	phosphodiesterase inhibitor				Phase 2
cipargamin	antimalarial agent				Phase 2
cipemastat	metalloproteinase inhibitor	ADAM17, MMP1, MMP13, MMP2, MMP3, MMP8, MMP9			Phase 3
ciprofibrate	PPAR receptor agonist	PPARA	endocrinology	hyperlipidemia	Launched
ciprofloxacin	bacterial DNA gyrase inhibitor	TOP2A	otolaryngology	otitis	Launched
ciproxifan	histamine receptor antagonist	ADRA2A, ADRA2C, HRH3, HRH4, HTR3A			Preclinical
CIQ	glutamate receptor potentiator	GRIN2C, GRIN2D			Preclinical
cirazoline	adrenergic receptor agonist	ADRA1A			Preclinical
cis-aconitic-acid		ACO2			Preclinical
cis-ACPD	glutamate receptor agonist	GRM2, GRM3, GRM6, GRM7, GRM8			Preclinical
cis-exo-camphanediol-2,3	nitric oxide stimulant	NOS3			Phase 1
cis-urocanic-acid	serotonin receptor agonist	HTR2A			Phase 2
cis-9,trans-11-conjugated-linoleic-acid					Launched
cisapride	serotonin receptor agonist	HTR2A, HTR3A, HTR4, KCNH2			Withdrawn
cisatracurium	acetylcholine receptor antagonist	CHRNA2	neurology/psychiatry, critical care	muscle relaxant, endotracheal intubation	Launched
cisplatin	DNA alkylating agent, DNA synthesis inhibitor	XIAP	oncology	testicular carcinoma, ovarian cancer, bladder cancer	Launched
citalopram	selective serotonin reuptake inhibitor (SSRI)	ADRA1A, CHRM1, HRH1, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	Launched
citarinostat	HDAC inhibitor				Phase 1
CITCO	constitutive androstane receptor (CAR) agonist	NR1I3			Preclinical
citicoline	glutathione transferase stimulant, membrane permeability enhancer	ACHE, SLC1A2	neurology/psychiatry, ophthalmology	stroke, Alzheimer's disease, senile dementia, Parkinson's Disease, attention-deficit/hyperactivity disorder (ADHD), glaucoma	Launched
citiolone	lipotropic, mucolytic agent				Preclinical
citric-acid	coagulation factor inhibitor	AKR1B1, ANG, APRT, BHMT, C8G, CA4, CPB1, CS, CTDSP1, GNMT, HGS, HS3ST3A1, IL4I1, ITPA, LSM6, MDH2, MIF, PDE5A, PKD2L1, PLEKHA1, RNASE1, RNASE3, SRC, TNFSF13B, UCK2			Preclinical
CJ-033466	serotonin receptor agonist	HTR4			Preclinical
CJ-13610	lipoxygenase inhibitor				Phase 2
CK-101	EGFR inhibitor				Preclinical
CK-636	actin related protein inhibitor	ACTR2, ACTR3, ARPC1B, ARPC2, ARPC3, ARPC4, ARPC5			Preclinical
CKD-712	NFkB pathway inhibitor	JAK2, STAT1			Phase 1
CKI-7	casein kinase inhibitor	CSNK1G2			Preclinical
CL-218872	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2			Phase 1
CL-225385					Phase 2
cladribine	adenosine deaminase inhibitor, ribonucleotide reductase inhibitor	ADA, PNP, POLA1, POLE, POLE2, POLE3, POLE4, RRM1, RRM2, RRM2B	hematologic malignancy	hairy cell leukemia	Launched
clamikalant	ATP-sensitive potassium channel antagonist				Preclinical
clanfenur	anticancer agent				Preclinical
clarithromycin	bacterial 50S ribosomal subunit inhibitor	CYP3A4	otolaryngology, pulmonary, infectious disease	pharyngitis, tonsillitis, sinusitis, bronchitis, pneumonia, skin infections, otitis	Launched
clavulanate	beta lactamase inhibitor		otolaryngology	otitis	Launched
clebopride	dopamine receptor antagonist	ACHE, DRD2	gastroenterology	nausea	Launched
clemastine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis, urticaria	Launched
clemizole	HCV inhibitor		allergy	allergic rhinitis	Launched
clenbuterol	adrenergic receptor agonist	ABCC8, ADRB2, KCNJ11	pulmonary	chronic obstructive pulmonary disease (COPD), asthma	Launched
cleviprex	calcium channel blocker	CACNA1C, CACNA1D, CACNA1F, CACNA1S	cardiology	hypertension	Launched
clevudine	DNA polymerase inhibitor		infectious disease	hepatitis B	Launched
clidinium	acetylcholine receptor antagonist	CHRM1, CHRM3	gastroenterology	peptic ulcer disease (PUD), irritable bowel syndrome, enterocolitis	Launched
climbazole	enzyme inducer		dermatology	dandruff, eczema	Launched
clinafloxacin	bacterial DNA gyrase inhibitor				Phase 3
clindamycin	protein synthesis inhibitor		infectious disease	respiratory tract infections, pneumonia, skin infections, gynecologic infections, intra-abdominal infections, bacterial septicemia, bone and joint infections	Launched
clindamycin-palmitate	bacterial 50S ribosomal subunit inhibitor		infectious disease	intra-abdominal infections, skin infections, pneumonia, peritonitis, gynecologic infections	Launched
clindamycin-phosphate	protein synthesis inhibitor		obstetrics/gynecology	bacterial vaginosis	Launched
clinofibrate	lipase clearing factor inhibitor	LPL	endocrinology	hypertriglyceridemia	Launched
clioquinol	chelating agent	OPRK1			Withdrawn
clobenpropit	histamine receptor antagonist	HRH1, HRH2, HRH3, HRH4			Preclinical
clobetasol-propionate	glucocorticoid receptor agonist	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	Launched
clobetasone-butyrate	corticosteroid agonist	NR3C1	dermatology	eczema, psoriasis, dermatitis	Launched
clobutinol	antitussive				Withdrawn
clocortolone-pivalate	steroid	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	Launched
clodronic-acid	bone resorption inhibitor	SLC25A4, SLC25A5, SLC25A6	orthopedics, endocrinology, hematologic malignancy	osteoporosis, hyperparathyroidism, hypercalcemia, multiple myeloma	Launched
clofarabine	ribonucleotide reductase inhibitor	POLA1, POLD1, POLE, RRM1, RRM2, RRM2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	Launched
clofazimine	GK0582 inhibitor		infectious disease	leprosy	Launched
clofedanol	histamine receptor antagonist	HRH1	pulmonary	cough suppressant	Launched
clofibrate	PPAR receptor agonist	LPL, PPARA	endocrinology, cardiology	hyperlipidemia, cholesterol	Launched
clofibric-acid	PPAR receptor agonist	PPARA	endocrinology	hyperlipidemia	Launched
clofilium	potassium channel blocker	KCNA5, KCNH1			Phase 2
clofoctol	protein synthesis inhibitor		infectious disease	gram-positive bacterial infections	Launched
clomesone	DNA inhibitor				Phase 1
clomethiazole	GABA receptor antagonist, GABA receptor modulator	GABRA1	neurology/psychiatry	Parkinson's Disease, sedative, muscle relaxant	Launched
clomifene	estrogen receptor antagonist	ESR1	obstetrics/gynecology	infertility	Launched
clomipramine	serotonin transporter (SERT) inhibitor	GSTP1, HTR2A, HTR2B, HTR2C, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	obsessive compulsive disorder (OCD)	Launched
clonidine	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C	cardiology, neurology/psychiatry	hypertension, attention-deficit/hyperactivity disorder (ADHD)	Launched
clonixin	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology, infectious disease	rheumatoid arthritis, soft tissue infection	Preclinical
clonixin-lysinate	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	Launched
clopamide	sodium/chloride cotransporter inhibitor		cardiology	hypertension	Launched
cloperastine	antitussive		pulmonary	cough suppressant	Launched
cloperastine-fendizoate	potassium channel antagonist				Preclinical
clopidogrel	purinergic receptor antagonist	P2RY12	cardiology, neurology/psychiatry	myocardial infarction, stroke, peripheral artery disease (PAD), acute coronary syndrome (ACS)	Launched
clopidol			infectious disease	coccidiosis	Launched
cloprostenol-(+/-)	prostaglandin receptor agonist	PTGDR, PTGER1, PTGER3, PTGFR, TBXA2R	obstetrics/gynecology	endometriosis	Launched
cloranolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	cardiology	hypertension	Launched
clorgiline	monoamine oxidase inhibitor	MAOA			Phase 2
clorotepine	adrenergic receptor antagonist, dopamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, DRD2, HRH1, HTR2C, HTR6	neurology/psychiatry	psychosis	Launched
clorprenaline	adrenergic receptor agonist	ADRB1, ADRB2	pulmonary	asthma	Launched
clorsulon	glycolysis inhibitor		infectious disease	gastrointestinal roundworms, lungworms, liver flukes, lice, mites	Launched
closantel	chitinase inhibitor, NFkB pathway inhibitor		infectious disease	liver flukes	Launched
clotiapine			neurology/psychiatry	psychosis	Launched
clotrimazole	cytochrome P450 inhibitor, imidazoline receptor ligand	CYP3A4, KCNN4, NR1I2, NR1I3, TRPM2, TRPM4, TRPM8	infectious disease	vulvovaginal candidiasis, oropharyngeal candidiasis	Launched
cloxacillin	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	Launched
cloxyquin	potassium channel activator	KCNK18			Preclinical
clozapine	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CALY, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR5A, HTR6, HTR7	neurology/psychiatry	schizophrenia	Launched
CL316243	adrenergic receptor agonist	ADRB3, UCP1, UCP2, UCP3			Phase 2
CM-4620	calcium release activated channel modulator				Phase 2
CMPD-1	p38 MAPK inhibitor	GNRHR, MAPK14			Preclinical
CNQX	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4			Phase 1
CNX-2006	EGFR inhibitor	EGFR			Preclinical
CNX-774	Bruton's tyrosine kinase (BTK) inhibitor	BTK			Preclinical
CO-101244	glutamate receptor antagonist	GRIN2B			Preclinical
CO-102862	sodium channel blocker	SCN4A, SCN9A			Phase 1
cobicistat	cytochrome P450 inhibitor	CYP3A4, CYP3A43, CYP3A5, CYP3A7	infectious disease	human immunodeficiency virus (HIV-1)	Launched
cobimetinib	MEK inhibitor	MAP2K1	oncology	melanoma	Launched
coenzyme-A		ACAT2, CRAT, CS, DBI, HMGCR, KAT2A, KAT2B, KAT5			Launched
coenzyme-I		AASS, ACADS, ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH7, AKR1B1, AKR1C1, AKR1C2, AKR1C3, AKR1C4, ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, ALDH2, ALDH3A1, ALDH3A2, ALDH3B1, ALDH3B2, ALDH4A1, ALDH5A1, ALDH6A1, ALDH7A1, ALDH9A1, AMT, BDH1, BLVRA, BLVRB, CDO1, CYB5R3, CYP17A1, CYP4A11, DHCR7, DHFR, DLAT, DLD, EHHADH, GAPDH, GAPDHS, GLUD1, GLUD2, GPD1, GSR, H6PD, HADH, HADHA, HIBADH, HMGCR, HMOX1, HMOX2, HPGD, HSD11B1, HSD11B2, HSD17B1, HSD17B10, HSD17B2, HSD17B3, HSD17B4, HSD17B7, HSD17B8, HSD3B1, HSD3B2, IDH3A, IDH3B, IDH3G, IMPDH1, IMPDH2, LDHA, LDHAL6A, LDHAL6B, LDHB, LDHC, MDH1, MDH2, ME1, ME2, ME3, MSMO1, MT-ND1, MT-ND2, MT-ND3, MT-ND4, MT-ND4L, MT-ND5, MT-ND6, MTHFD1, MTHFD2, NDUFA1, NDUFA10, NDUFA11, NDUFA12, NDUFA13, NDUFA2, NDUFA3, NDUFA4, NDUFA4L2, NDUFA5, NDUFA6, NDUFA7, NDUFA8, NDUFA9, NDUFAB1, NDUFB1, NDUFB10, NDUFB2, NDUFB3, NDUFB4, NDUFB5, NDUFB6, NDUFB7, NDUFB8, NDUFB9, NDUFC1, NDUFC2, NDUFS1, NDUFS2, NDUFS3, NDUFS4, NDUFS5, NDUFS6, NDUFS7, NDUFS8, NDUFV1, NDUFV2, NDUFV3, NNT, NQO2, NSDHL, OGDH, PDHA1, PDHA2, PDHB, PHGDH, PYCR1, PYCR2, QDPR, RDH5, SORD, TSTA3, TYR, UGDH			Phase 2
coenzyme-Q10					Launched
COH29	ribonucleotide reductase inhibitor				Phase 1
colchicine	microtubule inhibitor	GLRA1, GLRA2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	rheumatology, endocrinology	gout, fever	Launched
colforsin	adenylyl cyclase activator	ADCY2, ADCY5			Phase 2
colforsin-daproate	adenylyl cyclase activator				Launched
colfosceril-palmitate	pulmonary surfactant		pulmonary	respiratory distress syndrome (RDS)	Launched
colistimethate	bacterial permeability inducer		infectious disease	gram-negative bacterial infections	Launched
colistin	bacterial permeability inducer		infectious disease	gram-negative bacterial infections, gram-negative bacterial infections	Launched
combretastatin-A-4	tubulin polymerization inhibitor				Phase 2
compound-w	beta-secretase inhibitor	BACE1			Preclinical
compound-401	DNA dependent protein kinase inhibitor	MTOR, PRKDC			Preclinical
compound-58112					Preclinical
conivaptan	vasopressin receptor antagonist	AVPR1A, AVPR2	endocrinology	hyponatremia	Launched
convallatoxin	cardiac glycoside				Preclinical
copanlisib	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG	hematologic malignancy	follicular lymphoma	Launched
copper-histidine		SLC15A3, SLC15A4, SLC38A5			Phase 3
COR-170	cannabinoid receptor inverse agonist	CNR2			Preclinical
cordycepin	DNA inhibitor				Phase 1/Phase 2
corosolic-acid	PKC inhibitor, protein tyrosine kinase inhibitor	HSD11B1, PTPN1			Phase 2
CORT-108297	glucocorticoid receptor antagonist				Preclinical
corticosterone	mineralocorticoid receptor agonist	HSD11B1, NCOA1, NR3C2			Preclinical
cortisone	glucocorticoid receptor agonist	NR3C1	gastroenterology, rheumatology, dermatology	ulcerative colitis, rheumatoid arthritis, psoriasis, joint inflammation, eczema	Launched
cortisone-acetate	glucocorticoid receptor agonist	NR3C1	pulmonary, rheumatology, allergy, dermatology, ophthalmology, gastroenterology, infectious disease	asthma, rheumatoid arthritis, urticaria, osteoarthritis, psoriasis, allergic rhinitis, conjunctivitis, ulcerative colitis, meningitis	Launched
cortodoxone	androgen receptor antagonist	AR			Phase 3
costunolide	telomerase inhibitor				Preclinical
cot-inhibitor-1	MAPK-interacting kinase inhibitor	MAP3K8			Preclinical
cot-inhibitor-2	MAPK-interacting kinase inhibitor	MAP3K8			Preclinical
COTI-2	anticancer agent				Phase 1
cotinine	nicotine metabolite				Phase 2
coumarin	vitamin K antagonist	CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP2A6	gastroenterology, pulmonary	ulcerative colitis, asthma, celiac disease	Launched
coumophos	cholinesterase inhibitor				Preclinical
CP-105,696	leukotriene receptor antagonist				Preclinical
CP-316819	glycogen phosphorylase inhibitor	PYGL			Preclinical
CP-339818	potassium channel blocker	KCNA3			Preclinical
CP-376395	corticotropin releasing factor receptor antagonist	CRHR1			Phase 1
CP-471474	matrix metalloprotease inhibitor	MMP1, MMP13, MMP2, MMP3, MMP9			Preclinical
CP-532623	cholesteryl ester transfer protein inhibitor	CETP			Phase 1
CP-547632	kinase inhibitor				Phase 2
CP-640186	acetyl-CoA carboxylase inhibitor	ACACA, ACACB			Preclinical
CP-673451	PDGFR tyrosine kinase receptor inhibitor	KIT, PDGFRA, PDGFRB			Preclinical
CP-724714	EGFR inhibitor, protein tyrosine kinase inhibitor	ERBB2			Phase 2
CP-775146	PPAR receptor agonist	PPARA			Preclinical
CP-91149	glycogen phosphorylase inhibitor	PYGL			Preclinical
CP-93129	serotonin receptor agonist	HTR1A			Preclinical
CP-94253	serotonin receptor agonist	HTR1B			Preclinical
CP-945,598	cannabinoid receptor antagonist	CNR1			Phase 3
CP-99994	tachykinin antagonist	TACR1			Phase 2
CPA-inhibitor	carboxypeptidase inhibitor	CPA1, CPA2			Preclinical
CPCCOEt	glutamate receptor antagonist	GRM1			Preclinical
CPI-0610	bromodomain inhibitor	BRD4			Phase 2
CPI-1189	tumor necrosis factor release inhibitor	TNF			Phase 2
CPI-1205	EZH2 inhibitor				Phase 1/Phase 2
CPI-169	histone lysine methyltransferase inhibitor	EZH2			Preclinical
CPI-203	bromodomain inhibitor	BRD4			Preclinical
CPI-360	histone lysine methyltransferase inhibitor	EZH2			Preclinical
CPI-444	adenosine receptor antagonist				Phase 1/Phase 2
CPI-613	pyruvate dehydrogenase inhibitor	PDHA1			Phase 3
CPP	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			Phase 2
CPSI-1306-(+/-)	macrophage migration inhibiting factor inhibitor	MIF			Preclinical
CQS					Preclinical
creatine		CKB, CKM, CKMT1A, CKMT2, GAMT, SLC6A8			Launched
creatinine					Preclinical
creatinol-phosphate					Launched
crenigacestat	notch signaling inhibitor				Preclinical
crenolanib	PDGFR tyrosine kinase receptor inhibitor	CSF1R, FLT3, KIT, PDGFRA, PDGFRB			Phase 3
cresol					Launched
cresopirine					Preclinical
cridanimod	progesterone receptor agonist	PGR	infectious disease	influenza A virus infection	Launched
crisaborole	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4C, PDE4D	dermatology	dermatitis	Launched
crisdesalazine	free radical scavenger				Preclinical
crizotinib	ALK tyrosine kinase receptor inhibitor	ALK, MET	oncology	non-small cell lung cancer (NSCLC)	Launched
crizotinib-(S)	MTH1 inhibitor	NUDT1			Preclinical
croconazole	bacterial cell wall synthesis inhibitor		infectious disease	fungal infection	Launched
crolibulin	tubulin polymerization inhibitor				Phase 1/Phase 2
cromakalim		KCNJ8			Phase 2
cromoglicic-acid	immunosuppressant	KCNMA1, S100P	pulmonary, ophthalmology, allergy, gastroenterology	asthma, conjunctivitis, urticaria, ulcerative colitis	Launched
crotamiton	antipruritic		infectious disease	scabies	Launched
CRT0044876					Preclinical
cryptotanshinone	acetylcholinesterase inhibitor, STAT inhibitor	STAT3			Preclinical
crystal-violet	other antibiotic				Launched
CR8-(R)	CDK inhibitor	CCNA2			Preclinical
CS-110266	dopamine receptor agonist	SLC6A3			Preclinical
CS-917	fructose biphosphate inhibitor	FBP1			Phase 2
CT-7758	integrin antagonist	ITGA4			Phase 2
CTEP	glutamate receptor antagonist	GRM5			Preclinical
CTS-1027	metalloproteinase inhibitor	MMP1, MMP13, MMP2, MMP3, MMP9			Phase 2
CTS21166	beta-secretase inhibitor	BACE1			Phase 1
CT7001	CDK inhibitor				Phase 1/Phase 2
CU-CPT-4a	toll-like receptor inhibitor	TLR3			Preclinical
CU-T12-9	toll-like receptor agonist	TLR1, TLR2			Preclinical
CUDC-101	EGFR inhibitor	EGFR, ERBB2			Phase 1
CUDC-427	apoptosis inhibitor	XIAP			Phase 1
CUDC-907	PI3K inhibitor	HDAC2, PIK3R1			Phase 2
CUR-61414	smoothened receptor antagonist	DHH, IHH, SMO			Phase 1
curcumin	cyclooxygenase inhibitor, histone acetyltransferase inhibitor, lipoxygenase inhibitor, NFkB pathway inhibitor	APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CHRM3, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH			Launched
curcumol	JAK inhibitor	JAK1, JAK2, JAK3			Phase 1
cutamesine	sigma receptor agonist	SIGMAR1			Phase 2
CV-1808	adenosine receptor agonist	ADORA2A			Preclinical
CVT-10216	aldehyde dehydrogenase inhibitor	ALDH2			Phase 1
CW-008	PKA activator	PRKACA			Preclinical
CX-4945	casein kinase inhibitor	CSNK2A1, CSNK2A2, DAPK3, HIPK3			Phase 1/Phase 2
CX-516	glutamate receptor modulator				Phase 2/Phase 3
CX-5461	RNA polymerase inhibitor				Phase 1
CXD101	HDAC inhibitor				Phase 1/Phase 2
cyacetacide					Preclinical
cyamemazine	serotonin receptor antagonist	HTR1A, HTR2A, HTR2C, HTR7	neurology/psychiatry	schizophrenia, anxiety	Launched
cyanocobalamin	methylmalonyl CoA mutase stimulant, vitamin B	MUT	hematology, infectious disease, gastroenterology	anemia, fish tapeworm infestation, celiac disease	Launched
cyanopindolol	adrenergic receptor antagonist	ADRB1, HTR1A, HTR1D			Phase 2
cyclamic-acid					Preclinical
cyclandelate	calcium channel blocker		cardiology, rheumatology	claudication, arteriosclerosis, Raynaud's disease	Launched
cyclic-AMP		CNGA3, TRPM7			Preclinical
cyclizine	histamine receptor modulator	HRH1, SULT1E1	gastroenterology, neurology/psychiatry	nausea, vomiting, vertigo, motion sickness	Launched
cyclobenzaprine	adrenergic receptor agonist, serotonin receptor agonist	HTR2A	neurology/psychiatry	spasms	Launched
cyclocreatine	creatine kinase substrate				Phase 1
cyclocytidine	DNA synthesis inhibitor, RNA synthesis inhibitor				Preclinical
cycloheximide	protein synthesis inhibitor	RPL3			Preclinical
cyclopamine	hedgehog pathway inhibitor				Preclinical
cyclopenthiazide	thiazide diuretic		cardiology	hypertension, congestive heart failure	Launched
cyclopentolate	acetylcholine receptor antagonist		ophthalmology	mydriasis, cycloplegia	Launched
cyclophosphamide	DNA alkylating agent	CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP3A7	hematologic malignancy, oncology	Hodgkin's lymphoma, small lymphocytic lymphoma (SLL), breast cancer, neuroblastoma, Burkitt's lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), true histiocytic lymphoma (THL), retinoblastoma, ovarian cancer	Launched
cyclopiazonic-acid	ATPase inhibitor	ATP2A1			Preclinical
cycloserine-(D)	bacterial cell wall synthesis inhibitor	GRIN1	infectious disease	tuberculosis, tuberculosis	Launched
cyclosporin-A	calcineurin inhibitor	ABCB11, CAMLG, FPR1, PPIA, PPIF, PPP3CA, PPP3R2, SLC10A1, SLCO1B1, SLCO1B3	rheumatology, dermatology	rheumatoid arthritis, psoriasis	Launched
cyclothiazide	glutamate receptor modulator	CA2, GRIA1, GRIA2, GRIA3, GRIA4, SLC12A3	cardiology	hypertension	Launched
cyclovalone	breast cancer resistance protein inhibitor	ABCG2	gastroenterology	bile stimulation	Launched
cyclovirobuxin-D	calcium channel modulator				Preclinical
CycLuc1					Preclinical
CYC065	CDK inhibitor				Phase 1
CYC116	Aurora kinase inhibitor	AURKA, AURKB, KDR			Phase 1
CYM-50260	sphingosine 1-phosphate receptor agonist	S1PR4			Preclinical
CYM-50358	sphingosine 1-phosphate receptor antagonist	S1PR4			Preclinical
CYM-50769	neuropeptide receptor antagonist	NPBWR1			Preclinical
CYM-5442	sphingosine 1-phosphate receptor agonist	S1PR1			Preclinical
CYM-5520	sphingosine 1-phosphate receptor agonist	S1PR2			Preclinical
CYM-5541	sphingosine 1-phosphate receptor agonist	S1PR3			Preclinical
cypermethrin			infectious disease	flea control	Launched
cyproheptadine	histamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, HRH1, HTR2A, HTR2C, HTR6, HTR7	allergy, otolaryngology, ophthalmology, dermatology	allergic rhinitis, vasomotor rhinitis, conjunctivitis, urticaria, dermatographism	Launched
cyproterone-acetate	androgen receptor antagonist	ADORA1, AR	oncology	prostate cancer	Launched
cyromazine					Launched
cysteamine	tissue transglutaminase inhibitor	NPY2R, SST	metabolism	cystinosis	Launched
CYT-997	tubulin polymerization inhibitor	TUBB			Phase 2
cytarabine	ribonucleotide reductase inhibitor	POLA1, POLB, POLD1, POLE	hematologic malignancy	acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)	Launched
cytidine		UCK2			Launched
cytisine	acetylcholine receptor agonist	CHRNA2, CHRNA3, CHRNA4, CHRNA6, CHRNA7, CHRNB2, CHRNB4	neurology/psychiatry	nicotinism	Launched
cytochalasin-B	microtubule inhibitor	ACTB			Phase 2
cytochlor					Phase 1
cyt387	JAK inhibitor	JAK1, JAK2, JAK3			Phase 3
CY208-243	dopamine receptor agonist	CALY			Phase 2
CZC-54252	leucine rich repeat kinase inhibitor	LRRK2			Preclinical
CZC24832	PI3K inhibitor	PIK3CG			Preclinical
C106					Phase 3
C11-Acetate		ABAT, ACE, AKR1C3, CA2, CELA1, ESR2, FFAR2, FFAR3, HPRT1, LTA4H, MMP12, NOS1, NOS3, PLA2G1B, PTPN1, SOD1, TXN			Phase 3
C188-9	STAT inhibitor				Preclinical
C34	toll-like receptor inhibitor	TLR4			Preclinical
C646	histone acetyltransferase inhibitor	EP300			Preclinical
D,L-mevalonic-acid-lactone					Preclinical
D-(+)-maltose		MGAM			Preclinical
D-alpha-tocopheryl-succinate					Launched
D-delta-tocopherol					Launched
D-limonene					Phase 1
D-phenylalanine	enkephalinase inhibitor	CCBL1, CRH, HCAR3			Preclinical
D-serine	glutamate receptor agonist	GLRA1, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SERPINB3			Launched
D-157495	decapping scavenger enzyme inhibitor				Preclinical
D-3263	transient receptor potential channel agonist				Phase 1
D-4476	TGF beta receptor inhibitor	CSNK1A1, CSNK1D, TGFB1			Preclinical
D-64131	microtubule inhibitor	TUBB			Preclinical
D-7193					Phase 2
DAA-1106	benzodiazepine receptor agonist	TSPO			Preclinical
dabigatran	thrombin inhibitor	F2	neurology/psychiatry, hematology	stroke, systemic embolism, pulmonary embolism (PE), deep vein thrombosis (DVT)	Launched
dabigatran-etexilate	thrombin inhibitor	F2	neurology/psychiatry, hematology	stroke, systemic embolism, pulmonary embolism (PE), deep vein thrombosis (DVT)	Launched
dabrafenib	RAF inhibitor	BRAF, LIMK1, NEK11, RAF1, SIK1	oncology	melanoma	Launched
dacarbazine	DNA alkylating agent	PGD, POLA2	oncology, hematologic malignancy	melanoma, Hodgkin's lymphoma	Launched
dacinostat	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9			Phase 1
daclatasvir	HCV inhibitor		infectious disease	hepatitis C	Launched
dacomitinib	EGFR inhibitor	EGFR, ERBB2, ERBB4			Launched
dactinomycin	RNA polymerase inhibitor	POLR2A	oncology	testicular carcinoma, Wilm's tumor, rhabdomyosarcoma, Ewing's sarcoma, gestational trophoblastic disease (GTD)	Launched
daidzein	estrogen receptor agonist	ESRRA, ESRRB, ESRRG, TRPC5			Phase 2
daidzin	antioxidant	ALDH2			Phase 1
dalargin	opioid receptor agonist	OPRM1			Phase 2
dalbavancin	bacterial cell wall synthesis inhibitor	PNLIP	infectious disease	skin infections	Launched
dalcetrapib	cholesteryl ester transfer protein inhibitor	CETP			Phase 3
dalfampridine	potassium channel blocker	KCNA1, KCNA10, KCNA2, KCNA3, KCNA4, KCNA5, KCNA6, KCNA7, KCNB1, KCNB2, KCNC1, KCNC2, KCNC3, KCNC4, KCND1, KCND2, KCND3, KCNF1, KCNG1, KCNG2, KCNG3, KCNG4, KCNH1, KCNH2, KCNH3, KCNH4, KCNH5, KCNH6, KCNH7, KCNH8, KCNJ13, KCNJ5, KCNQ1, KCNQ2, KCNQ3, KCNQ4, KCNQ5, KCNS1, KCNS2, KCNS3, KCNV1, KCNV2	neurology/psychiatry	multiple sclerosis	Launched
dalfopristin	antibacterial 				Preclinical
daltroban	thromboxane receptor antagonist	TBXA2R			Phase 3
daminozide	KDM2A inhibitor	KDM2A, KDM7A, PHF8			Preclinical
danazol	estrogen receptor antagonist, progesterone receptor agonist	AR, CCL2, ESR1, GNRHR, GNRHR2, PGR	obstetrics/gynecology, cardiology	endometriosis, angioedema	Launched
danegaptide	gap junction modulator				Phase 2
danirixin	CC chemokine receptor antagonist	CXCR2			Phase 2
danofloxacin	bacterial DNA gyrase inhibitor		pulmonary	bovine respiratory disease (BRD)	Launched
danoprevir	HCV inhibitor				Phase 3
dantrolene	calcium channel blocker	RYR1, RYR3	neurology/psychiatry, endocrinology	spasms, malignant hyperthermia (MH)	Launched
dantron	laxative				Withdrawn
danusertib	Aurora kinase inhibitor, growth factor receptor inhibitor	AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK			Phase 2
dapagliflozin	sodium/glucose cotransporter inhibitor	SLC5A1, SLC5A2	endocrinology	diabetes mellitus	Launched
dapansutrile	anti-inflammatory agent				Phase 2
daphnetin	protein kinase inhibitor				Preclinical
dapiprazole	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D	ophthalmology	mydriasis	Launched
dapivirine	non-nucleoside reverse transcriptase inhibitor	CYP3A4, CYP3A5			Phase 3
dapoxetine	selective serotonin reuptake inhibitor (SSRI)	HTR1A, HTR1B, HTR2C, SLC6A4	urology	premature ejaculation (PE)	Launched
daprodustat	hypoxia inducible factor inhibitor	EGLN1			Phase 3
dapsone	bacterial antifolate	DHFR	dermatology, infectious disease	dermatitis herpetiformis (DH), leprosy	Launched
DAPT	gamma secretase inhibitor				Preclinical
daptomycin	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, endocarditis	Launched
darapladib	phospholipase inhibitor	PLA2G7			Phase 3
darglitazone	PPAR receptor antagonist	PPARG			Phase 2
darifenacin	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence	Launched
darolutamide	androgen receptor antagonist	AR	oncology	prostate cancer	Launched
darunavir	HIV protease inhibitor	CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	Launched
darusentan	endothelin receptor antagonist	EDNRA			Phase 3
dasabuvir	HCV inhibitor		infectious disease	hepatitis C	Launched
dasatinib	Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, SRC inhibitor, tyrosine kinase inhibitor	ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	Launched
dasotraline	dopamine-norepinephrine-serotonin reuptake inhibitor				Phase 3
DAU-5884	acetylcholine receptor antagonist	CHRM3			Preclinical
daucosterol	apoptosis stimulant				Phase 2
daunorubicin	RNA synthesis inhibitor, topoisomerase inhibitor	TOP2A, TOP2B	hematologic malignancy	acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)	Launched
dazmegrel	thromboxane synthase inhibitor	TBXAS1			Phase 2
dazoxiben	thromboxane synthase inhibitor	TBXAS1			Phase 2
DBeQ	ATPase inhibitor	CASP3			Preclinical
DBPR-211	cannabinoid receptor antagonist				Preclinical
DBPR108	dipeptidyl peptidase inhibitor	DPP4			Phase 1
DC-260126	free fatty acid receptor antagonist	FFAR1			Preclinical
DCC-2618	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	KIT, PDGFRA			Phase 1
DCEBIO	potassium channel activator	KCNN2, KCNN3, KCNN4			Preclinical
DCP-LA	protein kinase activator				Preclinical
DCPIB	chloride channel blocker, gap junction modulator, glutamate inhibitor	SLC1A2			Preclinical
DDR1-IN-1	discoidin domain receptor inhibitor	DDR1, DDR2			Preclinical
deazaguanine	DNA synthesis inhibitor				Preclinical
Debio-0932	HSP inhibitor				Phase 1
debrisoquin	adrenergic neuron blocker	SLC6A2	cardiology	hypertension	Launched
decamethonium	acetylcholine receptor agonist	ACHE, CHRNA2	neurology/psychiatry	muscle relaxant	Launched
decamethoxine	antiseptic				Phase 2
decernotinib	JAK inhibitor	JAK3			Phase 2/Phase 3
decitabine	DNA methyltransferase inhibitor	DNMT1, DNMT3A	hematologic malignancy, hematology	myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)	Launched
declopramide	cell cycle inhibitor				Preclinical
decloxizine	histamine receptor antagonist				Preclinical
decoquinate	antiprotozoal agent		infectious disease	coccidiosis	Launched
defactinib	focal adhesion kinase inhibitor	PTK2			Phase 2
deferasirox	chelating agent	CYP3A4	hematology	transfusional hemosiderosis, thalassemia, iron overload	Launched
deferasirox-iron-chelate					Launched
deferiprone	chelating agent	UGT1A6	hematology	transfusional hemosiderosis, thalassemia, iron overload	Launched
deferoxamine-mesylate	chelating agent		hematology	acute iron intoxication, iron overload	Launched
deflazacort	glucocorticoid receptor agonist	NR3C1	rheumatology	joint inflammation	Launched
deforolimus	mTOR inhibitor	MTOR			Phase 3
degarelix	gonadotropin releasing factor hormone receptor antagonist	GNRHR	oncology	prostate cancer	Launched
dehydroacetic-acid					Preclinical
dehydrocholate					Preclinical
dehydrocholate-acid					Preclinical
dehydrocorydaline	acetylcholinesterase inhibitor	ACHE			Phase 3
dehydroepiandrosterone	protein synthesis stimulant	ESR1, ESR2, G6PD, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, HSD17B1, NR1I2, NR1I3, PPARA, SIGMAR1, SULT2A1, SULT2B1	endocrinology	menopause	Launched
dehydroepiandrosterone-sulfate	androgen receptor agonist, estrogen receptor agonist	AR, ESR1, ESR2	endocrinology	menopause	Launched
delafloxacin	antiinfective drug				Phase 3
delamanid	bacterial cell wall synthesis inhibitor		infectious disease	tuberculosis	Launched
delanzomib	proteasome inhibitor	CMA1, CTSG, CYP3A4, ELANE			Phase 1/Phase 2
delapril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	Launched
delavirdine	non-nucleoside reverse transcriptase inhibitor	CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	Launched
delcasertib	PKC inhibitor				Phase 1
delgocitinib	JAK inhibitor				Phase 2
delivert	angiotensin receptor agonist	AGTR1, AGTR2	critical care	sepsis	Launched
delpazolid	antibacterial				Phase 2
delphinidin	membrane permeability inhibitor	GLO1			Phase 2
delta-tocotrienol	HMGCR inhibitor	HMGCR			Phase 1
deltarasin	phosphodiesterase inhibitor	KRAS			Preclinical
demecarium	acetylcholinesterase inhibitor	ACHE, BCHE	ophthalmology	intraocular pressure, glaucoma	Launched
demeclocycline	bacterial 30S ribosomal subunit inhibitor		endocrinology, infectious disease, ophthalmology, urology	fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, cholera, syphilis, listeria, anthrax, actinomycosis, tularemia, brucellosis	Launched
denatonium-benzoate					Preclinical
denopamine	adrenergic receptor agonist		cardiology	angina pectoris	Launched
denotivir	antiviral		infectious disease	virus herpes simplex (HSV), skin infections	Launched
deoxyarbutin	tyrosinase inhibitor				Preclinical
deoxycholic-acid	biliverdin reductase A activator, G protein-coupled receptor agonist	FPR1, GPBAR1	endocrinology	submental fat	Launched
deoxycorticosterone-acetate	progestogen hormone	NR3C2			Preclinical
deoxyepinephrine	adrenergic receptor agonist, dopamine receptor agonist	ADRA1A, DRD1, DRD2			Preclinical
deptropine	histamine receptor antagonist	HRH1			Preclinical
dequalinium	PKC inhibitor	KCNN1, KCNN3	infectious disease	first-aid antiseptic	Launched
deracoxib	cyclooxygenase inhibitor	PTGS2	rheumatology	osteoarthritis	Launched
derazantinib	tyrosine kinase inhibitor				Phase 2
deserpidine	angiotensin converting enzyme inhibitor	ACE, SLC18A2	cardiology	hypertension	Launched
desidustat	hypoxia inducible factor prolyl hydroxylase inhibitor				Preclinical
desipramine	tricyclic antidepressant	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A4, SMPD1	neurology/psychiatry	depression	Launched
desisobutyryl-ciclesonide	cytochrome P450 inhibitor		allergy	allergic rhinitis	Launched
deslanoside	Na/K-ATPase inhibitor	ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B1, ATP1B2, ATP1B3, FXYD2	cardiology	congestive heart failure, cardiac arrythmia	Launched
desloratadine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis, urticaria	Launched
deslorelin	gonadotropin releasing factor hormone receptor agonist				Phase 2
desmethylclozapine	acetylcholine receptor agonist	HTR2C			Phase 2
desmopressin-acetate	vasopressin receptor agonist	AVPR1A, AVPR1B, AVPR2, OXTR	endocrinology, urology	central diabetes insipidus, nocturnal enuresis	Launched
desogestrel	progesterone receptor agonist	ESR1, PGR	endocrinology	contraceptive	Launched
desonide	glucocorticoid receptor agonist	NR3C1, PLA2G1B	gastroenterology	Crohn's disease	Launched
desoximetasone	glucocorticoid receptor agonist	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	Launched
desoxycorticosterone-pivalate	corticosteroid agonist	NR3C2	endocrinology	Addison's disease	Launched
desoxycortone	mineralocorticoid receptor agonist	NR3C1, NR3C2			Preclinical
desoxypeganine	acetylcholinesterase inhibitor, monoamine oxidase inhibitor	ACHE			Phase 1
desvenlafaxine	serotonin–norepinephrine reuptake inhibitor (SNRI)	SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	Launched
detomidine	adrenergic receptor agonist	ADRA2A	neurology/psychiatry	sedative	Launched
devazepide	CCK receptor antagonist				Preclinical
dexamethasone	glucocorticoid receptor agonist	ANXA1, NOS2, NR0B1, NR3C1, NR3C2	endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology	hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis	Launched
dexamethasone-acetate	glucocorticoid receptor agonist		endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology	hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis	Launched
dexchlorpheniramine	histamine receptor antagonist		allergy, cardiology	allergic conjunctivitis, allergic rhinitis, urticaria, angioedema	Launched
dexfosfoserine	membrane integrity inhibitor	CFTR, GRM4, GRM6, GRM7, GRM8, KCNC4, PDPK1, PIM1, PRKACA, PRKCQ, PYGL, PYGM, REG1A, RHO, SERPINB3, SMAD2, TAOK2			Preclinical
dexlansoprazole	ATPase inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD), erosive esophagitis (EE)	Launched
dexloxiglumide	CCK receptor antagonist	CCKAR			Phase 3
dexmedetomidine	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C	neurology/psychiatry	sedative	Launched
dexniguldipine	calmodulin antagonist	ADORA3			Phase 2
dexpanthenol			gastroenterology	paralytic ileus	Launched
dexrazoxane	chelating agent, topoisomerase inhibitor	TOP2A, TOP2B	cardiology	cardiomyopathy	Launched
dextran			hematology, critical care	thrombosis, hypovolemia	Launched
dextromethorphan	glutamate receptor antagonist, sigma receptor agonist	CHRNA2, CHRNA3, CHRNA4, CHRNA7, CHRNB2, CHRNB4, CYBA, CYBB, GRIN3A, NCF1, NCF2, NCF4, OPRD1, OPRK1, OPRM1, PGRMC1, RAC1, RAC2, SIGMAR1, SLC6A2, SLC6A4	pulmonary	cough suppressant	Launched
dextrorotation-nimorazole-phosphate-ester	antiinfective drug				Preclinical
dextrose			endocrinology	hypoglycemia	Launched
DFB	glutamate receptor agonist	GRM5			Preclinical
DG-172	PPAR receptor inverse agonist	PPARD			Preclinical
DG051	leukotriene synthesis inhibitor				Preclinical
DH-97	melatonin receptor antagonist	MTNR1B			Preclinical
DHBP	ryanodine receptor blocker				Preclinical
diacerein	interleukin inhibitor	IL1B	rheumatology	osteoarthritis	Launched
diacetamate					Preclinical
diadenosine-tetraphosphate	adenosine kinase inhibitor	P2RY13, P2RY2			Phase 1
dianhydrogalactitol	DNA alkylating agent				Phase 3
diarylpropionitrile	estrogen receptor agonist	ESR2			Preclinical
diatrizoic-acid			radiology	contrast agent	Launched
diaveridine	dihydrofolate reductase inhibitor		infectious disease	coccidiosis	Launched
diazoxide	potassium channel activator	ATP1A1, CA1, CA2, KCNJ11, KCNJ8, KCNMA1, SLC12A3	endocrinology	hypoglycemia	Launched
dibekacin	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	Launched
dibenzepine	norepinephrine reputake inhibitor				Preclinical
dibenzothiophene					Preclinical
dibutyl-phthalate		TRPA1			Preclinical
dichlorisone-acetate					Phase 2
dichloroacetate	pyruvate dehydrogenase kinase inhibitor				Phase 3
dichlorophen	anticestodal agent		infectious disease	hookworm, tapeworm	Launched
dichlorvos	acetylcholinesterase inhibitor				Launched
diclazuril	antiprotozoal agent		infectious disease	equine protozoal myeloencephalitis (EPM)	Launched
diclofenac	cyclooxygenase inhibitor	AKR1C3, ALOX5, ASIC1, ASIC3, KCNQ2, KCNQ3, PLA2G2A, PPARG, PTGS1, PTGS2, SCN4A	rheumatology, neurology/psychiatry	rheumatoid arthritis, osteoarthritis, migraine headache	Launched
diclofenamide	carbonic anhydrase inhibitor	CA1, CA12, CA2, CA4, CA7	ophthalmology, neurology/psychiatry	glaucoma, epilepsy	Launched
diclofensine	dopamine reuptake inhibitor	DRD1, MAOA, MAOB			Phase 3
dicloralurea					Preclinical
dicloxacillin	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	Launched
dicoumarol	NADPH inhibitor	CRYZ, NQO1, VKORC1	hematology	deep vein thrombosis (DVT)	Launched
dicyclohexylamine					Preclinical
dicycloverine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	gastroenterology	irritable bowel syndrome	Launched
didanosine	nucleoside reverse transcriptase inhibitor	PNP	infectious disease	human immunodeficiency virus (HIV-1)	Launched
dideoxyadenosine	nucleoside reverse transcriptase inhibitor				Phase 1
didox	ribonucleotide reductase inhibitor	RRM1	oncology	breast cancer	Launched
dienestrol	estrogen receptor agonist	ESR1	endocrinology	menopause	Launched
dienogest	progesterone receptor agonist	PGR	endocrinology, obstetrics/gynecology	contraceptive, endometriosis	Launched
diethylcarbamazine	lipoxygenase inhibitor	ALOX5, PTGS1	infectious disease	filariasis	Launched
diethylstilbestrol	estrogen receptor agonist	ESR1, ESR2, ESRRB, ESRRG			Withdrawn
diethyltoluamide	ionotropic receptor IR40a activator		dermatology	sunscreen lotion	Launched
difenpiramide	cyclooxygenase inhibitor, prostaglandin inhibitor		neurology/psychiatry	pain relief	Launched
diflorasone-diacetate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	Launched
difloxacin	bacterial DNA gyrase inhibitor		infectious disease	skin infections, urinary tract infections	Launched
diflunisal	prostanoid receptor antagonist	PTGS1, PTGS2	rheumatology	rheumatoid arthritis, osteoarthritis	Launched
difluprednate	glucocorticoid receptor agonist	NR3C1	ophthalmology	endogenous uveitis	Launched
diftalone	cyclooxygenase inhibitor		endocrinology	thyroiditis	Launched
digitoxigenin	ATPase inhibitor	ATP1A1			Preclinical
digitoxin	ATPase inhibitor	ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B1, ATP1B2, ATP1B3, FXYD2	cardiology	congestive heart failure, cardiac arrythmia	Launched
digoxigenin	steroid				Preclinical
digoxin	ATPase inhibitor	ATP1A1	cardiology	congestive heart failure, atrial fibrillation (AF)	Launched
dihomo-gamma-linolenic-acid	prostanoid receptor agonist	PTGS1, PTGS2			Phase 2
dihydrexidine	dopamine receptor agonist	DRD1, DRD2, DRD3, DRD4, DRD5			Phase 2
dihydroartemisinin	antimalarial agent		infectious disease	malaria	Launched
dihydroergocristine	adrenergic receptor antagonist, prolactin inhibitor	ADRA1A, ADRB1, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR3A, HTR4, HTR5A, HTR6, HTR7	neurology/psychiatry	senile dementia, cerebrovascular insufficiency	Launched
dihydroergotamine	serotonin receptor agonist	ADRA2A, DRD2, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR7	neurology/psychiatry	migraine headache	Launched
dihydromyricetin					Preclinical
dihydrostreptomycin	bacterial 30S ribosomal subunit inhibitor				Withdrawn
dihydrotachysterol	vitamin analog	VDR	orthopedics, endocrinology	rickets, hypocalcemia, osteomalacia	Launched
dihydroxyacetone			dermatology	skin protectant	Launched
dihydroxyphenylglycine	glutamate receptor agonist	GRM1, GRM5			Preclinical
diiodothyropropionic-acid	thyroid hormone stimulant				Phase 2
dilazep	adenosine reuptake inhibitor	SLC29A1	cardiology	coronary heart disease	Launched
dilmapimod	p38 MAPK inhibitor				Phase 1
diloxanide	protein synthesis inhibitor		infectious disease	amebiasis	Launched
diltiazem	calcium channel blocker	CACNA1C, CACNA1S, CACNA2D1, CACNG1, HTR3A, KCNA5	cardiology	hypertension, angina pectoris	Launched
DIM-C-pPhCO2Me	nuclear receptor antagonist				Preclinical
dimaprit	histamine receptor agonist	HRH2, HRH3, HRH4			Preclinical
dimemorfan	sigma receptor agonist	SIGMAR1	pulmonary	cough suppressant	Launched
dimenhydrinate	histamine receptor antagonist	HRH1	neurology/psychiatry, gastroenterology	motion sickness, nausea, vomiting	Launched
dimercaprol	chelating agent		neurology/psychiatry	metal toxicity	Launched
dimercaptosuccinic-acid	chelating agent	DNMT1	neurology/psychiatry	metal toxicity	Launched
dimesna	tubulin polymerization inhibitor				Phase 3
dimethadione	oxazolidine antiepileptic				Preclinical
dimethicone			dermatology	cosmetic	Launched
dimethindene-(S)-(+)	acetylcholine receptor antagonist	HRH1			Preclinical
dimethisoquin	local anesthetic		neurology/psychiatry	local anesthetic	Launched
dimethyl-fumarate	nuclear factor erythroid derived, like (NRF2) activator	KEAP1	neurology/psychiatry	multiple sclerosis	Launched
dimethyl-isosorbide	cosmetic moisturizer				Preclinical
dimetindene	cholinergic receptor antagonist, histamine receptor antagonist	HRH1	allergy	allergic rhinitis	Launched
dimetridazole	bacterial DNA inhibitor		infectious disease	protozoan infection	Launched
diminazene-aceturate	angiotensin converting enzyme activator	AOC1, PRDX5, PRSS1			Phase 3
dimpylate	acetylcholinesterase inhibitor	ACHE	infectious disease	flea control	Launched
dinaciclib	CDK inhibitor	CDK1, CDK2, CDK5, CDK9			Phase 3
dinitolmide			infectious disease	coccidiosis	Launched
dinoprost	prostacyclin analog	PTGDR, PTGDR2, PTGER1, PTGER2, PTGER3, PTGER4, PTGFR, TBXA2R	obstetrics/gynecology	labor induction	Launched
dinoprostone	prostanoid receptor agonist	CATSPER1, CATSPER2, CATSPER3, CATSPER4, PTGDR, PTGDR2, PTGER1, PTGER2, PTGER3, PTGER4, PTGFR, TBXA2R			Withdrawn
dioscin	apoptosis stimulant	CXCR3			Preclinical
diosgenin	steroid				Preclinical
diosmetin	aryl hydrocarbon receptor agonist	CYP1B1	dermatology	cosmetic	Launched
diosmin	aryl hydrocarbon receptor agonist, capillary stabilizing agent	AHR	cardiology, hematology, dermatology	chronic venous insufficiency (CVI), edema, deep vein thrombosis (DVT), statis dermatitis, heavy leg syndrome	Launched
dioxybenzone	topical sunscreen agent				Preclinical
dipeptamin					Launched
diperodon	local anesthetic				Preclinical
diphemanil	acetylcholine receptor antagonist	CHRM3	neurology/psychiatry	spasms	Launched
diphencyprone	immunostimulant				Phase 2
diphenhydramine	histamine receptor antagonist	HRH1	neurology/psychiatry	headache	Launched
diphenidol	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4	neurology/psychiatry	vertigo	Launched
diphenyleneiodonium	nitric oxide synthase inhibitor	NOS2, NOS3			Preclinical
diphenylguanidine					Preclinical
diphenylpyraline	dopamine reuptake inhibitor	HRH1, SLC6A3	allergy	allergic rhinitis	Launched
dipivefrine	adrenergic receptor agonist		ophthalmology	glaucoma, intraocular pressure	Launched
dipraglurant	glutamate receptor negative allosteric modulator	GRM5			Phase 2
DIPT	dopamine reuptake inhibitor, serotonin reuptake inhibitor	HTR1A, HTR2A, HTR2C			Launched
dipyridamole	phosphodiesterase inhibitor	ADA, PDE10A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE6A, PDE6B, PDE6C, PDE6D, PDE6G, PDE6H, PDE7A, PDE7B, PDE8A, PDE8B, PDE9A, SLC29A1	cardiology	coronary artery disease (CAD), peripheral artery disease (PAD), hypertension	Launched
dipyrocetyl	chelating agent		endocrinology, neurology/psychiatry	fever, pain relief	Launched
diquafosol	purinergic receptor activator				Phase 3
dirithromycin	bacterial 50S ribosomal subunit inhibitor		pulmonary	bronchitis	Launched
diroximel-fumarate	anti-inflammatory agent				Phase 3
disodium-sebacate		HBB			Phase 1
disopyramide	sodium channel blocker	CHRM1, CHRM2, CHRM3, KCND2, KCND3, KCNH2, SCN5A	cardiology	ventricular tachycardia (VT), ventricular arrhythmias	Launched
disulfiram	aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist	ALDH2, DBH	neurology/psychiatry	abstinence from alcohol	Launched
dithranol	DNA synthesis inhibitor		dermatology	psoriasis	Launched
ditiocarb-sodium-trihydrate	immunostimulant	CA1, CA2, CA4			Phase 3
ditolylguanidine	sigma receptor agonist	GRIN1, GRIN2A, GRIN2B, SIGMAR1			Preclinical
dixanthogen					Preclinical
dixyrazine	antipsychotic				Preclinical
dizocilpine-(+)	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			Preclinical
dizocilpine-(-)	glutamate receptor antagonist				Phase 1
DMAB-anabaseine	adrenergic receptor agonist	CHRNA7			Preclinical
DMeOB	glutamate receptor modulator	GRM5			Preclinical
DMH1	ALK tyrosine kinase receptor inhibitor	ACVR1			Preclinical
DMH4	VEGFR inhibitor	KDR			Preclinical
DMNB	DNA dependent protein kinase inhibitor				Preclinical
DMP-543	acetylcholine release enhancer				Phase 2
DMP-777	elastase inhibitor	MPO			Phase 2
DMPS	chelating agent				Phase 1
DMSO	control vehicle				Preclinical
DNQX	glutamate receptor antagonist	GRIA1, GRIA2, GRIK1, GRIN1, GRIN2A, GRIN2B			Preclinical
dobutamine	adrenergic receptor agonist	ADRB1, ADRB2	cardiology	congestive heart failure	Launched
docebenone	lipoxygenase inhibitor	ALOX5			Phase 2
docetaxel	tubulin polymerization inhibitor	BCL2, MAP2, MAP4, MAPT, NR1I2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)	Launched
doconexent	PPAR receptor agonist	FFAR1, PTGS1, PTGS2			Launched
doconexent-ethyl-ester	omega 3 fatty acid stimulant		endocrinology	hypertriglyceridemia	Launched
docosanol	lipase clearing factor inhibitor	TLR7	dental	cold sore	Launched
docusate	laxative		gastroenterology	constipation	Launched
dodecyl-sulfate		LYZ			Preclinical
dofequidar	MRP inhibitor, P glycoprotein inhibitor	ABCB1			Phase 3
dofetilide	potassium channel blocker	KCNH1, KCNH2, KCNJ12, KCNK2			Withdrawn
dolasetron	serotonin receptor antagonist	HTR3A	gastroenterology	nausea, vomiting	Launched
dolastatin-10	tubulin polymerization inhibitor	TUBB			Phase 2
dolutegravir	HIV integrase inhibitor	CYP3A4, CYP3A5, CYP3A7, POU2F2, UGT1A1	infectious disease	human immunodeficiency virus (HIV-1)	Launched
domiphen					Preclinical
domperidone	dopamine receptor antagonist	DRD2, DRD3	infectious disease	fescue toxicosis	Launched
donepezil	acetylcholinesterase inhibitor	ACHE	neurology/psychiatry	Alzheimer's disease	Launched
donitriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR5A, HTR6			Phase 2
dopamine	dopamine receptor agonist	DBH, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR7, SLC6A2, SLC6A3, SLC6A4	cardiology, neurology/psychiatry	ventricular arrhythmias, depression, headache, tremors	Launched
doramapimod	p38 MAPK inhibitor	MAPK11, MAPK12, MAPK13, MAPK14			Phase 2
doramectin			infectious disease	gastrointestinal roundworms	Launched
doravirine	non-nucleoside reverse transcriptase inhibitor				Launched
doripenem	bacterial cell wall synthesis inhibitor	DPEP1	infectious disease	intra-abdominal infections, urinary tract infections, pyelonephritis	Launched
dorsomorphin	AMPK inhibitor	ACVR1, BMPR1A, BMPR1B, EPHA2, FKBP1A, FLT1, FLT3, KDR, LCK, MKNK1, PRKAA1, RPS6KA1, SRC			Preclinical
dorzolamide	carbonic anhydrase inhibitor	CA1, CA12, CA14, CA2, CA4, CA7	ophthalmology	intraocular pressure, glaucoma	Launched
dosulepin	norepinephrine reuptake inhibitor, serotonin–norepinephrine reuptake inhibitor (SNRI), tricyclic antidepressant	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, SLC6A2, SLC6A4	neurology/psychiatry	depression	Launched
DOTMP					Preclinical
dovitinib	EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB			Phase 3
doxapram	potassium channel blocker		pulmonary, neurology/psychiatry	respiratory depression, central nervous system depression, acute hypercapnia (AHC)	Launched
doxazosin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D	urology, cardiology	benign prostatic hyperplasia (BPH), hypertension	Launched
doxepin	histamine receptor antagonist	HRH1, SLC6A2, SLC6A4	neurology/psychiatry	depression, anxiety	Launched
doxercalciferol	vitamin D receptor agonist	VDR	nephrology, endocrinology	chronic kidney disease (CKD), hyperparathyroidism	Launched
doxifluridine	thymidylate synthase inhibitor	TYMS	oncology	colorectal cancer	Launched
doxofylline	adenosine receptor antagonist	ADORA1, PDE4A, PDE4B, PDE4C, PDE4D	pulmonary	asthma	Launched
doxorubicin	topoisomerase inhibitor	TOP2A	hematologic malignancy, oncology	acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilm's tumor, breast cancer, ovarian cancer, Hodgkin's lymphoma, bladder cancer, multiple myeloma	Launched
doxycycline	bacterial 30S ribosomal subunit inhibitor, metalloproteinase inhibitor	MMP8	dental	periodontitis	Launched
doxylamine	histamine receptor antagonist	HRH1	neurology/psychiatry	sedative	Launched
DpC					Phase 1
DPC-681	HIV protease inhibitor				Phase 1
DPCPX	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Phase 1
DPI-201106	sodium channel activator	ADRB2			Phase 2
DPO-1	potassium channel blocker	KCNA5			Preclinical
DPPE	histamine receptor antagonist	ABCB1, HRH1			Phase 3
DQP-1105	glutamate receptor antagonist	GRIN2C, GRIN2D			Preclinical
DR-2313	PARP inhibitor	PARP1, PARP3			Preclinical
DR-4485	serotonin receptor antagonist	HTR7			Preclinical
DRF053-(R)	CDK inhibitor	CSNK1A1			Preclinical
drofenine			neurology/psychiatry	spasms	Launched
droloxifene	selective estrogen receptor modulator (SERM)	ESR1			Phase 3
dromostanolone-propionate	androgen receptor modulator	AR	oncology	breast cancer	Launched
dronedarone	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, KCNA5, KCNH2, KCNK2, SCN1A	cardiology	atrial fibrillation (AF)	Launched
droperidol	dopamine receptor antagonist	ADRA1A, DRD2, DRD3, DRD4, HTR2A	gastroenterology	nausea, vomiting	Launched
dropropizine	antitussive		pulmonary	cough suppressant	Launched
drospirenone	mineralocorticoid receptor antagonist	AR, NR3C2, PGR	endocrinology	contraceptive	Launched
drotaverine	phosphodiesterase inhibitor		obstetrics/gynecology	labor induction	Launched
droxicam	cyclooxygenase inhibitor	PTGS1	rheumatology	rheumatoid arthritis, osteoarthritis	Launched
droxidopa	norepinephrine precursor	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH	cardiology, neurology/psychiatry	hypertension, Parkinson's Disease	Launched
droxinostat	HDAC inhibitor	HDAC6, HDAC8			Preclinical
DSM265	dihydroorotate dehydrogenase inhibitor				Phase 2
DSPC					Preclinical
DSR-6434	toll-like receptor agonist	TLR7			Preclinical
DS2-(806622)					Preclinical
DU-728	structural glycoprotein antagonist	ITGA2B, ITGB3			Phase 1
duloxetine	norepinephrine reuptake inhibitor, serotonin–norepinephrine reuptake inhibitor (SNRI)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression, generalized anxiety disorder (GAD), muscle pain, peripheral neuropathy	Launched
DUP-697	cyclooxygenase inhibitor	PTGS2			Phase 1
dutasteride	5 alpha reductase inhibitor	SRD5A1, SRD5A2, SRD5A3	urology	benign prostatic hyperplasia (BPH)	Launched
duvelisib	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			Launched
DVD-111					Phase 2
DWK-1339	beta amyloid aggregation inhibitor				Preclinical
dyclonine	sodium channel blocker	SCN10A, SCN5A	neurology/psychiatry	local anesthetic	Launched
dydrogesterone	progesterone receptor agonist	PGR	obstetrics/gynecology	infertility	Launched
dynasore	dynamin inhibitor	DNM1, DNM1L, DNM2			Preclinical
dynole-34-2	dynamin inhibitor	DNM1			Preclinical
dyphylline	adenosine receptor antagonist, phosphodiesterase inhibitor	PDE4A	pulmonary	asthma, bronchitis, emphysema	Launched
DY131	estrogen-related receptor agonist	ESRRB, ESRRG			Preclinical
D609	phospholipase inhibitor				Preclinical
E-2001	antioxidant				Preclinical
E-2012	gamma secretase modulator	APH1A, APH1B, PSENEN			Phase 1
E-4031	potassium channel blocker	KCNH1, KCNH2			Phase 1
E-64	calpain inhibitor, cysteine protease inhibitor	CTSS			Preclinical
eact	calcium-activated chloride channel inhibitor	ANO1			Preclinical
EB-47	PARP inhibitor	PARP1			Preclinical
ebastine	histamine receptor antagonist	CYP3A4, HRH1	allergy	allergic rhinitis, urticaria	Launched
EBPC	aldose reductase inhibitor	AKR1B1			Preclinical
ebrotidine	histamine receptor antagonist	HRH2			Withdrawn
ebselen	cyclooxygenase inhibitor, glutathione peroxidase agonist, H+/K+-ATPase inhibitor, nitric oxide synthase inhibitor	ALB			Phase 2/Phase 3
EC-144	HSP inhibitor	HSP90AA1, HSP90AB1			Preclinical
EC-23	retinoid receptor agonist	RARA, RARB, RARG			Preclinical
ecabapide					Phase 3
ecabet	gastrin inhibitor, urease inhibitor	NOXO1	ophthalmology	dry eye syndrome	Launched
ecamsule-triethanolamine			dermatology	skin protectant, sunscreen lotion	Launched
echinomycin	DNA intercalating agent				Phase 2
econazole	lanosterol demethylase inhibitor, sterol demethylase inhibitor	NPY1R, NPY2R, TRPM2, TRPV5	infectious disease	tinea pedis, tinea cruris, tinea corporis, tinea versicolor, cutaneous candidiasis	Launched
ectoine	anti-inflammatory agent				Launched
edaglitazone	PPAR receptor agonist	PPARG			Phase 2
edaravone	nootropic agent	BCL2	neurology/psychiatry	stroke	Launched
edasalonexent	NFkB pathway inhibitor				Phase 3
edelfosine	phospholipase inhibitor				Phase 2
editol					Preclinical
EDO-S101	HDAC inhibitor				Phase 1/Phase 2
edonerpic-maleate	beta amyloid inhibitor				Preclinical
edoxaban	coagulation factor inhibitor	F10	neurology/psychiatry, hematology, cardiology	stroke, pulmonary embolism (PE), systemic embolism, deep vein thrombosis (DVT), atrial fibrillation (AF)	Launched
edoxudine	DNA directed DNA polymerase inhibitor		infectious disease	virus herpes simplex (HSV)	Launched
edrophonium	acetylcholinesterase inhibitor	ACHE, BCHE	neurology/psychiatry	myasthenia gravis	Launched
EDTMP	chelating agent				Preclinical
EED226	polycomb protein inhibitor	EED			Preclinical
efaproxiral	hemoglobin oxygen release stimulant	HBA1, HBB			Phase 3
efaroxan	adrenergic receptor antagonist	ADORA2A			Phase 2
efatutazone	PPAR receptor agonist	PPARG			Phase 2
efavirenz	HIV protease inhibitor	CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	Launched
efinaconazole	lanosterol demethylase inhibitor	CYP51A1	infectious disease	onychomycosis	Launched
efletirizine	antihistamine				Phase 3
eflornithine	ornithine decarboxylase inhibitor	ARG2, ODC1	dermatology	facial hair reduction	Launched
efloxate	vasodilator				Preclinical
efonidipine	calcium channel blocker		cardiology	hypertension	Launched
EF5	cytochrome P450 activator				Phase 2
EGF816	EGFR inhibitor	EGFR			Phase 2
eglumetad	glutamate receptor agonist	GRM2, GRM3, GRM6, GRM8			Phase 2
EG00229	neuropilin receptor antagonist	NRP1			Preclinical
EHop-016	Ras GTPase inhibitor	RAC1, RAC3			Preclinical
EIPA	sodium/hydrogen exchanger inhibitor, transient receptor potential polycystic inhibitor	ADRA2A, ASIC1, PKD2L1			Preclinical
EIT-hydrobromide	nitric oxide synthase inhibitor	NOS2, NOS3			Preclinical
EI1	histone lysine methyltransferase inhibitor	EZH2			Preclinical
elacestrant	estrogen receptor degrader				Phase 3
elacridar	P glycoprotein inhibitor	ABCB1			Phase 1
elactocin	exportin antagonist	XPO1			Phase 1
elacytarabine	antineoplastic agent	DCK			Phase 3
elafibranor	PPAR receptor agonist	PPARA, PPARD, PPARG			Phase 3
elagolix	gonadotropin releasing factor hormone receptor antagonist	GNRHR			Launched
elbasvir	HCV inhibitor		infectious disease	hepatitis C	Launched
eldecalcitol	bone formation stimulant	VDR			Phase 3
eleclazine	late sodium current inhibitor				Phase 3
elemene	VEGFR inhibitor				Phase 3
elesclomol	oxidative stress inducer	HSPA1A			Phase 3
eletriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR7	neurology/psychiatry	migraine headache	Launched
eliglustat	glycosyl transferase inhibitor	UGCG	hematology	Gaucher disease	Launched
elinogrel	purinergic receptor antagonist	P2RY12			Phase 2
eliprodil	glutamate receptor antagonist	GRIN1, GRIN2B			Phase 3
ellagic-acid	glutathione transferase inhibitor, non-nucleoside reverse transcriptase inhibitor	CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CSNK2A1, GSK3B, PRKACA, PRKCA, PRKCB, SQLE, SYK			Phase 2
ELN-441958	bradykinin receptor antagonist	BDKRB1			Preclinical
eltanexor	exportin inhibitor				Preclinical
eltanolone	GABA receptor positive allosteric modulator	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB2, GABRG2			Phase 3
eltoprazine	serotonin receptor agonist	HTR1A, HTR1B			Phase 2
eltrombopag	thrombopoietin receptor agonist	MPL	hematology, infectious disease	anemia, hepatitis C, thrombocytopenia	Launched
eluxadoline	opioid receptor agonist, opioid receptor antagonist	OPRD1, OPRK1, OPRM1	gastroenterology	irritable bowel syndrome	Launched
elvitegravir	HIV integrase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	Launched
emamectin	GABA receptor agonist				Preclinical
embelin	HCV inhibitor, XIAP inhibitor	XIAP			Preclinical
EMD-1214063	hepatocyte growth factor receptor inhibitor	MET			Phase 2
EMD-386088	serotonin receptor agonist	HTR6			Preclinical
EMD-53998	phosphodiesterase inhibitor	TNNC1			Phase 1
EMD-66684	angiotensin receptor antagonist	AGTR1			Preclinical
EMD534085	kinesin inhibitor				Preclinical
emedastine	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	Launched
emeramide	antioxidant				Phase 2
emetine	protein synthesis inhibitor	RPS2			Phase 2
emiglitate	alpha glucoside inhibitor				Preclinical
emixustat	retinoid isomerohydrolase inhibitor				Phase 3
emodepside	nematocide				Phase 1
emodin	11-beta hydroxysteroid dehydrogenase inhibitor	CSNK2A1			Preclinical
emorfazone	anti-inflammatory agent, cyclooxygenase inhibitor		dental	mouth inflammation	Launched
emoxipin					Phase 3
empagliflozin	sodium/glucose cotransporter inhibitor	SLC5A1, SLC5A2	endocrinology	diabetes mellitus	Launched
emricasan	caspase inhibitor	CASP1, CASP3, CASP7			Phase 2
emtricitabine	nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	Launched
enalapril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, congestive heart failure, left ventricular systolic dysfunction (LVSD)	Launched
enalaprilat	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	Launched
enasidenib	isocitrate dehydrogenase inhibitor	IDH1	hematologic malignancy	acute myeloid leukemia (AML)	Launched
enbucrilate			dermatology	skin lacerations, tissue adhesive	Launched
enciprazine	GABA receptor modulator	GABRA1			Phase 3
encorafenib	RAF inhibitor	BRAF	oncology	melanoma	Launched
endo-IWR-1	PARP inhibitor	TNKS, TNKS2			Preclinical
endoxifen	estrogen receptor antagonist	ESR1			Phase 2
enflurane	membrane permeability inhibitor	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9	neurology/psychiatry	anesthetic	Launched
enilconazole	sterol demethylase inhibitor	CYP19A1, CYP1A2, CYP2B6, CYP2C9, CYP2J2, CYP3A4, CYP3A5, NR1I2, PPARA, PTGER2	infectious disease	skin infections	Launched
eniluracil	dihydropyrimidine dehydrogenase inhibitor	AOX1, DPYD, XDH			Phase 3
eniporide	sodium/hydrogen antiport inhibitor				Preclinical
enisamium-iodide					Launched
ENMD-2076	Aurora kinase inhibitor, FLT3 inhibitor, VEGFR inhibitor	AURKA, FLT3, KDR, PDGFRA, PTK2, SRC			Phase 2
enocitabine	DNA synthesis inhibitor	CMPK1, RRM1, TYMS	hematologic malignancy	acute myeloid leukemia (AML)	Launched
enoxacin	topoisomerase inhibitor	TOP2A	infectious disease	urinary tract infections, gonorrhea	Launched
enoximone	phosphodiesterase inhibitor	PDE3A	cardiology	congestive heart failure	Launched
enoxolone	gap junction modulator	HSD11B1	gastroenterology, otolaryngology	peptic ulcer disease (PUD), common cold	Launched
enprofylline	phosphodiesterase inhibitor	ADORA1, ADORA2A, ADORA2B, ADORA3, PDE4A, PDE4B			Phase 3
enrofloxacin	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	Launched
entacapone	catechol O methyltransferase inhibitor	COMT	neurology/psychiatry	Parkinson's Disease	Launched
entasobulin	tubulin polymerization inhibitor				Preclinical
entecavir	DNA replication inhibitor, nucleoside reverse transcriptase inhibitor		infectious disease	hepatitis B	Launched
entinostat	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC9			Phase 3
entrectinib	ALK tyrosine kinase receptor inhibitor, proto-oncogene tyrosine protein kinase inhibitor	ALK, NTRK1, NTRK2, NTRK3, ROS1	oncology	non-small cell lung cancer (NSCLC)	Launched
enzalutamide	androgen receptor antagonist	AR	oncology	prostate cancer	Launched
enzastaurin	PKC inhibitor	AKT1, GSK3B, PRKCA, PRKCB, PRKCD, PRKCG			Phase 3
EN460	endoplasmic reticulum oxidation inhibitor	ERO1A			Preclinical
EO-1428	p38 MAPK inhibitor	MAPK11, MAPK14			Preclinical
epacadostat	indoleamine 2,3-dioxygenase inhibitor	IDO1			Phase 3
epalrestat	aldose reductase inhibitor	AKR1B1	nephrology	diabetic nephropathy	Launched
eperezolid	bacterial 30S ribosomal subunit inhibitor				Phase 1
eperisone	acetylcholine receptor antagonist	CYP2J2	neurology/psychiatry	amyotrophic lateral sclerosis (ALS), spasms, head injury, spinal injury	Launched
epetraborole	leucyl-tRNA synthetase inhibitor				Preclinical
ephedrine	adrenergic receptor agonist	ACHE, ADRA1A, ADRB2, SLC18A2, SLC6A2	cardiology, pulmonary, neurology/psychiatry, endocrinology	hypotension, asthma, narcolepsy, obesity	Launched
ephedrine-(racemic)	adrenergic receptor agonist	ADRA1A, ADRA2A, ADRB1, ADRB2, ATF1, ATF2, ATF3, ATF4, ATF5, ATF6, ATF7, FOS, IL2, JDP2, JUN, NFATC1, SLC6A2, SLC6A3, SLC6A4, TNF	cardiology, pulmonary, neurology/psychiatry, endocrinology	hypotension, asthma, narcolepsy, obesity	Launched
epiandrosterone	steroid	G6PD			Preclinical
epicatechin-gallate-(-)	bacterial DNA gyrase inhibitor	BACE1, FASN			Phase 2
epiestriol					Preclinical
epigallocatechin-(-)					Phase 2
epigallocatechin-gallate-(-)	bacterial DNA gyrase inhibitor	ELANE, EP300, FASN, KAT2B, MMP14, MMP2			Phase 2/Phase 3
epinastine	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	Launched
epinephrine	adrenergic receptor agonist, carbonic anhydrase activator, neurotransmitter	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, TNF	cardiology, allergy, pulmonary	cardiac arrest, anaphylactic shock, asthma	Launched
epirizole	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	Launched
epirubicin	topoisomerase inhibitor	CHD1, TOP2A	oncology	breast cancer	Launched
epitiostanol	androgen receptor agonist	AR	oncology	breast cancer	Launched
eplerenone	cytochrome P450 inhibitor	NR3C2	cardiology	congestive heart failure, hypertension	Launched
epomediol	cholesterol inhibitor	CYP7A1	neurology/psychiatry	itching	Launched
epoprostenol	prostacyclin analog	P2RY12, PTGER1, PTGER4, PTGIR, PTGIS	cardiology	hypertension	Launched
epothilone-A	microtubule stabilizing agent				Preclinical
epothilone-B	microtubule stabilizing agent, tubulin polymerization inhibitor	TUBB			Phase 3
epothilone-D	microtubule stabilizing agent, tubulin polymerization inhibitor	TUBB			Phase 2
EPPTB	trace amine associated receptor antagonist	TAAR1			Preclinical
eprazinone	mucolytic agent		pulmonary	bronchospasm	Launched
eprinomectin	benzodiazepine receptor agonist		infectious disease	gastrointestinal roundworms, lungworms	Launched
epristeride	5 alpha reductase inhibitor				Preclinical
eprobemide	monoamine oxidase inhibitor	MAOA	neurology/psychiatry	depression	Launched
eprodisate	amyloid protein inhibitor, antiamyloidogenic agent	SAA1			Phase 3
eprosartan	angiotensin receptor antagonist	AGTR1	cardiology	hypertension	Launched
eptifibatide	platelet aggregation inhibitor	ITGA2B, ITGB3	cardiology	acute coronary syndrome (ACS), percutaneous coronary intervention (PCI)	Launched
EPZ-5676	histone lysine methyltransferase inhibitor	DOT1L			Phase 1
EPZ004777	histone lysine methyltransferase inhibitor	DOT1L			Preclinical
EPZ005687	histone lysine methyltransferase inhibitor	EZH2			Preclinical
EPZ011989	histone lysine methyltransferase inhibitor	EZH2			Preclinical
EPZ015666	protein arginine N-methyltransferase inhibitor	PRMT5			Preclinical
EPZ020411	protein arginine N-methyltransferase inhibitor	PRMT6			Preclinical
equilin	estrogen receptor agonist	HSD17B1			Preclinical
equol	estrogen receptor agonist	ESR1, ESR2			Launched
ER-27319	mediator release inhibitor, SYK inhibitor	SYK			Preclinical
ER-50891	retinoid receptor antagonist	RARA			Preclinical
erastin	ion channel antagonist	VDAC2			Preclinical
eravacycline	antibacterial				Launched
erbstatin-analog	EGFR inhibitor, tyrosine kinase inhibitor	EGFR			Preclinical
ercalcitriol	vitamin D receptor agonist	VDR			Phase 1
erdafitinib	FGFR inhibitor	FGFR1, FGFR2, FGFR3, FGFR4			Launched
erdosteine	mucolytic agent		pulmonary, infectious disease	bronchitis, cough suppressant, chronic obstructive pulmonary disease (COPD), respiratory tract infections	Launched
ergocalciferol	vitamin analog	VDR	endocrinology, orthopedics	hypoparathyroidism, rickets, hypophosphatemia	Launched
ergonovine	adrenergic receptor agonist, serotonin receptor agonist	ADRA1A, HTR1E	hematology	postpartum hemorrhage (PPH)	Launched
ergosterol	vitamin D precursor				Preclinical
ergotamine	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, DRD1, DRD2, DRD5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, SLC6A2	neurology/psychiatry	migraine headache	Launched
eribulin	microtubule inhibitor		oncology	breast cancer	Launched
ERK5-IN-1	MAP kinase inhibitor	MAPK7			Preclinical
erlotinib	EGFR inhibitor	EGFR, NR1I2	oncology	non-small cell lung cancer (NSCLC), pancreatic cancer	Launched
ertapenem	bacterial cell wall synthesis inhibitor		infectious disease	intra-abdominal infections, skin infections, pneumonia, urinary tract infections, gynecologic infections, postpartum endomyometritis	Launched
erteberel	estrogen receptor agonist	ESR1, ESR2			Phase 2
ertugliflozin	sodium/glucose cotransporter inhibitor	SLC5A2	endocrinology	diabetes mellitus	Launched
erythritol					Launched
erythromycin	NFkB pathway inhibitor	MLNR	infectious disease	listeria, respiratory tract infections, skin infections, syphilis, amebiasis, pelvic inflammatory disease, chlamydia, diphtheria, erythrasma	Launched
erythromycin-estolate	bacterial 50S ribosomal subunit inhibitor	ABCB1, ALB, CYP3A4, CYP51A1, KCNH2, MLNR, SLC47A1	infectious disease	listeria, respiratory tract infections, skin infections, syphilis, amebiasis, pelvic inflammatory disease, chlamydia, diphtheria, erythrasma	Launched
erythromycin-ethylsuccinate	cytochrome P450 inhibitor, protein synthesis inhibitor	ABCB1, ALB, CYP3A4, CYP51A1, KCNH2, MLNR, SLC47A1	infectious disease	listeria, respiratory tract infections, skin infections, syphilis, amebiasis, pelvic inflammatory disease, chlamydia, diphtheria, erythrasma	Launched
erythrosine	coloring agent				Preclinical
esaprazole					Phase 2
esaxerenone	mineralocorticoid receptor antagonist				Preclinical
escin	nitric oxide synthase stimulant		dermatology	varicose veins	Launched
escitalopram	selective serotonin reuptake inhibitor (SSRI)	SLC6A4	neurology/psychiatry	depression, generalized anxiety disorder (GAD)	Launched
esculin	antioxidant				Phase 1
eseroline-(-)	acetylcholinesterase inhibitor	OPRD1, OPRM1			Preclinical
ESI-09	EPAC inhibitor	RAPGEF3, RAPGEF4			Preclinical
eslicarbazepine-acetate	sodium channel blocker	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	Launched
esmolol	adrenergic receptor antagonist	ADRB1	cardiology	ventricular tachycardia (VT), hypertension	Launched
esomeprazole	ATPase inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, peptic ulcer disease (PUD)	Launched
esonarimod	antirheumatic drug				Preclinical
estetrol	selective estrogen receptor modulator (SERM)	ESR1			Phase 3
estradiol	estrogen receptor agonist	ESR1, ESR2, GPER1, KCNMA1, NR1I2	endocrinology	contraceptive	Launched
estradiol-acetate	estrogen receptor agonist	ESR1	endocrinology, obstetrics/gynecology	menopause, vaginal atrophy	Launched
estradiol-benzoate	contraceptive agent	ESR1			Preclinical
estradiol-cypionate	estrogen receptor agonist	ESR1	endocrinology	hypoestrogenism, menopause	Launched
estradiol-valerate	estrogen receptor agonist	ESR1	oncology, endocrinology, obstetrics/gynecology	prostate cancer, hypoestrogenism, menopause, vaginal atrophy	Launched
estradiol-3-O-sulfamate	steryl sulfatase inhibitor				Phase 2
estramustine	DNA alkylating agent	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	Launched
estramustine-phosphate	DNA synthesis inhibitor, microtubule inhibitor	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	Launched
estriol	estrogen receptor agonist	ESR1, ESR2	endocrinology, obstetrics/gynecology, infectious disease	menopause, vaginal atrophy, urinary tract infections	Launched
estrone	estrogen receptor agonist, estrogenic hormone	ESR1, ESR2	endocrinology	menopause	Launched
estropipate	estrogen receptor agonist	ESR1, ESR2	orthopedics, endocrinology, obstetrics/gynecology	osteoporosis, menopause, vaginal atrophy, hypoestrogenism	Launched
etacrynic-acid	sodium/potassium/chloride transporter inhibitor	ATP1A1, SLC12A1	cardiology, gastroenterology, nephrology, rheumatology	hypertension, congestive heart failure, edema, hepatic cirrhosis, chronic renal failure, nephrotic syndrome	Launched
etafenone	calcium channel blocker				Launched
etamsylate	hemostatic agent		hematology	hemorrhage	Launched
etanidazole	bacterial cell wall synthesis inhibitor				Phase 3
etazolate	phosphodiesterase inhibitor	GABRB3, PDE4A			Phase 2
ETC-159	beta catenin inhibitor, porcupine inhibitor	PORCN			Phase 1
ETC-206	MAPK-interacting kinase inhibitor				Phase 1
etebenecid	uricosuric blocker				Preclinical
eterobarb	anticonvulsant				Phase 2
ethacizin	anticonvulsant		cardiology	ventricular tachycardia (VT), Wolff-Parkinson-White Syndrome (WPW)	Launched
ethacridine-lactate-monohydrate	DNA intercalating agent				Preclinical
ethambutol	bacterial cell wall synthesis inhibitor		infectious disease	tuberculosis	Launched
ethamivan	respiratory stimulant				Preclinical
ethanolamine-oleate	immunostimulant	F12, FABP4, FFAR1, FFAR4, PLD2	gastroenterology	esophageal varices	Launched
ethaverine	calcium channel blocker		neurology/psychiatry	muscle relaxant, spasms	Launched
ethenzamide	analgesic agent		neurology/psychiatry, endocrinology, otolaryngology	headache, fever, common cold	Launched
ethimizol					Phase 1
ethinyl-estradiol	estrogen receptor agonist, estrogenic hormone	ESR1, ESR2, NR1I2	endocrinology	contraceptive	Launched
ethionamide	mycolic synthesis inhibitor		infectious disease	tuberculosis	Launched
ethisterone	progestogen hormone	TYR	endocrinology	amenorrhea	Launched
ethopabate	antiprotozoal agent		infectious disease	coccidiosis	Launched
ethosuximide	succinimide antiepileptic	CACNA1G, CACNA1H, CACNA1I	neurology/psychiatry	epilepsy	Launched
ethotoin	hydantoin antiepileptic	SCN5A	neurology/psychiatry	seizures	Launched
ethoxyquin	antioxidant				Preclinical
ethoxzolamide	carbonic anhydrase inhibitor	CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9	ophthalmology, gastroenterology	glaucoma, duodenal ulcer disease	Launched
ethyl-paraben					Preclinical
ethyl-pyruvate	tumor necrosis factor production inhibitor				Phase 2
ethyl-vanillin					Preclinical
ethyl-2-(carbamoyloxy)benzoate					Phase 1
ethylenediaminetetraacetic-acid	PKC inhibitor		neurology/psychiatry	metal toxicity	Launched
ethylnorepinephrine	bronchodilator				Preclinical
ethynodiol-diacetate		ESR1, PGR	endocrinology	contraceptive	Launched
ethynylcytidine	antimetabolite				Preclinical
eticlopride	dopamine receptor antagonist	DRD2, DRD3, DRD4			Preclinical
etidronic-acid	bone resorption inhibitor	ATP6V1A, PTPRS	endocrinology, orthopedics	Paget's disease, heterotopic ossification	Launched
etifenin	renal function diagnostic agent				Preclinical
etifoxine	GABA receptor modulator	GABRA1, GABRA2, GABRA3, GABRA5	neurology/psychiatry	anxiety	Launched
etilefrine	adrenergic receptor agonist	ADRA1A, ADRB1	neurology/psychiatry, otolaryngology, endocrinology, pulmonary	headache, nasal congestion, fever, cough suppressant, common cold	Launched
etilevodopa	dopamine receptor agonist	DRD3			Phase 3
etizolam	benzodiazepine receptor agonist	GABRA1	neurology/psychiatry	insomnia, anxiety	Launched
etodolac	cyclooxygenase inhibitor	PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	Launched
etofenamate	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry, rheumatology	muscle pain, joint pain	Launched
etofibrate	PPAR receptor agonist	PPARA	endocrinology	hypertriglyceridemia	Launched
etofylline	adenosine receptor antagonist	ADORA1	pulmonary	asthma, bronchitis	Launched
etofylline-clofibrate	platelet aggregation inhibitor	PPARA	endocrinology	hyperlipidemia	Launched
etomidate	GABA receptor modulator	ADRA2B, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ	neurology/psychiatry	general anaesthetic	Launched
etomoxir	carnitine palmitoyltransferase inhibitor	CPT1A			Phase 2
etonogestrel	progesterone receptor agonist	ESR1, PGR	endocrinology	contraceptive	Launched
etoposide	topoisomerase inhibitor	TOP2A, TOP2B	oncology	non-small cell lung cancer (NSCLC)	Launched
etoposide-phosphate	topoisomerase inhibitor	TOP2A	oncology	testicular carcinoma, small cell lung cancer	Launched
etoricoxib	cyclooxygenase inhibitor	PTGS2	rheumatology	rheumatoid arthritis, psoriatic arthritis, osteoarthritis, gout, ankylosing spondylitis	Launched
etosalamide	anti-inflammatory agent				Preclinical
etoxybamide					Phase 2
ETP-45658	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			Preclinical
ETP-46464	ATR kinase inhibitor				Preclinical
etrabamine	dopamine receptor agonist				Phase 2
etrasimod	sphingosine 1-phosphate receptor antagonist				Phase 3
etravirine	non-nucleoside reverse transcriptase inhibitor	CYP2C19, CYP2C9, CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	Launched
etretinate	protein synthesis inhibitor	RARA, RXRG			Withdrawn
eucalyptol	acetylcholinesterase inhibitor	ACHE	dental	gingivitis	Launched
eucatropine	acetylcholine receptor antagonist				Preclinical
eugenol	androgen receptor antagonist	AR	dental	toothache	Launched
EUK-134	catalase stimulant	APP, SOD2			Preclinical
eupatilin	mucus protecting agent				Launched
evacetrapib	cholesteryl ester transfer protein inhibitor	CETP			Phase 3
evans-blue	glutamate receptor negative allosteric modulator	GRIA1, PTPN1			Launched
evatanepag	prostaglandin inhibitor	PTGER2, PTGER4			Phase 2
evenamide	voltage-gated sodium channel blocker				Phase 2
everolimus	mTOR inhibitor	MTOR	oncology, neurology/psychiatry, genetics, urology	breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma	Launched
evobrutinib	Bruton's tyrosine kinase (BTK) inhibitor				Phase 2
evocalcet	calcium sensitizer				Phase 3
evodiamine	ATPase inhibitor, TRPV agonist	TRPV1			Preclinical
EVP-6124	acetylcholine receptor agonist	CHRNA7			Phase 3
EVP4593	NFkB pathway inhibitor				Preclinical
EW-7197	TGF beta receptor inhibitor	ACVR1B, TGFBR1			Phase 2
EX-527	SIRT inhibitor	SIRT1			Phase 2
exalamide	membrane permeability inhibitor				Launched
examorelin	growth hormone releasing factor agonist	GHRHR, GHSR			Phase 2
exatecan-mesylate	topoisomerase inhibitor	TOP1			Phase 3
exemestane	aromatase inhibitor	CYP19A1	oncology	breast cancer	Launched
exenatide	GLP receptor agonist	GLP1R	endocrinology	diabetes mellitus	Launched
exherin	cadherin antagonist	CDH2			Phase 2
exifone	nootropic agent	TYR			Withdrawn
exisulind	phosphodiesterase inhibitor	PDE5A			Phase 3
exo-IWR-1	WNT signaling inhibitor negative control	TNKS			Preclinical
EXO-1	ARF inhibitor				Preclinical
ezatiostat	glutathione transferase inhibitor	GSTP1			Phase 2
ezetimibe	cholesterol inhibitor, Niemann-Pick C1-like 1 protein antagonist	ANPEP, NPC1L1, SOAT1	endocrinology, metabolism	hyperlipidemia, hypercholesterolemia, sitosterolemia	Launched
ezutromid	utrophin enhancer	UTRN			Phase 2
E3330	NFkB pathway inhibitor				Preclinical
E7046	prostanoid receptor antagonist				Phase 1
E7449	PARP inhibitor	PARP1, PARP2, TNKS, TNKS2			Phase 2
E7820	angiogenesis inhibitor				Phase 2
F-11440	serotonin receptor agonist	HTR1A			Phase 2
F-16915					Preclinical
fadrozole	aromatase inhibitor	CYP11B1, CYP19A1	oncology	breast cancer	Launched
fagomine	glucosidase inhibitor	GLB1			Phase 2
falecalcitriol	vitamin D receptor agonist	VDR	endocrinology	hyperparathyroidism	Launched
famciclovir	DNA polymerase inhibitor		dental, infectious disease	cold sore, genitial herpes, shingles	Launched
famotidine	histamine receptor antagonist	HRH2	gastroenterology	heartburn	Launched
famprofazone	cyclooxygenase inhibitor				Preclinical
fananserin	dopamine receptor antagonist, serotonin receptor antagonist	HTR2A			Phase 2
fanetizole	neutrophil superoxide production				Phase 3
fantofarone	calcium channel blocker				Preclinical
farampator	ionotropic glutamate receptor agonist				Preclinical
farnesyl-thiosalicylic-acid-amide	Ras GTPase inhibitor	HRAS			Phase 1
faropenem	lactamase inhibitor		infectious disease, pulmonary, otolaryngology	pneumonia, bronchitis, skin infections, urinary tract infections, sinusitis	Launched
faropenem-medoxomil	lactamase inhibitor		otolaryngology, infectious disease, pulmonary	sinusitis, pneumonia, bronchitis, skin infections, urinary tract infections	Launched
fasoracetam	GABA receptor antagonist				Preclinical
fasudil	rho associated kinase inhibitor	PKIA, PRKACA, ROCK1, ROCK2	neurology/psychiatry	cerebral vasospasm	Launched
favipiravir	RNA polymerase inhibitor				Phase 3
FCE-22250	DNA directed DNA polymerase inhibitor				Phase 1
fdcyd	DNA methyltransferase inhibitor				Phase 2
febuprol	choleretic agent				Launched
febuxostat	xanthine oxidase inhibitor	XDH	nephrology	hyperuricemia	Launched
fedratinib	FLT3 inhibitor, JAK inhibitor	BRD4, JAK1, JAK2, JAK3, TYK2	hematologic malignancy	myelofibrosis	Launched
felbamate	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B	neurology/psychiatry	epilepsy	Launched
felbinac	cyclooxygenase inhibitor	CTSL	rheumatology, neurology/psychiatry	rheumatoid arthritis, muscle pain	Launched
felbinac-ethyl	cyclooxygenase inhibitor	PTGS1, PTGS2			Launched
felodipine	calcium channel blocker	CFTR	cardiology	hypertension	Launched
felypressin	vasopressin receptor agonist				Preclinical
fenaclon					Preclinical
fenbendazole	tubulin polymerization inhibitor	TUBB	infectious disease	gastrointestinal parasites, gastrointestinal roundworms	Launched
fenbufen	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	Launched
fenclonine-(+/-)	tryptophan hydroxylase inhibitor	PAH, TPH1, TPH2			Preclinical
fendiline	calcium channel blocker	HTR2B			Preclinical
fenebrutinib	Bruton's tyrosine kinase (BTK) inhibitor				Phase 2
fenigam	benzodiazepine receptor agonist	GABBR1, GABBR2	neurology/psychiatry	posttraumatic stress disorder, anxiety, depression	Launched
fenipentol	choleretic agent		gastroenterology	bile stimulation	Launched
fenobam	glutamate receptor antagonist	GRM5			Phase 2
fenofibrate	PPAR receptor agonist	MMP25, PPARA	endocrinology	hypercholesterolemia, hypertriglyceridemia	Launched
fenofibric-acid	cytochrome P450 inhibitor	CLCN1, PPARA	cardiology	dyslipidemia	Launched
fenoldopam	dopamine receptor agonist	DRD1, DRD4	cardiology	hypertension	Launched
fenoprofen	prostaglandin inhibitor	PTGS1, SLC5A8	rheumatology	rheumatoid arthritis, osteoarthritis	Launched
fenoterol	adrenergic receptor agonist	ADRB2			Withdrawn
fenoverine	acetylcholine receptor antagonist		neurology/psychiatry	spasms	Launched
fenoxaprop-p-ethyl		NOS3			Preclinical
fenretinide	apoptosis stimulant, retinoid receptor agonist	RARA			Phase 3
fenspiride	bronchodilator		pulmonary, otolaryngology	asthma, otitis, sinusitis, rhinopharyngitis, laryngitis	Launched
fenthion	cholinesterase inhibitor				Launched
fentiazac	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry, rheumatology	muscle pain, joint pain	Launched
fenticonazole	bacterial cell wall synthesis inhibitor		infectious disease	vulvovaginal candidiasis	Launched
FERb-033	EGFR inhibitor	ERBB2			Preclinical
ferroquine	antimalarial agent				Phase 2
ferrostatin-1	ferroptosis inhibitor				Preclinical
ferulic-acid	antioxidant	CA1, CA12, CA14, CA2, CA4, CA6, CA9			Phase 2
fesoterodine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence	Launched
fevipiprant	prostaglandin inhibitor				Phase 2
fexaramine	FXR agonist	NR1H4			Preclinical
fexinidazole					Phase 3
fexofenadine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis, urticaria	Launched
fezolinetant	neurokinin receptor antagonist				Phase 2
FG-2216	hypoxia inducible factor prolyl hydroxylase inhibitor	EGLN1, EGLN2, HIF1A			Phase 2
FG-4592	hypoxia inducible factor prolyl hydroxylase inhibitor	EGLN1, EGLN2, EGLN3			Phase 3
FG-7142	GABA benzodiazepine site receptor inverse agonist				Preclinical
FGIN-1-27	inositol monophosphatase inhibitor	TSPO			Preclinical
FGIN-1-43	benzodiazepine receptor agonist	TSPO			Preclinical
FH-535	PPAR receptor antagonist, WNT signaling inhibitor	PPARD, PPARG			Preclinical
FH1	hepatocyte function enhancer				Preclinical
fiacitabine	DNA synthesis inhibitor				Phase 2
fidarestat	aldose reductase inhibitor	AKR1B1			Phase 3
fidaxomicin	RNA polymerase inhibitor		gastroenterology	diarrhea	Launched
filanesib	kinesin inhibitor, kinesin-like spindle protein inhibitor	KIF11			Phase 3
filgotinib	JAK inhibitor	JAK1, JAK2, JAK3, TYK2			Phase 3
fimasartan	angiotensin receptor antagonist	AGTR1	cardiology	hypertension, congestive heart failure	Launched
finafloxacin	bacterial DNA gyrase inhibitor		infectious disease, pulmonary	intra-abdominal infections, chronic obstructive pulmonary disease (COPD), cystic fibrosis	Launched
finasteride	5 alpha reductase inhibitor	AKR1D1, SRD5A1, SRD5A2	endocrinology	androgenetic alopecia	Launched
fingolimod	immunosuppressant, sphingosine 1-phosphate receptor agonist	S1PR1, S1PR5	neurology/psychiatry	multiple sclerosis	Launched
fipexide	psychoactive drug				Withdrawn
FIPI	phospholipase inhibitor	PLD1, PLD2			Preclinical
fipronil	chloride channel blocker, GABA gated chloride channel blocker		infectious disease	flea control	Launched
firategrast	integrin antagonist	ITGA4			Phase 2
firocoxib	cyclooxygenase inhibitor	PTGS2	rheumatology	osteoarthritis	Launched
firsocostat	acetyl-CoA carboxylase inhibitor				Phase 2
fisetin	Aurora kinase inhibitor	CDK6, FASN			Preclinical
fisogatinib	fibroblast growth factor inhibitor				Phase 1
FIT	opioid receptor agonist	OPRD1			Preclinical
FK-33-824	opioid receptor agonist	OPRM1			Phase 2
FK-3311	cyclooxygenase inhibitor	PTGS2			Phase 2
FK-409	guanylyl cyclase activator				Phase 2
FK-866	niacinamide phosphoribosyltransferase inhibitor	NAMPT			Phase 2
FK-888	tachykinin antagonist	TACR1, TACR2			Phase 2
FK-962	somatostatin receptor agonist				Phase 2
flavin-adenine-dinucleotide		ACAD8, ACADM, ACADS, ACOX1, AIFM1, CYB5R1, CYB5R3, DAO, DLD, DPYD, ERO1LB, FDXR, GCDH, GFER, GSR, IL4I1, IVD, MAOA, MAOB, NOS1, NQO1, NQO2, POR, TXNRD1, XDH			Preclinical
flavoxate	acetylcholine receptor antagonist	CHRM1, CHRM2	urology	urinary incontinence, interstitial cystitis (IC), urethritis, prostatitis	Launched
flecainide	sodium channel blocker	KCNA5, KCNA7, SCN5A	cardiology	ventricular tachycardia (VT), atrial fibrillation (AF), ventricular arrhythmias	Launched
fleroxacin	topoisomerase inhibitor	TOP2A	infectious disease, gastroenterology	gonorrhea, enteritis, diarrhea, respiratory tract infections	Launched
FLI-06	notch signaling inhibitor				Preclinical
flibanserin	serotonin receptor agonist	DRD4, HTR1A, HTR2A	neurology/psychiatry	hypoactive sexual desire disorder	Launched
flindokalner	potassium channel agonist	KCNMA1, KCNN4, KCNQ2, KCNQ4, KCNQ5			Phase 3
floctafenine	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	Launched
flopropione	serotonin receptor antagonist	HTR1A	neurology/psychiatry	spasms	Launched
florfenicol	protein synthesis inhibitor		pulmonary	bovine respiratory disease (BRD)	Launched
florifenine	anti-inflammatory agent				Preclinical
flosequinan	phosphodiesterase inhibitor				Withdrawn
floxuridine	DNA synthesis inhibitor	TYMS	oncology	colorectal cancer	Launched
FLT3-IN-1	FLT3 inhibitor				Preclinical
flubendazole	tubulin polymerization inhibitor	TUBB	infectious disease	gastrointestinal parasites	Launched
flucloxacillin	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology, dermatology, gastroenterology	gram-positive bacterial infections, tonsillitis, sinusitis, pneumonia, eczema, endocarditis, meningitis, enteritis, bacterial septicemia	Launched
fluconazole	sterol demethylase inhibitor	CYP51A1	infectious disease	esophageal candidiasis, meningitis	Launched
flucytosine	other antifungal	DNMT1	infectious disease	bacterial septicemia, endocarditis, urinary tract infections, meningitis	Launched
fludarabine	ribonucleotide reductase inhibitor	ADA, DCK, POLA1, RRM1, RRM2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	Launched
fludarabine-phosphate	ribonucleotide reductase inhibitor	POLA1, POLD1, POLE, RRM1, RRM2, RRM2B	hematologic malignancy	chronic lymphocytic leukemia (CLL)	Launched
fludrocortisone-acetate		NR3C2	endocrinology	Addison's disease, adrenogenital syndrome	Launched
fludroxycortide	glucocorticoid receptor agonist	NR3C1, SERPINA6	infectious disease, dermatology	skin infections, psoriasis	Launched
flufenamic-acid	chloride channel blocker	AKR1C3, ANO1, AR, GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, PANX1, PANX2, PANX3, PKD2L1, PTGS1, PTGS2, TRPC5, TRPM2, TRPM5			Preclinical
flumatinib	Bcr-Abl kinase inhibitor	ABL1, PDGFRB			Phase 3
flumazenil	benzodiazepine receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ	neurology/psychiatry	sedative	Launched
flumecinol					Launched
flumequine	topoisomerase inhibitor		infectious disease	urinary tract infections	Launched
flumethasone	glucocorticoid receptor agonist	NR3C1, PLA2G1B	otolaryngology, infectious disease, dermatology	otitis, ear infections, corticosteroid-responsive dermatoses	Launched
flumethasone-pivalate	glucocorticoid receptor agonist	NR3C1, SERPINA6	allergy	allergic rhinitis	Launched
flumexadol					Preclinical
flunarizine	calcium channel blocker	CACNA1G, CACNA1H, CACNA1I, CALM1, HRH1	neurology/psychiatry, cardiology	migraine headache, vertigo, peripheral artery disease (PAD)	Launched
flunisolide	cytochrome P450 inhibitor	NR3C1	allergy	allergic rhinitis	Launched
flunixin-meglumin	prostanoid receptor antagonist		pulmonary	bovine respiratory disease (BRD)	Launched
fluocinolone-acetonide	glucocorticoid receptor agonist	NR3C1, SERPINA6	dermatology	seborrheic dermatitis	Launched
fluocinonide	glucocorticoid receptor agonist	NR3C1, SERPINA6, SMO	dermatology	seborrheic dermatitis, eczema	Launched
fluorescein		SLC22A6	ophthalmology	ophthalmology diagnostic	Launched
fluorometholone	glucocorticoid receptor agonist	NR3C1	ophthalmology	eye inflammation	Launched
fluorometholone-acetate		NR3C1	ophthalmology	eye inflammation	Launched
fluoromethylcholine					Launched
fluoxetine	selective serotonin reuptake inhibitor (SSRI)	ANO1, HTR2B, SLC6A4	neurology/psychiatry	depression, obsessive compulsive disorder (OCD), bulimia nervosa, panic disorders, bipolar disorder	Launched
flupentixol	dopamine receptor antagonist	ADRA1A, CHRM1, DRD1, DRD2, DRD3, DRD5, HTR2A	neurology/psychiatry	schizophrenia, depression	Launched
fluphenazine	dopamine receptor antagonist	CALM1, DRD1, DRD2, DRD5, HRH1, HTR2A, HTR6, HTR7	neurology/psychiatry	schizophrenia	Launched
fluphenazine-decanoate	dopamine receptor antagonist	DRD2, HTR1B, HTR4	neurology/psychiatry	schizophrenia	Launched
flupirtine	glutamate receptor antagonist	ADRA2A, KCNQ1, KCNQ2	neurology/psychiatry	pain relief	Launched
fluprazine	serotonin receptor agonist	HTR1A, HTR1B			Phase 1
fluralaner	GABA receptor antagonist				Preclinical
flurbiprofen-(+/-)	cyclooxygenase inhibitor		rheumatology	rheumatoid arthritis, osteoarthritis	Launched
flurbiprofen-(S)-(+)	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	rheumatoid arthritis, osteoarthritis	Launched
flurbiprofen-axetil	analgesic agent				Launched
flurizan	gamma secretase inhibitor	APH1B, BACE1, IKBKG, PSEN1, PSEN2, PTGS1, PTGS2			Phase 3
flurofamide	urease inhibitor				Preclinical
flurothyl					Preclinical
fluroxene	local anesthetic				Preclinical
fluspirilene	dopamine receptor antagonist	CACNG1, DRD2, HRH1, HTR1A, HTR1D, HTR1E, HTR2A	neurology/psychiatry	schizophrenia	Launched
flutamide	androgen receptor antagonist	AHR, AR	oncology	prostate cancer	Launched
fluticasone-propionate	glucocorticoid receptor agonist	NR3C1, NR3C2, PGR, PLA2G4A	dermatology	corticosteroid-responsive dermatoses	Launched
flutrimazole	sterol demethylase inhibitor		infectious disease	mycosis	Launched
fluvastatin	HMGCR inhibitor	HMGCR	endocrinology, cardiology	hypercholesterolemia, congenital heart defects	Launched
fluvoxamine	selective serotonin reuptake inhibitor (SSRI)	SLC6A4	neurology/psychiatry	obsessive compulsive disorder (OCD)	Launched
fmoc-L-leucine	PPAR receptor agonist				Phase 2
FN-1501	tyrosine kinase inhibitor				Phase 1
folic-acid	folate receptor ligand	FOLR2, FOLR3, SLC19A1, SLC46A1	hematology	megaloblastic anemia	Launched
fomepizole	alcohol dehydrogenase inhibitor	ADH1A, ADH1B, ADH1C, AKR1A1, CAT	critical care	poison antidote	Launched
fomocaine	voltage-gated sodium channel modulator		neurology/psychiatry	local anesthetic	Launched
fondaparinux	coagulation factor inhibitor	F10, SERPINC1	hematology	deep vein thrombosis (DVT)	Launched
foretinib	VEGFR inhibitor	FLT1, FLT4, KDR, MET			Phase 2
formestane	aromatase inhibitor	CYP19A1	oncology	breast cancer	Launched
formononetin	alcohol dehydrogenase inhibitor	ADH1C, SLC5A2			Preclinical
formoterol	adrenergic receptor agonist	ADRB2	pulmonary	asthma, chronic obstructive pulmonary disease (COPD), bronchospasm	Launched
forodesine	purinergic receptor antagonist	PNP	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	Launched
foropafant	platelet activating factor receptor antagonist	PTAFR			Phase 3
forskolin	adenylyl cyclase activator	ADCY2, ADCY5, GNAS			Launched
fosamprenavir	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	Launched
fosaprepitant-dimeglumine	tachykinin antagonist	TACR1	gastroenterology	nausea, vomiting	Launched
fosbretabulin	tubulin polymerization inhibitor, VE-cadherin antagonist	CDH5			Phase 3
foscarnet	DNA polymerase inhibitor		infectious disease	cytomegalovirus retinitis, acquired immunodeficiency syndrome (AIDS), virus herpes simplex (HSV)	Launched
fosfestrol	synthetic estrogen	ESR1, ESR2	oncology	prostate cancer	Launched
fosfluconazole	other antifungal				Preclinical
fosfomycin	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections	Launched
fosfosal	phosphodiesterase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	Launched
fosfructose	fructose diphosphate stimulant				Phase 3
fosinopril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, congestive heart failure	Launched
fosinoprilat	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	Launched
fosphenytoin	sodium channel blocker	SCN5A	neurology/psychiatry	epilepsy, seizures	Launched
fostamatinib	SYK inhibitor	SYK	hematology	chronic immune thrombocytopenia (ITP)	Launched
fostemsavir	antiviral				Phase 3
fotemustine	thioredoxin inhibitor		oncology	melanoma	Launched
foxy-5	WNT5a peptide mimetic	WNT5A			Phase 2
FPA-124	AKT inhibitor				Preclinical
FPH1-(BRD-6125)	hepatocyte function enhancer				Preclinical
FPL-12495	glutamate receptor antagonist				Phase 1
FPL-55712	leukotriene receptor antagonist				Phase 1
FPL-62064	cyclooxygenase inhibitor, lipoxygenase inhibitor				Phase 2
FPL-64176	calcium channel activator	CACNA1C, CACNA1S			Preclinical
FPS-ZM1	RAGE receptor antagonist	AGER			Preclinical
FR-122047	cyclooxygenase inhibitor				Preclinical
FR-139317	endothelin receptor antagonist	EDNRA			Phase 1
FR-180204	MAP kinase inhibitor	MAPK1, MAPK3			Preclinical
FRAX486	serine/threonine kinase inhibitor	PAK1, PAK2, PAK3, PAK4			Preclinical
frentizole	immunosuppressant				Phase 1
freselestat	elastase inhibitor	CELA1, ELANE			Preclinical
frovatriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D	neurology/psychiatry	migraine headache	Launched
fruquintinib	VEGFR inhibitor	KDR	oncology	colorectal cancer	Launched
ftaxilide					Preclinical
ftorafur	thymidylate synthase inhibitor	TYMS	oncology	colorectal cancer	Launched
FT011	TGF beta receptor inhibitor				Preclinical
fucoxanthin	anticancer agent				Phase 2
fudosteine	mucolytic agent		pulmonary	chest congestion	Launched
fulvestrant	estrogen receptor antagonist	ESR1, ESR2, GPER1	oncology	breast cancer	Launched
fumagillin	methionine aminopeptidase inhibitor	METAP2	infectious disease	microsporidiosis	Launched
fumonisin-B1		CERS1			Preclinical
funapide	sodium channel blocker				Preclinical
furagin	antibacterial				Preclinical
furaltadone	bacterial DNA inhibitor		infectious disease	gram-negative bacterial infections	Launched
furamidine	protein arginine N-methyltransferase inhibitor	PRMT1			Preclinical
furazolidone	bacterial DNA inhibitor		gastroenterology, infectious disease	diarrhea, enteritis, cholera	Launched
furegrelate	thromboxane synthase inhibitor	TBXAS1			Phase 1
furosemide	diuretic	CA2, GPR35, SLC12A1, SLC12A2	cardiology, rheumatology	edema, hypertension, congestive heart failure, nephrotic syndrome	Launched
fursultiamine	vitamin B		metabolism	thiamine deficiency	Launched
furvina	quorum sensing signaling inhibitor				Preclinical
fusidic-acid	bacterial 30S ribosomal subunit inhibitor		dermatology	acne vulgaris (AV)	Launched
futibatinib	FGFR inhibitor				Phase 3
F351	TGF beta receptor inhibitor	TGFB1			Phase 2
g-caryophyllene	acetylcholinesterase inhibitor	ACHE			Preclinical
G-1	G protein-coupled receptor agonist	GPER1			Preclinical
G-15	estrogen receptor antagonist	GPER1			Preclinical
G-749	tyrosine kinase inhibitor				Preclinical
GABA-linoleamide	benzodiazepine receptor agonist				Phase 2
gabapentin	calcium channel blocker	ADORA1, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CACNG2, CACNG3, CACNG4, CACNG5, CACNG6, CACNG7, CACNG8, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B	infectious disease, neurology/psychiatry	virus herpes simplex (HSV), shingles, seizures, restless leg syndrome	Launched
gabapentin-enacarbil	adrenergic receptor agonist	CACNA1G	neurology/psychiatry	restless leg syndrome, postherpetic neuralgia	Launched
gabazine	GABA receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRG2			Preclinical
gabexate	serine protease inhibitor	PRSS1, TPSAB1	gastroenterology	pancreatitis	Launched
gaboxadol	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRD, GABRR1, GABRR2, GABRR3			Phase 3
gadobutrol	radiopaque medium		radiology	MRI contrast agent	Launched
gadodiamide	radiopaque medium		radiology	MRI contrast agent	Launched
gadopentetic-acid	contrast agent	PGD	radiology	contrast agent	Launched
gadoterate-meglumine	radiopaque medium		radiology	MRI contrast agent	Launched
gadoteridol	radiopaque medium		radiology	MRI contrast agent	Launched
GAL-021	calcium channel blocker				Preclinical
galantamine	acetylcholinesterase inhibitor	ACHE, BCHE, CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG	neurology/psychiatry	senile dementia	Launched
galeterone	androgen receptor modulator	AR, CYP17A1			Phase 3
galidesivir	antiviral				Phase 1
gallamine-triethiodide	acetylcholine receptor antagonist	CHRM2, CHRNA1	neurology/psychiatry	muscle relaxant	Launched
gallic-acid	beta amyloid protein neurotoxicity inhibitor, PPAR receptor agonist	CA1, CA12, CA14, CA2, CA4, CA6, CA9, SELP			Preclinical
gallium-triquinolin-8-olate					Phase 1
gallopamil	L-type calcium channel blocker	ATP2A2	cardiology	hypertension, cardiac arrythmia	Launched
gambogic-acid	caspase activator	BCL2			Phase 2
gamithromycin	antibacterial 				Preclinical
gamma-aminobutyric-acid	benzodiazepine receptor agonist	GABBR1, GABBR2, GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2, GATM, KCTD12, KCTD16, KCTD8, SLC6A1			Preclinical
gamma-linolenic-acid	cyclooxygenase inhibitor, prostanoid receptor agonist	PTGS1, PTGS2			Phase 2
ganaxolone	GABA receptor modulator	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6			Phase 3
ganciclovir	DNA polymerase inhibitor		infectious disease	cytomegalovirus (CMV)	Launched
ganetespib	HSP inhibitor	HSP90AA1			Phase 3
ganoderic-acid-a	JAK inhibitor				Preclinical
GANT-58	GLI antagonist	GLI1			Preclinical
GANT-61	GLI antagonist	GLI1, GLI2			Preclinical
garenoxacin	topoisomerase inhibitor	TOP2A	infectious disease	respiratory tract infections	Launched
gastrodin					Phase 2
gatifloxacin	bacterial DNA gyrase inhibitor				Withdrawn
gavestinel	glutamate receptor antagonist	GLRB, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B			Phase 3
GBR-12783	dopamine reuptake inhibitor				Preclinical
GBR-12935	dopamine reuptake inhibitor	AGTR1, SLC6A3			Preclinical
GBR-13069	dopamine reuptake inhibitor	SLC6A3			Preclinical
GDC-0068	AKT inhibitor	AKT1, AKT2, AKT3, PRKG1			Phase 3
GDC-0077	PI3K inhibitor				Phase 1
GDC-0084	mTOR inhibitor, PI3K inhibitor				Phase 2
GDC-0152	XIAP inhibitor	BIRC2, BIRC3, BIRC7, XIAP			Phase 1
GDC-0349	Pim kinase inhibitor	PIK3CA			Phase 1
GDC-0575	CHK inhibitor				Phase 1
GDC-0623	MEK inhibitor				Phase 1
GDC-0810	selective estrogen receptor destabilizer	ESR1			Phase 2
GDC-0834	Bruton's tyrosine kinase (BTK) inhibitor	BTK			Phase 1
GDC-0879	RAF inhibitor	BRAF			Preclinical
GDC-0927	estrogen receptor antagonist				Phase 1
GDC-0941	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			Phase 2
GDC-0980	mTOR inhibitor, PI3K inhibitor	FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK			Phase 2
GDC-0994	MAP kinase inhibitor	MAPK1, MAPK3			Phase 1
gedunin	HSP inhibitor	HSP90AA1			Preclinical
gefapixant	purinergic receptor antagonist				Phase 3
gefitinib	EGFR inhibitor	EGFR	oncology	non-small cell lung cancer (NSCLC)	Launched
geldanamycin	HSP inhibitor	HSP90AA1			Preclinical
gemcadiol	antilipemic				Phase 2
gemcitabine	ribonucleotide reductase inhibitor	CMPK1, RRM1, RRM2, TYMS	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer	Launched
gemcitabine-elaidate	apoptosis inhibitor, DNA synthesis inhibitor	CMPK1, RRM1, TYMS			Phase 1
gemfibrozil	lipoprotein lipase activator	LPL, PPARA, SLCO1B1, SLCO1B3, SLCO2B1	endocrinology, cardiology	hyperlipidemia, coronary heart disease	Launched
gemifloxacin	bacterial DNA gyrase inhibitor		pulmonary, infectious disease	bronchitis, pneumonia	Launched
gemigliptin	dipeptidyl peptidase inhibitor				Launched
genipin	choleretic agent				Preclinical
geniposide	GLP receptor agonist	GLP1R			Preclinical
geniposidic-acid	cyclooxygenase inhibitor				Preclinical
genistein	tyrosine kinase inhibitor	CFTR, ESR1, ESR2, ESRRA, ESRRB, ESRRG, NCOA1, NCOA2, PPARG, PTK2B, TOP2A, TRPC5			Phase 2/Phase 3
gentamycin	bacterial 50S ribosomal subunit inhibitor	HSPA8	infectious disease, critical care	bone and joint infections, endocarditis, pelvic inflammatory disease, meningitis, pneumonia, urinary tract infections, sepsis	Launched
gentiopicrin	glutamate receptor downregulator	GRIN2B			Phase 3
genz-123346	glucosylceramidase inhibitor	UGCG			Preclinical
genz-644282	topoisomerase inhibitor	TOP1			Phase 1
gepefrine	adrenergic receptor agonist		cardiology	hypotension	Launched
gepon					Phase 1
gepotidacin	topoisomerase inhibitor				Phase 2
geranyl-farnesylacetate	mucin production enhancer				Phase 2
gestodene	contraceptive agent		endocrinology	contraceptive	Launched
gestrinone	progesterone receptor antagonist	AR, ESR1, PGR	obstetrics/gynecology	endometriosis	Launched
GF109203X	PKC inhibitor	PDPK1, PIM1, PRKCI, PRKCZ			Preclinical
GGsTop	gamma glutamyltransferase Inhibitor	GGT1			Preclinical
GGTI-298	GGTase inhibitor	CDKN1A			Preclinical
gilteritinib	FLT3 inhibitor	FLT3			Launched
gimeracil	dihydropyrimidine dehydrogenase inhibitor	DPYD	oncology	gastric adenocarcinoma	Launched
ginkgolide-A	GABA receptor antagonist	GLRA1, GLRB			Preclinical
ginkgolide-B	platelet activating factor receptor antagonist	GLRA1, GLRA2, GLRA3, GLRB, HTR3A, HTR3B			Phase 3
ginsenoside-C-K	NFkB pathway inhibitor, nitric oxide synthase inhibitor	PTGS2			Phase 1
ginsenoside-RD	calcium channel blocker				Phase 3
ginsenoside-RE	anti-inflammatory agent				Phase 1
ginsenoside-RE3	angiogenesis inhibitor, apoptosis stimulant	KCNH2			Launched
givinostat	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9			Phase 3
GKA-50	glucokinase activator	GCK			Preclinical
GKT137831	NADPH oxidase inhibitor	NOX1, NOX4			Phase 2
GK921	transglutaminase inhibitor	TGM2			Preclinical
glafenine	DeltaF508-CFTR Correctors	CFTR			Withdrawn
glasdegib	hedgehog pathway inhibitor	SMO	hematologic malignancy	acute myeloid leukemia (AML)	Launched
glecaprevir	serine protease inhibitor		infectious disease	hepatitis C	Launched
glesatinib	tyrosine kinase inhibitor				Phase 2
gliclazide	ATP channel blocker, insulin secretagogue		endocrinology	diabetes mellitus	Launched
glimepiride	insulin secretagogue	ABCC8, KCNJ1, KCNJ11	endocrinology	diabetes mellitus	Launched
glipizide	sulfonylurea	ABCC8, KCNJ10, KCNJ11, PPARG	endocrinology	diabetes mellitus, hyperglycemia	Launched
gliquidone	sulfonylurea	ABCC8, KCNJ10, KCNJ8	endocrinology	diabetes mellitus	Launched
Gln-1062	cholinesterase inhibitor				Preclinical
GLPG0187	integrin antagonist				Phase 1
GLPG0492	androgen receptor modulator	AR			Phase 1
GLPG0492-R-enantiomer	androgen receptor modulator	AR			Phase 1
GLPG1837	CFTR channel potentiator				Phase 2
glucaric-acid					Phase 1
gluconolactone		LCT			Launched
glucosamine	glycosylated protein precursor	IL1B	neurology/psychiatry, rheumatology	muscle pain, rheumatoid arthritis, joint pain, backache	Launched
glutathione	antioxidant	ESD, GGT1, GLO1, GLRX, GLRX2, GPX1, GPX2, GPX3, GPX4, GPX5, GPX6, GPX7, GPX8, GSR, GSS, GSTA1, GSTA2, GSTA3, GSTA4, GSTA5, GSTK1, GSTM1, GSTM2, GSTM3, GSTM4, GSTM5, GSTO1, GSTO2, GSTP1, GSTT1, GSTZ1, HAGH, HPGDS, LTC4S, MGST1, MGST2, MGST3, TXNDC12			Phase 3
glutathione-monoisopropyl-ester	lipid peroxidase inhibitor				Phase 2
gly-gln					Phase 2
glyburide	ATP channel blocker, insulin secretagogue, sulfonylurea	ABCA1, ABCB11, ABCC8, ABCC9, CFTR, CPT1A, KCNJ1, KCNJ11, KCNJ5, KCNJ8, SLCO2B1	endocrinology	diabetes mellitus, hyperglycemia	Launched
glycerol-monolaurate	beta lactamase inhibitor				Launched
glycerol-phenylbutyrate	sigma receptor ligand				Phase 1
glycitein	tumor necrosis factor release inhibitor	TNF			Phase 3
glycopyrrolate	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	gastroenterology	peptic ulcer disease (PUD)	Launched
GM-1485	immunophilin ligand	FKBP1A			Preclinical
GMX1778	NAMPT inhibitor	NAMPT			Phase 1/Phase 2
GNE-7915	leucine rich repeat kinase inhibitor				Preclinical
GNF-2	Bcr-Abl kinase inhibitor	ABL1, BCR			Preclinical
GNF-5	Bcr-Abl kinase inhibitor	ABL1, BCR			Preclinical
GNF-5837	growth factor receptor inhibitor	NTRK1, NTRK2, NTRK3			Preclinical
GNF-7	glucokinase inhibitor, protein kinase inhibitor	GCK, TNK2			Preclinical
GNTI	opioid receptor antagonist	OPRK1, OPRM1			Preclinical
go-6983	protein kinase inhibitor	PRKCA, PRKCB, PRKCD, PRKCG, PRKCZ			Preclinical
golgicide-A	ARF inhibitor	GBF1			Preclinical
golvatinib	VEGFR inhibitor	KDR, MET			Phase 2
gonadorelin	gonadotropin releasing factor hormone receptor agonist	GNRHR	obstetrics/gynecology	cystic ovaries, reproductive synchrony	Launched
goserelin-acetate	gonadotropin releasing factor hormone receptor agonist	GNRHR, LHCGR	oncology, obstetrics/gynecology	prostate cancer, breast cancer, endometriosis	Launched
gossypol	BCL inhibitor, MCL1 inhibitor	BCL2			Phase 2
GPBAR-A	G protein-coupled receptor agonist	GPBAR1			Preclinical
GPI-1046	FKBP inhibitor	FKBP1A			Preclinical
GPi-688	glycogen phosphorylase inhibitor				Preclinical
GPP-78	NAMPT inhibitor	NAMPT			Preclinical
GPR120-modulator-1	G protein-coupled receptor modulator	FFAR4			Preclinical
GP1a	cannabinoid receptor agonist	CNR2			Preclinical
GP2a	cannabinoid receptor agonist	CNR2			Preclinical
GR-103691	dopamine receptor antagonist	DRD3			Preclinical
GR-113808	serotonin receptor antagonist	HTR4			Preclinical
GR-127935	serotonin receptor antagonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6			Preclinical
GR-135531	melatonin receptor agonist				Preclinical
GR-144053	integrin antagonist	ITGA2B, ITGB3			Preclinical
GR-159897	tachykinin antagonist	TAC1, TACR2			Preclinical
GR-235	estrogen receptor agonist, FXR antagonist, progesterone receptor agonist	NR1H4			Launched
GR-79236	adenosine receptor agonist	ADORA1, ADORA2A			Phase 1
gramicidin	bacterial permeability inducer		infectious disease	first-aid antibiotic	Launched
gramine	norepinephrine reputake inhibitor				Preclinical
granisetron	serotonin receptor antagonist	HTR3A	gastroenterology	nausea, vomiting	Launched
grapiprant	prostaglandin inhibitor	PTGER4	rheumatology	osteoarthritis	Launched
grazoprevir	HCV inhibitor		infectious disease	hepatitis C	Launched
griseofulvin	tubulin polymerization inhibitor	KRT12	infectious disease	ringworm, tinea pedis	Launched
GR125487	serotonin receptor antagonist	HTR4			Preclinical
GR46611	serotonin receptor agonist	HTR1D			Preclinical
GS-143	ubiquitin ligase inhibitor	BTRC, NFKBIA			Preclinical
GS-39783	GABA receptor modulator	GABBR1			Preclinical
GS-6201	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Phase 1
GS-9620	toll-like receptor agonist	TLR7			Phase 2
GS-967	voltage-gated sodium channel blocker				Preclinical
GS-9973	SYK inhibitor	SYK			Phase 2
GSK-J1	histone demethylase inhibitor	KDM6B			Preclinical
GSK-J2	histone demethylase inhibitor				Preclinical
GSK-J4	histone lysine demethylase inhibitor	KDM6A, KDM6B			Preclinical
GSK-J5	histone demethylase control				Preclinical
GSK-LSD-1	histone lysine demethylase inhibitor	KDM1A			Preclinical
GSK-3-inhibitor-IX	glycogen synthase kinase inhibitor, lipoxygenase inhibitor	GSK3A, GSK3B			Preclinical
GSK0660	PPAR receptor antagonist	PPARD			Preclinical
GSK1059615	PI3K inhibitor	PIK3CG			Phase 1
GSK1070916	Aurora kinase inhibitor	AURKA, AURKB, AURKC, CYP2D6, CYP3A4			Phase 1
GSK1292263	glucose dependent insulinotropic receptor agonist	GRPR			Phase 2
GSK1562590	urotensin receptor antagonist	UTS2R			Preclinical
GSK163090	serotonin receptor antagonist	HTR1A, HTR1B, HTR1D			Phase 2
GSK1838705A	insulin growth factor receptor inhibitor	ALK, IGF1R, INSR, RPS6KA1			Preclinical
GSK189254	histamine receptor antagonist				Phase 2
GSK1904529A	IGF-1 inhibitor, insulin growth factor receptor inhibitor, insulin receptor ligand	IGF1R, INSR			Preclinical
GSK2110183	AKT inhibitor	AKT1, AKT2, AKT3			Phase 2
GSK2126458	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG			Phase 1
GSK2190915	lipoxygenase inhibitor	ALOX5AP			Phase 2
GSK2193874	transient receptor potential channel antagonist	TRPV4			Preclinical
GSK2194069	fatty acid synthase inhibitor	FASN			Preclinical
GSK2239633A	CC chemokine receptor antagonist				Preclinical
GSK2256098	kinase inhibitor				Phase 2
GSK2256294A	epoxide hydolase inhibitor	EPHX2			Phase 1
GSK2330672	bile acid transporter inhibitor	SLC10A2			Phase 2
GSK2334470	phosphoinositide dependent kinase inhibitor	AURKA, AURKB, PDPK1			Preclinical
GSK239512	histamine receptor antagonist				Preclinical
GSK256066	phosphodiesterase inhibitor	PDE4A			Phase 2
GSK2578215A	leucine rich repeat kinase inhibitor	LRRK2			Preclinical
GSK2606414	protein kinase inhibitor	EIF2AK3, MYLK2			Preclinical
GSK2636771	PI3K inhibitor	PIK3CB			Phase 2
GSK2656157	PERK inhibitor				Preclinical
GSK269962	rho associated kinase inhibitor	ROCK1, ROCK2			Preclinical
GSK2801	bromodomain inhibitor	BAZ2A, BAZ2B			Preclinical
GSK2816126	histone lysine methyltransferase inhibitor	EZH2			Phase 1
GSK2830371	protein phosphatase inhibitor	PPM1D			Preclinical
GSK2837808A	lactate dehydrogenase inhibitor	LDHA			Preclinical
GSK2838232	HIV gag inhibitor				Phase 2
GSK2879552	histone lysine demethylase inhibitor	KDM1A			Phase 1/Phase 2
GSK2881078	androgen receptor modulator				Phase 2
GSK2981278	ROR modulator				Phase 1/Phase 2
GSK2982772	RIPK inhibitor				Phase 2
GSK3117391	HDAC inhibitor				Phase 1/Phase 2
GSK3179106	RET tyrosine kinase inhibitor				Phase 1
GSK3326595	protein arginine N-methyltransferase inhibitor				Phase 1/Phase 2
GSK356278	phosphodiesterase inhibitor				Preclinical
GSK369796	potassium channel antagonist				Phase 1
GSK37647	free fatty acid receptor agonist	FFAR4			Preclinical
GSK3787	PPAR receptor antagonist	PPARD			Preclinical
GSK429286A	rho associated kinase inhibitor	ROCK1			Preclinical
GSK461364	PLK inhibitor	PLK1			Phase 1
GSK503	histone lysine methyltransferase inhibitor	EZH2			Preclinical
GSK650394	serum/glucocorticoid regulated kinase inhibitor	SGK1, SGK2			Preclinical
GSK656	leucyl-tRNA synthetase inhibitor				Preclinical
GSK690693	AKT inhibitor	AKT1, AKT2, AKT3, PAK4, PAK6, PAK7, PRKCQ, PRKG1, PRKX			Phase 1
GSK9027	glucocorticoid receptor agonist	NR3C1			Preclinical
GSK923295	centromere associated protein inhibitor	CENPE			Phase 1
GTP-14564	FLT3 inhibitor, tyrosine kinase inhibitor	CSF1R, FLT3, KIT, PDGFRB			Preclinical
GTS21	cholinergic receptor agonist	CHRNA7			Phase 1/Phase 2
guacetisal	immunosuppressant		pulmonary	cough suppressant	Launched
guadecitabine	DNA methyltransferase inhibitor				Phase 3
guaiacol	local anesthetic	CA2	pulmonary	cough suppressant	Launched
guaifenesin	expectorant		pulmonary	cough suppressant	Launched
guanaben-acetate	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C	cardiology	hypertension	Launched
guanadrel	adrenergic inhibitor		cardiology	hypertension	Launched
guancydine	antihypertensive agent				Preclinical
guanethidine	adrenergic inhibitor	SLC6A2	cardiology	hypertension	Launched
guanfacine	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C	cardiology	hypertension	Launched
guanidine	HSP inhibitor	ALDH2, DLG4, GAMT, RNASE1	neurology/psychiatry	Lambert-Eaton myasthenic syndrome (LEMS)	Launched
guanidinoethyldisulfide-bicarbonate	nitric oxide synthase inhibitor	NOS2			Phase 2
guanidinopropionic-acid	creatine kinase inhibitor	CKM			Phase 2
guanosine		PNP			Preclinical
Gue-1654	oxoeicosanoid receptor modulator	OXER1			Preclinical
guvacine	GABA uptake inhibitor	SLC6A1, SLC6A11, SLC6A12, SLC6A13			Preclinical
GW-0742	PPAR receptor agonist	PPARD			Preclinical
GW-1100	G protein-coupled receptor agonist	FFAR1			Preclinical
GW-1929	PPAR receptor agonist	PPARG			Preclinical
GW-2580	cFMS kinase inhibitor	CSF1R			Preclinical
GW-311616	elastase inhibitor, leukocyte elastase inhibitor	ELANE			Phase 1
GW-3965	LXR agonist	NR1H2, NR1H3			Preclinical
GW-405833	cannabinoid receptor agonist	CNR2			Preclinical
GW-4064	FXR agonist	NR1H4			Preclinical
GW-438014A	neuropeptide receptor antagonist	NPY5R			Preclinical
GW-441756	growth factor receptor inhibitor	NTRK1			Preclinical
GW-501516	PPAR receptor agonist	PPARA, PPARD			Phase 2
GW-5074	leucine rich repeat kinase inhibitor, RAF inhibitor	NTRK1, RAF1			Phase 1/Phase 2
GW-542573X	calcium channel activator	KCNN1			Preclinical
GW-583340	EGFR inhibitor	EGFR, ERBB2			Preclinical
GW-627368	prostanoid receptor antagonist	PTGER4			Preclinical
GW-6471	PPAR receptor antagonist	PPARA			Preclinical
GW-7647	PPAR receptor agonist	PPARA			Preclinical
GW-788388	ALK tyrosine kinase receptor inhibitor	LCK, MAPK14, TGFBR1			Preclinical
GW-803430	melanin inhibitor	KCNH2, MCHR1			Phase 1
GW-842166	cannabinoid receptor agonist	CNR2			Phase 2
GW-843682X	PLK inhibitor	PLK1, PLK3			Preclinical
GW-9508	free fatty acid receptor agonist, G protein-coupled receptor agonist	FFAR1, FFAR4			Preclinical
GW-9662	PPAR receptor antagonist	NCOA2, PPARG, RXRA			Preclinical
GW274150	nitric oxide synthase inhibitor				Phase 2
GYKI-52466	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4			Preclinical
gynostemma-extract	calcium channel modulator				Phase 2
GZD824	Bcr-Abl kinase inhibitor	ABL1, BCR			Preclinical
G007-LK	tankyrase inhibitor	TNKS, TNKS2			Preclinical
H-151	STING antagonist				Preclinical
H-89	PKA inhibitor	GSG2, PKIA, PRKACA			Preclinical
HA-1004	calcium channel blocker				Phase 2
HA-130	autotaxin inhibitor	ENPP2			Preclinical
HA-966-(R)-(+)	glutamate receptor agonist	GRIA1			Preclinical
HA-966-(S)-(-)	glutamate receptor antagonist	GRIA1			Preclinical
halazone			infectious disease	disinfectant	Launched
halcinonide	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	Launched
halobetasol-propionate	glucocorticoid receptor agonist	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	Launched
halofantrine	antimalarial agent	KCNN4	infectious disease	malaria	Launched
halofuginone	collagenase inhibitor	COL1A1, MMP2	rheumatology	scleroderma	Launched
halopemide	phospholipase inhibitor	PLD1, PLD2			Phase 2
haloperidol	dopamine receptor antagonist	DRD1, DRD2, DRD3, DRD4, DRD5, GRIN2B, HRH1, HTR1A, HTR1D, HTR2A, HTR2B, HTR7, KCNH1	neurology/psychiatry	schizophrenia, Tourette's disorder	Launched
haloperidol-decanoate	psychoactive drug	DRD2, DRD3, DRD4, HTR2A	neurology/psychiatry	schizophrenia	Launched
haloprogin	other antifungal		infectious disease	tinea pedis	Launched
halothane	glutamate receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, KCNK10, KCNK12, KCNK13, KCNK15, KCNK18, KCNK2, KCNK3, KCNK9	neurology/psychiatry	general anaesthetic	Launched
harmane	monoamine oxidase inhibitor	MAOA, MAOB			Preclinical
harringtonine	protein synthesis inhibitor				Phase 3
HA14-1	BCL inhibitor	BCL2			Preclinical
HBED	chelating agent				Phase 3
HC-030031	TRPA1 channel blocker	TRPA1			Phase 1
HC-067047	transient receptor potential channel antagonist	TRPV4			Preclinical
HC-070	transient receptor potential channel antagonist				Preclinical
heclin	ubiquitin ligase inhibitor	NEDD4, SMURF2, WWP1			Preclinical
HEMADO	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Preclinical
hematoporphyrin			neurology/psychiatry	depression, psychosis	Launched
hematoxylin					Preclinical
hemin	enzyme inducer		hematology, cardiology	acute intermittent porphyria (AIP), hypertension, ventricular tachycardia (VT)	Launched
hemomex-s		PPARG			Launched
hepsulfam	DNA cross-linking				Preclinical
heptaminol	vasoconstrictor		cardiology	hypotension	Launched
HER2-Inhibitor-1	EGFR inhibitor				Preclinical
hesperadin	Aurora kinase inhibitor	AURKB			Preclinical
hesperetin	ACAT inhibitor	DGAT1, MTTP, SOAT1, SOAT2			Launched
hesperidin	flavanone glycoside	AURKB, CACNA1B			Launched
hetacillin	bacterial cell wall synthesis inhibitor		obstetrics/gynecology	mastitis	Launched
hexachlorophene	potassium channel activator	GLUD1, SDHD	infectious disease	gram-positive bacterial infections	Launched
hexamethonium	cholinergic receptor antagonist	CHRNA2, CHRNA3, CHRNA4, CHRNA6			Preclinical
hexamethylenebisacetamide	AKT inhibitor, differentiation inducer, NFKB pathway inhibitor	AKT1			Phase 2
hexaminolevulinate			radiology	diagnostic agent	Launched
hexasodium-phytate					Phase 2
hexestrol	synthetic estrogen	AKR1C1, ESR1, ESR2	endocrinology	hypoestrogenism	Launched
hexetidine	local anesthetic		otolaryngology, infectious disease, dental, gastroenterology	pharyngitis, meningitis, laryngitis, gingivitis, ulcerative colitis	Launched
hexonic-acid					Preclinical
hexoprenaline	adrenergic receptor agonist	ADRB2	pulmonary	asthma	Launched
hexylcaine	sodium channel blocker	SCN5A	neurology/psychiatry	local anesthetic	Launched
hexylene-glycol		AKR1C3, CTPS1, DLG4, HSP90AA1, NOS3, PGF, PLA2G1B, PTPN1, SELP			Preclinical
hexylresorcinol	local anesthetic	TYR	infectious disease	skin infections, first-aid antiseptic	Launched
higenamine	adrenergic receptor agonist	ADRB2			Phase 1
hippuric-acid					Preclinical
histamine	histamine receptor agonist	HRH1, HRH2, HRH3, HRH4	allergy	allergic rhinitis	Launched
HJC-0350	GTPase inhibitor	RAPGEF4			Preclinical
HKI-357	EGFR inhibitor	EGFR			Phase 1
HLCL-61	protein arginine N-methyltransferase inhibitor	PRMT5			Preclinical
HM-30181	P glycoprotein inhibitor				Phase 1
HMN-214	PLK inhibitor	PLK1			Phase 1
HOKU-81	bronchodilator				Preclinical
homatropine	acetylcholine receptor antagonist	CHRM1	ophthalmology	uveal tract inflammation, pupil dilation	Launched
homatropine-methylbromide	acetylcholine receptor antagonist	CHRM5	ophthalmology	uveal tract inflammation	Launched
homidium					Preclinical
homochlorcyclizine	antihistamine	HRH1	allergy	allergic rhinitis	Launched
homoharringtonine	protein synthesis inhibitor	RPL3	hematologic malignancy	chronic myeloid leukemia (CML)	Launched
homoquinolinic-acid	glutamate receptor agonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			Preclinical
homosalate	HSP inducer				Preclinical
homoveratrylamine	monoamine oxidase inhibitor				Preclinical
honokiol	AKT inhibitor	ALOX5, PTGS1, PTGS2			Phase 3
hordenine					Preclinical
HP-228	nitric oxide synthase inhibitor				Preclinical
hPGDS-IN-1	prostaglandin inhibitor				Preclinical
HPPH	photosensitizing agent				Phase 2
HQK-1001					Phase 2
HSR6071	antiallergic agent				Preclinical
HT-2157	galanin receptor 3 antagonist				Phase 1/Phase 2
HTH-01-015	protein kinase inhibitor	NUAK1			Preclinical
HTHQ	antioxidant				Preclinical
HTMT	histamine receptor agonist	HRH4			Preclinical
huperzine-A	acetylcholinesterase inhibitor	ACHE			Phase 2
hyaluronic-acid		C1QBP, CD44, HABP2, HAPLN1, HAPLN3, HAPLN4, HMMR, ICAM1, NCAN, VCAN	rheumatology, urology	osteoarthritis, interstitial cystitis (IC)	Launched
hycanthone	RNA synthesis inhibitor		infectious disease	schistosomiasis	Launched
hydralazine	vasodilator		cardiology	hypertension	Launched
hydrastine-(1R,9S)	tyrosine hydroxylase inhibitor				Preclinical
hydrastinine	hemostatic agent				Preclinical
hydrochlorothiazide	thiazide diuretic	CA1, CA12, CA2, CA4, CA9, KCNMA1, SLC12A3	cardiology	hypertension, congestive heart failure	Launched
hydrocortisone	glucocorticoid receptor agonist	ANXA1, NOS2, NR3C1, NR3C2	dermatology, neurology/psychiatry	eczema, psoriasis, seborrheic dermatitis, itching	Launched
hydrocortisone-acetate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	Launched
hydrocortisone-butyrate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses, eczema	Launched
hydrocortisone-hemisuccinate					Phase 2/Phase 3
hydrocortisone-phosphate			pulmonary, gastroenterology, hematologic malignancy, ophthalmology	asthma, nausea, vomiting, multiple myeloma, contact dermatitis, enteritis, colitis	Launched
hydrocortisone-valerate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	Launched
hydroflumethiazide	sodium/potassium/chloride transporter inhibitor	ATP1A1, CA1, CA12, CA2, CA4, CA9, KCNMA1, SLC12A1, SLC12A3	cardiology, gastroenterology, rheumatology, nephrology	edema, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, chronic renal failure, acute glomerulonephritis (AGN), hypertension	Launched
hydroquinidine	antiarrhythmic		cardiology	cardiac arrythmia	Launched
hydroquinone	melanin inhibitor	TYR	dermatology	dyschromia	Launched
hydroxocobalamin	vitamin B				Launched
hydroxyamphetamine	trace amine associated receptor agonist	TAAR1	ophthalmology	mydriasis	Launched
hydroxychloroquine	antimalarial agent	TLR7, TLR9	infectious disease	malaria	Launched
hydroxyfasudil	rho associated kinase inhibitor	PKIA, PRKACA, ROCK1			Preclinical
hydroxyprogesterone	progesterone receptor agonist	PGR	obstetrics/gynecology	spontaneous preterm birth	Launched
hydroxyprogesterone-acetate	progesterone receptor agonist	PGR			Launched
hydroxypropyl-beta-cyclodextrin					Phase 2/Phase 3
hydroxysafflor-yellow-A	antitumor agent				Preclinical
hydroxystilbamidine					Launched
hydroxytacrine-maleate-(R,S)	cholinesterase inhibitor	ACHE			Preclinical
hydroxytoluic-acid					Preclinical
hydroxyurea	ribonucleotide reductase inhibitor	RRM1, RRM2, RRM2B	hematologic malignancy, oncology	chronic myeloid leukemia (CML), head and neck squamous cell carcinoma (HNSCC)	Launched
hydroxyzine	antihistamine	HRH1	neurology/psychiatry, allergy, dermatology	anxiety, urticaria, itching, dermatosis	Launched
hygromycin-B	polypeptide synthesis inhibitor				Preclinical
hymecromone	monoamine oxidase inhibitor	MAOA, MAOB			Phase 2
hyodeoxycholic-acid	atherosclerosis formation inhibitor				Phase 1
hyoscyamine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4	gastroenterology, urology, neurology/psychiatry, allergy	peptic ulcer disease (PUD), acute abdominal visceral spasm, ulcerative colitis, interstitial cystitis (IC), enterocolitis, irritable bowel syndrome, tremors, allergic rhinitis	Launched
hypericin	tyrosine kinase inhibitor				Phase 3
hyperin	aldose reductase inhibitor	ACE, AKR1B1			Preclinical
hypoestoxide	IKK inhibitor	IKBKB, IL1B, TNF			Phase 1
hypoxanthine	PARP inhibitor	PNP			Preclinical
H2L-5765834	lysophosphatidic acid receptor antagonist	LPAR1, LPAR3			Preclinical
I-BET-762	bromodomain inhibitor	BRD2, BRD3, BRD4			Phase 2
I-BET151	bromodomain inhibitor	BRD2, BRD3, BRD4			Preclinical
I-BRD9	bromodomain inhibitor	BRD9			Preclinical
I-BZA					Phase 2
I-BZA2					Phase 3
I-CBP-112	bromodomain inhibitor	CREBBP, EP300			Preclinical
IACS-10759	mitochondrial complex I inhibitor				Preclinical
IB-MECA	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Phase 3
ibandronate	bone resorption inhibitor	FDPS	orthopedics	osteoporosis	Launched
IBC-293	hydroxycarboxylic acid receptor agonist	HCAR3			Preclinical
iberdomide	cereblon modulator				Preclinical
ibiglustat	glucosylceramidase inhibitor				Preclinical
IBMX	phosphodiesterase inhibitor	ADORA1, PDE2A, PDE3B, PDE4D, PDE5A, PDE6G, PDE7A, PDE8A, PDE9A			Preclinical
ibotenic-acid	glutamate receptor agonist	GRIN1			Preclinical
ibrolipim	lipoprotein lipase activator	LPL			Phase 2
ibrutinib	Bruton's tyrosine kinase (BTK) inhibitor	BLK, BMX, BTK	hematologic malignancy	chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)	Launched
ibudilast	leukotriene receptor antagonist, phosphodiesterase inhibitor	IL1B, IL6, PDE3A, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A	pulmonary, neurology/psychiatry	asthma, stroke	Launched
ibuprofen	cyclooxygenase inhibitor		neurology/psychiatry, rheumatology, otolaryngology, obstetrics/gynecology, endocrinology, dental	headache, muscle pain, rheumatoid arthritis, backache, common cold, menstrual pain, fever, toothache	Launched
ibuprofen-(S)	cyclooxygenase inhibitor	ASIC1, PTGS1, PTGS2, SLC5A8	neurology/psychiatry	pain relief	Launched
ibuprofen-lysine	cyclooxygenase inhibitor		cardiology	patent ductus arteriosus (PDA)	Launched
ibuprofen-piconol	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	Launched
ibuproxam	cyclooxygenase inhibitor, prostaglandin inhibitor	ALOX5	endocrinology, rheumatology, neurology/psychiatry	fever, joint inflammation, pain relief	Launched
ibutamoren	growth hormone secretagogue receptor agonist	GHR, GHSR			Phase 2
ibutilide	potassium channel blocker	CACNA1C, KCNH2	cardiology	atrial fibrillation (AF)	Launched
ICA-069673	voltage-gated potassium channel activator	KCNQ2, KCNQ3			Preclinical
ICA-110381	voltage-gated potassium channel activator	KCNQ2			Preclinical
ICA-121431	sodium channel blocker	SCN1A, SCN3A			Preclinical
icariin	phosphodiesterase inhibitor	PDE5A			Phase 3
icaritin	PPAR receptor antagonist	PDE5A			Phase 3
icatibant-acetate	bradykinin receptor antagonist	BDKRB2	cardiology	angioedema	Launched
ICG-001	beta-catenin inhibitor	CTNNB1			Preclinical
ICI-118,551	adrenergic receptor antagonist	ADRB2, ADRB3			Phase 2
ICI-162846	histamine receptor antagonist	HRH2			Phase 1
ICI-169369	serotonin receptor antagonist				Phase 2
ICI-185,282	thromboxane receptor antagonist				Phase 1
ICI-192605	thromboxane receptor antagonist	TBXA2R			Phase 2
ICI-199441	opioid receptor agonist	CYP2D6, OPRD1, OPRK1, OPRM1, UTS2R			Preclinical
ICI-215,001	adrenergic receptor agonist	ADRB3			Preclinical
ICI-63197	phosphodiesterase inhibitor				Preclinical
ICI-89406	adrenergic receptor antagonist	ADRB1, ADRB2			Phase 1
icilin	TRPV agonist	TRPA1, TRPM8			Phase 1
iclaprim	dihydrofolate reductase inhibitor				Phase 3
icomucret	mucin production enhancer	LTB4R2			Phase 3
icosapent	platelet aggregation inhibitor	ACSL3, ACSL4, FADS1, FFAR1, PPARD, PPARG, PTGS1, PTGS2, SLC8A1, TRPV1	endocrinology	hypertriglyceridemia	Launched
icotinib	EGFR inhibitor	EGFR	oncology	non-small cell lung cancer (NSCLC)	Launched
iCRT-14	beta catenin inhibitor, WNT signaling inhibitor	CTNNB1, TCF4			Preclinical
IC261	casein kinase inhibitor	CSNK1A1, CSNK1D, CSNK1E, CSNK1G2			Preclinical
ID-1101	insulin sensitizer	INS			Phase 1
ID-8					Preclinical
idalopirdine	serotonin receptor antagonist	HTR6			Phase 3
idarubicin	topoisomerase inhibitor	TOP2A	hematologic malignancy	acute myeloid leukemia (AML)	Launched
idasanutlin	MDM inhibitor	MDM2, TP53			Phase 3
idazoxan	adrenergic receptor antagonist	ADRA2A, PTGS2			Phase 3
idebenone	calcium channel modulator		neurology/psychiatry, ophthalmology	Alzheimer's disease, Friedreich's ataxia, Leber hereditary optic neuropathy (LHON)	Launched
idelalisib	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG	hematologic malignancy	chronic lymphocytic leukemia (CLL)	Launched
IDF-11774	hypoxia inducible factor inhibitor				Preclinical
IDH-305	isocitrate dehydrogenase inhibitor				Phase 2
idoxuridine	DNA directed DNA polymerase inhibitor, DNA synthesis inhibitor		infectious disease	virus herpes simplex (HSV)	Launched
IDO5L	indoleamine 2,3-dioxygenase inhibitor	IDO1			Preclinical
IDRA-21	glutamate receptor positive allosteric modulator	GRIA1, GRIA2, GRIA3, GRIA4			Preclinical
idramantone					Preclinical
idronoxil	XIAP inhibitor	ENOX2, SPHK1			Phase 3
IEM1460	glutamate receptor antagonist	GRIA2			Preclinical
IEM1754	glutamate receptor antagonist	GRIA1			Preclinical
ifenprodil	adrenergic receptor antagonist, glutamate receptor antagonist	GRIN2B			Launched
ifosfamide	DNA alkylating agent	CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1	oncology, urology	testicular carcinoma, hemorrhagic cystitis	Launched
igmesine	sigma receptor agonist	SIGMAR1			Phase 2
iguratimod	cyclooxygenase inhibitor, NFkB pathway inhibitor	PTGS2	rheumatology	rheumatoid arthritis	Launched
IKK-16	IKK inhibitor	IKBKB			Preclinical
IKK-2-inhibitor	IKK inhibitor, SYK inhibitor	IKBKB			Preclinical
IKK-2-inhibitor-V	IKK inhibitor, NFkB pathway inhibitor	IKBKB			Phase 1
ilaprazole	proton pump inhibitor		gastroenterology	gastroesophageal reflux disease (GERD)	Launched
ilepcimide	anticonvulsant				Phase 3
ilomastat	matrix metalloprotease inhibitor	ACAN, ADAM28, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP8, MMP9			Phase 3
iloperidone	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR6, HTR7	neurology/psychiatry	schizophrenia	Launched
iloprost	platelet aggregation inhibitor, prostanoid receptor agonist	PTGDR, PTGER1, PTGER2, PTGER3, PTGER4, PTGFR, PTGIR, TBXA2R	pulmonary	pulmonary arterial hypertension (PAH)	Launched
imatinib	Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET	hematologic malignancy, oncology	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)	Launched
Imazodan	phosphodiesterase inhibitor				Phase 1
imeglimin	gluconeogenesis inhibitor				Phase 2
imetit	histamine receptor agonist	HRH3, HRH4			Preclinical
imexon	apoptosis stimulant, ribonucleotide reductase inhibitor				Phase 2
imidacloprid	acetylcholine receptor antagonist				Launched
imidafenacin	acetylcholine receptor antagonist	CHRM1, CHRM3	neurology/psychiatry	spasms	Launched
imidapril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, congestive heart failure	Launched
imidazoacridinone	anticancer agent				Preclinical
imidurea	other antibiotic				Preclinical
imiloxan	adrenergic receptor antagonist	ADRA2A, ADRA2B			Phase 1
imipenem	bacterial cell wall synthesis inhibitor		infectious disease	pneumonia, urinary tract infections, intra-abdominal infections, gynecologic infections, bacterial septicemia, bone and joint infections, skin infections, endocarditis	Launched
imipramine	norepinephrine reputake inhibitor, serotonin reuptake inhibitor	ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7, KCND2, KCND3, KCNH1, KCNH2, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry, urology	depression, nocturnal enuresis	Launched
imiquimod	interferon inducer, toll-like receptor agonist	TLR7, TLR8	dermatology, infectious disease, oncology	actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)	Launched
imirestat	aldose reductase inhibitor				Preclinical
imisopasem-manganese	superoxide dismutase mimetic				Preclinical
immepip	histamine receptor agonist	HRH3, HRH4			Preclinical
immethridine	histamine receptor agonist	HRH3			Phase 1
impentamine	histamine receptor antagonist	HRH3			Preclinical
IMREG-1					Phase 3
inarigivir	antiviral				Phase 2
inarigivir-soproxil	antiviral				Phase 2
INC-280	c-Met inhibitor	MET			Phase 3
INCA-6	calcineurin inhibitor	NFATC1			Preclinical
INCB-003284	CC chemokine receptor antagonist				Phase 2
INCB-057643	bromodomain inhibitor				Phase 1/Phase 2
INCB-3284	CC chemokine receptor antagonist	CCR2			Phase 2
incyclinide	matrix metalloprotease inhibitor				Phase 2
indacaterol	adrenergic receptor agonist	ADRB1, ADRB2	pulmonary	chronic obstructive pulmonary disease (COPD)	Launched
indalpine	selective serotonin reuptake inhibitor (SSRI)	SLC6A4			Withdrawn
indapamide	thiazide diuretic	CA2, HTR3A, KCNQ1	cardiology	hypertension, congestive heart failure	Launched
indatraline	norepinephrine transporter inhibitor	MAOA, MAOB			Preclinical
indeglitazar	PPAR receptor agonist	NCOA1, PPARA, PPARD, PPARG			Phase 2
indeloxazine	norepinephrine reuptake inhibitor, serotonin reuptake inhibitor				Withdrawn
indibulin	tubulin polymerization inhibitor				Phase 1/Phase 2
indinavir	HIV protease inhibitor	CYP3A4, CYP3A5, CYP3A7	infectious disease	human immunodeficiency virus (HIV-1)	Launched
indiplon	benzodiazepine receptor agonist	GABRA1			Phase 3
indirubin	CDK inhibitor, glycogen synthase kinase inhibitor	CDK1, CDK5, GSK3A			Phase 2/Phase 3
indirubin-3-monoxime	CDK inhibitor, glycogen synthase kinase inhibitor	CDK1, CDK2, CDK5, CDK5R1, GSK3B			Preclinical
indisulam	CDK inhibitor	CA1, CA12, CA14, CA2, CA6, CA7, CA9			Phase 2
indium(III)-isopropoxide					Preclinical
indium-tri(2-propanolate)					Preclinical
indobufen	cyclooxygenase inhibitor, platelet aggregation inhibitor	PTGS1, PTGS2	hematology	thrombosis	Launched
indocyanine-green	contrast agent	SLCO1B1	cardiology	vascular imaging agent	Launched
indole-3-carbinol	aryl hydrocarbon receptor agonist, indoleamine 2,3-dioxygenase inhibitor	AHR			Phase 2/Phase 3
indole-3-pyrubate	melatonin receptor agonist				Phase 2
indomethacin	cyclooxygenase inhibitor	GLO1, PLA2G2A, PPARA, PPARG, PTGDR2, PTGR2, PTGS1, PTGS2, SLC46A1	rheumatology, orthopedics	rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, bursitis, tendinitis	Launched
indoprofen	cyclooxygenase inhibitor, prostanoid receptor antagonist	CXCR1, CXCR2, PTGS1, PTGS2			Withdrawn
indoramin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2B, ADRA2C	urology, cardiology	benign prostatic hyperplasia (BPH), hypertension	Launched
indoximod	indoleamine 2,3-dioxygenase inhibitor	IDO1			Phase 2
ingenol	PKC activator	PRKCD, PRKCE	dermatology	keratosis	Launched
ingenol-mebutate	PKC activator	PRKCA, PRKCB, PRKCD, PRKCE, PRKCG	dermatology	actinic keratosis (AK)	Launched
INH1	Hec1 inhibitor	NDC80			Preclinical
inimur	other antifungal				Launched
iniparib	PARP inhibitor	PARP1			Phase 3
inosine	neurotrophic agent	PARP1, PNP			Launched
inositol	insulin sensitizer	CDIPT	obstetrics/gynecology	polycystic ovary syndrom (PCOS)	Launched
inositol-hexanicotinate			dermatology, cardiology, rheumatology, neurology/psychiatry	statis dermatitis, claudication, Raynaud's disease, hypertension, insomnia, atherosclerosis, restless leg syndrome, schizophrenia, psoriasis, acne vulgaris (AV)	Launched
INS316	purinergic receptor antagonist				Phase 2
INT-747	FXR agonist				Phase 3
INT-767	FXR agonist	GPBAR1			Phase 1
integrin-antagonist-1	integrin antagonist	ITGAV, ITGB6			Phase 1
INX-08189	antiviral				Phase 2
iobenguane	antineoplastic agent		oncology, cardiology, endocrinology	neuroblastoma, congestive heart failure, pheochromocytoma	Launched
iocetamic-acid	radiopaque medium		radiology	contrast agent	Launched
iodipamide	radiopaque medium	ALB	radiology	contrast agent	Launched
iodixanol	radiopaque medium		radiology	contrast agent	Launched
iodoantipyrine					Preclinical
iododexetimide	acetylcholine receptor antagonist				Phase 2
iodophenpropit	histamine receptor antagonist	HRH3, HRH4			Preclinical
iodoquinol	antiseptic		infectious disease	amebiasis	Launched
iohexol	radiopaque medium		radiology	contrast agent	Launched
iopamidol	radiopaque medium		radiology	contrast agent	Launched
iopanic-acid	thyroid hormone inhibitor				Withdrawn
iopodic-acid			radiology	contrast agent	Launched
iopromide	radiopaque medium		radiology	contrast agent	Launched
iothalamic-acid-d3	radiopaque medium				Preclinical
ioversol	radiopaque medium		radiology	contrast agent	Launched
IOWH032	CFTR channel antagonist	CFTR			Phase 2
ioxaglic-acid	radiopaque medium		radiology	contrast agent	Launched
ioxilan	radiopaque medium		radiology	angiography	Launched
IOX1	histone demethylase inhibitor	EGLN1, KDM3A, KDM4C, KDM6B			Preclinical
IOX2	hypoxia inducible factor inhibitor	EGLN1, KDM2A, KDM5C			Preclinical
IPA-3	p21 activated kinase inhibitor	PAK1			Preclinical
IPAG					Preclinical
ipidacrine	acetylcholinesterase inhibitor	ACHE			Phase 3
IPI549	PI3K inhibitor				Phase 2
ipragliflozin-L-proline	sodium/glucose cotransporter inhibitor	SLC5A2	endocrinology	diabetes mellitus	Launched
ipratropium	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	pulmonary	bronchospasm, chronic obstructive pulmonary disease (COPD), bronchitis, emphysema	Launched
ipriflavone	bone resorption inhibitor		orthopedics	osteoporosis	Launched
iproniazid	monoamine oxidase inhibitor	MAOA, MAOB			Withdrawn
ipsapirone	serotonin receptor agonist	HTR1A			Phase 3
irbesartan	angiotensin receptor antagonist	AGTR1, JUN, SLC10A1	cardiology, nephrology	hypertension, diabetic nephropathy	Launched
irganox-1010	antioxidant				Preclinical
iRGD-peptide	integrin signaling activator				Preclinical
irinotecan	topoisomerase inhibitor	TOP1, TOP1MT	oncology	colorectal cancer	Launched
IRL-2500	endothelin receptor antagonist	EDNRB			Preclinical
irosustat	steroid sulfatase inhibitor	CA2, STS			Phase 2
irsogladine	phosphodiesterase inhibitor	PDE4A	gastroenterology	peptic ulcer disease (PUD)	Launched
isamoltane	adrenergic receptor antagonist	HTR1A, HTR1B			Phase 1
isavuconazole	cytochrome P450 inhibitor	CYP3A4			Phase 3
isaxonine	nerve growth factor agonist				Withdrawn
isbufylline	phosphodiesterase inhibitor				Phase 2
isepamicin	protein synthesis inhibitor		infectious disease	pneumonia, peritonitis	Launched
ISO-1	macrophage migration inhibiting factor inhibitor	MIF			Preclinical
isobutamben	local anesthetic				Preclinical
isobutyramide	gene expression stimulant	HBE1, HBG1			Phase 2
isocarboxazid	monoamine oxidase inhibitor	MAOA, MAOB	neurology/psychiatry	depression	Launched
isoconazole	fungal lanosterol demethylase inhibitor	CYP17A1	infectious disease	gram-positive bacterial infections	Launched
isodibut	aldehyde reductase inhibitor				Phase 2
isoetharine	adrenergic receptor agonist		pulmonary	bronchospasm, asthma	Launched
isofloxythepin	dopamine receptor antagonist				Phase 2
isoflupredone-acetate		NR3C1			Preclinical
isoflurane	inhaled anaesthetic	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9	neurology/psychiatry	general anaesthetic	Launched
isoflurophate	cholinesterase inhibitor	ACHE, BCHE	ophthalmology	glaucoma	Launched
isoguvacine	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRR1, GABRR2, GABRR3			Preclinical
isoleucine					Launched
isoliquiritigenin	guanylate cyclase activator	GABBR1			Preclinical
isometheptene-mucate			neurology/psychiatry	headache	Launched
isoniazid	FABI inhibitor	CYP1A2, CYP2C19, CYP2C8, CYP2E1, CYP3A4	infectious disease	tuberculosis	Launched
isopentyl-4-methoxycinnamate			dermatology	sunscreen lotion	Launched
isoprenaline	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3	cardiology, pulmonary	bradycardia, heart block, asthma	Launched
isopropamide-iodide	acetylcholine receptor antagonist	CHRM3, CHRM4	gastroenterology	peptic ulcer disease (PUD), gastrointestinal acidosis	Launched
isopropyl-myristate			dermatology	cosmetic	Launched
isopropyl-palmitate	cosmetic moisturizer		dermatology	cosmetic	Launched
isoquercitrin	antioxidant				Phase 2/Phase 3
Isoquinoline,-6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro,					Preclinical
isosorbide	nitric oxide stimulant		cardiology	angina pectoris, coronary artery disease (CAD)	Launched
isosorbide-dinitrate	nitric oxide stimulant	GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3, NPR1	cardiology	angina pectoris, coronary artery disease (CAD)	Launched
isosorbide-mononitrate	nitric oxide stimulant	GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3	cardiology	angina pectoris, coronary artery disease (CAD)	Launched
isosteviol					Phase 2
isotiquimide					Phase 1
isotretinoin	retinoid receptor agonist	RARA, RARB, RARG	dermatology	acne vulgaris (AV)	Launched
isovaleramide	alcohol dehydrogenase inhibitor				Phase 2
isoxepac	anti-inflammatory agent				Phase 2
isoxicam	cyclooxygenase inhibitor	PTGS1, PTGS2			Withdrawn
isoxsuprine	adrenergic receptor agonist	ADRB2	rheumatology, cardiology	Raynaud's disease, arteriosclerosis, Buerger's disease	Launched
ispinesib	kinesin inhibitor	KIF11			Phase 2
isradipine	calcium channel blocker	CACNA1D, CACNA1F, CACNA2D1	cardiology	hypertension	Launched
ISRIB	eukaryotic translation initiation factor inhibitor, PERK inhibitor	EIF2A, EIF2AK3			Preclinical
istaroxime	ATPase inhibitor	ATP1A1			Phase 2
istradefylline	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3	neurology/psychiatry	Parkinson's Disease, dyskinesia	Launched
ISX-9	neural stem cell inducer	NEUROD1			Preclinical
itacitinib	JAK inhibitor	JAK1			Phase 3
ITD-1	TGF beta receptor inhibitor	TGFBR2			Preclinical
ITE	aryl hydrocarbon receptor agonist	AHR			Preclinical
ITI214	phosphodiesterase inhibitor	PDE1A			Phase 1/Phase 2
itopride	dopamine receptor antagonist	CHRM3, DRD2	gastroenterology, neurology/psychiatry	dyspepsia, gastroparesis, heartburn, nausea, vomiting, anorexia	Launched
itraconazole	cytochrome P450 inhibitor		infectious disease	onychomycosis, histoplasmosis, blastomycosis, aspergillosis	Launched
ITX3	GEF inhibitor	TRIO			Preclinical
ITX5061	SR-BI inhibitor				Phase 1
IT1t	CC chemokine receptor antagonist	CXCR4			Preclinical
IU1	ubiquitin C-terminal hydrolase inhibitor	USP14			Preclinical
ivabradine	HCN channel blocker, potassium channel blocker, sodium channel blocker	HCN1, HCN3, HCN4	cardiology	angina pectoris	Launched
ivacaftor	CFTR channel potentiator	CFTR	pulmonary	cystic fibrosis	Launched
ivermectin	benzodiazepine receptor agonist	CHRNA7, P2RX7	infectious disease	gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies	Launched
ivosidenib	isocitrate dehydrogenase inhibitor	IDH1	hematologic malignancy	acute myeloid leukemia (AML)	Launched
IWP-L6	porcupine inhibitor	PORCN			Preclinical
ixabepilone	microtubule stabilizing agent	TUBB	oncology	breast cancer	Launched
ixazomib	proteasome inhibitor		hematologic malignancy	multiple myeloma	Launched
ixazomib-citrate	proteasome inhibitor		hematologic malignancy	multiple myeloma	Launched
JAK3-inhibitor-V	JAK inhibitor	JAK3			Preclinical
JD-5037	cannabinoid receptor antagonist				Preclinical
JDTic	opioid receptor antagonist	OPRK1			Phase 1
JHW-007	dopamine reuptake inhibitor	SLC6A3			Preclinical
JI-101	kinase inhibitor				Phase 1/Phase 2
JIB04	histone lysine demethylase inhibitor	KDM4E			Preclinical
JK-184	hedgehog pathway inhibitor				Preclinical
JLK-6	gamma secretase inhibitor	PSEN1			Preclinical
JNJ-10191584	histamine receptor antagonist	HRH4			Preclinical
JNJ-10397049	orexin receptor antagonist	HCRTR1, HCRTR2			Preclinical
JNJ-16259685	glutamate receptor antagonist	GRM1			Preclinical
JNJ-1661010	FAAH inhibitor	FAAH			Preclinical
JNJ-17203212	TRPV antagonist	TRPV1			Preclinical
JNJ-26481585	HDAC inhibitor	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, MDM2			Phase 2
JNJ-26990990	anticonvulsant				Phase 2
JNJ-27141491	CC chemokine receptor antagonist	CCR2			Preclinical
JNJ-37822681	dopamine receptor antagonist	DRD2			Phase 2
JNJ-38877605	tyrosine kinase inhibitor	MET			Phase 1
JNJ-38877618	c-Met inhibitor				Phase 1
JNJ-39758979	histamine receptor antagonist				Phase 2
JNJ-40411813	glutamate receptor positive allosteric modulator	GRM2			Phase 2
JNJ-42041935	hypoxia inducible factor prolyl hydroxylase inhibitor	PDK2			Preclinical
JNJ-42165279	FAAH inhibitor	FAAH			Phase 2
JNJ-47965567	purinergic receptor antagonist	P2RX7			Preclinical
JNJ-54175446	purinergic receptor antagonist				Phase 1
JNJ-63533054	G protein-coupled receptor agonist	GPR139			Preclinical
JNJ-64619178	protein arginine N-methyltransferase inhibitor				Phase 1
JNJ-678	RSV fusion inhibitor				Phase 1
JNJ-7706621	CDK inhibitor	AURKA, AURKB, CDK1, CDK2			Preclinical
JNJ-7777120	histamine receptor antagonist	HRH4			Preclinical
josamycin	bacterial 50S ribosomal subunit inhibitor		pulmonary	bronchitis	Launched
JPH203	solute carrier family member inhibitor				Preclinical
JQ1-(+)	bromodomain inhibitor	BRD4, BRDT			Preclinical
JTC-801	opioid receptor antagonist	OPRL1			Phase 2
JTE-013	lysophospholipid receptor antagonist	P2RY10, S1PR2			Preclinical
JTE-607	cytokine production inhibitor	IL10, IL1B, IL6, TNF			Phase 2
JTE-907	cannabinoid receptor inverse agonist	CNR2			Phase 1
JW-55	tankyrase inhibitor	TNKS, TNKS2			Preclinical
JW-642	monoacylglycerol lipase inhibitor	MGLL			Preclinical
JW-67	WNT pathway inhibitor	APC, AXIN1, GSK3B			Preclinical
JW-74	tankyrase inhibitor, WNT signaling inhibitor	TNKS, TNKS2			Preclinical
JX-401	p38 MAPK inhibitor	MAPK14			Preclinical
JZL-184	monoacylglucerol lipase inhibitor	MGLL			Preclinical
JZL-195	FAAH inhibitor, monoacylglycerol lipase inhibitor	FAAH, MGLL			Preclinical
J147	BDNF inducer				Phase 1
K-MAP					Phase 2
K-Ras(G12C)-inhibitor-12	K-Ras inhibitor	KRAS			Preclinical
K-Ras(G12C)-inhibitor-6	K-Ras inhibitor				Preclinical
K-strophanthidin	ATPase inhibitor	ATP1A1			Phase 2
K-247					Phase 1
K-858	kinesin-like spindle protein inhibitor	KIF11			Preclinical
kaempferol	bone resorption inhibitor, estrogen-related receptor inverse agonist	AKR1B1, ALOX15B, ALOX5, AR, CYP1B1, GLO1, HSD17B1, UGT3A1			Preclinical
KAF-156	antimalarial agent				Preclinical
kainic-acid	kainate receptor agonist	GRIA1, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5			Preclinical
kakonein	GABA receptor antagonist, serotonin receptor antagonist				Phase 2
kanamycin	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	Launched
karenitecin	topoisomerase inhibitor	TOP1			Phase 3
kartogenin	chondrocyte differentiation stimulator	FLNA			Preclinical
kasugamycin	bacterial 30S ribosomal subunit inhibitor				Preclinical
KB-R7943	sodium/calcium exchange inhibitor	SLC8A1, TRPC3, TRPC5, TRPC6			Preclinical
KB-SRC-4	SRC inhibitor	SRC			Preclinical
KBG	neprilysin inhibitor	MME			Phase 2
KD-023	ACAT inhibitor	ACACA, ACACB			Phase 2
KD025	rho associated kinase inhibitor	ROCK2			Phase 2
kenpaullone	CDK inhibitor, glycogen synthase kinase inhibitor	CCNB1, CDK1, CDK5, GSK3B			Preclinical
ketanserin	serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, DRD1, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A, HTR7, SLC18A1, SLC18A2	cardiology	hypertension	Launched
ketoconazole	sterol demethylase inhibitor	KCNA10	dermatology	seborrheic dermatitis	Launched
ketohexokinase-inhibitor-1	kinase inhibitor				Preclinical
ketoprofen	cyclooxygenase inhibitor	PTGS1, PTGS2, SLC5A8	rheumatology	rheumatoid arthritis, osteoarthritis	Launched
ketorolac	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	Launched
ketotifen	histamine receptor agonist, leukotriene receptor antagonist, phosphodiesterase inhibitor	HRH1	neurology/psychiatry	itching	Launched
kevetrin	p53 activator				Phase 1
KF-38789	P selectin inhibitor	SELP			Preclinical
KG-5	RAF inhibitor	BRAF, FLT3, KIT, PDGFRB			Preclinical
KH-CB19	CDC inhibitor	CLK1, CLK3, DYRK1A			Preclinical
khellin	vasodilator				Phase 2
KHK-IN-1	hexokinase inhibitor	KHK			Preclinical
KHS-101	neural stem cell inducer	TACC3			Preclinical
KI-16425	lysophosphatidic acid receptor antagonist	LPAR1, LPAR3			Preclinical
KI-20227	c-Fms inhibitor	CSF1R, KDR, KIT, PDGFRB			Preclinical
KI-8751	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	KDR			Preclinical
kifunensine	mannosidase inhibitor	MAN1B1, MAN2A1			Phase 1
kinetin	cell division inducer		dermatology	sunburn	Launched
ki16198	lipoprotein antagonist	LPA			Preclinical
KL-001	proteasome inhibitor	CRY1, CRY2			Preclinical
KM-0118	anticancer agent				Phase 1
KME-4	prostaglandin inhibitor				Preclinical
KML29	monoacylglucerol lipase inhibitor	MGLL			Preclinical
KN-62	calcium/calmodulin dependent protein kinase inhibitor, purinergic receptor antagonist	AKT1, CAMK2A, CHEK1, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, P2RX7, PRKCA, ROCK1, RPS6KB1, SGK1			Preclinical
KN-93	calcium/calmodulin dependent protein kinase inhibitor	CAMK2A			Preclinical
Ko143	BCRP inhibitor	ABCB1, ABCC1			Preclinical
KP-1212					Phase 2
KPT-185	exportin antagonist	XPO1			Preclinical
KPT-276	exportin antagonist	XPO1			Preclinical
KPT-9274	NAMPT inhibitor				Phase 1
KR-33494	cell death inhibitor 				Preclinical
KRCA-0008	ALK inihibitor	ALK			Preclinical
KRN-633	VEGFR inhibitor	FLT1, FLT4, KDR			Preclinical
KS-176	BCRP inhibitor	ABCG2			Preclinical
KT-433	uricosuric agent				Phase 2
KU-0063794	mTOR inhibitor	MTOR			Preclinical
KU-55933	ATM kinase inhibitor	ATM, PRKDC			Preclinical
KU-60019	ATM kinase inhibitor	ATM			Preclinical
kuromanin	ribosyl cyclase inhibitor	CD38			Preclinical
KU14R	imidazoline receptor antagonist				Preclinical
KW-2449	Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor	ABL1, AURKA, AURKB, FLT3			Phase 1
KW-2478	HSP inhibitor				Phase 1/Phase 2
KW-3902	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Phase 3
KX2-391	SRC inhibitor, tubulin polymerization inhibitor	SRC			Phase 3
kynurenic-acid	glutamate receptor antagonist	GPR35, GRIN1, GRIN2A, GRIN2B			Phase 1
KY02111	WNT pathway inhibitor	DKK1			Preclinical
K02288	bone morphogenic protein inhibitor	BMP1			Preclinical
K145	sphingosine kinase inhibitor	SPHK2			Preclinical
L-(+)-rhamnose-monohydrate					Preclinical
L-alanine		AARS, AARS2, ABAT, AGXT, AGXT2, GPRC6A, GPT, GPT2, KYNU, NFS1, PHYKPL, SLC1A4, SLC36A1, SLC7A8			Launched
L-arginine	nitric oxide precursor	ARG2, ASL, ASS1, AZIN2, GPRC6A, NOS2, NOS3, SLC7A1, SLC7A3, SLC7A4	cardiology, neurology/psychiatry, urology, obstetrics/gynecology, otolaryngology	congestive heart failure, hypertension, coronary artery disease (CAD), claudication, senile dementia, erectile dysfunction, infertility, common cold	Launched
L-ascorbyl-6-palmitate					Preclinical
L-asparagine		ASNS, ASRGL1, NARS, NARS2, SLC1A5, SLC38A3			Phase 3
L-asparagine-N-hydroxy					Preclinical
L-aspartic-acid	metallic radical formation stimulant	ACY1, ACY3, ADSS, ADSSL1, ASNS, ASPA, ASPH, ASRGL1, ASS1, CAD, DARS, DARS2, GOT1, GOT2, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, LYZ, PAICS, RNASE1, SLC1A1, SLC25A12, SLC25A13			Launched
L-citrulline	nitric oxide stimulant	ASS1, DDAH1, DDAH2, GPRC6A, NOS1, NOS2, NOS3, OTC, PADI1, PADI2, PADI3, PADI4, PADI6	cardiology, urology	hypertension, erectile dysfunction	Launched
L-cysteine		CARS, CARS2, CBS, CDO-1, CDO1, CSAD, CTH, GCLC, GCLM, GOT1, GSS, MGMT, NFS1, SLC19A3	rheumatology	osteoarthritis, rheumatoid arthritis	Launched
L-cysteinesulfinic-acid	glutamate receptor agonist	GRM1, GRM5, GSR, HMGCS2, PAPOLA, PRDX2			Preclinical
L-cystine		CTNS, SLC3A1, SLC7A11, SLC7A9			Launched
L-ergothioneine	free radical scavenger				Phase 3
L-glutamic-acid	glutamate receptor agonist	AADAT, AASS, ABAT, ALDH18A1, ASNS, BCAT1, BCAT2, CCBL2, DNPEP, EARS2, ENPEP, EPRS, FOLH1, FPGS, FTCD, GAD1, GAD2, GATB, GCLC, GCLM, GGCX, GLS, GLS2, GLUD1, GLUD2, GLUL, GMPS, GOT1, GOT2, GPT, GPT2, GRIA1, GRIA2, GRIA3, GRIA4, GRID1, GRID2, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, GRM1, GRM2, GRM3, GRM4, GRM6, GRM7, GRM8, LGSN, NADSYN1, NAGS, OPLAH, PFAS, PGCP, PSAT1, SLC1A1, SLC1A2, SLC1A3, SLC1A6, SLC1A7, SLC25A18, SLC25A22, SLC7A11, TAT			Launched
L-glutamine		CTPS1, GLUL, GPRC6A, PPAT	gastroenterology, dental, neurology/psychiatry, rheumatology	diarrhea, mucositis, muscle pain, joint pain, peptic ulcer disease (PUD), ulcerative colitis, Crohn's disease, anxiety, insomnia	Launched
L-hydroxyproline					Launched
L-kynurenine	aryl hydrocarbon receptor agonist				Phase 1
L-leucine		BCAT1, BCAT2, LARS, LARS2, LCMT1, LCMT2			Phase 3
L-lysine	serotonin receptor agonist	GPRC6A, KARS, SLC7A1, SLC7A2, SLC7A3, SLC7A4			Phase 2
L-methionine	voltage-gated calcium channel ligand	BHMT, BHMT2, METAP2, MTR, MTRR	pulmonary, allergy, neurology/psychiatry	asthma, allergic rhinitis, depression, Parkinson's Disease, schizophrenia	Launched
L-mimosine	dopamine beta hydroxylase inhibitor, eukaryotic translation initiation factor inhibitor	DBH, EIF5A			Preclinical
L-monomethylarginine	nitric oxide synthase inhibitor	NOS1, NOS2			Phase 3
L-NAME	nitric oxide synthase inhibitor	NOS3			Phase 2/Phase 3
L-NIL	nitric oxide synthase inhibitor	NOS1, NOS2, NOS3			Preclinical
L-phenylisopropyladenosine					Preclinical
L-proline	glutamate receptor agonist	EPRS, L3HYPDH, P3H1, P3H2, P3H3, P4HA1, P4HA2, PARS2, PPIA, PPIB, PPIC, PPIF, PPIG, PPIH, PRODH, PROSC, PYCR1, PYCR2, PYCRL, SLC6A14, SLC6A7			Launched
L-quisqualic-acid	glutamate receptor agonist	FOLH1, GRIA2, GRIK1, GRIK2, GRM1, GRM2, GRM3, GRM5, GRM7, GRM8			Preclinical
L-theanine	glutamate receptor antagonist				Launched
L-threonine		TARS, TARS2, THNSL1			Phase 2
L-valine					Phase 2
L-152804	neuropeptide receptor antagonist	NPY5R			Preclinical
L-161982	prostanoid receptor antagonist	PTGER4			Preclinical
L-165041	PPAR receptor agonist	PPARD			Preclinical
L-168049	glucagon receptor antagonist	GCGR			Preclinical
L-365260	CCK receptor antagonist	CCKAR, CCKBR, KCNQ1			Phase 2
L-368899	oxytocin receptor antagonist	AVPR1A, AVPR2, OXTR			Phase 1
L-655,708	GABA receptor inverse agonist	GABRA1, GABRA2, GABRA3, GABRA5, GABRG2			Preclinical
L-655240	thromboxane receptor antagonist	PTGES			Phase 1
L-670596	prostanoid receptor antagonist				Preclinical
L-689560	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			Preclinical
L-690330	inositol monophosphatase inhibitor	IMPA1			Preclinical
L-693403	sigma receptor agonist, sigma receptor antagonist	DRD2, SIGMAR1			Preclinical
L-694247	serotonin receptor agonist	HTR1A, HTR1B, HTR1D			Preclinical
L-701252	glutamate receptor antagonist	GRIN1			Preclinical
L-701324	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			Preclinical
L-732,138	tachykinin antagonist	TACR1, TACR2			Preclinical
L-733060	tachykinin antagonist	TACR1			Preclinical
L-741742	dopamine receptor antagonist	DRD3, DRD4, SCN1A, SCN3A			Preclinical
L-745870	dopamine receptor antagonist	DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR6, HTR7			Preclinical
L-755507	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3			Preclinical
L-760735	tachykinin antagonist	TACR1			Preclinical
L-778123	farnesyltransferase inhibitor	FNTA, FNTB, PGGT1B			Phase 1
L-798106	prostanoid receptor antagonist	PTGER3			Preclinical
L-838417	GABA receptor partial agonist	GABRA1, GABRA2, GABRA3, GABRA5			Preclinical
labetalol	adrenergic receptor antagonist	ADRA1D, ADRB1, ADRB2	cardiology	hypertension	Launched
lacidipine	calcium channel blocker	CACNA1C	cardiology	hypertension	Launched
lacitol	laxative		gastroenterology	constipation	Launched
lactulose	laxative		gastroenterology	portal-systemic encephalopathy (PSE)	Launched
lafutidine	histamine receptor antagonist	HRH2	gastroenterology	duodenal ulcer disease, peptic ulcer disease (PUD)	Launched
lamivudine	nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1), acquired immunodeficiency syndrome (AIDS), hepatitis B	Launched
lamotrigine	serotonin receptor antagonist, sodium channel blocker	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	epilepsy, bipolar disorder	Launched
lanabecestat	beta secretase inhibitor				Phase 3
lanatoside-C	cardiac glycoside				Preclinical
landiolol	adrenergic receptor antagonist	ADRB1	cardiology	cardiac arrythmia	Launched
lanifibranor	PPAR receptor agonist				Phase 2
lanoconazole	sterol demethylase inhibitor		infectious disease	fungal infection	Launched
lansoprazole	ATPase inhibitor	ATP4A, ATP4B	gastroenterology	heartburn	Launched
lapatinib	EGFR inhibitor	EGFR, ERBB2	oncology	breast cancer	Launched
lappaconite	sodium channel blocker				Phase 2
laquinimod	immunosuppressant	CXCL2			Phase 3
larazotide-acetate	tight junction regulator				Phase 2
laropiprant	prostanoid receptor antagonist	PTGDR, PTGDR2, PTGER1, PTGER2, PTGER3, PTGFR, PTGIR, TBXA2R	cardiology	cholesterol	Launched
larotrectinib	tropomyosin receptor kinase inhibitor	NTRK1, NTRK2, NTRK3			Launched
lasalocid	bacterial permeability inducer		infectious disease	coccidiosis	Launched
lasmiditan	serotonin receptor agonist				Launched
lasofoxifene	selective estrogen receptor modulator (SERM)	ESR1, ESR2	orthopedics, oncology	osteoporosis, breast cancer	Launched
latanoprost	prostanoid receptor agonist	PTGFR	ophthalmology	ocular hypertension, glaucoma	Launched
latrepirdine	glutamate receptor antagonist	HRH1, HTR6			Phase 3
latrunculin-B	actin polymerization inhibitor	ACTA1, MKL1, SPIRE2			Phase 1
lauric-acid	bacterial permeability inducer	GPR84, HNF4A, LTF, LY96, PLA2G2A, TLR4			Phase 3
lauric-diethanolamide					Preclinical
laurocapram					Phase 3
lazabemide	monoamine oxidase inhibitor	MAOB			Phase 3
lazertinib	tyrosine kinase inhibitor				Phase 1/Phase 2
LB-100	protein phosphatase inhibitor				Phase 2
LB42708	farnesyltransferase inhibitor				Preclinical
LCL-161	XIAP inhibitor	BIRC2, XIAP			Phase 2
LCQ908	diacylglycerol O acyltransferase inhibitor	DGAT1			Phase 3
LCZ696	angiotensin receptor antagonist		cardiology	angioedema, hypotension	Launched
LDC1267	protein tyrosine kinase inhibitor	AXL, MERTK, TYRO3			Preclinical
LDN-209929	haspin kinase inhibitor	GSG2			Preclinical
LDN-212854	bone morphogenic protein inhibitor	ABL1, ACVR1, RIPK2			Preclinical
LDN-27219	tissue transglutaminase inhibitor	TGM2			Preclinical
LDN-57444	ubiquitin C-terminal hydrolase inhibitor				Preclinical
LDN193189	bone morphogenic protein inhibitor	ACVR1, BMPR1A			Preclinical
LE-135	retinoid receptor agonist	RARB			Preclinical
ledipasvir	HCV inhibitor		infectious disease	hepatitis C	Launched
leflunomide	dihydroorotate dehydrogenase inhibitor, PDGFR tyrosine kinase receptor inhibitor	AHR, DHODH, PTK2B	rheumatology	rheumatoid arthritis	Launched
lemborexant	orexin receptor antagonist	HCRTR1, HCRTR2			Launched
lenalidomide	anticancer agent	TNF	hematologic malignancy	multiple myeloma, mantle cell lymphoma (MCL), myelodysplastic diseases (MDS)	Launched
leniolisib	PI3K inhibitor				Phase 2/Phase 3
lenvatinib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	FLT4, KDR	oncology	thyroid cancer	Launched
leonurine	anti-inflammatory agent				Preclinical
LEQ506	G protein signaling inhibitor				Phase 1
lercanidipine	calcium channel blocker	CACNA2D1	cardiology	hypertension	Launched
lerisetron	serotonin receptor antagonist	HTR3A			Phase 3
lersivirine	non-nucleoside reverse transcriptase inhibitor				Phase 2
lesinurad	uric acid diuretic	SLC22A12	rheumatology	gout	Launched
lestaurtinib	FLT3 inhibitor, growth factor receptor inhibitor, JAK inhibitor	FLT3, NTRK1			Phase 3
leteprinim	nerve growth factor agonist				Phase 2
letermovir	CMV terminase inhibitor		infectious disease	cytomegalovirus (CMV)	Launched
letosteine	mucolytic agent		pulmonary, infectious disease	bronchitis, pneumonia	Launched
letrazuril	antiinfective drug				Phase 1
letrozole	aromatase inhibitor	CYP19A1	oncology	breast cancer	Launched
leucomethylene-blue	nitric oxide production inhibitor, tau aggregation inhibitor	MAPT			Phase 3
leucovorin	folate receptor ligand		oncology	osteosarcoma	Launched
leucylleucine-methyl-ester					Phase 2
leuprolide	gonadotropin releasing factor hormone receptor agonist	GNRHR	oncology	prostate cancer	Launched
levalbuterol	adrenergic receptor agonist	ADRB2	pulmonary	bronchospasm	Launched
levallorphan	opioid receptor antagonist	CHRNA2, OPRM1	pulmonary	respiratory depression	Launched
levamisole	acetylcholine receptor agonist	ALPL			Withdrawn
levamlodipine	calcium channel blocker		cardiology	hypertension	Launched
levcromakalim	potassium channel activator	KCNJ5			Phase 3
levetiracetam	calcium channel blocker	CACNA1B, SCN1A, SV2A	neurology/psychiatry	seizures	Launched
levo-phencynonate	acetylcholine receptor antagonist	CHRM1			Launched
levobetaxolol	adrenergic receptor antagonist	ADRB1, ADRB2	ophthalmology	intraocular pressure, glaucoma	Launched
levobunolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	ophthalmology	glaucoma, ocular hypertension	Launched
levobunolol-(+)	adrenergic receptor antagonist				Preclinical
levobunolol-(+/-)	adrenergic receptor antagonist				Preclinical
levocabastine	histamine receptor antagonist	HRH1, NTSR2	ophthalmology	conjunctivitis	Launched
levocarnitine		CRAT, CROT	endocrinology	carnitine deficiency	Launched
levocarnitine-propionate	carnitine palmitoyltransferase inhibitor	CRAT	neurology/psychiatry, endocrinology	peripheral neuropathy, carnitine deficiency	Launched
levocetirizine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis, urticaria	Launched
levodopa	dopamine precursor	DRD1, DRD2, DRD3, DRD4, DRD5, GPR143	neurology/psychiatry	Parkinson's Disease	Launched
levodropropizine	antitussive		pulmonary	cough suppressant	Launched
levofloxacin	bacterial DNA gyrase inhibitor	TOP2A	infectious disease, otolaryngology, pulmonary, urology	pneumonia, sinusitis, bronchitis, skin infections, prostatitis, urinary tract infections, pyelonephritis, anthrax, plague	Launched
levomenol			neurology/psychiatry, infectious disease	spasms, skin infections	Launched
levomenthol		OPRK1, TRPA1, TRPM8, TRPV3	neurology/psychiatry	pain relief	Launched
levomepromazine	dopamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR2A, HTR2C	neurology/psychiatry, gastroenterology	psychosis, schizophrenia, bipolar disorder, nausea, insomnia	Launched
levomequitazine	histamine receptor antagonist	HRH1			Phase 2
levonordefrin	vasodilator	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, SLC6A2	hematology	hemorrhage	Launched
levonorgestrel	estrogen receptor agonist, glucocorticoid receptor antagonist, progesterone receptor agonist, progesterone receptor antagonist	PGR	endocrinology	contraceptive	Launched
levopropoxyphene	antitussive		pulmonary	cough suppressant	Launched
levosimendan	calcium sensitizer	KCNJ11, KCNJ8, PDE3A, TNNC1	cardiology	congestive heart failure	Launched
levosulpiride	dopamine receptor antagonist	CA1, CA12, CA7, DRD2, DRD3	neurology/psychiatry, gastroenterology, urology	schizophrenia, psychosis, anxiety, vertigo, dyspepsia, irritable bowel syndrome, premature ejaculation (PE)	Launched
levothyroxine	thyroid hormone stimulant	THRA, THRB	endocrinology	myxedema coma	Launched
LFM-A13	Bruton's tyrosine kinase (BTK) inhibitor	BTK			Preclinical
LGD-6972	glucagon receptor antagonist				Phase 2
LGK-974	porcupine inhibitor	PORCN			Phase 2
LH846	casein kinase inhibitor	CSNK1D			Preclinical
liarozole	cytochrome P450 inhibitor	CYP19A1, CYP26A1			Phase 2/Phase 3
licarbazepine	voltage-gated sodium channel blocker	SCN5A			Phase 3
licochalcone-A	topoisomerase inhibitor	PTPN1			Phase 3
licofelone	cyclooxygenase inhibitor, lipoxygenase inhibitor	ALOX5, PLA2G2E, PTGS2			Phase 3
licogliflozin	sodium/glucose cotransporter inhibitor				Preclinical
licostinel	NMDA receptor antagonist 				Phase 1
lidamidine	adrenergic receptor agonist		gastroenterology	diarrhea	Launched
lidocaine	histamine receptor agonist	EGFR, SCN10A, SCN5A, SCN9A	neurology/psychiatry, dermatology, hematology	itching, eczema, hemorrhage	Launched
lidoflazine	calcium channel blocker	SCN1A, SCN3A, SLC29A1	cardiology	coronary artery disease (CAD)	Launched
lifirafenib	RAF inhibitor				Phase 1/Phase 2
lifitegrast	lymphocyte function-associated antigen negative modulator		ophthalmology	dry eye syndrome	Launched
ligustilide	tumor necrosis factor production inhibitor	TNF			Preclinical
limaprost-alfadex	prostanoid receptor agonist	PTGER1	cardiology	claudication	Launched
LIMKi-3	LIM kinase inhibitor	LIMK1			Preclinical
limonin	HIV protease inhibitor				Preclinical
linaclotide	guanylate cyclase activator	GUCY2C	gastroenterology	irritable bowel syndrome, constipation	Launched
linagliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	Launched
linalool	anticonvulsant				Phase 1
linaprazan	ATP-sensitive potassium channel inhibitor				Preclinical
lincomycin	bacterial 30S ribosomal subunit inhibitor		gastroenterology	enteritis	Launched
lindane		GABRB1, GLRA1, GLRA2, GLRA3, GLRB	infectious disease	scabies	Launched
linezolid	bacterial 50S ribosomal subunit inhibitor	MAOA, MAOB	infectious disease	pneumonia, skin infections	Launched
linifanib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK			Phase 3
linoleic-acid	oxidative stress inducer	FABP4, FFAR1, FFAR4, HNF4A, KCNB1, PPARG, TRPM8			Phase 3
linopirdine	potassium channel blocker	KCNQ2, KCNQ3, KCNQ4, KCNQ5			Phase 3
linsidomine	nitric oxide donor		urology	erectile dysfunction	Launched
linsitinib	IGF-1 inhibitor	IGF1R, INSR, INSRR			Phase 3
lintopride	serotonin receptor antagonist				Preclinical
liothyronine	thyroid hormone stimulant	THRA, THRB	endocrinology	hypothyroidism, myxedema coma	Launched
liothyronine-(isomer)					Preclinical
lipoamide					Preclinical
liquiritin	antioxidant				Preclinical
liraglutide	GLP receptor agonist	GLP1R	endocrinology	weight-loss aid, diabetes mellitus	Launched
liranaftate	fungal squalene epoxidase inhibitor		infectious disease	fungal infection	Launched
lirimilast	phosphodiesterase inhibitor				Phase 2
lisadimate	topical sunscreen agent		dermatology	sunscreen lotion	Launched
lisinopril	angiotensin converting enzyme inhibitor	ACE, ACE2	cardiology, endocrinology	hypertension, congestive heart failure, diabetes mellitus	Launched
lisofylline	interleukin receptor antagonist, STAT inhibitor				Phase 2
lisuride	dopamine receptor agonist	ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6	neurology/psychiatry	Parkinson's Disease	Launched
lithium-acetoacetate		FAH			Preclinical
lithium-citrate			neurology/psychiatry	bipolar disorder, depression	Launched
lithocholic-acid	FXR antagonist, vitamin D receptor agonist	GPBAR1, NR1H4, NR1I2, VDR			Preclinical
litronesib	kinesin-like spindle protein inhibitor	KIF11			Phase 2
lixivaptan	vasopressin receptor antagonist	AVPR2			Phase 3
LM-22A4	tropomyosin receptor kinase inhibitor	NTRK2			Preclinical
LMI070	survival motor neuron protein modulator	SMN1			Phase 1/Phase 2
LMK-235	HDAC inhibitor	HDAC4, HDAC5			Preclinical
LM11A-31	neurotrophic agent	NGFR			Phase 1
lobeline	acetylcholine receptor antagonist	CHRNA10, CHRNA9, SLC18A2	neurology/psychiatry	smoking cessation	Launched
lobendazole	anthelmintic agent				Preclinical
lobenzarit	immunosuppressant		rheumatology	rheumatoid arthritis	Launched
lodenosine	antiretroviral 				Phase 2
lodoxamide	histamine receptor antagonist		ophthalmology	vernal keratoconjunctivitis (VKC)	Launched
lofemizole	cyclooxygenase inhibitor				Phase 3
lofepramine	norepinephrine reuptake inhibitor, serotonin–norepinephrine reuptake inhibitor (SNRI)	HTR1A, SLC6A2, SLC6A4	neurology/psychiatry	depression	Launched
lofexidine	adrenergic receptor agonist		neurology/psychiatry	opioid withdrawal	Launched
lomefloxacin	bacterial DNA gyrase inhibitor		infectious disease	respiratory tract infections, urinary tract infections	Launched
lomeguatrib	O6-alkylguanine-DNA alkyltransferase inhibitor	MGMT			Phase 2
lomerizine	calcium channel blocker	CACNA1B, SCN5A	neurology/psychiatry	migraine headache	Launched
lometrexol	glycinamide ribonucleotide formyltransferase inhibitor	GART			Phase 2
lomitapide	microsomal trigylceride transfer protein inhibitor	MTTP	endocrinology	hypercholesterolemia	Launched
lomustine	DNA synthesis inhibitor		hematologic malignancy, oncology	Hodgkin's lymphoma, brain tumors	Launched
lonafarnib	farnesyltransferase inhibitor	FNTA, HRAS, KRAS, NRAS			Phase 3
lonidamine	glucokinase inhibitor	GCK			Launched
loperamide	opioid receptor agonist	CACNA1A, CALM1, OPRD1, OPRK1, OPRM1, POMC	gastroenterology	diarrhea	Launched
lopinavir	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	Launched
loracarbef	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology, pulmonary	ear infections, laryngitis, bronchitis, pneumonia, urinary tract infections, skin infections	Launched
loratadine	histamine receptor antagonist	HRH1	allergy, neurology/psychiatry	allergic rhinitis, itching	Launched
loreclezole	benzodiazepine receptor agonist	GABRB2, GABRB3			Phase 2
lorediplon	GABA receptor modulator	GABRA1			Phase 2
lorglumide	CCK receptor antagonist	CCKAR, CCKBR			Phase 1
lorlatinib	ALK tyrosine kinase receptor inhibitor	ALK	oncology	non-small cell lung cancer (NSCLC)	Launched
lornoxicam	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology, neurology/psychiatry	osteoarthritis, sciata	Launched
losartan	angiotensin receptor antagonist	AGTR1	cardiology, nephrology	hypertension, diabetic nephropathy, hypertension	Launched
losmapimod	p38 MAPK inhibitor	MAPK14			Phase 3
lotamilast	phosphodiesterase inhibitor				Preclinical
loteprednol	glucocorticoid receptor agonist, phospholipase inhibitor	NR3C1	ophthalmology	conjunctivitis	Launched
lovastatin	HMGCR inhibitor	HDAC2, HMGCR, ITGAL, NR1I2	cardiology, endocrinology	coronary heart disease, myocardial infarction, hypercholesterolemia	Launched
loxapine	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HRH2, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR5A, HTR6, HTR7, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	schizophrenia	Launched
loxistatin-acid	cysteine peptidase inhibitor	CTSB			Preclinical
loxoprofen	cyclooxygenase inhibitor, prostanoid receptor antagonist	PTGS2	neurology/psychiatry	pain relief	Launched
LP-533401	tryptophan hydroxylase inhibitor				Preclinical
LPA2-antagonist-1	lysophosphatidic acid receptor antagonist	LPAR2			Preclinical
LRRK2-IN-1	leucine rich repeat kinase inhibitor	LRRK2			Preclinical
LSN-2463359	glutamate receptor positive allosteric modulator	GRM5			Preclinical
LSZ-102	selective estrogen receptor modulator (SERM)				Phase 1
LTA					Phase 2
LTB4	leukocyte activator	LTB4R, LTB4R2			Phase 2
LTX-315	anticancer agent				Phase 2
Lu-AA-47070	adenosine receptor antagonist	ADORA2A			Phase 2
lubiprostone	chloride channel activator	CLCN2	gastroenterology	constipation, irritable bowel syndrome	Launched
lucanthone	endonuclease inhibitor	APEX1, TOP1, TOP2A			Phase 2
lucitanib	FGFR inhibitor, VEGFR inhibitor	FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET			Phase 2
LUF-5834	adenosine receptor agonist	ADORA2A, ADORA2B			Preclinical
lufenuron	chitin inhibitor		infectious disease	flea control	Launched
luliconazole	sterol demethylase inhibitor		infectious disease	tinea pedis, tinea cruris, tinea corporis	Launched
lumacaftor	CFTR channel agonist	CFTR	pulmonary	cystic fibrosis	Launched
lumateperone	dopamine receptor modulator, serotonin receptor antagonist	DRD2, HTR2A			Launched
lumefantrine	antimalarial agent	ATP1A1	infectious disease	malaria	Launched
lumiracoxib	cyclooxygenase inhibitor	PTGS1, PTGS2			Withdrawn
lupanine	sodium channel blocker	INS			Phase 1
lurasidone	dopamine receptor antagonist, serotonin receptor antagonist	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7	neurology/psychiatry	schizophrenia	Launched
lurbinectedin	DNA binding agent				Phase 3
lusaperidone	adrenergic receptor antagonist				Preclinical
lusutrombopag	thrombopoietin receptor agonist				Launched
lutein	antioxidant		ophthalmology	macular degeneration, cataracts, retinitis pigmentosa (RP)	Launched
luteolin	glucosidase inhibitor	TOP1			Phase 2
luzindole	melatonin receptor antagonist	MTNR1A, MTNR1B			Preclinical
LXH254	RAF inhibitor				Phase 1
LXR-623	LXR agonist	AR, NR1H2, NR1H3, NR1I2, NR3C1			Phase 1
LXS196	PKC inhibitor				Phase 1
LX1031	tryptophan hydroxylase inhibitor	TPH1			Phase 2
LX7101	LIM kinase inhibitor, rho associated kinase inhibitor	LIMK2, ROCK1, ROCK2			Phase 1/Phase 2
lycopene	free radical scavenger				Launched
lylamine	cannabinoid receptor agonist	CNR1			Preclinical
lymecycline	bacterial 50S ribosomal subunit inhibitor		dermatology	acne vulgaris (AV)	Launched
lynestrenol	progestogen hormone		endocrinology	contraceptive	Launched
lypressin	vasopressin receptor agonist	AVPR1A, AVPR1B, AVPR2	endocrinology	central diabetes insipidus	Launched
LY2090314	glycogen synthase kinase inhibitor	GSK3B			Phase 2
LY2109761	TGF beta receptor inhibitor	TGFBR1, TGFBR2			Preclinical
LY2140023	glutamate receptor agonist	GRM3			Phase 3
LY215490	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4, GRIK1			Phase 1
LY2157299	TGF beta receptor inhibitor	TGFBR1			Phase 2/Phase 3
LY2183240	FAAH inhibitor, FAAH reuptake inhibitor	FAAH			Preclinical
LY2228820	p38 MAPK inhibitor	MAPK14			Phase 2
LY223982	leukotriene receptor antagonist	LTB4R			Phase 2
LY225910	CCK receptor antagonist	CCKBR			Preclinical
LY231617	lipid peroxidase inhibitor				Preclinical
LY2334737	antitumor agent, ribonucleotide reductase inhibitor				Phase 1
LY2365109	glycine transporter inhibitor	SLC6A9			Preclinical
LY2452473	androgen receptor modulator	AR			Phase 2
LY2510924	CC chemokine receptor antagonist				Phase 2
LY255283	leukotriene receptor antagonist	LTB4R, LTB4R2			Preclinical
LY2584702	ribosomal protein inhibitor	RPS6KB1			Phase 1
LY2603618	CHK inhibitor	CHEK1			Phase 2
LY2606368	CHK inhibitor	CHEK1			Phase 2
LY2608204	glucokinase activator	GCK			Phase 2
LY266097	serotonin receptor antagonist	HTR2B			Preclinical
LY2784544	JAK inhibitor	JAK2, JAK3			Phase 2
LY2795050	opioid receptor antagonist				Preclinical
LY2801653	MET inhibitor	MET			Phase 2
LY2811376	beta-secretase inhibitor	BACE1			Phase 1
LY2828360	cannabinoid receptor agonist				Phase 2
LY2857785	CDK inhibitor	CDK9			Preclinical
LY2874455	FGFR antagonist	FGFR1, FGFR2, FGFR3, FGFR4, KDR			Phase 1
LY288513	CCK receptor antagonist	CCKBR			Preclinical
LY2886721	beta-secretase inhibitor	BACE1			Phase 1/Phase 2
LY294002	DNA dependent protein kinase inhibitor, mTOR inhibitor, phosphodiesterase inhibitor, PI3K inhibitor, PLK inhibitor	AKT1, CHEK1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIM1, PLK1, PRKCA, PRKDC, ROCK1, RPS6KB1, SGK1			Preclinical
LY2979165	glutamate receptor agonist	GRM2			Phase 1
LY3000328	cathepsin inhibitor	CTSS			Phase 1
LY3009120	RAF inhibitor	BRAF, RAF1			Phase 1
LY3023414	mTOR inhibitor, PI3K inhibitor	MTOR			Phase 2
LY303511	casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor	BRD2, BRD3, BRD4			Preclinical
LY310762	serotonin receptor antagonist	HTR1D			Preclinical
LY311727	phospholipase inhibitor				Preclinical
LY3200882	TGF beta receptor inhibitor				Phase 1
LY320135	cannabinoid receptor antagonist	CNR1			Preclinical
LY3214996	ERK inhibitor				Phase 1
LY3295668	Aurora kinase inhibitor				Phase 1/Phase 2
LY334370	serotonin receptor agonist				Preclinical
LY344864	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR7			Preclinical
LY364947	p38 MAPK inhibitor, TGF beta receptor inhibitor	TGFBR1			Preclinical
LY393558	serotonin receptor antagonist	HTR1B, HTR1D, HTR2A, HTR2B			Preclinical
LY404187	glutamate receptor positive allosteric modulator	GRIA1, GRIA2, GRIA3, GRIA4			Preclinical
LY411575	gamma secretase inhibitor				Preclinical
LY450108	glutamate receptor modulator				Phase 1
LY456236	glutamate receptor antagonist	GRM1			Preclinical
m-chlorophenylbiguanide	serotonin receptor agonist	HTR3A, HTR3B			Preclinical
m-THP					Phase 1
M-14157	ATP-sensitive potassium channel antagonist	KCNQ1			Phase 2
M-25	smoothened receptor antagonist	DHH, IHH, SMO			Preclinical
m-3M3FBS	phospholipase activator	PLCB2, PLCB3, PLCD1, PLCG1, PLCG2			Preclinical
M-344	HDAC inhibitor	HDAC8			Preclinical
mabuprofen	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	Launched
mabuterol	adrenergic receptor agonist	ADRB2	pulmonary	asthma	Launched
macelignan	anti-inflammatory agent, antioxidant				Preclinical
macitentan	endothelin receptor antagonist	EDNRA, EDNRB	endocrinology	contraceptive	Launched
macitentan-n-butyl-analogue	endothelin receptor antagonist				Preclinical
macozinone	DPRE1 inhibitor				Preclinical
madecassoside	anti-inflammatory agent				Preclinical
madrasin	cell splicing inhibitor				Preclinical
mafenide	carbonic anhydrase inhibitor	CA12, CA14, CA2, CA4, CA6, CA9	infectious disease	first-aid antibiotic, skin infections	Launched
magnolol	PPAR receptor agonist	GABRA1, PPARG			Preclinical
malathion	cholinesterase inhibitor	ACHE	infectious disease	lice	Launched
malic-acid		PKD2L1			Launched
malotilate	protein synthesis stimulant		gastroenterology	hepatic cirrhosis	Launched
maltobionic-acid	matrix metalloprotease inhibitor		dermatology	cosmetic	Launched
mandelic-acid					Launched
mangafodipir	contrast agent		radiology	contrast agent	Launched
manidipine	calcium channel blocker	CACNA1C, CACNA1D	cardiology	hypertension	Launched
manitimus	dehydrogenase inhibitor				Preclinical
mannitol-D	diuretic		neurology/psychiatry, ophthalmology, gastroenterology	intracranial pressure, intraocular pressure, constipation	Launched
maprotiline	norepinephrine reputake inhibitor, tricyclic antidepressant	SLC6A2	neurology/psychiatry	depression, dysthymic disorder	Launched
maraviroc	CC chemokine receptor antagonist	CCR5	infectious disease	human immunodeficiency virus (HIV-1)	Launched
marbofloxacin	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	Launched
maribavir	cytomegalovirus inhibitor, protein kinase inhibitor	PYGM			Phase 3
marimastat	matrix metalloprotease inhibitor	MMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP19, MMP2, MMP20, MMP21, MMP23A, MMP24, MMP25, MMP26, MMP27, MMP28, MMP3, MMP7, MMP8, MMP9			Phase 3
maropitant	neurokinin receptor antagonist	TACR1	gastroenterology	vomiting	Launched
masitinib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, SRC inhibitor	FGFR3, KIT, PDGFRA, PDGFRB	dermatology	mastocytoma	Launched
masoprocol	lipoxygenase inhibitor	ALOX5	dermatology	actinic keratosis (AK)	Launched
matrine	opioid receptor agonist	OPRK1			Phase 2
mavacamten	myosin inhibitor 				Phase 3
mavatrep	transient receptor potential channel antagonist				Preclinical
mavoglurant	glutamate receptor antagonist	GRM5			Phase 2
maxacalcitol	vitamin D receptor agonist	VDR	endocrinology	hyperparathyroidism	Launched
maytansinol-isobutyrate					Preclinical
MBX-2982	glucose dependent insulinotropic receptor agonist	GPR119			Phase 2
MC-1		AADAT, ABAT, AGXT, AGXT2, ALAS1, AZIN2, BCAT1, BCAT2, CBS, CCBL1, CCBL2, CSAD, CTH, DDC, FTCD, GAD1, GAD2, GADL1, GCAT, GLDC, GOT1, GOT2, GPT, GPT2, HDC, IGSF10, KYNU, MOCOS, NFS1, OAT, ODC1, PDXDC1, PDXP, PHYKPL, PNPO, PROSC, PSAT1, PYGB, PYGL, PYGM, SCLY, SDS, SDSL, SEPSECS, SGPL1, SHMT1, SHMT2, SPTLC1, SPTLC2, SPTLC3, SRR, TAT, THNSL1			Phase 3
MCC950	NOD like receptor inhibitor	NLRP3			Preclinical
McN-5652-(+/-)	selective serotonin reuptake inhibitor (SSRI)				Preclinical
MCOPPB	nociceptin/orphanin FQ receptor agonist	OPRL1			Preclinical
mCPP	serotonin receptor agonist	HTR1A, HTR1D, HTR1E, HTR2A, HTR2B, HTR2C, HTR6			Phase 2
MC1568	HDAC inhibitor	HDAC2			Preclinical
MD-920	NFkB pathway inhibitor	AADACL2			Phase 1
mdivi-1	dynamin inhibitor	DNM1			Preclinical
MDL-11939	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			Phase 2
MDL-27531	glycine receptor agonist				Preclinical
MDL-29951	glutamate receptor antagonist	FBP1			Preclinical
MDL-72832	serotonin receptor agonist	HTR1A			Preclinical
MDL-73005EF	serotonin receptor antagonist	HTR1A			Phase 1
MDMS	DNA inhibitor				Phase 2
ME-0328	PPAR receptor antagonist	PARP3			Preclinical
mebendazole	tubulin polymerization inhibitor	TUBA1A, TUBB, TUBB4B	infectious disease	pinworm, whipworm, hookworm, ascariasis	Launched
mebeverine	acetylcholine receptor antagonist	CHRM1	gastroenterology	irritable bowel syndrome	Launched
mebhydrolin	antihistamine		allergy	allergic rhinitis, urticaria	Launched
mebicar	anxiolytic		neurology/psychiatry	anxiety	Launched
mebrofenin			radiology	diagnostic agent	Launched
mecamylamine	acetylcholine receptor antagonist	CHRNA1, CHRNA2, CHRNA3, CHRNA4, CHRNA6, CHRNA7, CHRNB4	cardiology	hypertension	Launched
mecarbinate					Preclinical
meclinertant	neurotensin receptor antagonist	NTSR1, NTSR2			Phase 2/Phase 3
meclizine	constitutive androstane receptor (CAR) agonist	NR1I3	gastroenterology, neurology/psychiatry	nausea, vomiting, motion sickness	Launched
meclocycline-sulfosalicylate	bacterial 50S ribosomal subunit inhibitor		dermatology, infectious disease	acne vulgaris (AV), skin infections	Launched
meclofenamic-acid	cyclooxygenase inhibitor, prostanoid receptor antagonist	ALOX5, CNR1, KCNQ2, KCNQ3, PTGS1, PTGS2	rheumatology, neurology/psychiatry, endocrinology	joint pain, muscle pain, rheumatoid arthritis, primary dysmenorrhea (PD)	Launched
meclofenoxate	nootropic agent		neurology/psychiatry	senile dementia, Alzheimer's disease	Launched
mecysteine	analgesic agent		pulmonary	chest congestion	Launched
medetomidine	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C	neurology/psychiatry	sedative	Launched
medica-16	ATP citrase lyase inhibitor	FFAR1			Phase 2
medorinone					Phase 1
medronic-acid	bone resorption inhibitor		radiology	skeletal imaging agent	Launched
medroxyprogesterone	progesterone receptor agonist	PGR	endocrinology	contraceptive	Launched
medroxyprogesterone-acetate	progesterone receptor agonist	ESR1, PGR	endocrinology	contraceptive	Launched
medrysone	glucocorticoid receptor agonist	NR3C1	ophthalmology	conjunctivitis, episcleritis	Launched
mefenamic-acid	cyclooxygenase inhibitor	KCNQ1, PTGS1, PTGS2, TRPM3	endocrinology	primary dysmenorrhea (PD)	Launched
mefexamide	psychoactive drug				Preclinical
mefloquine	adenosine receptor antagonist, hemoglobin antagonist		infectious disease	malaria	Launched
megestrol	progesterone receptor agonist		oncology	breast cancer	Launched
megestrol-acetate	progesterone receptor agonist	NR3C1, PGR	neurology/psychiatry, endocrinology	anorexia, cachexia	Launched
meglitinide	potassium channel blocker	CCR2			Phase 2
meglumine	excipient				Launched
meglutol	HMGCR inhibitor	HMGCR			Launched
meisoindigo	STAT inhibitor	STAT3			Phase 3
MEK1-2-inhibitor	MEK inhibitor	MAP2K2			Preclinical
melanotan-ii	melanocortin receptor agonist				Launched
melatonin	melatonin receptor agonist, nitric oxide synthase inhibitor	ASMT, CALM1, CALR, EPX, ESR1, HTR2B, MPO, MTNR1A, MTNR1B, NQO2, RORB	neurology/psychiatry	sleep cycle support	Launched
meldonium	gamma butyrobetaine hydroxylase inhibitor	BBOX1	cardiology	coronary artery disease (CAD)	Launched
melengestrol-acetate	progesterone receptor agonist				Preclinical
melevodopa	dopamine precursor, dopamine receptor agonist	DDC	neurology/psychiatry	Parkinson's Disease	Launched
meloxicam	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	Launched
melperone	dopamine receptor antagonist, serotonin receptor antagonist	DRD2, HTR2A	neurology/psychiatry	psychosis	Launched
melphalan	DNA alkylating agent, DNA inhibitor		hematologic malignancy	multiple myeloma	Launched
melphalan-n-oxide	hypoxia inducible factor inhibitor	HIF1A			Phase 1
meluadrine					Preclinical
memantine	glutamate receptor antagonist		neurology/psychiatry	Alzheimer's disease, senile dementia	Launched
menadione	mitochondrial DNA polymerase inhibitor, phosphatase inhibitor	AOX1, BGLAP, F10, F2, F7, F9, GGCX, NQO1, NQO2, PROC, PROS1, PROZ, VKORC1, VKORC1L1	gastroenterology, neurology/psychiatry, dermatology, rheumatology	ulcerative colitis, diarrhea, headache, varicose veins, rheumatoid arthritis	Launched
menadione-bisulfite	vitamin K	GGCX, VKORC1, VKORC1L1			Phase 2
menatetrenone	bone resorption inhibitor		orthopedics	osteoporosis	Launched
menbutone			gastroenterology	bile stimulation	Launched
mepacrine	cytokine production inhibitor, NFkB pathway inhibitor, TP53 activator	PLA2G1B	infectious disease	giardiasis	Launched
meparfylon					Preclinical
mepazine	MALT1 inhibitor (JH)	MALT1			Phase 2
mepenzolate	acetylcholine receptor antagonist		gastroenterology	peptic ulcer disease (PUD)	Launched
mephenesin	muscle relaxant		neurology/psychiatry	muscle relaxant	Launched
mephentermine	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3	cardiology	hypotension	Launched
mephenytoin	hydantoin antiepileptic	SCN5A	neurology/psychiatry	seizures	Launched
mepiroxol					Preclinical
mepivacaine	potassium channel blocker, sodium channel blocker		neurology/psychiatry	local anesthetic	Launched
meprednisone		NR3C1			Launched
meprylcaine	local anesthetic				Preclinical
meptazinol	opioid receptor agonist	BCHE	neurology/psychiatry	pain relief	Launched
mepyramine	histamine receptor antagonist	HRH1	otolaryngology, obstetrics/gynecology	common cold, menstrual pain	Launched
mequinol		TYR	dermatology	skin depigmentation	Launched
merbarone	topoisomerase inhibitor	TOP2A			Phase 2
merbromin	antiseptic		infectious disease	first-aid antiseptic	Launched
mercaptopurine	immunosuppressant, protein synthesis inhibitor, purine antagonist	HPRT1, IMPDH1, IMPDH2, PPAT	hematologic malignancy	acute lymphoblastic leukemia (ALL)	Launched
mercaptosuccinic-acid					Launched
Merck60	HDAC inhibitor	HDAC1, HDAC2			Preclinical
mericitabine	HCV inhibitor				Phase 2
merimepodib	inosine monophosphate dehydrogenase inhibitor	IMPDH1			Phase 2
meropenem	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, intra-abdominal infections, meningitis	Launched
mertansine	microtubule inhibitor				Phase 2
mesalazine	cyclooxygenase inhibitor, lipoxygenase inhibitor, prostanoid receptor antagonist	ALOX5, CHUK, IKBKB, MPO, PPARG, PTGS1, PTGS2	gastroenterology	ulcerative colitis, inflammatory bowel disease	Launched
mesna	antioxidant		urology	hemorrhagic cystitis	Launched
mesoridazine	dopamine receptor antagonist	DRD2, HTR2A	neurology/psychiatry	schizophrenia	Launched
mestinon	cholinesterase inhibitor	ACHE, BCHE	neurology/psychiatry	myasthenia gravis	Launched
mestranol	estrogen receptor agonist	ESR1	endocrinology	contraceptive	Launched
mesulergine	dopamine receptor agonist	HTR2A, HTR2B, HTR2C, HTR3A, HTR3B, HTR6, HTR7			Phase 2
meta-cresyl-acetate					Preclinical
metacetamol	analgesic agent				Preclinical
metacresol		INS			Launched
metafolin					Launched
metamizole	cyclooxygenase inhibitor, opioid receptor agonist	PTGS1			Withdrawn
metaphit	phencyclidine receptor acylator				Preclinical
metaproterenol	adrenergic receptor agonist	ADRB2	pulmonary	bronchospasm, asthma, bronchitis, emphysema	Launched
metaraminol	adrenergic receptor agonist	ADRA1A	cardiology	hypotension	Launched
metatinib	Bcr-Abl kinase inhibitor	ABL1, BCR			Phase 1
metaxalone	muscle relaxant		neurology/psychiatry	muscle pain	Launched
metazosin	adrenergic receptor antagonist	ADRA1A			Phase 2
metenkephalin	immunostimulant	OPRD1			Phase 2
metergoline	dopamine receptor agonist, serotonin receptor antagonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7	neurology/psychiatry, endocrinology	seasonal affective disorder, anxiety, hyperprolactinemia	Launched
metformin	insulin sensitizer	ACACB, PRKAB1	endocrinology	diabetes mellitus	Launched
methacholine	acetylcholine receptor agonist	CHRM2, CHRM4	pulmonary	bronchial hyperresponsiveness diagnostic	Launched
methacycline	protein synthesis inhibitor		pulmonary	bronchitis	Preclinical
methanesulfonyl-fluoride	acetylcholinesterase inhibitor	ACHE			Phase 2
methantheline	acetylcholine receptor antagonist	CHRM1, HRH2	gastroenterology, neurology/psychiatry, urology	peptic ulcer disease (PUD), irritable bowel syndrome, pancreatitis, dyskinesia, neurogenic bladder	Launched
methapyrilene	histamine receptor antagonist	HRH1			Withdrawn
metharbital	GABA receptor modulator	CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2	neurology/psychiatry	epilepsy	Launched
methazolamide	carbonic anhydrase inhibitor	CA1, CA12, CA14, CA2, CA4, CA7	ophthalmology	glaucoma, intraocular pressure	Launched
methenamine	bacterial DNA inhibitor		infectious disease	urinary tract infections	Launched
methiazole	anthelmintic agent				Preclinical
methicillin	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	Launched
methimazole	antithyroid agent	TPO	endocrinology	hyperthyroidism	Launched
methionine		METAP2			Launched
methiopril	angiotensin converting enzyme inhibitor	ACE			Phase 2
methocarbamol	muscle relaxant	CA1	neurology/psychiatry	muscle relaxant	Launched
methoprene-(s)					Preclinical
methotrexate	dihydrofolate reductase inhibitor	DHFR	oncology, hematologic malignancy, dermatology, rheumatology	gestational choriocarcinoma, hydatidiform mole, acute lymphoblastic leukemia (ALL), psoriasis, rheumatoid arthritis	Launched
methoxamine	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D	cardiology	hypotension	Launched
methoxsalen	DNA synthesis inhibitor	CYP1A1, CYP1A2, CYP2A13, CYP2A6, CYP3A4	dermatology	psoriasis	Launched
methoxyamine	DNA repair enzyme inhibitor	APEX1			Phase 2
methoxyflurane	membrane permeability inhibitor	ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, MT-ND1	neurology/psychiatry	general anaesthetic	Launched
methoxyphenamine	adrenergic receptor agonist		pulmonary	asthma	Launched
methscopolamine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	gastroenterology	peptic ulcer disease (PUD)	Launched
methsuximide	T-type calcium channel blocker	CACNA1G, CACNA1H, CACNA1I	neurology/psychiatry	seizures	Launched
methyclothiazide	chloride reabsorption inhibitor	SLC12A1, SLC12A3	cardiology	hypertension, edema	Launched
methyl-aminolevulinate	oxidizing agent	FCGR1A, FECH	dermatology	actinic keratosis (AK)	Launched
methyl-nicotinate					Phase 2
methyl-salicylate			endocrinology, neurology/psychiatry	fever, pain relief	Launched
methyl-5-hydroxytryptamine					Preclinical
methylatropine-nitrate	acetylcholine receptor antagonist	CHRM1			Preclinical
methylbenactyzium-bromide	cholinergic receptor antagonist				Preclinical
methylbenzethonium-chloride	other antibiotic				Preclinical
methylcobalamin	vitamin B				Phase 3
methyldopa	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C, DDC	cardiology	hypertension	Launched
methyldopate			cardiology	hypertension	Launched
methylene-blue	guanylyl cyclase inhibitor, nitric oxide production inhibitor	ACHE	hematology	methemoglobinemia	Launched
methylergometrine	dopamine receptor antagonist, serotonin receptor antagonist	DRD1, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C	hematology, neurology/psychiatry	postpartum hemorrhage (PPH), migraine headache	Launched
methyllycaconitine	acetylcholine receptor antagonist	CHRNA7			Preclinical
methylnaltrexone	opioid receptor antagonist	OPRD1, OPRK1, OPRM1	gastroenterology	constipation	Launched
methylparaben	other antifungal		dermatology	cosmetic	Launched
methylprednisolone	glucocorticoid receptor agonist	NR3C1	endocrinology, rheumatology, dermatology, infectious disease, allergy, hematology, neurology/psychiatry, gastroenterology	hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis	Launched
methylprednisolone-aceponate	anti-inflammatory agent, glucocorticoid receptor agonist	NR3C1	endocrinology, rheumatology, infectious disease, allergy, pulmonary, gastroenterology, dermatology, neurology/psychiatry, hematology	congenital adrenal hyperplasia, thyroiditis, hypercalcemia, rheumatoid arthritis, bursitis, epicondylitis, allergic rhinitis, asthma, ulcerative colitis, enteritis, osteoarthritis, psoriasis, multiple sclerosis, anemia	Launched
methylprednisolone-sodium-succinate	glucocorticoid receptor agonist		endocrinology, rheumatology, dermatology, pulmonary, allergy, infectious disease, ophthalmology, gastroenterology, hematology, neurology/psychiatry	hypercalcemia, thyroiditis, osteoarthritis, rheumatoid arthritis, seborrheic dermatitis, asthma, allergic rhinitis, shingles, conjunctivitis, ulcerative colitis, enteritis, anemia, multiple sclerosis, mycosis	Launched
methylthiouracil			endocrinology	hyperthyroidism	Launched
methysergide	serotonin receptor antagonist	HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7	neurology/psychiatry	headache	Launched
meticrane	diuretic		cardiology	edema	Launched
metipranolol	adrenergic receptor antagonist				Withdrawn
metirosine	tyrosine hydroxylase inhibitor	TH	cardiology	hypertension	Launched
metitepine	anti-HCVE2	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7			Preclinical
metixene	acetylcholine receptor antagonist	CHRM5	neurology/psychiatry	Parkinson's Disease	Launched
metoclopramide	dopamine receptor antagonist, serotonin receptor antagonist	CHRM1, DRD2, HTR3A, HTR3B, HTR4	gastroenterology	gastroparesis, nausea, vomiting	Launched
metocurine	acetylcholine receptor antagonist	CHRM2, CHRNA2	neurology/psychiatry	muscle relaxant	Launched
metolazone	carbonic anhydrase inhibitor	SLC12A3	cardiology	edema, hypertension	Launched
metoprolol	adrenergic receptor antagonist	ADRB1, ADRB2	cardiology	hypertension, angina pectoris, myocardial infarction	Launched
metoxibutropate	cyclooxygenase inhibitor	PTGS1, PTGS2			Launched
metrifonate	acetylcholinesterase inhibitor	ACHE			Phase 3
metrizamide	radiopaque medium		radiology	contrast agent	Launched
metrizoic-acid	radiopaque medium		radiology	contrast agent	Launched
metronidazole	DNA inhibitor	CYP2C9, CYP3A4	dermatology	rosacea	Launched
metyrapone	cytochrome P450 inhibitor	CYP11B1	nephrology	adrenal diagnostic agent	Launched
mevastatin	HMGCR inhibitor	HMGCR			Preclinical
mexeneone					Preclinical
mexiletine	sodium channel blocker	PLAU, SCN4A, SCN5A	cardiology	ventricular arrhythmias, ventricular tachycardia (VT)	Launched
mezlocillin	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	Launched
ME0328	PARP inhibitor	PARP3			Preclinical
MF-101	estrogen receptor agonist	CYP19A1, XDH			Phase 3
MG-132	proteasome inhibitor	PSMB1			Preclinical
MG-624	acetylcholine receptor antagonist	CHRNA7			Preclinical
MGCD-265	VEGFR inhibitor	AXL, MET			Preclinical
MI-14	PI4K inhibitor	PI4KB			Preclinical
mianserin	serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, HRH1, HRH2, HTR2A, HTR2B, HTR2C, HTR6, HTR7	neurology/psychiatry	depression	Launched
mibampator	glutamate receptor modulator	GRIA1			Phase 2
mibefradil	T-type calcium channel blocker	ANO1, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CATSPER1, CATSPER2, CATSPER3, CATSPER4			Withdrawn
micafungin	fungal 1,3-beta-D-glucan synthase inhibitor		infectious disease	candidemia, peritonitis, esophageal candidiasis	Launched
miconazole	bacterial cell wall synthesis inhibitor	TRPM2, TRPV5	infectious disease, neurology/psychiatry	yeast infection, itching	Launched
micronomicin	protein synthesis inhibitor		infectious disease	gram-negative bacterial infections	Launched
midafotel	glutamate receptor antagonist	GRIN2A, GRIN2B, GRIN2C, GRIN2D			Phase 3
midecamycin	protein synthesis inhibitor		infectious disease	respiratory tract infections, ear infections, skin infections	Launched
midodrine	adrenergic receptor agonist		cardiology	hypotension	Launched
midostaurin	FLT3 inhibitor, KIT inhibitor, PKC inhibitor	FLT3, PRKCG	hematologic malignancy	acute myeloid leukemia (AML)	Launched
mifepristone	glucocorticoid receptor antagonist, progesterone receptor antagonist	AR, NR1I2, NR3C1, PGR	endocrinology	hyperglycemia, diabetes mellitus	Launched
mifobate	PPAR receptor antagonist	PPARG			Phase 2
miglitol	glucosidase inhibitor	GAA, GANAB, GANC, MGAM	endocrinology	diabetes mellitus	Launched
miglustat	glycosyl transferase inhibitor	UGCG	hematology	Gaucher disease	Launched
milacemide	monoamine oxidase inhibitor	MAOB			Phase 3
milademetan	MDM inhibitor				Phase 1
milnacipran	serotonin–norepinephrine reuptake inhibitor (SNRI)	SLC6A2, SLC6A4	rheumatology	fibromyalgia	Launched
milrinone	phosphodiesterase inhibitor	PDE2A, PDE3A, PDE3B, PDE5A	cardiology	congestive heart failure	Launched
miltefosine	membrane integrity inhibitor	PLA2G1B	infectious disease	leishmaniasis	Launched
mimosine	DNA replication inhibitor	CCL2, SHMT1, SHMT2, TYR			Preclinical
minaprine	serotonin reuptake inhibitor	ACHE, CHRM1, DRD1, DRD2, HTR2A, HTR2B, HTR2C, MAOA, SLC6A4			Withdrawn
minerval	FAAH inhibitor				Phase 1/Phase 2
minocycline	bacterial 30S ribosomal subunit inhibitor		endocrinology, infectious disease, ophthalmology, urology	fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, tularemia, cholera, brucellosis	Launched
minodronic-acid	bone resorption inhibitor	FDPS, GGPS1	orthopedics	osteoporosis	Launched
minoxidil	KATP activator, Kir6 channel (KATP) activator, vasodilator	ABCC9, KCNJ1, KCNJ10, KCNJ11, KCNJ8, PTGS1	endocrinology	androgenetic alopecia	Launched
miocamycin	other antibiotic		infectious disease	urinary tract infections, chlamydia	Launched
MIRA-1	apoptosis stimulant				Preclinical
mirabegron	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3	urology	urinary incontinence	Launched
miridesap	amyloid protein inhibitor				Preclinical
mirin	MRE11A exonuclease inhibitor	MRE11A			Preclinical
miriplatin	DNA synthesis inhibitor		oncology	hepatocellular carcinoma (HCC)	Launched
mirodenafil	phosphodiesterase inhibitor	PDE5A	urology	erectile dysfunction	Launched
mirogabalin-besylate	calcium channel antagonist				Preclinical
mirtazapine	adrenergic receptor antagonist, serotonin receptor antagonist	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C	neurology/psychiatry	depression	Launched
misonidazole					Phase 3
misoprostol	prostanoid receptor agonist	PTGER2, PTGER3, PTGER4, PTGIR	gastroenterology	duodenal ulcer disease	Launched
mitapivat	pyruvate kinase isozyme activator				Preclinical
mitiglinide	insulin secretagogue	ABCC8, KCNJ10, PPARG	endocrinology	diabetes mellitus	Launched
mitoflaxone	antitumor agent	VWF			Phase 2
mitomycin-C	DNA alkylating agent, DNA synthesis inhibitor		oncology	pancreatic cancer, gastric adenocarcinoma	Launched
mitoquinone	antioxidant				Launched
mitotane	antineoplastic agent	CYP11A1, CYP11B1, ESR1	oncology	adrenal cortical carcinoma	Launched
mitoxantrone	topoisomerase inhibitor	TOP2A	neurology/psychiatry, oncology, hematologic malignancy	multiple sclerosis, prostate cancer, acute myeloid leukemia (AML)	Launched
mivacurium	acetylcholine receptor antagonist	CHRNA2	critical care, neurology/psychiatry	endotracheal intubation, muscle relaxant	Launched
mivebresib	bromodomain inhibitor				Phase 1
mivobulin	microtubule inhibitor				Phase 2
MIW-815	interferon inducer				Preclinical
mizolastine	histamine receptor antagonist	HRH1	allergy	urticaria, allergic rhinitis	Launched
mizoribine	immunosuppressant, inosine monophosphate dehydrogenase inhibitor	IMPDH1	transplant, rheumatology	organ rejection, nephrotic syndrome	Launched
MJ-15	cannabinoid receptor antagonist	CNR1			Preclinical
MK-0354	niacin receptor agonist	HCAR2, HCAR3			Phase 2
MK-0557	neuropeptide receptor antagonist				Phase 3
MK-0608	antiviral				Phase 1
MK-0752	gamma secretase inhibitor				Phase 1/Phase 2
MK-0773	androgen receptor modulator	AR			Phase 2
MK-0812	CC chemokine receptor antagonist	CCR2			Phase 2
MK-0893	glucagon receptor antagonist	GCGR			Phase 2
MK-1064	orexin receptor antagonist				Phase 1
MK-1775	WEE1 kinase inhibitor	WEE1			Phase 2
MK-1903	niacin receptor agonist				Phase 2
MK-2048	HIV integrase inhibitor				Preclinical
MK-2206	AKT inhibitor	AKT1, AKT2, AKT3			Phase 2
MK-2295	TRPV antagonist	TRPV1			Phase 2
MK-2461	FGFR inhibitor, VEGFR inhibitor	FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, MERTK, MET, MST1R, NTRK1, NTRK2, PDGFRB			Phase 1/Phase 2
MK-2894	prostaglandin inhibitor	PTGER4			Preclinical
MK-3207	calcitonin antagonist	CALCA			Phase 2
MK-3697	orexin receptor antagonist	HCRTR2			Phase 2
MK-4074	acetyl-CoA carboxylase inhibitor				Phase 1
MK-5046	bombesin receptor agonist	BRS3, GRPR, NMBR			Preclinical
MK-5108	Aurora kinase inhibitor	AURKA, AURKB, AURKC			Phase 1
MK-571	leukotriene receptor antagonist	ABCC2, CYSLTR1			Phase 2
MK-6096	orexin receptor antagonist	HCRTR1, HCRTR2			Phase 2
MK-7246	CRTH receptor antagonist				Preclinical
MK-7622	cholinergic receptor agonist				Phase 2
MK-8033	c-Met inhibitor	MET			Phase 1
MK-8245	stearoyl-CoA desaturase inhibitor	SCD			Phase 2
MK-8617	hypoxia inducible factor prolyl hydroxylase inhibitor				Preclinical
MK-8745	Aurora kinase inhibitor	AURKA			Preclinical
MK-886	lipoxygenase inhibitor				Preclinical
MK-8998	T-type calcium channel blocker				Phase 2
MKT-077	HSP inhibitor				Phase 1
MK2-IN-1	MAP kinase inhibitor	MAPKAPK2			Preclinical
MLN0128	mTOR inhibitor	MTOR, PIK3CA, PIK3CD, PIK3CG			Phase 2
MLN1117	PI3K inhibitor	PIK3CA			Phase 2
MLN2480	RAF inhibitor				Phase 1/Phase 2
MLN8054	Aurora kinase inhibitor	AURKA			Phase 1
MLN9708	proteasome inhibitor				Phase 3
ML10302	serotonin receptor partial agonist	HTR3A, HTR3B, HTR4			Preclinical
ML130	NOD1 inhibitor				Preclinical
ML133	potassium channel blocker				Preclinical
ML141	GTPase inhibitor	CDC42			Preclinical
ML161	protease-activated receptor inhibitor				Preclinical
ML167	CLK inhibitor, DYRK inhibitor	CLK4, DYRK1B			Preclinical
ML179	liver receptor homolog inverse agonist	NR5A2			Preclinical
ML193	G protein-coupled receptor antagonist	GPR55			Preclinical
ML204	transient receptor potential channel antagonist	TRPC4, TRPC5			Preclinical
ML213	potassium channel activator	KCNQ4			Preclinical
ML218	T-type calcium channel blocker	CACNA1G, CACNA1H, CACNA1I			Preclinical
ML228	hypoxia inducible factor activator	HIF1A			Preclinical
ML277	potassium channel activator	KCNQ1			Preclinical
ML281	serine/threonine kinase inhibitor	STK33			Preclinical
ML297	inward rectifier potassium channel activator	KCNJ3			Preclinical
ML298	phospholipase inhibitor	PLD2			Preclinical
ML314	neurotensin agonist	NTSR1			Preclinical
ML323	ubiquitin specific protease inhibitor	USP1			Preclinical
ML324	histone lysine demethylase inhibitor	KDM4A			Preclinical
ML3403	MAP kinase inhibitor	CYP3A4, MAPK11, MAPK12, MAPK14			Preclinical
ML347	ALK tyrosine kinase receptor inhibitor	ACVR1, ACVRL1, BMPR1A			Preclinical
ML348	lysophospholipase inhibitor	LYPLA1			Preclinical
ML365	potassium channel blocker	KCNK3, KCNK9			Preclinical
ML786	RAF inhibitor	BRAF, RAF1			Preclinical
ML9	myosin light chain kinase inhibitor	TRPC6			Preclinical
MM-102	WDR5/MLL interaction inhibitor				Preclinical
MM-11253	retinoid receptor antagonist	RARG			Preclinical
MM-206	STAT inhibitor				Preclinical
MMPX	phosphodiesterase inhibitor				Preclinical
MMV-390048	PI4K inhibitor				Preclinical
MM77	serotonin receptor antagonist	HTR1A			Preclinical
MN-64	tankyrase inhibitor	TNKS			Preclinical
MNITMT	lymphocyte inhibitor				Preclinical
mocetinostat	HDAC inhibitor	HDAC1, HDAC11, HDAC2, HDAC3			Phase 2
moclobemide	monoamine oxidase inhibitor	MAOA, MAOB	neurology/psychiatry	depression, anxiety	Launched
modaline					Preclinical
moexipril	angiotensin converting enzyme inhibitor	ACE, ACE2	cardiology	hypertension	Launched
mofegiline	monoamine oxidase inhibitor	MAOA, MAOB			Phase 1
mofezolac	cyclooxygenase inhibitor	PTGS1	rheumatology, orthopedics	rheumatoid arthritis, osteoporosis	Launched
moguisteine	ATP-sensitive potassium channel inhibitor				Phase 2
molidustat	hypoxia inducible factor inhibitor	EGLN2			Phase 3
molindone	dopamine receptor antagonist	DRD2, HRH1, HTR2A	neurology/psychiatry	schizophrenia	Launched
molsidomine	guanylate cyclase stimulant	GUCY1A3	cardiology	coronary artery disease (CAD)	Launched
mometasone	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	Launched
mometasone-furoate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	Launched
monastrol	kinesin inhibitor	KIF11			Preclinical
monensin	bacterial permeability inducer		infectious disease	gastrointestinal parasites	Launched
monepantel	mTOR inhibitor				Preclinical
monobenzone	melanin inhibitor	TYR	dermatology	skin depigmentation	Launched
monocrotaline	antitumor agent				Preclinical
monoctanoin			gastroenterology	gallstones	Launched
monomethyl-fumarate			neurology/psychiatry	multiple sclerosis	Launched
monosodium-alpha-luminol					Launched
monostearin					Preclinical
montelukast	leukotriene receptor antagonist	ALOX5, CYSLTR1	pulmonary, allergy	asthma, allergic rhinitis, exercise-induced bronchoconstriction (EIB)	Launched
moprolol	adrenergic receptor antagonist		cardiology, ophthalmology, neurology/psychiatry	hypertension, glaucoma, anxiety	Launched
moracizine	sodium channel blocker	SCN5A	cardiology	ventricular arrhythmias	Withdrawn
morantel	acetylcholine receptor agonist		infectious disease	tapeworm	Launched
morin	cytochrome P450 inhibitor	ADORA2A, ESR2, FASN, MCL1, SLC22A12			Preclinical
morinidazole	other antibiotic	CYP51A1			Launched
morniflumate	anti-inflammatory agent		neurology/psychiatry	pain relief	Launched
moroxydine	antiviral		infectious disease	influenza A virus infection	Launched
morphothiadin	antiinfective drug				Preclinical
mosapride	serotonin receptor agonist	HTR4	gastroenterology	hypertrophic gastritis (GHG), gastroesophageal reflux disease (GERD), dyspepsia, irritable bowel syndrome	Launched
motapizone	phosphodiesterase inhibitor				Preclinical
motesanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	FLT1, FLT4, KDR, KIT			Phase 3
motolimod	toll-like receptor agonist	TLR8			Phase 2
moxalactam	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections, gram-negative bacterial infections, skin infections, bone and joint infections, pneumonia, urinary tract infections, meningitis	Launched
moxaverine	phosphodiesterase inhibitor		neurology/psychiatry	spasms	Launched
moxidectin	chloride channel antagonist		infectious disease	gastrointestinal parasites	Launched
moxifloxacin	bacterial DNA gyrase inhibitor	TOP2A	otolaryngology, pulmonary, infectious disease	sinusitis, bronchitis, pneumonia, skin infections, intra-abdominal infections	Launched
moxisylyte	adrenergic receptor antagonist				Withdrawn
moxonidine	imidazoline receptor agonist	ADRA2A, ADRA2B, ADRA2C	cardiology	hypertension	Launched
mozavaptan	vasopressin receptor antagonist	AVPR1A, AVPR1B, AVPR2	endocrinology	hyponatremia	Launched
MPEP	glutamate receptor antagonist	GRM1, GRM4, GRM5			Preclinical
MPI-0479605	mitotic kinase inhibitor	TTK			Preclinical
Mps-BAY-2a	monopolar spindle 1 kinase inhibitor	TTK			Preclinical
Mps1-IN-1	monopolar spindle 1 kinase inhibitor	TTK			Preclinical
Mps1-IN-5	protein kinase inhibitor				Phase 1
MR-16728	acetylcholine release enhancer				Preclinical
MR-948	thromboxane synthase inhibitor	TBXAS1			Phase 1
MRK-016	GABA receptor inverse agonist	GABRA1, GABRA2, GABRA3, GABRA5			Phase 1
MRK-409	benzodiazepine receptor agonist				Phase 1
MRK-560	gamma secretase inhibitor	APP			Preclinical
MRS-1220	adenosine receptor antagonist	ADORA2B, ADORA3			Preclinical
MRS-1334	adenosine receptor antagonist	ADORA3			Preclinical
MRS-1845	calcium channel blocker				Preclinical
MRS-2578	purinergic receptor antagonist	P2RY6			Preclinical
MRS-3777	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Preclinical
MRX-2843	MER tyrosine kinase inhibitor				Phase 1
MS-424	glutamate transporter modulator				Phase 2
MSDC-0160	insulin sensitizer				Phase 2
MSDC-0602K	mitochondrial pyruvate carrier modulator				Phase 2
MSX-122	CC chemokine receptor antagonist	CXCR4			Phase 2
MTPG	glutamate receptor antagonist	GRM2, GRM3			Preclinical
mubritinib	protein tyrosine kinase inhibitor	EGFR, ERBB2			Phase 1
mupirocin	isoleucyl-tRNA synthetase inhibitor		infectious disease	impetigo	Launched
muscimol	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRR1, GABRR2, GABRR3			Phase 1
MUT056399	FABI inhibitor				Phase 1
MY-5445	phosphodiesterase inhibitor, platelet aggregation inhibitor	PDE5A			Preclinical
mycophenolate-mofetil	dehydrogenase inhibitor, inositol monophosphatase inhibitor	IMPDH1, IMPDH2	transplant	organ rejection	Launched
mycophenolic-acid	dehydrogenase inhibitor, inositol monophosphatase inhibitor	IMPDH1, IMPDH2	transplant	organ rejection	Launched
myricetin	androgen receptor agonist, cytochrome P450 inhibitor	PIK3CG			Preclinical
myricitrin	PKC inhibitor	NOS1, PRKCA			Preclinical
myristyl-nicotinate	topical sunscreen agent				Phase 1
M8-B	transient receptor potential channel antagonist	TRPM8			Preclinical
N-(p-amylcinnamoyl)-anthranilic-acid	phospholipase inhibitor				Preclinical
N-(2-chlorophenyl)-2-({(2E)-2-[1-(2-pyridinyl)ethylidene]hydrazino}carbothioyl)hydrazinecarbothioamide					Preclinical
N-[2-(piperidinylamino)ethyl]-4-iodobenzamide	sigma receptor ligand				Preclinical
N-acetyl-D-glucosamine		B4GALT1, B4GALT2, B4GALT3, B4GALT4, NAGK, NAGLU, NAGPA, RENBP			Phase 2/Phase 3
N-acetyl-tyrosine					Launched
N-acetylcarnosine					Launched
N-acetylglycyl-D-glutamic-acid	glutamate receptor agonist				Preclinical
N-acetylmannosamine					Phase 2
N-acetyltryptamine	melatonin receptor agonist				Preclinical
N-alpha-methylhistamine-dihydrochloride	histamine receptor agonist	HRH4			Phase 3
N-benzylnaltrindole	opioid receptor antagonist				Preclinical
N-cyclohexyl-2-benzothiazolesulfenamide					Preclinical
N-hydroxynicotinamide					Preclinical
N-methyl-(-)ephedrine-[1R,2S]					Preclinical
N-methylformamide					Phase 2
N-methyllidocaine-iodide	antiarrhythmic medication				Preclinical
N-methylpyrrolidone					Phase 1
N-methylquipazine	serotonin receptor agonist				Preclinical
N-MPPP	opioid receptor agonist				Preclinical
N-oxydiethylenebenzothiazole-2-sulfenamide					Preclinical
N-salicoylaminophenol	ribonucleotide reductase inhibitor				Phase 1/Phase 2
NAB-2	ubiquitin ligase transport promoter	NEDD4			Preclinical
nabumetone	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	rheumatoid arthritis, osteoarthritis	Launched
nadide	free radical scavenger	AHCY, AKR1A1, ALDH2, BLVRA, DHPS, DLD, GALE, HMGCR, HSD17B1, HSD17B4, IMPDH2, MGAM, P2RY11, SORD, TRPM2			Launched
nadifloxacin	bacterial DNA gyrase inhibitor		dermatology, infectious disease	acne vulgaris (AV), skin infections	Launched
nadolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	cardiology	angina pectoris, hypertension	Launched
NADPH		DRD2, DRD3, DRD4, GHSR, HTR2A, HTR2C			Preclinical
nafadotride	dopamine receptor antagonist	DRD2, DRD3, HTR1A			Preclinical
nafamostat	serine protease inhibitor	ASIC1, ASIC2, ASIC3, C1R, PRSS1, TPSAB1, TRPM7	cardiology	anticoagulent	Launched
nafcillin	bacterial cell wall synthesis inhibitor	CYP1A2, CYP3A4, SLC22A6	infectious disease	gram-positive bacterial infections	Launched
naftidrofuryl	adrenergic receptor antagonist		cardiology	claudication	Launched
naftifine	fungal squalene epoxidase inhibitor		infectious disease	tinea pedis, tinea cruris, tinea corporis	Launched
naftopidil	adrenergic receptor antagonist	ADRA1A	urology	benign prostatic hyperplasia (BPH)	Launched
nalbuphine	opioid receptor agonist, opioid receptor antagonist	OPRD1, OPRK1, OPRM1	neurology/psychiatry	pain relief	Launched
nalfurafine	opioid receptor agonist	OPRK1, OPRM1	nephrology	uremic pruritus	Launched
nalidixic-acid	bacterial DNA gyrase inhibitor		infectious disease	urinary tract infections	Launched
nalmefene	opioid receptor antagonist	OPRD1, OPRK1, OPRM1	pulmonary	respiratory depression	Launched
naloxegol	opioid receptor antagonist	OPRM1	gastroenterology	constipation	Launched
naloxone	opioid receptor antagonist	CREB1, ESR1, OPRD1, OPRK1, OPRM1, TLR4	pulmonary	respiratory depression	Launched
naloxone-benzoylhydrazone	opioid receptor antagonist	OPRK1, OPRM1			Preclinical
naltrexone	opioid receptor antagonist	OPRD1, OPRK1, OPRM1, SIGMAR1	neurology/psychiatry	abstinence from alcohol	Launched
naltriben	opioid receptor antagonist	OPRD1, OPRK1, OPRM1			Preclinical
naltrindole	opioid receptor antagonist	OPRD1, OPRK1, OPRM1			Preclinical
Nampt-IN-1					Preclinical
NAN-190	serotonin receptor agonist	ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1F			Preclinical
nanchangmycin	other antibiotic				Preclinical
napabucasin	STAT inhibitor	STAT3			Phase 3
napamezole	adrenergic receptor antagonist, monoamine reuptake inhibitor				Preclinical
naphazoline	adrenergic receptor agonist	ADRA1A, ADRA2A	ophthalmology	eye irritation	Launched
naphthoquine-phosphate	antimalarial agent		infectious disease	malaria	Launched
napirimus	immunosuppressant				Phase 1
naproxen	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry, rheumatology, dental, otolaryngology, endocrinology	pain relief, rheumatoid arthritis, headache, toothache, backache, muscle pain, common cold, fever	Launched
naquotinib	EGFR inhibitor				Phase 3
narasin	antiprotozoal agent		infectious disease	coccidiosis	Launched
naratriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F	neurology/psychiatry	migraine headache	Launched
naringenin	aromatase inhibitor, TRPV antagonist	CYP19A1, CYP1B1, ESR2, GLO1, HSD17B1			Phase 1
naringeninic-acid		HCAR2, PTGR1			Phase 1
naringin	cytochrome P450 inhibitor	SLCO1A2			Preclinical
naringin-dihydrochalcone	cytochrome P450 inhibitor				Preclinical
narlaprevir	HCV inhibitor				Phase 3
NAS-181	serotonin receptor antagonist	HTR1B			Preclinical
nastorazepide	CCK receptor antagonist	CCKBR			Phase 2
natamycin	fungal ergosterol inhibitor		ophthalmology, infectious disease	conjunctivitis, fungal keratosis, blepharitis	Launched
nateglinide	insulin secretagogue	ABCC8, KCNJ10, KCNJ11, PPARG	endocrinology	diabetes mellitus	Launched
NAV-26	voltage-gated sodium channel blocker	SCN9A			Preclinical
navarixin	CC chemokine receptor antagonist	CXCR1, CXCR2			Phase 2
navitoclax	BCL inhibitor	BCL2, BCL2L1, BCL2L2			Phase 2
naxagolide	dopamine receptor agonist				Phase 3
NB-001	antiviral				Preclinical
NBI-27914	corticotropin releasing factor receptor antagonist	CRHR1			Preclinical
NBI-74330-(+/-)	CC chemokine receptor antagonist	CXCR3			Preclinical
NBI-98782	vesicular monoamine transporter inhibitor				Preclinical
NBQX	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIN1, GRIN2A, GRIN2B			Preclinical
NCS-382	GABA receptor antagonist	GABBR1, GABBR2, SLC52A2			Preclinical
NCX-1015	interleukin sythesis stimulator				Preclinical
NDD-094					Preclinical
NDT-9513727	complement antagonist	C5AR1			Preclinical
NE-100	sigma receptor antagonist	SIGMAR1			Phase 2
nebivolol	adrenergic receptor antagonist	ADRB1	cardiology	hypertension	Launched
nebracetam	acetylcholine receptor agonist	CHRM1			Phase 3
NECA	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Launched
necrostatin-1	RIPK inhibitor	RIPK1			Preclinical
necrostatin-2	necroptosis inhibitor, RIPK inhibitor	RIPK2			Preclinical
nedaplatin	DNA inhibitor		oncology	non-small cell lung cancer (NSCLC), small cell lung cancer, esophageal cancer	Launched
nedocromil	histamine receptor antagonist	CYSLTR1, CYSLTR2, FPR1, HSP90AA1, PTGDR	neurology/psychiatry, ophthalmology	itching, conjunctivitis	Launched
nefazodone	adrenergic inhibitor, norepinephrine reuptake inhibitor, serotonin receptor antagonist, serotonin reuptake inhibitor	ADRA1A, ADRA1B, ADRA2A, CYP3A4, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A3, SLC6A4			Withdrawn
nefiracetam	acetylcholine receptor agonist, benzodiazepine receptor agonist	CHRM1			Phase 3
nefopam	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	Launched
nelarabine	DNA synthesis inhibitor, T cell inhibitor	POLA1	hematologic malignancy	acute lymphoblastic leukemia (ALL)	Launched
nelfinavir	HIV protease inhibitor	CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A7	infectious disease	human immunodeficiency virus (HIV-1)	Launched
nelociguat	guanylate cyclase stimulant				Preclinical
nelotanserin	serotonin receptor inverse agonist				Phase 2
nemazoline	adrenergic receptor agonist, adrenergic receptor antagonist				Phase 2
nemiralisib					Phase 2
nemonapride	dopamine receptor antagonist	DRD2, DRD3, DRD4	neurology/psychiatry	schizophrenia	Launched
nemorexant	orexin receptor antagonist				Preclinical
nemorubicin	topoisomerase inhibitor	TOP1, TOP2A			Phase 2
neo-gilurytmal			cardiology	cardiac arrythmia	Launched
neohesperidin					Preclinical
neohesperidin-dihydrochalcone					Preclinical
neomycin	bacterial 30S ribosomal subunit inhibitor	CXCR4	infectious disease, gastroenterology	first-aid antibiotic, hepatic encephalopathy (HE), intra-abdominal infections	Launched
neostigmine	acetylcholinesterase inhibitor	ACHE	neurology/psychiatry	myasthenia gravis	Launched
nepafenac	cyclooxygenase inhibitor	PTGS1, PTGS2	ophthalmology	eye inflammation	Launched
nepicastat	dopamine beta hydroxylase inhibitor	DBH			Phase 2
neratinib	EGFR inhibitor	EGFR, ERBB2, KDR	oncology	breast cancer	Launched
nerbacadol	cyclooxygenase inhibitor				Phase 3
neridronic-acid	bone resorption inhibitor	FDPS	endocrinology	brittle bone disease, Paget's disease	Launched
nesbuvir	RNA polymerase inhibitor				Phase 2
netilmicin	protein synthesis inhibitor		infectious disease	gram-negative bacterial infections	Launched
netupitant	tachykinin antagonist	TACR1	gastroenterology	nausea, vomiting	Launched
neurodazine	neurogenesis of non-pluripotent C2C12 myoblast inducer				Preclinical
neuropathiazol	neural stem cell inducer	BMP2, LIF			Preclinical
Neu2000	ionotropic glutamate receptor antagonist				Phase 2
nevirapine	non-nucleoside reverse transcriptase inhibitor	CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP3A4, CYP3A5	infectious disease	human immunodeficiency virus (HIV-1)	Launched
nexturastat-A	HDAC inhibitor	HDAC1, HDAC6			Preclinical
NFKB-activation-inhibitor-II	NFkB pathway inhibitor	RELA			Preclinical
NG-nitro-arginine	nitric oxide synthase inhibitor	NOS1, NOS2, NOS3			Phase 1
NGB-2904	dopamine receptor antagonist	DRD3			Preclinical
NGD-94-1	dopamine receptor antagonist	DRD4			Phase 1
NGD-98-2	corticotropin releasing factor receptor antagonist	CRHR1			Preclinical
NGP555	gamma secretase modulator				Phase 1
NHI-2	lactate dehydrogenase inhibitor	LDHA			Preclinical
NH125	eukaryotic translation elongation factor 2 inhibitor				Preclinical
NI-57	bromodomain inhibitor	BRD1, BRPF1, BRPF3			Preclinical
niacin	NAD precursor, vitamin B	DGAT2, HCAR1, HCAR2, HCAR3, NNMT, QPRT	endocrinology	hypertriglyceridemia	Launched
nialamide	monoamine oxidase inhibitor	COMT, MAOA, MAOB			Withdrawn
nibentan	potassium channel blocker				Phase 2
nicainoprol	angiotensin converting enzyme inhibitor				Preclinical
nicaraven	free radical scavenger				Phase 3
nicardipine	calcium channel blocker	ADORA3	cardiology	chronic stable angina, hypertension	Launched
nicergoline	adrenergic receptor antagonist	ADRA1A	rheumatology, neurology/psychiatry, cardiology, hematology	Raynaud's disease, migraine headache, atherosclerosis, thrombosis	Launched
niceritrol	NAD precursor		endocrinology	hyperlipidemia	Launched
niclosamide	DNA replication inhibitor, STAT inhibitor	STAT3	infectious disease	tapeworm	Launched
nicodicosapent	sterol regulatory element binding protein (SREBP) inhibitor				Preclinical
nicorandil	nitric oxide donor, potassium channel activator	KCNJ11	cardiology	angina pectoris	Launched
nicotinamide	protein synthesis stimulant	BST1, LDHA, PARP1, SIRT5	dermatology	acne vulgaris (AV)	Launched
nicotine	acetylcholine receptor agonist	CHAT, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB2, CHRNB3, CHRNB4, CYP19A1, TBXAS1, TRPA1	neurology/psychiatry	smoking cessation	Launched
nicotinyl-alcohol-tartrate			cardiology, neurology/psychiatry	vascular spasm, vertigo	Launched
NIDA-41020	cannabinoid receptor antagonist	CNR1			Preclinical
nifedipine	calcium channel blocker	CACNA1C, CACNA1D, CACNA1F, CACNA1H, CACNA1S, CACNA2D1, CACNB2, CALM1, GLRA1, GLRA3, GLRB, KCNA1, KCNA5, NR1I2, TRPM3	cardiology	vasospastic angina, chronic stable angina	Launched
nifekalant	potassium channel blocker		cardiology	ventricular arrhythmias, ventricular tachycardia (VT)	Launched
nifenalol	adrenergic receptor antagonist	ADRB1, ADRB2			Launched
nifenazone	analgesic agent		neurology/psychiatry	pain relief	Launched
niflumic-acid	cyclooxygenase inhibitor	ANO1, CLCN1, CLCNKA, CLCNKB, KCNQ1, PLA2G1B, PLA2G4A, PTGS1, PTGS2, UGT1A9	rheumatology, neurology/psychiatry	joint pain, muscle pain	Launched
nifuroxazide	bacterial DNA inhibitor		gastroenterology	colitis, diarrhea	Launched
nifursol	bacterial DNA inhibitor				Launched
nifurtimox	DNA inhibitor		infectious disease	Chagas disease, African trypanosomiasis	Launched
niguldipine-(R)-(-)					Preclinical
niguldipine-(S)-(+)	adrenergic receptor antagonist	ADRA1A			Preclinical
nikethamide	immunostimulant				Withdrawn
nilotinib	Abl kinase inhibitor, Bcr-Abl kinase inhibitor	ABL1, KIT	hematologic malignancy	chronic myeloid leukemia (CML)	Launched
nilutamide	androgen receptor antagonist	AR	oncology	prostate cancer	Launched
nilvadipine	calcium channel blocker	CACNA1C, CACNA1D	cardiology	hypertension, cerebral artery occlusion	Launched
nimesulide	cyclooxygenase inhibitor	LTF, PLA2G2E, PTGS1, PTGS2	rheumatology, obstetrics/gynecology	osteoarthritis, menstrual pain	Launched
nimodipine	calcium channel blocker	CFTR, NR3C2	hematology	hemorrhage	Launched
nimorazole	bacterial DNA inhibitor		oncology	head and neck squamous cell carcinoma (HNSCC)	Launched
nimustine	DNA alkylating agent				Launched
NIM811	mitochondrial permeability transition inhibitor				Phase 2
ningetinib-tosylate	protein tyrosine kinase inhibitor				Preclinical
nintedanib	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB	pulmonary	idiopathic pulmonary fibrosis (IPF)	Launched
niraparib	PARP inhibitor	PARP1	oncology	primary peritoneal cancer (PPC)	Launched
niridazole	phosphofructokinase inhibitor		infectious disease	schistosomiasis	Launched
nisin	bacterial cell wall synthesis inhibitor				Phase 1
nisoldipine	calcium channel blocker	CACNA1C, CACNA1D, CACNA1F, CACNA1S	cardiology	hypertension	Launched
nisoxetine	norepinephrine reuptake inhibitor	SLC6A2, SLC6A3, SLC6A4			Phase 1
nitarsone			dermatology	blackhead disease	Launched
nitazoxanide	pyruvate ferredoxin oxidoreductase inhibitor		gastroenterology	diarrhea	Launched
nitecapone	catechol O methyltransferase inhibitor	COMT			Phase 2
nitenpyram			infectious disease	flea control	Launched
nithiamide	bacterial DNA inhibitor				Preclinical
nitisinone	hydroxyphenylpyruvate dioxygenase inhibitor		metabolism	tyrosinemia	Launched
nitrendipine	calcium channel blocker	CACNA1D, CACNA2D1, KCNN4	cardiology	hypertension	Launched
nitrocaramiphen	cholinergic receptor antagonist	CHRM1			Preclinical
nitroflurbiprofen	cyclooxygenase inhibitor				Preclinical
nitrofurantoin	DNA inhibitor		infectious disease	urinary tract infections, pyelonephritis	Launched
nitrofurazone	bacterial DNA inhibitor		infectious disease	first-aid antibiotic	Launched
nitromide			infectious disease	coccidiosis	Launched
nitrosodimethylurea	DNA synthesis inhibitor				Preclinical
nitroxoline	cathepsin inhibitor	METAP2	infectious disease	urinary tract infections	Launched
nizatidine	histamine receptor antagonist	HRH2	gastroenterology	duodenal ulcer disease, erosive esophagitis (EE), ulcerative esophagitis (UE), gastroesophageal reflux disease (GERD)	Launched
nizofenone	ion channel antagonist		neurology/psychiatry	stroke	Launched
NK-252	nuclear factor erythroid derived, like (NRF2) activator	NFE2L2			Preclinical
NKP-1339	HSP inhibitor				Phase 1
NKY-80	adenylyl cyclase inhibitor	ADCY5			Preclinical
NLG919	indoleamine 2,3-dioxygenase inhibitor	IDO1			Phase 1
NMDA	glutamate receptor agonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			Preclinical
NMS-E973	HSP inhibitor				Preclinical
NMS-P715	protein kinase inhibitor				Preclinical
NMS-1286937	PLK inhibitor	FLT3, PLK1, PLK2, PLK3			Phase 2
NMS-873	ATPase inhibitor	VCP			Preclinical
NM107	RNA polymerase inhibitor				Phase 2
NN-DNJ	glucosidase inhibitor	GBA			Preclinical
NNC-05-2090	GABA uptake inhibitor, GAT inhibitor	SLC6A12			Preclinical
NNC-55-0396	T-type calcium channel blocker	CATSPER1, CATSPER2, CATSPER3, CATSPER4			Preclinical
NNC-63-0532	opioid receptor agonist	OPRL1			Preclinical
NNC-711	GABA uptake inhibitor	SIGMAR1, SLC6A1			Preclinical
NO-ASA	cyclooxygenase inhibitor	PTGS2			Phase 2
nobiletin	MEK inhibitor	MAP2K1			Preclinical
nocodazole	tubulin polymerization inhibitor	HPGDS			Preclinical
nolatrexed	thymidylate synthase inhibitor	TYMS			Phase 3
nomegestrol-acetate	progesterone receptor agonist	PGR	endocrinology	contraceptive	Launched
nomifensine	dopamine reuptake inhibitor, noradrenaline uptake inhibitor	DRD2, SLC6A2, SLC6A3			Withdrawn
nonivamide	TRPV agonist	TRPV1	rheumatology, neurology/psychiatry	rheumatoid arthritis, muscle pain	Launched
nonoxynol-9	membrane integrity inhibitor		endocrinology	contraceptive	Launched
nor-binaltorphimine	opioid receptor antagonist	OPRD1, OPRK1, OPRM1			Preclinical
norcyclobenzaprine	adrenergic receptor agonist, serotonin receptor antagonist				Preclinical
norelgestromin		PGR	endocrinology	contraceptive	Launched
norepinephrine	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, SLC18A1, SLC18A2	cardiology, allergy, neurology/psychiatry	hypertension, urticaria, headache, seasonal affective disorder	Launched
norethindrone	progesterone receptor agonist	PGR	obstetrics/gynecology	endometriosis	Launched
norethindrone-acetate	progesterone receptor agonist	PGR	endocrinology, orthopedics, obstetrics/gynecology	menopause, osteoporosis, vaginal atrophy	Launched
norethisterone-enanthate	contraceptive agent		endocrinology	contraceptive	Launched
noretynodrel	progestogen hormone	PGR	endocrinology	contraceptive	Launched
norfloxacin	bacterial DNA gyrase inhibitor	TOP2A	infectious disease, urology	urinary tract infections, gonorrhea, prostatitis	Launched
norfluoxetine	selective serotonin reuptake inhibitor (SSRI)	HTR2B			Phase 1
norgestimate	progesterone receptor agonist	ESR1, PGR	endocrinology	contraceptive	Launched
norgestrel	progesterone receptor agonist	AR, ESR1, PGR, SRD5A1	endocrinology	contraceptive	Launched
nornicotine	acetylcholine receptor agonist				Preclinical
nortriptyline	tricyclic antidepressant	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR6, KCNJ10, PGRMC1, SIGMAR1, SLC6A2, SLC6A4	neurology/psychiatry	depression	Launched
norvancomycin					Preclinical
noscapine	bradykinin receptor antagonist, tubulin polymerization inhibitor	SIGMAR1	pulmonary	cough suppressant	Launched
NOV-002		GSR			Phase 3
novobiocin	bacterial DNA gyrase inhibitor		obstetrics/gynecology	mastitis	Launched
NPC-01	steroid				Phase 3
NPC-15199	ICAM1 antagonist	PPARG			Phase 2
NPPB	chloride channel blocker	ANO1, CLCN2, CLCN7, TRPA1			Preclinical
NPS-2143	calcium receptor antagonist	CASR			Preclinical
NPS-2407	glutamate receptor antagonist				Preclinical
NPY-5RA972	neuropeptide receptor antagonist	NPY5R			Preclinical
NQDI-1	caspase inhibitor	CASP3			Preclinical
NS-018	JAK inhibitor	JAK1, JAK2, JAK3, TYK2			Phase 1/Phase 2
NS-11021	calcium-activated potassium channel activator	KCNMA1			Preclinical
NS-11394	GABA receptor agonist				Preclinical
NS-1643	voltage-gated potassium channel activator	KCNH2, KCNH6, KCNMA1			Preclinical
NS-19504	calcium-activated potassium channel activator	KCNMA1			Preclinical
NS-309	calcium-activated potassium channel activator	KCNN1, KCNN2, KCNN3, KCNN4			Preclinical
NS-3623	voltage-gated potassium channel activator	KCNH2			Preclinical
NS-3861	acetylcholine receptor agonist	CHRNA3, CHRNB4			Preclinical
NS-5806	voltage-gated potassium channel activator	KCND3			Preclinical
NS-8	potassium channel agonist	KCNMA1			Phase 2
NS-8593	calcium-activated potassium channel modulator	KCNN1, KCNN2, KCNN3			Preclinical
NS-9283	acetylcholine receptor allosteric modulator	CHRNA4			Preclinical
NSC-23766	Ras GTPase inhibitor				Preclinical
NSC-319726	p53 activator				Preclinical
NSC-3852	HDAC inhibitor	HDAC1			Preclinical
NSC-405020	matrix metalloprotease inhibitor	MMP1			Preclinical
NSC-4644	ACAT inhibitor, sterol regulatory element binding protein (SREBP) inhibitor	PYGM			Phase 2
NSC-5844	CC chemokine receptor agonist	CCR1			Preclinical
NSC-625987	CDK inhibitor	CDK2, CDK4			Preclinical
NSC-632839	ubiquitin specific protease inhibitor	SENP2, USP1, USP2, USP7			Preclinical
NSC-636819	histone demethylase inhibitor	KDM4A, KDM4B			Preclinical
NSC-663284	CDC inhibitor	CDC25A, CDC25B, CDC25C			Preclinical
NSC-697923	ubiquitin-conjugating enzyme inhibitor	UBE2N			Preclinical
NSC-95397	CDC inhibitor	CDC25A, CDC25B			Preclinical
NSC-9965	acetylcholine receptor antagonist	CHRNA4, CHRNB2			Preclinical
NSI-189	neurotrophic agent				Phase 2
NSP-805	phosphodiesterase inhibitor				Preclinical
NTNCB	neuropeptide receptor antagonist	NPY5R			Preclinical
NTRC-824	neurotensin receptor antagonist	NTSR2			Preclinical
nTZDpa	PPAR receptor agonist	PPARG			Preclinical
NT157	IGF-1 inhibitor	IGF1R			Preclinical
NU-1025	PARP inhibitor	PARP1			Preclinical
NU-2058	cyclin D inhibitor	CCNA2, CDK2			Preclinical
NU-6027	CDK inhibitor	CCNA2, CDK2			Preclinical
NU-7026	DNA dependent protein kinase inhibitor, mTOR inhibitor, PI3K inhibitor	PRKDC			Preclinical
NU-7441	DNA dependent protein kinase inhibitor	PRKDC			Preclinical
nuclomedone	immunosuppressant				Phase 3
nutlin-3	MDM inhibitor	MDM2, TP53			Preclinical
nuvenzepine	acetylcholine receptor antagonist				Preclinical
NVP-ADW742	insulin growth factor receptor inhibitor	IGF1R			Preclinical
NVP-AEW541	IGF-1 inhibitor	IGF1R, INSR			Preclinical
NVP-AUY922	HSP inhibitor	HSP90AA1, HSP90AB1			Phase 2
NVP-BEZ235	mTOR inhibitor, PI3K inhibitor	ATR, MTOR, PIK3CA, PIK3CD, PIK3CG			Phase 3
NVP-BGJ398	FGFR inhibitor	FGFR1, FGFR2, FGFR3, FGFR4, KDR			Phase 3
NVP-BHG712	ephrin inhibitor	EPHB4			Preclinical
NVP-BSK805	JAK inhibitor	JAK2			Preclinical
NVP-BVU972	MET inhibitor	MET			Preclinical
NVP-DPP728	dipeptidyl peptidase inhibitor	DPP4			Phase 2
NVP-HSP990	HSP inhibitor	HSP90AA1, HSP90AB1			Phase 1
NVP-TAE226	protein tyrosine kinase inhibitor	PTK2			Preclinical
NVP-TAE684	ALK tyrosine kinase receptor inhibitor	ALK, INSR			Preclinical
NVP-TNKS656	tankyrase inhibitor	TNKS2			Preclinical
NVP-231	ceramidase inhibitor	CERK			Preclinical
NVS-PAK1-1	p21 activated kinase inhibitor	PAK1			Preclinical
NXY-059	free radical scavenger				Phase 3
nystatin	fungal ergosterol inhibitor		infectious disease	esophageal candidiasis, skin infections, yeast infection	Launched
N20C	glutamate receptor antagonist				Preclinical
N6-cyclopentyladenosine	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3, SLC29A1			Preclinical
N6-methyladenosine					Preclinical
N6022	alcohol dehydrogenase inhibitor	ADH5			Phase 1/Phase 2
O-acetyl-L-serine		PTGS1			Preclinical
o-mercapto-benzoic-acid					Preclinical
O-1918	cannabinoid receptor antagonist				Preclinical
o-3M3FBS	phospholipase activator				Preclinical
O-304	AMPK activator				Preclinical
OAC1	Oct activator				Preclinical
OAC2	Oct activator	POU5F1			Preclinical
obatoclax	BCL inhibitor	BCL2			Phase 3
obeticholic-acid	FXR agonist	NR1H4	gastroenterology	primary biliary cholangitis	Launched
obidoxime	cholinesterase reactivator	ACHE	critical care, neurology/psychiatry	poison antidote, nerve gas poisoning	Launched
ocaperidone	serotonin receptor antagonist				Preclinical
ochromycinone	STAT inhibitor	STAT3			Phase 1
ocinaplon	GABA receptor modulator	GABRA1, GABRA2, GABRA3, GABRA5			Phase 3
OCO-1112	cholesterol inhibitor				Phase 2
octadecan-1-ol					Preclinical
octamethyltrisiloxane					Preclinical
octenidine	membrane integrity inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	Launched
octinoxate			dermatology	sunscreen lotion	Launched
octisalate			dermatology	sunscreen lotion	Launched
octocrylene			dermatology	sunscreen lotion	Launched
octodrine	antitumor agent				Preclinical
octopamine	trace amine associated receptor agonist	F10, TAAR1			Preclinical
octreotide	somatostatin receptor agonist	SSTR2, SSTR3, SSTR5	gastroenterology, endocrinology, oncology	diarrhea, acromegaly, carcinoid tumors	Launched
OC000459	CRTH receptor antagonist	PTGDR2			Phase 2
odanacatib	cathepsin inhibitor	CTSK			Phase 3
ODQ	guanylyl cyclase inhibitor	GUCY1A2, GUCY1A3, GUCY1B3			Preclinical
OF-1	bromodomain inhibitor	BRD1			Preclinical
ofloxacin	bacterial DNA gyrase inhibitor		infectious disease, otolaryngology, gastroenterology, endocrinology	respiratory tract infections, sinusitis, skin infections, bone and joint infections, intra-abdominal infections, diarrhea, fever, urinary tract infections	Launched
OG-L002	histone lysine demethylase inhibitor	KDM1A			Preclinical
ogerin	G protein-coupled receptor modulator				Preclinical
oglemilast	phosphodiesterase inhibitor				Phase 2
oglufanide	VEGF antagonist				Phase 2
OICR-9429	WDR5/MLL interaction inhibitor	WDR5			Preclinical
olanzapine	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, HRH1, HRH2, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR5A, HTR6, HTR7	neurology/psychiatry	schizophrenia, bipolar disorder	Launched
olaparib	PARP inhibitor	PARP1, PARP2	oncology	ovarian cancer	Launched
OLDA	TRPV agonist	GPR119			Preclinical
oleamide	cannabinoid receptor agonist	HTR7, PLA2G2A			Preclinical
oleandrin	Na/K-ATPase inhibitor				Phase 1
oleanolic-acid	G protein-coupled receptor agonist	GPBAR1			Preclinical
oleoylethanolamide	cannabinoid receptor agonist, glucose dependent insulinotropic receptor agonist, potassium channel blocker, PPAR receptor agonist	CNR1, GPR119, GPR55, PPARA			Preclinical
olesoxime	apoptosis stimulant				Phase 2/Phase 3
oleuropein	estrogen receptor agonist	GPER1			Phase 2
oligomycin-A	ATP synthase inhibitor, ATPase inhibitor	ATP5A1			Preclinical
olmesartan	angiotensin receptor antagonist	AGTR1	cardiology	hypertension	Launched
olmesartan-medoxomil	angiotensin receptor antagonist	AGTR1	cardiology	hypertension	Launched
olmutinib	Bruton's tyrosine kinase (BTK) inhibitor, EGFR inhibitor	BTK, EGFR	oncology	non-small cell lung cancer (NSCLC)	Launched
olodanrigan	angiotensin antagonist				Phase 2
olomoucine	CDK inhibitor	CDK1, CDK2, CDK5, MAPK1			Preclinical
olopatadine	histamine receptor antagonist	HRH1, S100A1, S100A12, S100A13, S100A2, S100B	ophthalmology	conjunctivitis	Launched
olprinone	phosphodiesterase inhibitor	PDE3A	cardiology	congestive heart failure	Launched
olsalazine	cyclooxygenase inhibitor	IFNG, TPMT	gastroenterology	ulcerative colitis	Launched
oltipraz	nuclear factor erythroid derived, like (NRF2) activator	ANG			Phase 3
olumacostat-glasaretil	acetyl-CoA carboxylase inhibitor				Phase 3
olvanil	TRPV agonist	CNR1, GPR119, TRPV1			Preclinical
omadacycline	bacterial 30S ribosomal subunit inhibitor		infectious disease	pneumonia	Launched
omapatrilat	metalloproteinase inhibitor	ACE, MME			Preclinical
omarigliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	Launched
ombitasvir	HCV inhibitor		infectious disease	hepatitis C	Launched
ombrabulin	tubulin polymerization inhibitor				Phase 3
OMDM-2	FAAH inhibitor	GPR119			Preclinical
omecamtiv-mecarbil	cardiac myosin activator	MYBPC3			Phase 3
omega-(4-iodophenyl)pentadecanoic-acid					Preclinical
omega-3-acid-esters	cholesterol inhibitor				Launched
omeprazole	ATPase inhibitor	ATP4A, CLCN2	gastroenterology	heartburn	Launched
omeprazole-magnesium	proton pump inhibitor	ATP4A, ATP4B	gastroenterology	gastroesophageal reflux disease (GERD), heartburn	Launched
omeprazole-sulfide	ATPase inhibitor				Phase 1
omtriptolide	ERK1 and ERK2 phosphorylation inhibitor				Preclinical
ON-01500	apoptosis stimulant				Preclinical
oncrasin-1	apoptosis stimulant				Preclinical
ONC201	AKT inhibitor, MAP kinase inhibitor	TNFSF10			Phase 2
ondansetron	serotonin receptor antagonist	HTR3A, HTR3B	gastroenterology	nausea, vomiting	Launched
ONO-AE3-208	prostanoid receptor antagonist	PTGER4			Preclinical
ONO-4059	Bruton's tyrosine kinase (BTK) inhibitor	BTK			Phase 1
ONO-4817	matrix metalloprotease inhibitor	MMP8			Phase 1
ONO-8130	prostanoid receptor antagonist	PTGER1			Preclinical
ONX-0914	proteasome inhibitor				Preclinical
ON123300	CDK inhibitor	CDK4, NUAK1, PDGFRB			Preclinical
OP-0595	beta lactamase inhibitor				Preclinical
OPC-21268	vasopressin receptor antagonist	AVPR1A, AVPR2, OXTR			Phase 1
opicapone	catechol O methyltransferase inhibitor	COMT			Phase 3
opipramol	sigma receptor agonist		neurology/psychiatry	generalized anxiety disorder (GAD)	Launched
oprozomib	proteasome inhibitor				Phase 1/Phase 2
OR-486	catechol O methyltransferase inhibitor	COMT			Preclinical
orantinib	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	AURKA, AURKB, EGFR, FGFR1, FGFR2, KDR, PDGFRA, PDGFRB			Phase 3
orbifloxacin	bacterial DNA gyrase inhibitor		infectious disease	urinary tract infections	Launched
ORE1001	angiotensin converting enzyme inhibitor	ACE2			Phase 1/Phase 2
ORG-12962	serotonin receptor agonist	HTR2A, HTR2B, HTR2C			Phase 2
ORG-25543	glycine transporter inhibitor	GLRB, SLC6A5			Preclinical
ORG-26576	glutamate receptor modulator				Phase 2
ORG-27569	cannabinoid receptor modulator	CNR1			Preclinical
ORG-9768	adrenergic receptor antagonist	ADRA2A			Phase 1
oridonin	BCL inhibitor	BCL2			Preclinical
oritavancin	bacterial cell wall synthesis inhibitor		infectious disease	skin infections	Launched
orlistat	lipase inhibitor	CNR1, DAGLA, DAGLB, FASN, LIPF, PNLIP	endocrinology	weight-loss aid	Launched
ormeloxifene	selective estrogen receptor modulator (SERM)		endocrinology	contraceptive	Launched
ornidazole	antiprotozoal agent		infectious disease	protozoan infection	Launched
ornipressin	vasoconstrictor				Preclinical
ornithine	NFkB pathway modulator	GPRC6A			Launched
orotic-acid		DHODH			Phase 2
orphanin-fq	opioid receptor agonist	OPRL1, OPRM1			Phase 1
orphenadrine	acetylcholine receptor antagonist		neurology/psychiatry	muscle pain	Launched
orteronel	androgen biosynthesis inhibitor, androgen receptor antagonist, cytochrome P450 inhibitor	CYP17A1			Phase 3
ORY-1001	histone lysine demethylase inhibitor	KDM1A			Phase 1/Phase 2
oseltamivir-carboxylate	neuraminidase inhibitor		infectious disease	influenza A virus infection	Launched
oseltamivir-phosphate	neuraminidase inhibitor	CES1, NEU1, NEU2	infectious disease	influenza A virus infection	Launched
osemozotan	serotonin receptor agonist	HTR1A			Phase 2/Phase 3
OSI-027	mTOR inhibitor	MTOR			Phase 1
OSI-420	EGFR inhibitor	EGFR			Preclinical
OSI-930	KIT inhibitor, VEGFR inhibitor	FLT1, KDR, KIT			Phase 1
osilodrostat	cytochrome P450 inhibitor				Launched
osimertinib	EGFR inhibitor	EGFR	oncology	non-small cell lung cancer (NSCLC)	Launched
ospemifene	selective estrogen receptor modulator (SERM)	ESR1, ESR2	obstetrics/gynecology, endocrinology	vaginal atrophy, dyspareunia, menopause	Launched
ostarine	androgen receptor modulator	AR			Phase 3
osthol	calcium channel blocker				Preclinical
OT-R-antagonist-1	oxytocin receptor antagonist	AVPR1A, OXTR			Preclinical
otamixaban	coagulation factor inhibitor	F10			Phase 3
otenzepad	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5			Phase 3
otilonium	acetylcholine receptor antagonist	CACNA1C	gastroenterology	irritable bowel syndrome	Launched
OTS167	maternal embryonic leucine zipper kinase inhibitor	MELK			Phase 1/Phase 2
OTS514	TOPK inhibitor				Preclinical
OTX015	bromodomain inhibitor	BRD2, BRD3, BRD4			Phase 1/Phase 2
ouabain	ATPase inhibitor	ATP1A1	cardiology	hypertension, cardiac arrythmia	Launched
OXA-06	rho associated kinase inhibitor	ROCK1, ROCK2			Preclinical
oxaceprol	anti-inflammatory agent				Preclinical
oxacillin	bacterial cell wall synthesis inhibitor		infectious disease	staphylococcal infections	Launched
oxacyclohexadecan-2-one	protein kinase inhibitor				Preclinical
oxaliplatin	DNA inhibitor		oncology	colorectal cancer	Launched
oxaloacetate	glutamate release inhibitor				Phase 2/Phase 3
oxantel	anthelmintic agent		infectious disease	gastrointestinal parasites	Launched
oxaprozin	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	Launched
oxatomide	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	Launched
oxcarbazepine	sodium channel blocker	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	Launched
oxelaidin	antitussive		pulmonary	cough suppressant	Launched
oxethazaine	local anesthetic		neurology/psychiatry	local anesthetic	Launched
OXF-BD-02	bromodomain inhibitor	BRD4			Preclinical
oxfendazole	anthelmintic agent		infectious disease	lungworms, tapeworm, gastrointestinal roundworms	Launched
oxfenicine	carnitine palmitoyltransferase inhibitor	CPT1A, CPT1B			Phase 1
oxibendazole	tubulin polymerization inhibitor	TUBB, TUBB4B	infectious disease	strongyles	Launched
oxiconazole	bacterial cell wall synthesis inhibitor		infectious disease	tinea pedis, tinea cruris, tinea corporis	Launched
oxidopamine	neurotoxin				Preclinical
oxiniacic-acid					Preclinical
oxiperomide	dopamine receptor antagonist				Phase 2
oxiracetam	acetylcholine receptor agonist		neurology/psychiatry	senile dementia	Launched
oxolamine	antitussive		pulmonary	cough suppressant	Launched
oxolinic-acid	bacterial DNA gyrase inhibitor				Preclinical
oxonic-acid	uricase inhibitor				Preclinical
oxotremorine-M	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4			Preclinical
oxotremorine-sesquifumarate	cholinergic receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4			Preclinical
oxprenolol	adrenergic receptor antagonist	ADRB1	cardiology	angina pectoris, hypertension, cardiac arrythmia	Launched
oxybenzone	lipase inhibitor	LIPE	dermatology	sunscreen lotion	Launched
oxybuprocaine	local anesthetic	SCN10A	neurology/psychiatry	local anesthetic	Launched
oxybutynin	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	urology	urinary incontinence	Launched
oxyclozanide			infectious disease	fascioliasis	Launched
oxyfedrine	adrenergic receptor agonist		cardiology	angina pectoris	Launched
oxymatrine					Launched
oxymetazoline	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C	otolaryngology	nasal congestion	Launched
oxyphenbutazone	cyclooxygenase inhibitor				Withdrawn
oxyphencyclimine	cholinergic receptor antagonist		gastroenterology	peptic ulcer disease (PUD)	Launched
oxyphenonium	cholinergic receptor antagonist	CHRM1, CHRM3	gastroenterology	peptic ulcer disease (PUD)	Launched
oxypurinol	xanthine oxidase inhibitor	XDH			Phase 2/Phase 3
oxyquinoline	chelating agent	METAP2	dermatology	cosmetic	Launched
oxytetracycline	bacterial 30S ribosomal subunit inhibitor		infectious disease, urology	chlamydia, urinary tract infections, skin infections, ear infections, gonorrhea, urethritis, Lyme disease	Launched
oxytocin	oxytocin receptor agonist	AVPR1A, AVPR1B, AVPR2, OXTR	obstetrics/gynecology	labor induction	Launched
ozagrel	thromboxane synthase inhibitor	TBXAS1	neurology/psychiatry	stroke	Launched
ozanimod	sphingosine 1-phosphate receptor agonist	S1PR1			Phase 3
ozenoxacin	antiinfective drug				Phase 3
ozolinone	diuretic				Phase 3
O4I1	Oct inducer	POU5F1			Preclinical
O6-benzylguanine	O6-alkylguanine-DNA alkyltransferase inhibitor	MGMT			Phase 3
p-dimethylinamyl-benzoate					Preclinical
PA-452	retinoid receptor antagonist	RXRA			Preclinical
PAC-1	caspase activator	CASP3			Phase 1
paclitaxel	tubulin polymerization inhibitor	BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)	Launched
PACOCF3	phospholipase inhibitor	PLA2G4A			Preclinical
pacritinib	FLT3 inhibitor, JAK inhibitor	FLT3, JAK1, JAK2, JAK3			Phase 3
padsevonil	antiepileptic				Phase 3
paeoniflorin	anticonvulsant				Preclinical
paeonol	anti-inflammatory agent				Preclinical
pafuramidine	DNA synthesis inhibitor				Phase 3
pagoclone	GABA receptor agonist				Phase 2/Phase 3
palbociclib	CDK inhibitor	CDK4, CDK6	oncology	breast cancer	Launched
palifosfamide	DNA alkylating agent				Phase 3
paliperidone	dopamine receptor antagonist, serotonin receptor antagonist	DRD2, HTR2A	neurology/psychiatry	schizophrenia	Launched
palmatine-chloride	dopamine synthesis inhibitor	CYP3A4			Preclinical
palmitoleic-acid					Preclinical
palmitoylcarnitine	protein kinase inhibitor				Preclinical
palmitoylethanolamide	cannabinoid receptor agonist	CNR2, GPR119, GPR55			Launched
palomid-529	AKT inhibitor, mTOR inhibitor	MTOR			Phase 1
palonosetron	serotonin receptor antagonist	HTR3A	gastroenterology	nausea, vomiting	Launched
palosuran	urotensin receptor antagonist	UTS2R			Phase 2
palovarotene	retinoid receptor agonist	RARG			Phase 3
pamabrom	diuretic		gastroenterology	bloating	Launched
pamidronate	bone resorption inhibitor	FDPS	endocrinology, oncology, hematologic malignancy	hypercalcemia, Paget's disease, breast cancer, multiple myeloma	Launched
pamiparib	PARP inhibitor				Phase 3
pancuronium	acetylcholine receptor antagonist	CHRM2, CHRM3, CHRNA1, CHRNA2	critical care, neurology/psychiatry	endotracheal intubation, muscle relaxant	Launched
panipenem	antibacterial 				Preclinical
panobinostat	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	multiple myeloma	Launched
pantethine	coenzyme A precursor				Launched
pantoprazole	ATPase inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD), erosive esophagitis (EE), Zollinger-Ellison syndrome	Launched
pantothenic-acid	coenzyme A precursor				Launched
PAOPA	dopamine receptor modulator	DRD2			Preclinical
papaverine	phosphodiesterase inhibitor	PDE10A, PDE4B, PDE5A	cardiology, hematology, gastroenterology	myocardial infarction, angina pectoris, pulmonary embolism (PE), colitis, vascular spasm	Launched
paquinimod	S100A9 inhibitor				Phase 2
para-toluenesulfonamide		CA12, CA2, CA6, CA9			Phase 3
paracetamol	cyclooxygenase inhibitor	FAAH, PTGS1, PTGS2, TRPV1	neurology/psychiatry, endocrinology	pain relief, fever	Launched
parachlorophenol	antiinfective drug		infectious disease	first-aid antiseptic	Launched
paramethadione	anticonvulsant	CACNA1G	neurology/psychiatry	seizures	Launched
paraxanthine	adenosine receptor antagonist				Phase 1
parbendazole	tubulin polymerization inhibitor	TUBB			Preclinical
parcetasal	anti-inflammatory agent				Preclinical
pardoprunox	dopamine receptor agonist, serotonin receptor agonist	DRD2, DRD3, DRD4, HTR1A, HTR7			Phase 3
parecoxib	cyclooxygenase inhibitor	LTF	neurology/psychiatry	pain relief	Launched
parethoxycaine	local anesthetic				Preclinical
pargyline	monoamine oxidase inhibitor	MAOA, MAOB	cardiology	hypertension	Launched
paricalcitol	vitamin D receptor agonist	VDR	nephrology, endocrinology	chronic kidney disease (CKD), hyperthyroidism	Launched
paritaprevir	HCV inhibitor		infectious disease	hepatitis C	Launched
paromomycin	bacterial 30S ribosomal subunit inhibitor		infectious disease	amebiasis	Launched
paroxetine	selective serotonin reuptake inhibitor (SSRI)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR2A, SLC6A2, SLC6A4	neurology/psychiatry	depression, obsessive compulsive disorder (OCD), generalized anxiety disorder (GAD), panic disorders, posttraumatic stress disorder, social anxiety disorder	Launched
paroxypropione	gonadotropin inhibitor				Launched
parsaclisib	PI3K inhibitor				Phase 2
parthenolide	NFkB pathway inhibitor				Phase 1
parthenolide-(-)	NFkB pathway inhibitor	HDAC1			Preclinical
parthenolide-(alternate-stereo)	NFkB pathway inhibitor	IKBKB, RELA			Preclinical
pasireotide	somatostatin receptor agonist	SSTR1, SSTR2, SSTR3, SSTR5	endocrinology	Cushing's syndrome, acromegaly	Launched
PAT-1251	lysyl oxidase inhibitor				Phase 1
pavinetant	neurokinin receptor antagonist				Phase 2
pazopanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3	oncology	renal cell carcinoma (RCC), soft tissue sarcoma (STS)	Launched
pazufloxacin	topoisomerase inhibitor		infectious disease	pneumonia, peritonitis, bacterial septicemia	Launched
PBI-4050	free fatty acid receptor agonist				Phase 2/Phase 3
PBT-1033	chelating agent				Preclinical
PCA-4248	platelet activating factor receptor antagonist	PTAFR			Phase 1
PCI-24781	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC6			Phase 3
PCI-27483	ERK1 and ERK2 phosphorylation inhibitor				Phase 2
PCI-29732	Bruton's tyrosine kinase (BTK) inhibitor	BTK			Preclinical
PCI-34051	HDAC inhibitor	HDAC1, HDAC10, HDAC6, HDAC8			Preclinical
PCO-400	potassium channel activator	KCNJ8			Phase 1
PD-0325901	MEK inhibitor	MAP2K1			Phase 2
PD-102807	acetylcholine receptor antagonist	CHRM4			Preclinical
PD-118057	potassium channel activator	KCNH2			Preclinical
PD-123319	angiotensin antagonist	AGTR2			Phase 1
PD-128907	dopamine receptor agonist	DRD2, DRD3			Preclinical
PD-153035	EGFR inhibitor	EGFR, KDR			Phase 1
PD-156707	endothelin receptor antagonist	EDNRA, EDNRB			Preclinical
PD-158780	EGFR inhibitor	EGFR			Preclinical
PD-160170	neuropeptide receptor antagonist	NPY1R			Preclinical
PD-161570	FGFR inhibitor	FGFR1			Preclinical
PD-166285	SRC inhibitor	EGFR, FGFR1, PDGFRB, PKMYT1, SRC, WEE1			Preclinical
PD-166793	collagenase inhibitor, metalloproteinase inhibitor	MMP13, MMP2, MMP3			Preclinical
PD-168077	dopamine receptor agonist	DRD2			Preclinical
PD-168393	EGFR inhibitor	EGFR, ERBB2, SRC			Preclinical
PD-168568	dopamine receptor antagonist	DRD2, DRD4			Preclinical
PD-173074	FGFR inhibitor, VEGFR inhibitor	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB			Preclinical
PD-173212	calcium channel blocker	CACNA1B			Preclinical
PD-184352	MEK inhibitor	MAP2K1, MAP3K1, MAP3K2			Phase 2
PD-198306	MAP kinase inhibitor, MEK inhibitor	MAP2K1, MAP2K2			Preclinical
PD-318088	MEK inhibitor				Preclinical
PD-407824	PKC inhibitor	WEE1			Preclinical
PD-81723	adenosine receptor agonist	ADORA1			Preclinical
PD-98059	MEK inhibitor	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1			Preclinical
PDD-00017273	PARG inhibitor				Preclinical
PDE10-IN-1	phosphodiesterase inhibitor	PDE10A			Preclinical
PDP-EA	FAAH activator	FAAH			Preclinical
PD1-PDL-inhibitor-1	programmed death ligand inhibitor	CD274			Preclinical
peficitinib	JAK inhibitor	JAK1, JAK2, JAK3	rheumatology	rheumatoid arthritis	Launched
pefloxacin	bacterial DNA gyrase inhibitor	TOP2A	infectious disease, urology	gastrointestinal infections, urethritis, gonorrhea, urinary tract infections	Launched
pelanserin	serotonin receptor antagonist	HTR2A			Phase 2
pelitinib	EGFR inhibitor	EGFR			Phase 2
pelrinone	phosphodiesterase inhibitor				Phase 2
pemafibrate	PPAR receptor agonist				Phase 3
pemetrexed	dihydrofolate reductase inhibitor, thymidylate synthase inhibitor	ATIC, DHFR, GART, TYMS	oncology	non-small cell lung cancer (NSCLC), mesothelioma	Launched
pemirolast	mediator release inhibitor	HRH1	pulmonary	asthma	Launched
pempidine	ganglionic blocker		cardiology	hypertension	Launched
penbutolol	adrenergic receptor antagonist	ADRB1, ADRB2, HTR1A, HTR1B	cardiology	hypertension	Launched
penciclovir	DNA directed DNA polymerase inhibitor		dental	cold sore	Launched
penfluridol	T-type calcium channel blocker	CACNA1G	neurology/psychiatry	schizophrenia	Launched
penicillamine-(D)	chelating agent		metabolism, rheumatology, nephrology	Wilson's disease, rheumatoid arthritis, cystinuria	Launched
penicillamine-(racemic)					Launched
penicillin-v-potassium	bacterial cell wall synthesis inhibitor		infectious disease	pneumonia, ear infections, skin infections, throat infections, cholera, scarlet fever	Launched
pentacosanoic-acid					Preclinical
pentagastrin	CCK receptor agonist	CCKBR	gastroenterology	anacidity diagnostic, gastric hypersecretion diagnostic	Launched
pentamidine	anti-pneumocystis agent	TRDMT1	infectious disease	pneumonia	Launched
pentetic-acid	chelating agent				Phase 2
pentolinium	cholinergic receptor antagonist	CHRNA10, CHRNA3, CHRNA4, CHRNB4	cardiology	hypertension	Launched
pentostatin	adenosine deaminase inhibitor, ribonucleotide reductase inhibitor	ADA	hematologic malignancy	hairy cell leukemia	Launched
pentoxifylline	phosphodiesterase inhibitor	ADORA1, ADORA2A, ADORA2B, ADRA2B, NT5E, PDE10A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE6A, PDE6B, PDE6C, PDE6D, PDE6G, PDE6H, PDE7A, PDE7B, PDE8A, PDE8B, PDE9A, TNF	cardiology	claudication	Launched
pentylenetetrazol	GABA receptor antagonist				Withdrawn
peposertib	DNA dependent protein kinase inhibitor				Phase 1/Phase 2
pepstatin	aspartic protease inhibitor	CTSB, CTSD, CTSL, REN			Preclinical
peramivir	neuraminidase inhibitor		infectious disease	influenza A virus infection	Launched
perchlozone			infectious disease	tuberculosis	Launched
peretinoin	retinoid receptor agonist	RXRA			Phase 3
perfluamine					Launched
perflubron	contrast agent		radiology	contrast agent	Launched
perfluorodecalin			dermatology	cosmetic	Launched
perfluorohexyloctane					Launched
pergolide	dopamine receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C			Withdrawn
perhexiline	carnitine palmitoyltransferase inhibitor	CPT1A	cardiology	angina pectoris	Launched
perifosine	AKT inhibitor	AKT1			Phase 3
perillyl-alcohol	apoptosis stimulant, farnesyltransferase inhibitor	FNTA			Phase 2
perindopril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, myocardial infarction, coronary artery disease (CAD)	Launched
perindoprilat	angiotensin converting enzyme inhibitor	ACE			Phase 2
permethrin			infectious disease	lice	Launched
perospirone	dopamine receptor antagonist, serotonin receptor antagonist	DRD2, DRD3, DRD4	neurology/psychiatry	schizophrenia, bipolar disorder	Launched
perphenazine	dopamine receptor antagonist	CALM1, DRD1, DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7	neurology/psychiatry, gastroenterology	schizophrenia, nausea, vomiting	Launched
peruvoside	cardiac glycoside				Phase 1
perzinfotel	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B			Phase 2
PETCM	caspase activator	CASP3			Preclinical
pevonedistat	nedd activating enzyme inhibitor	NAE1, UBA3			Phase 3
pexidartinib	tyrosine kinase inhibitor	CSF1R, FLT3, KIT			Launched
pexmetinib	MAP kinase inhibitor, TIE tyrosine kinase inhibitor	MAPK14, TEK			Phase 1
PF-02413873	progesterone receptor antagonist				Phase 1
PF-02545920	phosphodiesterase inhibitor	PDE10A			Phase 2
PF-03049423	phosphodiesterase inhibitor	PDE5A			Phase 2
PF-03084014	gamma secretase inhibitor				Phase 3
PF-03758309	p21 activated kinase inhibitor	PAK4			Phase 1
PF-03814735	Aurora kinase inhibitor	AURKA, AURKB			Phase 1
PF-03882845	mineralocorticoid receptor antagonist				Phase 1
PF-04136309	CC chemokine receptor antagonist				Phase 2
PF-04217903	c-Met inhibitor	MET			Phase 1
PF-04418948	prostaglandin inhibitor	PTGER2			Phase 1
PF-04447943	phosphodiesterase inhibitor	PDE9A			Phase 2
PF-04457845	FAAH inhibitor	FAAH			Phase 2
PF-04620110	diacylglycerol O acyltransferase inhibitor	DGAT1			Phase 1
PF-04691502	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA			Phase 2
PF-04885614	voltage-gated sodium channel blocker	SCN10A			Preclinical
PF-04937319	glucokinase activator	GCK			Phase 2
PF-04995274	serotonin receptor agonist				Phase 1
PF-05089771	sodium channel blocker				Preclinical
PF-05175157	acetyl-CoA carboxylase inhibitor				Phase 2
PF-05180999	phosphodiesterase inhibitor				Phase 1
PF-05190457	growth hormone secretagogue receptor inverse agonist	GHSR			Phase 2
PF-05212384	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA			Phase 2
PF-06260414	androgen receptor modulator				Phase 1
PF-06273340	tyrosine kinase receptor inhibitor				Phase 1
PF-06282999	myeloperoxidase inhibitor				Phase 1
PF-06305591	sodium channel blocker				Phase 1
PF-06409577	protein kinase activator				Phase 1
PF-06412562	dopamine receptor partial agonist				Phase 1
PF-06447475	serine/threonine kinase inhibitor	LRRK2			Preclinical
PF-06459988	receptor tyrosine protein kinase inhibitor				Phase 2
PF-06463922	ALK tyrosine kinase receptor inhibitor	ALK, FES, ROS1	oncology	non-small cell lung cancer (NSCLC)	Launched
PF-06650833	kinase inhibitor				Phase 1
PF-06651600	JAK inhibitor				Phase 2/Phase 3
PF-06747775	EGFR inhibitor				Phase 2
PF-06751979	beta secretase inhibitor				Phase 1
PF-06840003	indoleamine 2,3-dioxygenase inhibitor				Phase 1
PF-06873600	CDK inhibitor				Phase 2
PF-06928215	cyclic GMP-AMP synthase inhibitor				Preclinical
PF-3274167	oxytocin receptor antagonist	AVPR1A, OXTR			Phase 2
PF-3845	FAAH inhibitor	FAAH			Preclinical
PF-4191834	lipoxygenase inhibitor				Preclinical
PF-429242	SREBP inhibitor	MBTPS1			Preclinical
PF-431396	focal adhesion kinase inhibitor	PTK2, PTK2B			Preclinical
PF-4708671	ribosomal protein inhibitor	RPS6KB1			Preclinical
PF-477736	CHK inhibitor	CHEK1, CHEK2			Phase 1
PF-4800567	casein kinase inhibitor	CSNK1D, CSNK1E			Preclinical
PF-4981517	cytochrome P450 inhibitor	CYP3A4			Preclinical
PF-514273	cannabinoid receptor antagonist				Preclinical
PF-5274857	smoothened receptor antagonist	SMO			Preclinical
PF-562271	focal adhesion kinase inhibitor	PTK2, PTK2B			Phase 1
PF-573228	focal adhesion kinase inhibitor	CDK1, CDK2, CDK7, GSK3B, IKBKB			Preclinical
PF-670462	casein kinase inhibitor	CSNK1D, CSNK1E			Preclinical
PF-750	FAAH inhibitor	FAAH			Preclinical
PF-8380	autotaxin inhibitor	ENPP2			Preclinical
PF-915275	11-beta hydroxysteroid dehydrogenase inhibitor	HSD11B1			Phase 1
PFI-1	bromodomain inhibitor	BRD4			Preclinical
PFI-3	bromodomain inhibitor	PBRM1, SMARCA4			Preclinical
PFI-4	bromodomain inhibitor	BRPF1			Preclinical
PFK-015	phosphofructokinase inhibitor	PFKFB3			Phase 1
PFK-158	phosphofructokinase inhibitor	PFKFB3			Phase 1
PG-9	acetylcholine receptor agonist				Preclinical
PGL5001	JNK inhibitor	MAPK10, MAPK8, MAPK9			Phase 2
PH-797804	p38 MAPK inhibitor	MAPK11, MAPK14			Phase 2
PHA-543613	nicotinic receptor agonist				Preclinical
PHA-568487	nicotinic receptor agonist	CHRNA7			Preclinical
PHA-665752	c-Met inhibitor	MET			Preclinical
PHA-680632	Aurora kinase inhibitor	AURKA, AURKB, AURKC			Preclinical
PHA-767491	CDC inhibitor	CDK1, RPS6KB1			Preclinical
PHA-793887	CDK inhibitor	CDK1, CDK2, CDK4, CDK5, CDK7, CDK9			Phase 1
PHA-848125	CDK inhibitor, growth factor receptor inhibitor	CDK2, CDK4, CDK7, NTRK1			Phase 2
PHCCC	glutamate receptor agonist	GRM1, GRM4			Preclinical
phenacaine	local anesthetic		neurology/psychiatry	local anesthetic	Launched
phenacemide	sodium channel blocker	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	epilepsy, seizures	Launched
phenacetin	cyclooxygenase inhibitor	PTGS1			Withdrawn
phenazone	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	Launched
phenazopyridine	local anesthetic	SCN1A	infectious disease	urinary tract infections	Launched
phenelzine	monoamine oxidase inhibitor	ABAT, AOC3, GAD2, GPT, GPT2, MAOA, MAOB, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	Launched
phenethicillin	bacterial cell wall synthesis inhibitor				Launched
phenethyl-isothiocyanate	anticancer agent	CYP2E1			Phase 2
phenformin	AMPK activator	KCNJ8, PRKAA1			Withdrawn
phenindamine	histamine receptor antagonist	HRH1	allergy, otolaryngology	allergic rhinitis, common cold	Launched
phenindione	vitamin K antagonist	VKORC1	hematology	deep vein thrombosis (DVT)	Launched
pheniramine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis, urticaria	Launched
phenol		CA1, CA12, CA14, CA2, CA4, CA9	otolaryngology	pharyngitis	Preclinical
phenolphthalein	indicator dye	UGT1A9			Withdrawn
phenolsulfonphthalein					Launched
phenothiazine	dopamine receptor antagonist				Preclinical
phenothrin			infectious disease	lice	Launched
phenoxybenzamine	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C	cardiology, endocrinology	hypertension, pheochromocytoma	Launched
phenprobamate	muscle relaxant		neurology/psychiatry	anxiety, muscle relaxant	Launched
phenprocoumon	vitamin K antagonist	VKORC1	hematology	thrombosis, pulmonary embolism (PE)	Launched
phenserine	acetylcholinesterase inhibitor, beta amyloid synthesis inhibitor	ACHE, BCHE			Phase 3
phensuximide	succinimide antiepileptic		neurology/psychiatry	seizures	Launched
phentolamine	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C	endocrinology, cardiology	pheochromocytoma, hypertension	Launched
phenyl-aminosalicylate			infectious disease	tuberculosis	Launched
phenyl-salicylate	antiseptic		urology	interstitial cystitis (IC)	Launched
phenylacetylglutamine	DNA methylase inhibitor, protein synthesis inhibitor				Phase 2
phenylbenzimidazole-sulfonic-acid			dermatology	sunscreen lotion	Launched
phenylbutazone	cyclooxygenase inhibitor, prostanoid receptor antagonist	PTGIS, PTGS1, PTGS2			Withdrawn
phenylbutyrate	HDAC inhibitor	HDAC1	metabolism	urea cycle disorders	Launched
phenylephrine	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D	otolaryngology, gastroenterology, cardiology	nasal congestion, hemorrhoids, hypotension	Launched
phenylethyl-alcohol					Preclinical
phenylmercuric-acetate	other antifungal				Preclinical
phenylmethylsulfonyl-fluoride	serine protease inhibitor				Preclinical
phenylpiracetam	noradrenaline uptake inhibitor		neurology/psychiatry	anxiety, fatigue, depression	Launched
phenytoin	hydantoin antiepileptic	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	Launched
PhiKan-083	p53 stabilizing agent	TP53			Preclinical
phloretin	sodium/glucose cotransporter inhibitor	AQP9, CLCN3, SLC23A1			Launched
phlorizin	sodium/glucose cotransporter inhibitor	SLC5A1, SLC5A11, SLC5A2, SLC5A3			Preclinical
phloroglucin			neurology/psychiatry	spasms	Launched
phortress	aryl hydrocarbon receptor ligand	AHR			Phase 1
phosphatidylcholine			infectious disease, dermatology, gastroenterology, cardiology, obstetrics/gynecology	hepatitis B, hepatitis C, eczema, gallbladder disease, cholesterol, premenstrual syndrome	Launched
PHP-501	GABA receptor antagonist	GABRA1, GABRB2, GABRG2			Preclinical
PHT-427	AKT inhibitor, pyruvate dehydrogenase inhibitor	AKT2, PDPK1			Preclinical
phthalylsulfacetamide					Preclinical
phthalylsulfathiazole	dihydropteroate synthetase inhibitor		infectious disease, gastroenterology	dysentry, colitis	Launched
PHTPP	estrogen receptor antagonist	ESR2			Preclinical
physostigmine	acetylcholinesterase inhibitor, cholinesterase inhibitor	ACHE, BCHE	cardiology, neurology/psychiatry, ophthalmology, gastroenterology	hypotension, Alzheimer's disease, glaucoma, gastroparesis	Launched
phytonadione		BGLAP, GGCX	hematology	vitamin K deficiency, anticoagulation reversal	Launched
phytosphingosine					Phase 1
PI-103	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC			Preclinical
PI-828	PI3K inhibitor				Preclinical
pibenzimol	DNA inhibitor				Phase 2
piboserod	serotonin receptor antagonist	HTR2B, HTR4			Phase 2
picartamide	H+/K+-ATPase inhibitor	ATP4A			Phase 2
piceatannol	SYK inhibitor	ATP5A1, ATP5B, ATP5C1, IRF3			Preclinical
piclamilast	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4C, PDE4D			Phase 2
picolamine					Preclinical
picolinic-acid	chelating agent				Phase 2
piconol					Preclinical
picotamide	thromboxane receptor antagonist, thromboxane synthase inhibitor	TBXA2R	hematology	thrombosis	Launched
picrotin	GABA receptor antagonist	GLRA1, GLRA2, GLRA3, GLRB			Phase 2
picrotoxinin	GABA receptor antagonist	GLRA1, GLRA2, GLRA3, GLRB, HTR3A, HTR3B			Preclinical
pidolic-acid		ADAM28, AMY1A, AMY2A, AMY2B, ANG, CCL8, HCRT, IGLC1, KRTAP5-2, TFF2, VEGFA	dermatology	xerosis cutis	Launched
pidotimod	interferon receptor agonist, interleukin receptor agonist		infectious disease	immune adjuvant	Launched
pifithrin-alpha	TP53 inhibitor	TP53			Preclinical
pifithrin-cyclic	TP53 inhibitor	TP53			Preclinical
pifithrin-mu	HSP inhibitor	HSPA1A, TP53			Preclinical
PIK-293	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			Preclinical
PIK-294	PI3K inhibitor	PIK3CB, PIK3CD, PIK3CG			Preclinical
PIK-75	DNA protein kinase inhibitor, PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC			Preclinical
PIK-93	PI3K inhibitor	PI4KB, PIK3C3, PIK3CG			Preclinical
pikamilone					Phase 1
piketoprofen	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	Launched
pilaralisib	PI3K inhibitor				Phase 2
pilocarpine	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	ophthalmology, cardiology	glaucoma, hypertension	Launched
pilsicainide	sodium channel blocker	SCN5A	cardiology	cardiac arrythmia	Launched
PIM-1-Inhibitor-2	Pim kinase inhibitor	PIM1			Preclinical
PIM-447	Pim kinase inhibitor				Phase 1
pimavanserin	serotonin receptor inverse agonist	DRD2, HTR2A	neurology/psychiatry	Parkinson's Disease	Launched
pimecrolimus	calcineurin inhibitor		dermatology	eczema	Launched
pimethixene	antihistamine		neurology/psychiatry, allergy	attention-deficit/hyperactivity disorder (ADHD), anxiety, sleep cycle support, allergic rhinitis	Launched
pimobendan	calcium sensitizer, phosphodiesterase inhibitor	PDE3A	cardiology	congestive heart failure	Launched
pimodivir	antiviral				Phase 3
pimonidazole					Phase 3
pimozide	dopamine receptor antagonist	CACNA1I, CALM1, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, KCNA10, KCNH2	neurology/psychiatry	Tourette's disorder	Launched
pinacidil	ATP channel activator, potassium channel activator	ABCC8, ABCC9	cardiology	hypertension	Launched
pinanediol					Preclinical
pinaverium	T-type calcium channel blocker	CACNA1C	gastroenterology	irritable bowel syndrome	Launched
pincainide	antiarrhythmic				Phase 1
pindolol	adrenergic receptor antagonist	ADRB1, ADRB2, HTR1A, HTR2A, HTR2B	cardiology	hypertension	Launched
pindolol-(-)	adrenergic receptor antagonist, serotonin receptor antagonist	HTR1A			Phase 2
pinitol	gamma secretase inhibitor				Phase 2
pinocembrin	cytochrome P450 inhibitor	CYP1B1			Phase 2
pioglitazone	insulin sensitizer, PPAR receptor agonist	PPARG, TRPM3	endocrinology	diabetes mellitus	Launched
pipamperone	dopamine receptor antagonist	DRD2, HRH1, HTR1A, HTR1B, HTR1D, HTR2A	neurology/psychiatry	schizophrenia	Launched
pipecuronium	neuromuscular blocker	CHRM2, CHRM3, CHRNA2	neurology/psychiatry	anesthetic	Launched
pipemidic-acid	topoisomerase inhibitor		infectious disease	gram-negative bacterial infections	Launched
pipenzolate	cholinergic receptor antagonist	CHRM1	neurology/psychiatry	spasms	Launched
piperacetazine	dopamine receptor antagonist		neurology/psychiatry	schizophrenia	Launched
piperacillin	bacterial cell wall synthesis inhibitor		infectious disease	intra-abdominal infections, skin infections, pelvic inflammatory disease, pneumonia	Launched
piperaquine-phosphate	antimalarial agent		infectious disease	malaria	Launched
piperazine	benzodiazepine receptor agonist	GABRB3	infectious disease	gastrointestinal roundworms	Launched
piperazinedione	DNA synthesis inhibitor				Phase 2
piperidolate	acetylcholine receptor antagonist	CHRM1	neurology/psychiatry	spasms	Launched
piperine	monoamine oxidase inhibitor	MAOA, MAOB, TRPV1			Phase 1
piperonyl-butoxide	cytochrome P450 inhibitor		infectious disease	lice	Launched
pipobroman	DNA alkylating agent		hematology	polycythemia vera, thrombocythemia	Launched
pipofezine	selective serotonin reuptake inhibitor (SSRI)				Preclinical
pipotiazine	dopamine receptor antagonist	DRD1, DRD2, HTR1A, HTR2A	neurology/psychiatry	schizophrenia	Launched
pipotiazine-palmitate	dopamine receptor antagonist, serotonin receptor antagonist	DRD1, DRD2, HTR1A, HTR2A	neurology/psychiatry	schizophrenia	Launched
piracetam	acetylcholine receptor agonist	GRIA1, GRIA2, GRIA3, GRIA4	neurology/psychiatry	senile dementia	Launched
pirarubicin	topoisomerase inhibitor	TOP2A	oncology	breast cancer	Launched
pirenoxine	AGE inhibitor		ophthalmology	cataracts	Launched
pirenperone	serotonin receptor antagonist	HTR2A, HTR7			Preclinical
pirenzepine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	gastroenterology	peptic ulcer disease (PUD)	Launched
piretanide	glucocorticoid receptor agonist	SLC12A1, SLC12A2	cardiology	hypertension, edema	Launched
pirfenidone	TGF beta receptor inhibitor	FURIN, TNF	pulmonary	idiopathic pulmonary fibrosis (IPF)	Launched
piribedil	dopamine receptor agonist	ADRA1A, ADRA2A, ADRA2C, DRD2, DRD3, DRD4, HTR1A, HTR2B	neurology/psychiatry	Parkinson's Disease, dizziness	Launched
piricapiron	dopamine receptor antagonist, serotonin receptor antagonist	HTR2A			Phase 2
pirinixic-acid	PPAR receptor agonist	PPARA			Preclinical
pirlindole	monoamine oxidase inhibitor	MAOA	neurology/psychiatry	depression	Launched
pirmenol	acetylcholine receptor inhibitor				Preclinical
piroctone-olamine			infectious disease	fungal infection	Launched
pirodavir					Phase 2
piromidic-acid	bacterial DNA gyrase inhibitor				Phase 2
piroxicam	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	Launched
piroximone	phosphodiesterase inhibitor	PDE3A			Phase 2
pirozadil	hypolipidemic				Preclinical
pirquinozol	histamine release inhibitor				Phase 1
PIT	purinergic receptor antagonist	P2RY1			Preclinical
pitavastatin	HMGCR inhibitor	HMGCR	endocrinology	hyperlipidemia	Launched
pitolisant	histamine receptor antagonist	HRH3			Launched
pivagabine	corticotropin releasing factor receptor antagonist	CRHR1, CRHR2	neurology/psychiatry	depression	Launched
pivampicillin	bacterial cell wall synthesis inhibitor		pulmonary, infectious disease	bronchitis, pneumonia, gynecologic infections	Launched
pivanex	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC8			Phase 2
pivmecillinam	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections, gram-negative bacterial infections	Launched
pixantrone	topoisomerase inhibitor	TOP2A	hematologic malignancy	non-Hodgkin lymphoma (NHL)	Launched
pizotifen	serotonin receptor antagonist	HTR1A, HTR2A, HTR2C	neurology/psychiatry	migraine headache	Launched
PI3K-IN-2	PI3K inhibitor				Phase 2
PI3Kd-IN-2	PI3K inhibitor				Preclinical
PI4KIII-beta-inhibitor-1	PI4K inhibitor	PI4K2B			Preclinical
PJ-34	PARP inhibitor	EEF2, PARP1, PARP15, PARP3			Preclinical
PK-THPP	potassium channel blocker	KCNK9			Preclinical
PK-11195	benzodiazepine receptor antagonist	TSPO			Phase 1
PK-44	dipeptidyl peptidase inhibitor	DPP4			Preclinical
PKI-166	EGFR inhibitor	EGFR			Phase 1
PKI-179	mTOR inhibitor, PI3K inhibitor	MTOR			Phase 1
pleconaril					Phase 3
plerixafor	CC chemokine receptor antagonist	ACKR3, CCR4, CXCR4	hematologic malignancy	non-Hodgkin lymphoma (NHL), multiple myeloma	Launched
plicamycin	alcohol dehydrogenase inhibitor		oncology, endocrinology	testicular carcinoma, Paget's disease, hypercalcemia	Launched
plinabulin	tubulin polymerization inhibitor				Phase 3
plovamer-acetate		TAT, TH, YARS, YARS2			Phase 2
plumbagin	anticancer agent				Preclinical
plurisin-1	stearoyl-CoA desaturase inhibitor	SCD			Preclinical
PLX4720	RAF inhibitor	BRAF, KDR			Preclinical
PLX51107	bromodomain inhibitor				Phase 1
PLX647	receptor tyrosine protein kinase inhibitor	CSF1R, KIT			Preclinical
PLX8394	serine/threonine kinase inhibitor	BRAF			Phase 1/Phase 2
PMPA	glutamate receptor antagonist	FOLH1			Preclinical
PNU-120596	acetylcholine receptor agonist	CHRNA7			Preclinical
PNU-142633	serotonin receptor agonist	HTR1D			Phase 2
PNU-177864	dopamine receptor antagonist	DRD3			Preclinical
PNU-22394	serotonin receptor agonist	HTR2A, HTR2B, HTR2C, MAOA, MAOB			Phase 2
PNU-282987	cholinergic receptor agonist	CHRNA7			Preclinical
PNU-37883	ATP-sensitive potassium channel antagonist				Preclinical
PNU-74654	beta-catenin inhibitor	CTNNB1, TCF4			Preclinical
PNU-89843	benzodiazepine receptor agonist	GABBR1			Preclinical
pocapavir	Enterovirus capsid inhibitor				Preclinical
podophyllotoxin	microtubule inhibitor, tubulin polymerization inhibitor	IGF1R, TOP2A, TUBA4A, TUBB	infectious disease	genital warts	Launched
polaprezinc	chelating agent				Preclinical
polidocanol	local anesthetic		dermatology	varicose veins	Launched
polydatin	ICAM1 expression inhibitor	ICAM1			Phase 2
polyinosine	immunostimulant	HPRT1, IMPDH2, PYGM			Preclinical
polymyxin-B-sulfate	bacterial permeability inducer		ophthalmology	eye infection	Launched
polythiazide	sodium/chloride cotransporter inhibitor	SLC12A3	cardiology, gastroenterology, rheumatology, nephrology	edema, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis (AGN), chronic renal failure, hypertension	Launched
pomalidomide	angiogenesis inhibitor, tumor necrosis factor production inhibitor		hematologic malignancy	multiple myeloma	Launched
ponatinib	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	Launched
ponesimod	sphingosine 1-phosphate receptor agonist	S1PR1			Phase 3
posaconazole	sterol demethylase inhibitor	CYP3A4	infectious disease	oropharyngeal candidiasis	Launched
potassium-canrenoate	mineralocorticoid receptor antagonist	NR3C2	cardiology	edema	Launched
potassium-iodide			pulmonary	asthma, bronchitis, emphysema	Launched
potassium-p-aminobenzoate			rheumatology, urology	scleroderma, dermatomyositis, Peyronie's disease	Launched
pozanicline	acetylcholine receptor antagonist	CHRNA4, CHRNB2			Phase 2
poziotinib	EGFR inhibitor	EGFR, ERBB2, ERBB4			Phase 2
PP-1	SRC inhibitor	HCK, RET			Preclinical
PP-121	protein tyrosine kinase inhibitor	ABL1, EGFR, HCK, KDR, MTOR, PDGFRA, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC, SRC			Preclinical
PP-2	SRC inhibitor	ABL1, LCK, RIPK2, SRC			Preclinical
PPT	estrogen receptor agonist	ESR1			Preclinical
PPY-A	Abl kinase inhibitor	ABL1, BCR			Preclinical
PP242	mTOR inhibitor	MTOR, PASK			Preclinical
PQ-401	IGF-1 inhibitor	IGF1R			Preclinical
PR-619	DUB inhibitor				Preclinical
practolol	adrenergic receptor antagonist	ADRB1			Withdrawn
pradefovir	cytochrome P450 activator				Phase 2
pralatrexate	dihydrofolate reductase inhibitor	DHFR	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	Launched
pralidoxime	acetylcholinesterase inhibitor	ACHE, BCHE	critical care	organophosphate poisoning	Launched
pralidoxime-chloride	acetylcholinesterase inhibitor	ACHE, BCHE	pulmonary	respiratory depression	Launched
pralmorelin	growth hormone releasing peptide ligand agonist				Launched
pramipexole	dopamine receptor agonist	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C	neurology/psychiatry	Parkinson's Disease	Launched
pramiracetam	acetylcholine receptor agonist		neurology/psychiatry	senile dementia	Launched
pramoxine	topical anesthetic		dermatology	corticosteroid-responsive dermatoses	Launched
pranidipine	calcium channel blocker	CACNA1C			Phase 2
pranlukast	leukotriene receptor antagonist	CYSLTR1, CYSLTR2, IL5, MUC2, NFKB1, RNASE3, TNF	pulmonary	bronchospasm, asthma	Launched
pranoprofen	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	Launched
prasterone-acetate					Preclinical
prasugrel	purinergic receptor antagonist	P2RY12	cardiology	myocardial infarction, acute coronary syndrome (ACS)	Launched
pravadoline	cyclooxygenase inhibitor	CNR1, CNR2			Preclinical
pravastatin	HMGCR inhibitor	HMGCR, SLCO1B1	endocrinology, cardiology	hypercholesterolemia, myocardial infarction, hyperlipidemia	Launched
praziquantel	anthelmintic agent		infectious disease	gastrointestinal parasites, cystic hydatid disease, schistosomiasis	Launched
prazosin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, KCNH2, KCNH6, KCNH7	cardiology	hypertension	Launched
PRE-084	sigma receptor agonist	SIGMAR1			Preclinical
preclamol	dopamine receptor agonist	DRD2			Phase 2
prednicarbate	phospholipase activator	PLA2G1B	dermatology, ophthalmology, neurology/psychiatry	eczema, contact dermatitis, itching	Launched
prednisolone	glucocorticoid receptor agonist	NR3C1, NR3C2, SERPINA6	ophthalmology, dermatology, infectious disease	conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis	Launched
prednisolone-acetate	glucocorticoid receptor agonist	NR3C1	ophthalmology, dermatology, infectious disease	conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis	Launched
prednisolone-hemisuccinate	glucocorticoid receptor agonist	NR3C1			Preclinical
prednisolone-sodium-phosphate	glucocorticoid receptor agonist	NR3C1	allergy, pulmonary, ophthalmology, infectious disease, rheumatology, endocrinology, neurology/psychiatry, gastroenterology, hematology	allergic rhinitis, asthma, contact dermatitis, mycosis, lupus, hypercalcemia, thyroiditis, congenital adrenal hyperplasia, multiple sclerosis, ulcerative colitis, enteritis, thrombocythemia, pneumonia, meningitis, psoriatic arthritis, rheumatoid arthritis	Launched
prednisolone-tebutate	anti-inflammatory agent				Launched
prednisone	glucocorticoid receptor agonist	HSD11B1, NR3C1	endocrinology, rheumatology, infectious disease, dermatology, ophthalmology, hematology, gastroenterology, neurology/psychiatry	congenital adrenal hyperplasia, hypercalcemia, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, bursitis, osteoarthritis, epicondylitis, dermatomyositis, psoriasis, mycosis, conjunctivitis, anemia, ulcerative colitis, enteritis, multiple sclerosis, meningitis	Launched
pregnenolone	glutamate receptor modulator	SULT2B1	rheumatology	rheumatoid arthritis	Launched
pregnenolone-succinate	GABA receptor negative allosteric modulator	CYP17A1			Preclinical
preladenant	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Phase 3
prenylamine	calcium channel blocker				Withdrawn
presatovir	RSV fusion inhibitor				Phase 2
pretomanid	nitric oxide donor	FASN			Launched
pridinol	muscle relaxant		neurology/psychiatry	muscle relaxant	Launched
pridopidine	dopamine receptor antagonist				Phase 2
prilocaine	local anesthetic	SCN5A	neurology/psychiatry	anesthetic	Launched
primaquine	antimalarial agent, DNA inhibitor		infectious disease	malaria	Launched
PRIMA1	TP53 inhibitor	ACHE			Preclinical
primidone	GABA receptor antagonist	CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	Launched
prinaberel	estrogen receptor agonist	ESR2, NCOA1			Phase 2
prinomastat	matrix metalloprotease inhibitor				Phase 3
priralfinamide	sodium channel blocker	CACNA1B			Phase 3
prisotinol					Phase 2
pritelivir	helicase primase inhibitor				Phase 2
PRLX-93936	voltage-dependent anion selective channel protein inhibitor				Phase 1/Phase 2
PRN1008	Bruton's tyrosine kinase (BTK) inhibitor				Preclinical
PRN1371	protein tyrosine kinase inhibitor				Phase 1
proacipimox	cholesterol inhibitor				Phase 1
proadifen	nitric oxide synthase inhibitor	NOS1			Preclinical
probenecid	uricosuric blocker	PANX1, SLC22A11, SLC22A6, SLC22A8, SLCO1C1	nephrology, rheumatology	hyperuricemia, gout	Launched
probucol	atherogenesis inhibitor	ABCA1, ABCB11, CES1	cardiology	coronary artery disease (CAD)	Launched
procainamide	sodium channel blocker	DNMT1, SCN5A	cardiology	ventricular arrhythmias, ventricular tachycardia (VT)	Launched
procaine	HMGCR inhibitor	CHRNA2, GRIN3A, HTR3A, KCNMA1, KCNMB1, KCNMB2, KCNMB3, KCNMB4, KCNN1, KCNN2, KCNN3, KCNN4, MAOA, MAOB, RYR1, RYR2, SCN10A, SLC6A3	neurology/psychiatry	anesthetic	Launched
procarbazine	monoamine oxidase inhibitor		hematologic malignancy	Hodgkin's lymphoma	Launched
procaterol	adrenergic receptor agonist	ADRB2	pulmonary	asthma	Launched
prochlorperazine	dopamine receptor antagonist	DRD1, DRD2, DRD3, DRD4	gastroenterology	nausea, vomiting	Launched
procodazole	immunostimulant				Preclinical
procyanidin-B-2					Phase 2
procyclidine	acetylcholine receptor antagonist		neurology/psychiatry	parkinsonism, Parkinson's Disease, akathisia, dystonia	Launched
procysteine	glutathione synthase stimulant				Phase 3
profenamine	butyrylcholinesterase inhibitor, cholinergic receptor antagonist	CHRM1	neurology/psychiatry	Parkinson's Disease	Launched
proflavine-hemisulfate	topical anesthetic	F2			Phase 2
progesterone	progesterone receptor agonist	CATSPER1, CATSPER2, CATSPER3, CATSPER4, CYP17A1, ESR1, NR3C2, OPRK1, PGR, TRPC5	obstetrics/gynecology, endocrinology	infertility, amenorrhea	Launched
proglumetacin	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	Launched
proglumide	CCK receptor antagonist	CCKAR, CCKBR			Withdrawn
proguanil	dihydrofolate reductase inhibitor	DHFR	infectious disease	malaria	Launched
prolylleucylglycinamide	melanocyte-stimulating hormone release inhibitor				Phase 2
promazine	dopamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR2A, HTR2C	neurology/psychiatry	schizophrenia	Launched
promestriene	estrogen receptor agonist	ESR1	endocrinology	androgenetic alopecia	Launched
promethazine	histamine receptor antagonist	HRH1	neurology/psychiatry, allergy	sedative, allergic rhinitis	Launched
pronethalol	adrenergic receptor antagonist				Withdrawn
propacetamol	cyclooxygenase inhibitor	PTGS2	endocrinology, neurology/psychiatry	fever, pain relief	Launched
propafenone	antiarrhythmic	ADRB1, ADRB2, KCNA5, KCNH2	cardiology	atrial fibrillation (AF), ventricular tachycardia (VT), ventricular arrhythmias	Launched
propagermanium	CCR agonist, interferon receptor agonist	CCR2	infectious disease	hepatitis B	Launched
propantheline	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4	gastroenterology	peptic ulcer disease (PUD)	Launched
propatylnitrate			cardiology	angina pectoris	Launched
propentofylline	adenosine reuptake inhibitor, phosphodiesterase inhibitor	PDE1A	neurology/psychiatry	stroke	Launched
propidium-iodide		ACHE			Preclinical
propiolactone			infectious disease	antiseptic	Launched
propiverine	acetylcholine receptor antagonist	CHRM1	urology	urinary incontinence	Launched
propofol	benzodiazepine receptor agonist	FAAH, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, SCN2A, SCN4A	neurology/psychiatry	anesthetic	Launched
propoxur			infectious disease	flea control	Launched
propoxycaine	local anesthetic		neurology/psychiatry	anesthetic	Launched
propranolol	adrenergic receptor antagonist	ADRB1, ADRB2	cardiology, neurology/psychiatry	hypertension, angina pectoris, migraine headache	Launched
propranolol-(R)	adrenergic receptor antagonist	ADRB2, ADRB3			Preclinical
propranolol-(S)	adrenergic receptor antagonist	ADRB1, HTR1A, HTR5A, SLC10A1			Preclinical
propyl-benzoate					Launched
propylene-glycol					Launched
propylhexedrine	adrenergic receptor agonist		otolaryngology, endocrinology, allergy	nasal congestion, fever, allergic rhinitis	Launched
propylparaben					Launched
propylthiouracil	thyroid peroxidase inhibitor	DIO1, TPO	endocrinology	hyperthyroidism, Grave's disease, goiter	Launched
propyphenazone	anti-inflammatory agent				Preclinical
proquazone	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	Launched
proscillaridin-A			cardiology	congestive heart failure, cardiac arrythmia	Launched
protionamide			infectious disease	tuberculosis	Launched
protirelin	thyrotropin releasing hormone receptor agonist	TRHR	radiology	thyroid function diagnostic	Launched
protoporphyrin-IX	heme oxygenase inhibitor	HMOX1			Preclinical
protriptyline	tricyclic antidepressant	SLC6A2, SLC6A4	neurology/psychiatry	depression	Launched
proxodolol	adrenergic receptor antagonist				Launched
proxyfan	histamine receptor modulator	HRH3			Preclinical
proxymetacaine	sodium channel blocker	SCN10A, SCN5A	neurology/psychiatry	anesthetic	Launched
Proxyphylline			pulmonary	asthma	Launched
PRT062070	JAK inhibitor, SYK inhibitor	SYK			Phase 2/Phase 3
PRT062607	SYK inhibitor	FGR, MAP3K9, SYK			Phase 2
PRT4165	polycomb repressive complex inhibitor	PRC1			Preclinical
prucalopride	serotonin receptor agonist	HTR4	gastroenterology	constipation	Launched
prulifloxacin	bacterial DNA gyrase inhibitor		infectious disease, pulmonary, gastroenterology	urinary tract infections, bronchitis, diarrhea	Launched
pruvanserin	serotonin receptor antagonist	HTR2A, HTR2C			Phase 2
PRX-07034	serotonin receptor antagonist				Phase 1
PRX-08066	serotonin receptor antagonist	HTR2B			Phase 2
PSB-06126	NTPDase inhibitor	ENTPD3			Preclinical
PSB-11	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA3			Preclinical
PSB-1115	adenosine receptor antagonist	ADORA1, ADORA2B, ADORA3			Preclinical
PSB-36	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Preclinical
PSB-603	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Preclinical
PSI-6130	RNA polymerase inhibitor				Phase 1
PSI-697	P selectin inhibitor				Phase 1
PSI-7976	HCV inhibitor				Preclinical
PSN-375963	glucose dependent insulinotropic receptor agonist	GPR119			Preclinical
PSNCBAM-1	cannabinoid receptor modulator	CNR1			Preclinical
psoralen		MAOA, MAOB	dermatology	psoriasis, eczema, vitiligo	Launched
PS178990	androgen receptor modulator	AR			Phase 1
PT-2385	hypoxia inducible factor inhibitor	EPAS1			Phase 1
PTC-028	BMI-1 inhibitor				Preclinical
PTC-209	BMI-1 inhibitor				Preclinical
pterostilbene	cyclooxygenase inhibitor, PPAR receptor agonist	PTGS2			Phase 2/Phase 3
PU-H71	HSP inhibitor	HSP90AA1			Phase 1
puerarin	serotonin receptor antagonist				Phase 2
pumosetrag	serotonin receptor agonist	HTR3A, HTR4			Phase 2
purmorphamine	smoothened receptor agonist	SMO			Preclinical
puromycin	protein synthesis inhibitor	NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1			Preclinical
purvalanol-A	CDK inhibitor	CDK1, CDK2, CDK4, CDK5, CSNK1G3, RPS6KA1, SRC			Preclinical
purvalanol-B	tyrosine kinase inhibitor	CDK2, CDK4, CDK5, MAPK1, MAPK3, SRPK2			Preclinical
putrescine	tissue transglutaminase inhibitor	AMD1, KCNJ4, ODC1			Phase 2
PX-12	thioredoxin inhibitor	CNR1, TXN			Phase 2
PX-478	hypoxia inducible factor inhibitor				Phase 1
PYM50028	neurotrophic agent				Phase 2
PYR-41	ubiquitin activating enzyme inhibitor				Preclinical
pyrantel	acetylcholine receptor agonist, nicotinic receptor agonist		infectious disease	gastrointestinal roundworms	Launched
pyrantel-pamoate	neuromuscular blocker		infectious disease	hookworm, tapeworm	Launched
pyrazinamide	fatty acid synthase inhibitor	FASN	infectious disease	tuberculosis	Launched
pyrazinoylguanidine	diuretic				Phase 1
pyrazolanthrone	JNK inhibitor	MAPK10, MAPK8, MAPK8IP1, MAPK9, TTK			Preclinical
pyrazoloacridine	topoisomerase inhibitor	TOP1, TOP2A			Phase 2
pyrethrins			infectious disease	flea control	Launched
pyridoxal		PDXK	neurology/psychiatry	epilepsy	Launched
pyridoxal-isonicotinoyl-hydrazone	apoptosis stimulant				Phase 2
pyridoxamine	AGE inhibitor				Phase 3
pyridoxine	vitamin B	DDC, PDXK	metabolism	vitamin B6 deficiency	Launched
pyrimethamine	dihydrofolate reductase inhibitor	DHFR, SLC47A1	infectious disease	malaria	Launched
pyrintegrin	integrin signaling activator				Preclinical
pyrithione-zinc	ATP synthase inhibitor	KCNQ1, KCNQ2, KCNQ4, KCNQ5	dermatology	dandruff, cosmetic	Launched
pyrithyldione	psychoactive drug				Withdrawn
pyritinol			rheumatology, neurology/psychiatry	rheumatoid arthritis, senile dementia	Launched
pyronaridine	antimalarial agent				Phase 3
pyrotinib	kinase inhibitor				Phase 3
pyroxamide	HDAC inhibitor	HDAC1			Phase 1
pyrrolidine-dithiocarbamate	NFkB pathway inhibitor	HSD11B1, RELA			Preclinical
pyrvinium-pamoate	androgen receptor antagonist	AR	infectious disease	pinworm	Launched
PZ-2891	pantothenate kinase activator				Preclinical
P22077	ubiquitin specific protease inhibitor	USP7			Preclinical
P276-00	CDK inhibitor	CDK1, CDK4, CDK9			Phase 2
P5091	ubiquitin specific protease inhibitor	USP7			Preclinical
P7C3	NAMPT inhibitor	NAMPT			Preclinical
Q-203	ATP synthase inhibitor				Phase 2
quazinone	phosphodiesterase inhibitor	PDE3A, PDE3B			Phase 2
quercetin	polar auxin transport inhibitor	ATP5A1, ATP5B, ATP5C1, HCK, HIBCH, PIK3CG, PIM1, STK17B, UGT3A1	neurology/psychiatry, allergy	fatigue, allergic rhinitis, drowsiness	Launched
quetiapine	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A2	neurology/psychiatry	schizophrenia, bipolar disorder	Launched
quiflapon	leukotriene synthesis inhibitor	ALOX5, ALOX5AP			Phase 2
quinagolide	dopamine receptor agonist	DRD2	endocrinology	hyperprolactinemia	Launched
quinapril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, congestive heart failure, angioedema	Launched
quinaprilat	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, angioedema	Launched
quinelorane	dopamine receptor agonist	DRD2, DRD3			Phase 3
quinestrol	estrogen receptor agonist	ESR1, ESR2	endocrinology	menopause	Launched
quinethazone	thiazide diuretic		cardiology	hypertension	Launched
quinidine	sodium channel blocker	KCNA5, KCNA7, KCNH1, KCNH2, KCNH5, KCNK1, KCNK6, SCN5A, SLC29A4	infectious disease, cardiology	malaria, atrial fibrillation (AF), ventricular arrhythmias	Launched
quinine	hemozoin biocrystallization inhibitor	GP9, KCNB2, KCNN4, SLC29A4	infectious disease	malaria	Launched
quinine-ethyl-carbonate			infectious disease	malaria	Launched
quinolinic-acid	glutamate receptor agonist				Preclinical
quinpirol-(-)	dopamine receptor agonist	DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C			Phase 2
quipazine	serotonin receptor agonist	HTR1A, HTR1D, HTR2A, HTR2B, HTR2C, HTR3A, HTR3B, HTR6, SLC6A4			Preclinical
quizartinib	FLT3 inhibitor	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET			Phase 3
QX-222	sodium channel blocker				Preclinical
QX-314	sodium channel blocker	MAPK14, TGFBR1			Preclinical
R-121919	CRF receptor antagonist				Preclinical
R-1479	HCV inhibitor				Phase 1
R-1485	serotonin receptor antagonist	HTR6			Phase 1
R-1487	p38 MAPK inhibitor				Phase 1
R-268712	serine/threonine kinase inhibitor	TGFBR1			Preclinical
R-428	AXL kinase inhibitor	AXL			Phase 2
R-59022	diacylglycerol kinase inhibitor, protein kinase inhibitor	DGKA			Preclinical
R-96544	serotonin receptor antagonist	HTR2A			Preclinical
rabeprazole	ATPase inhibitor, gastrin inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD), duodenal ulcer disease, Zollinger-Ellison syndrome	Launched
rac-BHFF	GABA receptor positive allosteric modulator	GABBR1			Preclinical
racecadotril	enkephalinase inhibitor	MME	gastroenterology	diarrhea	Launched
raclopride	dopamine receptor antagonist	DRD2, DRD3, HTR1A			Launched
ractopamine	adrenergic receptor agonist		endocrinology	weight-gain aid	Launched
radafaxine	dopamine-norepinephrine reuptake inhibitor	SLC6A3			Phase 2
radezolid	bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor				Phase 2
radiprodil	acetylcholine receptor antagonist				Phase 2
radotinib	Bcr-Abl kinase inhibitor				Phase 3
RAD140	androgen receptor modulator				Phase 1
RAF265	RAF inhibitor, VEGFR inhibitor	BRAF			Phase 2
RAF709	RAF inhibitor				Preclinical
ralinepag	IP1 prostacyclin receptor agonist				Phase 3
raloxifene	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	ESR1, ESR2	orthopedics, oncology	osteoporosis, breast cancer	Launched
raltegravir	HIV integrase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	Launched
raltitrexed	thymidylate synthase inhibitor	FPGS, TYMS	oncology	mesothelioma	Launched
ramatroban	prostanoid receptor antagonist	PTGDR2, TBXA2R	cardiology, pulmonary	coronary artery disease (CAD), asthma	Launched
ramelteon	melatonin receptor agonist	MTNR1A, MTNR1B	neurology/psychiatry	insomnia	Launched
ramifenazone	cyclooxygenase inhibitor		neurology/psychiatry, endocrinology	pain relief, fever	Launched
ramipril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	Launched
ramosetron	serotonin receptor antagonist	HTR3A	gastroenterology	nausea, vomiting, irritable bowel syndrome	Launched
ranirestat	aldose reductase inhibitor	AKR1B1			Phase 3
ranitidine	histamine receptor antagonist	HRH2	gastroenterology	heartburn	Launched
ranolazine	sodium channel blocker	SCN10A, SCN9A	cardiology	chronic stable angina	Launched
rapastinel	glutamate receptor agonist				Phase 2
rasagiline	monoamine oxidase inhibitor	BCL2, MAOB	neurology/psychiatry	Parkinson's Disease	Launched
rauwolscine	adrenergic receptor antagonist	ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR1E, HTR2B			Preclinical
ravoxertinib	ERK1 and ERK2 phosphorylation inhibitor	MAPK1, MAPK3			Phase 1
ravuconazole	sterol demethylase inhibitor				Phase 2
RBC8	Ral GTPase inhibitor	RALA, RALB			Preclinical
rebamipide	free radical scavenger	FPR1	gastroenterology	peptic ulcer disease (PUD), gastritis	Launched
rebastinib	Bcr-Abl kinase inhibitor, TIE tyrosine kinase inhibitor, VEGFR inhibitor	ABL1, BCR, FGR, FLT3, HCK, LYN, SRC			Phase 1/Phase 2
reboxetine	adrenergic receptor antagonist	SLC6A2	neurology/psychiatry	depression	Launched
Rec-15/2615	adrenergic receptor antagonist	ADRA1A			Phase 2
refametinib	MEK inhibitor	MAP2K1, MAP2K2			Phase 2
regadenoson	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3	radiology	myocardial perfusion imaging (MPI)	Launched
regorafenib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK	oncology	colorectal cancer, gastrointestinal stromal tumors (GIST)	Launched
relcovaptan	vasopressin receptor antagonist	AVPR1A, AVPR1B, AVPR2, OXTR			Phase 2
relebactam	beta lactamase inhibitor				Launched
relugolix	gonadotropin releasing factor hormone receptor antagonist				Phase 3
remacemide	glutamate receptor antagonist	GRIN1			Phase 3
remetinostat	HDAC inhibitor				Phase 2
remimazolam	benzodiazepine receptor agonist	GABBR1			Phase 3
remodelin	transferase inhibitor	NAT10			Preclinical
remoxipride	dopamine receptor antagonist	DRD2, DRD3, DRD4, HTR2A, SIGMAR1			Withdrawn
repaglinide	insulin secretagogue	ABCC8, KCNJ11, PPARG	endocrinology	diabetes mellitus	Launched
reparixin	CC chemokine receptor antagonist	CXCR1, CXCR2			Phase 3
repotrectinib	receptor tyrosine protein kinase inhibitor				Phase 1/Phase 2
repsox	TGF beta receptor inhibitor	TGFBR1			Preclinical
resatorvid	toll-like receptor inhibitor	TLR4			Phase 3
reserpine	vesicular monoamine transporter inhibitor	SLC18A1, SLC18A2	cardiology	hypertension	Launched
resibufogenin	Na/K-ATPase inhibitor				Phase 2
resiquimod	toll-like receptor agonist	TLR7, TLR8			Phase 3
resmetirom	thyroid hormone receptor agonist				Phase 3
resminostat	HDAC inhibitor	HDAC1, HDAC3, HDAC6, HDAC8			Phase 2
resorcinol	phosphodiesterase inhibitor	CA12, CA14, CA2, PTGS1	dermatology	acne vulgaris (AV), eczema, psoriasis, seborrheic dermatitis	Launched
resorcinol-monoacetate	antiseptic				Launched
resveratrol	cytochrome P450 inhibitor, SIRT activator	CSNK2A1, NQO2, PTGS1, PTGS2			Launched
retagliptin	dipeptidyl peptidase inhibitor				Phase 1
retapamulin	protein synthesis inhibitor		infectious disease	impetigo	Launched
retaspimycin	HSP inhibitor	HSP90AA1			Phase 3
retinaldehyde			dermatology	cosmetic	Launched
retinol	retinoid receptor ligand	ALDH1A1, ALDH1A2, ALDH1A3, DHRS3, DHRS4, LRAT, NR2C2, RBP1, RBP3, RDH11, RDH12, RDH13, RDH14, RDH5, RDH8, RETSAT, RHO, RLBP1, RXRA, RXRB, RXRG	dermatology	cosmetic, acne vulgaris (AV), keratosis	Launched
retinyl-acetate					Launched
retinyl-palmitate					Launched
REV-5901	leukotriene receptor antagonist, lipoxygenase inhibitor	ALOX5			Phase 2
revaprazan	potassium-competitive acid antagonist	ATP4A	gastroenterology	gastritis	Launched
revefenacin	cholinergic receptor antagonist				Launched
reversan	MRP inhibitor	ABCC1			Preclinical
reversine	Aurora kinase inhibitor	AURKB, INCENP, MAP2K1			Preclinical
reynoutrin	antioxidant				Preclinical
RGB-286638	CDK inhibitor	CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK9, FLT3, GSK3B, JAK2, MAP3K7, MAPK9			Phase 1
RGFP966	HDAC inhibitor	HDAC3			Preclinical
RGX-104	LXR agonist				Phase 1
RG108	DNA methyltransferase inhibitor	DNMT1, DNMT3B			Preclinical
RG1530	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	FGFR1, FGFR2			Phase 1
RG2833	HDAC inhibitor	HDAC1, HDAC3			Phase 1
RG4733	gamma secretase inhibitor	PSEN1			Phase 2
RG7112	MDM inhibitor	MDM2			Phase 1
RG7800	RNA splicing modifier				Preclinical
RG7834	antiviral				Preclinical
RHC-80267	triacylglycerol lipase inhibitor	DAGLA, DAGLB			Preclinical
rhein		HSP90AA1			Phase 1
rheochrysidin	protein tyrosine kinase inhibitor	PTPN1			Preclinical
rhodamine-123					Phase 1
RI-1		RAD51			Preclinical
ribavirin	antiviral	ADK, ENPP1, IMPDH1, IMPDH2, NT5C2	infectious disease	hepatitis C	Launched
ribitol					Preclinical
ribociclib	CDK inhibitor	CDK4, CDK6	oncology	breast cancer	Launched
riboflavin	vitamin B	BLVRB, RFK	gastroenterology	jaundice	Launched
riboflavin-tetrabutyrate	antioxidant				Preclinical
riboflavin-5-phosphate-sodium		BLVRB, DHODH, DPYD, HAO1, HAO2, MT-ND1, NOS1, PNPO, POR, PPCDC, RFK, RPS6KA4, SGK1			Launched
ribostamycin	bacterial 30S ribosomal subunit inhibitor	P4HB	infectious disease	human immunodeficiency virus (HIV-1)	Launched
ribostamycin-sulfate	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	Launched
ricinoleic-acid	prostanoid receptor agonist	PTGER3			Launched
ridinilazole	antibacterial				Phase 3
rifabutin	protein synthesis inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	Launched
rifampin	RNA polymerase inhibitor	NR1I2, SLCO1A2, SLCO1B1, SLCO1B3	infectious disease	tuberculosis, meningitis	Launched
rifamycin	DNA directed RNA polymerase inhibitor	SLCO1A2, SLCO1B1, SLCO1B3, SLCO2B1	infectious disease	tuberculosis, leprosy	Launched
rifamycin-sv	RNA synthesis inhibitor				Phase 3
rifapentine	RNA polymerase inhibitor	CYP2C8, CYP2C9, CYP3A4	infectious disease	tuberculosis	Launched
rifaximin	RNA synthesis inhibitor		gastroenterology	diarrhea, irritable bowel syndrome, hepatic encephalopathy (HE)	Launched
rigosertib	cell cycle inhibitor, PLK inhibitor	PLK1			Phase 3
rilapladib	phospholipase inhibitor				Phase 2
rilmenidine	adrenergic receptor agonist, imidazoline receptor agonist	ADRA2A	cardiology	hypertension	Launched
rilpivirine	non-nucleoside reverse transcriptase inhibitor	NR1I2, SCN10A	infectious disease	human immunodeficiency virus (HIV-1)	Launched
riluzole	glutamate inhibitor	KCNK10, KCNK2, KCNK4, KCNN4, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A, SLC7A11	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)	Launched
rimantadine	antiviral, RNA synthesis inhibitor		infectious disease	influenza A virus infection	Launched
rimcazole	sigma receptor antagonist	SIGMAR1			Phase 1
rimegepant	calcitonin antagonist	CALCA			Launched
rimeporide	sodium/hydrogen exchanger inhibitor				Phase 1
rimexolone	glucocorticoid receptor agonist	NR3C1, SERPINA6	ophthalmology	anterior uveitis	Launched
rimonabant	cannabinoid receptor antagonist	CNR1, GPR55			Withdrawn
riociguat	guanylate cyclase stimulant	GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3	cardiology	hypertension	Launched
riodipine	calcium channel blocker				Phase 2
riodoxol	other antibiotic				Launched
ripasudil	rho associated kinase inhibitor	ROCK1, ROCK2	ophthalmology	glaucoma, ocular hypertension	Launched
ripazepam	benzodiazepine receptor agonist	GABRA1			Phase 2
ripretinib	receptor tyrosine protein kinase inhibitor				Phase 3
risdiplam	RNA splicing inhibitor				Phase 2/Phase 3
risedronate	osteoclast inhibitor	FDPS	orthopedics, endocrinology	osteoporosis, Paget's disease	Launched
rislenemdaz	ionotropic glutamate receptor antagonist				Preclinical
risperidone	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, HTR7	neurology/psychiatry	schizophrenia, bipolar disorder, irritability	Launched
RITA	MDM inhibitor	MDM2			Preclinical
ritanserin	serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7			Phase 3
ritodrine	adrenergic receptor agonist		obstetrics/gynecology	premature labor	Withdrawn
ritonavir	HIV protease inhibitor	CYP1A2, CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP2E1, CYP3A4, CYP3A5, CYP3A7	infectious disease	human immunodeficiency virus (HIV-1)	Launched
rivanicline	acetylcholine receptor agonist	CHRNA4, CHRNB2, CXCL8			Phase 2
rivaroxaban	coagulation factor inhibitor	F10	neurology/psychiatry, hematology, cardiology	stroke, systemic embolism, atrial fibrillation (AF), deep vein thrombosis (DVT), pulmonary embolism (PE)	Launched
rivastigmine	acetylcholinesterase inhibitor	ACHE, BCHE	neurology/psychiatry	Alzheimer's disease, Parkinson's Disease, senile dementia	Launched
rizatriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F	neurology/psychiatry	migraine headache	Launched
RKI-1447	rho associated kinase inhibitor	CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2			Preclinical
RLX					Preclinical
RMC-4550	SHIP2 phosphatase inhibitor				Preclinical
RN-1	histone demethylase inhibitor	KDM1A			Preclinical
RN-1734	TRPV antagonist	TRPV4			Preclinical
RN-1747	TRPV agonist	TRPV4			Preclinical
Ro-04-5595	glutamate receptor antagonist	GRIN2B			Preclinical
Ro-08-2750	NGF binding inhibitor	NGF, NGFR			Preclinical
Ro-10-5824	dopamine receptor agonist	DRD4			Preclinical
Ro-106-9920	NFkB pathway inhibitor				Preclinical
Ro-1138452	prostanoid receptor antagonist	PTGIR			Preclinical
Ro-15-4513	GABA benzodiazepine site receptor inverse agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB2, GABRG2			Preclinical
Ro-19-4605	GABA benzodiazepine site receptor inverse agonist	GABRA1, GABRA2, GABRA3, GABRA5			Preclinical
Ro-20-1724	phosphodiesterase inhibitor	PDE3A, PDE4A, PDE4B, PDE4C, PDE4D			Preclinical
Ro-25-6981	glutamate receptor antagonist, monamine transporter modulator	GRIN2B			Preclinical
Ro-28-1675	glucokinase activator	GCK			Preclinical
Ro-3	purinergic receptor antagonist	P2RX3			Preclinical
Ro-3306	CDK inhibitor	CDK1			Preclinical
Ro-48-6791	GABA receptor modulator				Preclinical
Ro-48-8071	oxidosqualene cyclase inhibitor	LSS			Preclinical
Ro-4987655	MEK inhibitor	MAP2K1			Phase 1
Ro-5028442	vasopressin receptor antagonist				Phase 1
Ro-5126766	MEK inhibitor, RAF inhibitor	BRAF, MAP2K1, MAP2K2, RAF1			Phase 1
Ro-5263397	trace amine associated receptor agonist				Preclinical
Ro-60-0175	serotonin receptor agonist	HTR2A, HTR2B, HTR2C			Preclinical
Ro-61-8048	kynurenine 3-monooxygenase inhibitor	KMO			Preclinical
Ro-67-7476	glutamate receptor positive allosteric modulator	GRM1			Preclinical
Ro-90-7501	beta amyloid protein neurotoxicity inhibitor	APP			Preclinical
Ro-9187	HCV inhibitor				Preclinical
robalzotan	serotonin receptor antagonist	HTR1A			Phase 2
roblitinib	FGFR inhibitor				Preclinical
rociletinib	EGFR inhibitor	EGFR			Phase 3
rocuronium	acetylcholine receptor antagonist	CHRM2, CHRNA2, HTR3A	neurology/psychiatry	anesthetic	Launched
rofecoxib	cyclooxygenase inhibitor	ELN, PTGS2			Withdrawn
roflumilast	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4C, PDE4D	pulmonary	chronic obstructive pulmonary disease (COPD), bronchitis	Launched
rogaratinib	FGFR inhibitor				Phase 2/Phase 3
rolapitant	neurokinin receptor antagonist				Phase 3
rolipram	phosphodiesterase inhibitor				Phase 3
rolitetracycline	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	Launched
roluperidone					Phase 2
rolziracetam					Phase 2
romidepsin	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	Launched
ronidazole	antiprotozoal agent		infectious disease	histomoniasis, dysentry	Launched
ropinirole	dopamine receptor agonist	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C	neurology/psychiatry	Parkinson's Disease, restless leg syndrome	Launched
ropivacaine	sodium channel blocker	SCN10A	neurology/psychiatry	anesthetic	Launched
roquinimex	angiogenesis inhibitor, tumor necrosis factor production inhibitor				Phase 3
rosamicin	protein synthesis inhibitor				Phase 2
roscovitine	CDK inhibitor	CDK2, CDK9			Phase 2
rose-bengal	contrast agent, immunostimulant		radiology	diagnostic agent	Launched
rose-bengal-lactone	coloring agent		ophthalmology	staining agent	Launched
rosiglitazone	insulin sensitizer, PPAR receptor agonist	FFAR1, PPARG, TRPC5, TRPM3			Withdrawn
rosiptor	SHIP1 phosphatase activator				Phase 2
rosmarinic-acid	GABA transaminase inhibitor	MCL1, TYR			Launched
rosoxacin	topoisomerase inhibitor		infectious disease	urinary tract infections	Launched
rostafuroxine	ATPase inhibitor	ATP1A1			Phase 2
rosuvastatin	HMGCR inhibitor	HMGCR	endocrinology, cardiology	hyperlipidemia, dyslipidemia, hypertriglyceridemia, hypercholesterolemia, atherosclerosis	Launched
rotigotine	dopamine receptor agonist	ADRA2B, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A	neurology/psychiatry	Parkinson's Disease, restless leg syndrome	Launched
rotundine	serotonin receptor agonist	DRD1, DRD2, DRD3, HTR1A	neurology/psychiatry	anxiety, sedative	Launched
rovazolac	LXR agonist				Preclinical
roxarsone	antiprotozoal agent		endocrinology	weight-gain aid	Launched
roxatidine-acetate	histamine receptor antagonist	HRH2	gastroenterology	Zollinger-Ellison syndrome, erosive esophagitis (EE), gastroesophageal reflux disease (GERD), gastritis	Launched
roxithromycin	bacterial 50S ribosomal subunit inhibitor	MLNR	infectious disease	respiratory tract infections, urinary tract infections, skin infections	Launched
RP-001	sphingosine 1-phosphate receptor agonist	S1PR1			Preclinical
RP67580					Preclinical
RQ-00203078	transient receptor potential channel antagonist	TRPM8			Preclinical
RRx-001	glucose 6-phosphate dehydrogenase inhibitor	G6PD			Phase 3
RS-0481	immunostimulant				Phase 2
RS-100329	adrenergic receptor antagonist	ADRA1A, ADRA1D			Preclinical
RS-102221	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			Preclinical
RS-102895	CCR antagonist	CCR2			Preclinical
RS-127445	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			Phase 1
RS-16566	serotonin receptor antagonist				Preclinical
RS-17053	adrenergic receptor antagonist	ADRA1A, ADRA1D			Preclinical
RS-23597-190	serotonin receptor antagonist	HTR4			Preclinical
RS-39604	serotonin receptor antagonist	HTR4			Preclinical
RS-45041-190	imidazoline receptor agonist				Preclinical
RS-504393	CC chemokine receptor antagonist	CCL2, CCR2			Preclinical
RS-56812	serotonin receptor partial agonist	HTR3A			Preclinical
RS-67333	serotonin receptor partial agonist	HTR4			Preclinical
RS-67506	serotonin receptor partial agonist	HTR4			Preclinical
RS-79948	adrenergic receptor antagonist	ADRA2A			Preclinical
RSV604	RSV replication inhibitor				Phase 2
RTA-408	nitric oxide production inhibitor	NFE2L2			Phase 2
RU-SKI-43	hedgehog pathway inhibitor	HHAT			Preclinical
RU-24969	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A, HTR6			Phase 1
RU-28318	cytochrome P450 inhibitor	NR3C2			Phase 2
RU-42173	adrenergic receptor agonist	ADRB2			Phase 2
RU-58841	androgen receptor antagonist	AR			Phase 2
rubitecan	topoisomerase inhibitor	TOP1			Phase 3
ruboxistaurin	PKC inhibitor				Phase 3
rucaparib	PARP inhibitor	PARP1, PARP2			Phase 3
rucinol	tyrosinase inhibitor	TYR			Phase 1
rufinamide	voltage-gated sodium channel blocker	GRM5, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	Launched
rufloxacin	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	Launched
rupatadine	histamine receptor antagonist, platelet activating factor receptor antagonist	HRH1, PTAFR	allergy	allergic rhinitis, urticaria	Launched
rutaecarpine	cyclooxygenase inhibitor	PTGS2			Preclinical
rutin	antioxidant, capillary stabilizing agent, nitric oxide scavenger	AKR1C3	rheumatology, otolaryngology, gastroenterology, neurology/psychiatry, allergy	joint pain, nasal congestion, constipation, irritability, allergic rhinitis	Launched
ruxolitinib	JAK inhibitor	JAK1, JAK2, JAK3, TYK2	hematologic malignancy, hematology	myelofibrosis, polycythemia vera	Launched
ruxolitinib-(S)	JAK inhibitor	JAK1, JAK2			Preclinical
RV1729	PI3K inhibitor				Phase 1
RWJ-21757	toll-like receptor agonist	TLR7			Phase 2
RWJ-50271	integrin inhibitor	ICAM1			Preclinical
RWJ-67657	MAP kinase inhibitor	MAPK14, PTGS2			Phase 1
RX-3117	CDK inhibitor, DNA synthesis inhibitor	CDK2, DNMT1			Phase 1/Phase 2
RX-821002	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C			Preclinical
ryuvidine	histone lysine methyltransferase inhibitor	CDK2, CDK4			Preclinical
R112	SYK inhibitor	SYK			Phase 1
R306465	HDAC inhibitor				Phase 1
R406	SYK inhibitor	RET, SYK			Phase 1
R547	CDK inhibitor	CDK1, CDK2, CDK4, CDK7			Phase 1
S-isopropylisothiourea	nitric oxide synthase inhibitor	NOS3			Preclinical
S-methylcysteine		CTSD, MGMT			Phase 1
S-nitrosoglutathione	nitric oxide stimulant	PTPN1			Phase 1
S-sulfo-L-cysteine	glutamate receptor agonist				Preclinical
S-trityl-L-cysteine	mitotic kinesin inhibitor				Preclinical
S-07662	CAR antagonist	NR1I3			Preclinical
S-111	PARP inhibitor	PARP1			Phase 2
S-14506	serotonin receptor agonist	HTR1A			Preclinical
S-17092	prolyl endopeptidase inhibitor				Preclinical
S-3304	matrix metalloprotease inhibitor				Phase 1/Phase 2
S-38093	histamine receptor antagonist				Preclinical
SA-47	FAAH inhibitor	FAAH			Preclinical
saccharin	DNA polymerase inhibitor	CA1, CA12, CA2, CA9			Launched
saclofen	GABA receptor antagonist	GABBR1, GABBR2, KCTD12, KCTD16, KCTD8			Preclinical
sacubitril	neprilysin inhibitor	MME	cardiology	congestive heart failure	Launched
sacubitrilat	neprilysin inhibitor				Preclinical
safflower-yellow	anti-inflammatory agent				Preclinical
safinamide	dopamine reuptake inhibitor, glutamate inhibitor, monoamine oxidase inhibitor	MAOB	neurology/psychiatry	Parkinson's Disease	Launched
safingol	PKC inhibitor	TRPM3			Phase 1
safranal	benzodiazepine receptor agonist	GABBR1			Phase 2
SAG	smoothened receptor agonist	SMO, TRPC6			Preclinical
salazodine					Phase 2
salicin	anti-inflammatory agent				Phase 1
salicyl-alcohol					Preclinical
salicylamide	analgesic agent		neurology/psychiatry, endocrinology	pain relief, fever	Launched
salicylanilide	other antibiotic				Preclinical
salicylic-acid	cyclooxygenase inhibitor, prostanoid receptor antagonist	AKR1C1, ASIC3, PTGS1, PTGS2	dermatology, endocrinology, neurology/psychiatry	acne vulgaris (AV), fever, pain relief	Launched
salidroside	beta amyloid protein neurotoxicity inhibitor	APP			Preclinical
salinomycin			infectious disease	coccidiosis	Launched
salirasib	mTOR inhibitor	TRPA1			Phase 2
salmeterol	adrenergic receptor agonist	ADRB2	pulmonary	asthma, chronic obstructive pulmonary disease (COPD), bronchospasm	Launched
salsolinol-1-carboxylic-acid					Preclinical
salubrinal	eukaryotic translation initiation factor inhibitor	EIF2S1			Preclinical
salvianolic-acid-A	matrix metalloprotease inhibitor				Phase 1
salvianolic-acid-B	EGFR inhibitor, metalloproteinase inhibitor	MMP9			Phase 2
salvinorin-A	opioid receptor agonist	OPRD1, OPRK1, OPRM1			Phase 1
sal003	eukaryotic translation initiation factor inhibitor	EIF2A			Preclinical
SAM-315	serotonin receptor antagonist				Preclinical
sameridine	opioid receptor modulator				Preclinical
sanazole					Phase 1
sancycline	antitumor agent				Preclinical
sangivamycin	DNA inhibitor				Phase 1
sanguinarium-chloride	apoptosis stimulant	CASP3			Phase 1
SANT-1	smoothened receptor antagonist	SHH, SMO			Preclinical
SANT-2	smoothened receptor antagonist	SHH, SMO			Preclinical
sapacitabine	DNA synthesis inhibitor				Phase 3
sapropterin	phenylalanine 4-hydroxylase stimulant	NOS3, PAH, TH, TPH1	metabolism	hyperphenylalaninemia (HPA)	Launched
saquinavir	HIV protease inhibitor	CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	Launched
SAR-245409	PI3K inhibitor	MTOR, PIK3CG			Phase 1/Phase 2
saracatinib	SRC inhibitor	ABL1, LCK, SRC, YES1			Phase 2/Phase 3
sarafloxacin	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	Launched
sarcosine	glycine transporter inhibitor	SLC6A9			Phase 2
sardomozide	S-adenosylmethionine decarboxylase inhibitor				Preclinical
sari-59-801					Phase 1
saroglitazar	PPAR receptor agonist	PPARA, PPARG	endocrinology, cardiology, gastroenterology	diabetes mellitus, dyslipidemia, non-alcoholic steatohepatitis (NASH)	Launched
sarpogrelate	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C	endocrinology, cardiology, rheumatology	diabetes mellitus, angina pectoris, Raynaud's disease, atherosclerosis, Buerger's disease	Launched
SAR131675	VEGFR inhibitor	FLT4			Preclinical
SAR405	PI3K inhibitor	PIK3C3			Preclinical
SAR405838	MDM inhibitor	MDM2			Phase 1
SAR407899	rho associated kinase inhibitor	ROCK1			Phase 2
sasapyrine	NFkB pathway inhibitor	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	Launched
satraplatin	DNA alkylating agent				Phase 3
savolitinib	c-Met inhibitor	MET			Phase 3
saxagliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	Launched
SB-200646	serotonin receptor antagonist	HTR2B, HTR2C			Preclinical
SB-202190	p38 MAPK inhibitor	AKT1, ALOX5, CHEK1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SGK1			Preclinical
SB-203186	serotonin receptor antagonist	HTR4			Preclinical
SB-203580	p38 MAPK inhibitor	AKT1, ALOX5, CHEK1, CYP2D6, CYP3A4, GAK, GSK3B, LCK, MAPK1, MAPK10, MAPK11, MAPK12, MAPK14, MAPK8, MAPK9, PRKCA, RAF1, RIPK2, ROCK1, RPS6KB1, SGK1, SRC, TNF			Preclinical
SB-205384	GABA receptor modulator	GABRA3, GABRA5, GABRA6			Preclinical
SB-206553	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			Preclinical
SB-216641	serotonin receptor antagonist	HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C			Preclinical
SB-216763	glycogen synthase kinase inhibitor	CCNA2, CDK2, GSK3A, GSK3B			Preclinical
SB-218078	CHK inhibitor	CHEK1			Preclinical
SB-218795	tachykinin antagonist	TACR3			Preclinical
SB-221284	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			Preclinical
SB-222200	tachykinin antagonist	TACR3			Preclinical
SB-225002	CC chemokine receptor antagonist	CXCR2			Preclinical
SB-228357	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			Preclinical
SB-2343	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG			Phase 1
SB-239063	p38 MAPK inhibitor	MAPK11, MAPK14, PTGS2			Preclinical
SB-242235	p38 MAPK inhibitor	HSPB1, MAPK14			Phase 1
SB-243213	serotonin receptor inverse agonist	HTR2A, HTR2B, HTR2C, HTR6			Phase 1
SB-258585	serotonin receptor antagonist	HTR6			Preclinical
SB-268262	calcitonin antagonist	CALCA			Preclinical
SB-269970	serotonin receptor antagonist	HTR7			Preclinical
SB-271046	serotonin receptor antagonist	HTR6			Phase 1
SB-297006	CC chemokine receptor antagonist	CCR3			Preclinical
SB-328437	CCR antagonist				Preclinical
SB-334867	orexin receptor antagonist	HCRTR1, HCRTR2			Preclinical
SB-366791	TRPV antagonist	TRPV1			Preclinical
SB-399885	serotonin receptor antagonist	HTR6			Preclinical
SB-408124	orexin receptor antagonist	HCRTR1, HCRTR2			Preclinical
SB-415286	glycogen synthase kinase inhibitor	GSK3A, GSK3B, RPS6KB1			Preclinical
SB-431542	TGF beta receptor inhibitor	ACVR1C, TGFBR1			Preclinical
SB-452533	TRPV antagonist	TRPV1			Preclinical
SB-505124	ALK tyrosine kinase receptor inhibitor	TGFBR1			Preclinical
SB-525334	TGF beta receptor inhibitor	TGFBR1			Preclinical
SB-590885	RAF inhibitor	BRAF			Preclinical
SB-612111	nociceptin/orphanin FQ receptor antagonist	OPRL1			Preclinical
SB-649868	orexin receptor antagonist				Phase 2
SB-657510	urotensin receptor antagonist	UTS2R			Preclinical
SB-683698	integrin antagonist	ITGA4, ITGAV, ITGB1, ITGB7			Phase 1
SB-705498	TRPV antagonist	TRPV1			Phase 2
SB-706375	urotensin receptor antagonist	UTS2R			Preclinical
SB-742457	serotonin receptor antagonist	HTR6			Phase 3
SB-743921	kinesin-like spindle protein inhibitor	KIF11			Phase 1/Phase 2
SB-747651A	kinase inhibitor	AKT1, AKT3, ROCK1, RPS6KA5, RPS6KB1			Preclinical
SB-756050	G protein-coupled receptor agonist	GPBAR1			Phase 1
SB-772077B	rho associated kinase inhibitor	ROCK1, ROCK2			Preclinical
SB-939	HDAC inhibitor	HDAC1, HDAC10, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC9			Phase 3
SBE-13	PLK inhibitor	PLK1			Preclinical
SBHA	HDAC inhibitor	HDAC1, HDAC3			Preclinical
SBI-115	G protein-coupled receptor antagonist				Preclinical
SC-10	protein kinase activator	PRKCA			Preclinical
SC-12267	dihydroorotate dehydrogenase inhibitor	IL17A			Phase 2
SC-144	P glycoprotein inhibitor				Preclinical
SC-19220	prostanoid receptor antagonist	PTGER1			Preclinical
SC-236	cyclooxygenase inhibitor	PTGS2			Preclinical
SC-51089	prostanoid receptor antagonist	PTGER1			Preclinical
SC-560	cyclooxygenase inhibitor	PTGS1			Preclinical
SC-9	protein tyrosine kinase activator	PRKCA			Preclinical
scabertopin	anticancer agent				Preclinical
SCH-202676	G protein-coupled receptor modulator	CHRM1, CHRM2, DRD1, DRD2			Preclinical
SCH-221510	nociceptin/orphanin FQ receptor agonist	OPRL1			Preclinical
SCH-23390	dopamine receptor antagonist	DRD1, DRD5, HTR2C, KCNJ4, KCNJ6			Preclinical
SCH-28080	ATPase inhibitor	ATP4A			Phase 1
SCH-51344	MTH1 inhibitor	NUDT1			Preclinical
SCH-58261	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Preclinical
SCH-900776	CHK inhibitor	CDK2, CHEK1			Phase 2
schisandrin-B	antioxidant	ATR			Preclinical
schisandrol-B	lipid peroxidase inhibitor				Phase 3
sclareol					Preclinical
sclareolide	other antifungal				Launched
SCMC-Lys	mucolytic agent	GSTP1	pulmonary	chronic obstructive pulmonary disease (COPD)	Launched
scopine					Launched
scopolamine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, SI	neurology/psychiatry, gastroenterology	motion sickness, vomiting, nausea	Launched
scopolamine-N-oxide	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4			Preclinical
SCP-1	analgesic agent				Phase 1
scriptaid	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9			Preclinical
SCS					Preclinical
SD-0006	p38 MAPK inhibitor				Phase 2
SD-169	p38 MAPK inhibitor	MAPK14			Preclinical
SD-208	TGF beta receptor inhibitor	TGFBR1			Preclinical
SD-2590	matrix metalloprotease inhibitor	MMP1, MMP13, MMP2			Preclinical
SDM25N	opioid receptor antagonist	OPRD1			Preclinical
SDZ-NKT-343	tachykinin antagonist	TACR1			Phase 1
SDZ-SER-082	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			Preclinical
SDZ-WAG-994	adenosine receptor agonist	ADORA1			Phase 2
SDZ-205-557	serotonin receptor antagonist	HTR3A, HTR3B			Preclinical
SDZ-21009	adrenergic receptor antagonist, serotonin receptor antagonist	HTR1A, HTR1B			Preclinical
SDZ-220-040	glutamate receptor antagonist	GRIN1			Preclinical
SDZ-220-581	glutamate receptor antagonist	GRIN1			Preclinical
Se-methylselenocysteine					Phase 2
secalciferol	vitamin D receptor agonist	VDR	critical care	bone fracture	Launched
seclazone	anti-inflammatory agent				Phase 1
seclidemstat	histone demethylase inhibitor				Phase 1
secnidazole	acetylcholinesterase inhibitor, microtubule inhibitor		infectious disease	protozoan infection	Launched
secoisolariciresinol-(-)					Phase 2
secoisolariciresinol-diglucoside	antioxidant				Phase 2
securinine	GABA receptor antagonist, TP53 activator	GABRA1			Preclinical
segesterone-acetate	progesterone receptor agonist	PGR			Launched
seladelpar	PPAR receptor agonist				Phase 3
selamectin	nematocide		infectious disease	flea control	Launched
selegiline	monoamine oxidase inhibitor	MAOA, MAOB	neurology/psychiatry	Parkinson's Disease	Launched
selenomethionine					Launched
seletalisib	PI3K inhibitor				Preclinical
selexipag	IP1 prostacyclin receptor agonist, platelet aggregation inhibitor	PTGIR	pulmonary	pulmonary arterial hypertension (PAH)	Launched
selfotel	glutamate receptor antagonist	GRIN2A, GRIN2B, GRIN2C, GRIN2D			Phase 3
selinexor	exportin antagonist	XPO1	hematologic malignancy	multiple myeloma	Launched
selitrectinib	protein tyrosine kinase inhibitor				Phase 1/Phase 2
selonsertib	MAP kinase activator				Phase 2
selumetinib	MEK inhibitor	MAP2K1			Phase 3
semagacestat	gamma secretase inhibitor	PSEN1			Phase 3
semapimod	cytokine production inhibitor, p38 MAPK inhibitor	MAPK14			Phase 2
semaxanib	VEGFR inhibitor	FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET			Phase 3
semustine	DNA alkylating agent				Phase 3
SEN-1269	beta amyloid inhibitor	APP			Preclinical
senicapoc	intermediate conductance potassium channel blocker	KCNN4			Phase 3
sennoside-A	glycoside agonist		gastroenterology	constipation	Launched
sennoside-protonated					Preclinical
seocalcitol	vitamin D receptor agonist	VDR			Phase 3
SEP-227900	D-amino acid oxidase Inhibitor	DAO			Phase 1
seratrodast	prostanoid receptor antagonist	TBXA2R	pulmonary	asthma	Launched
serdemetan	MDM inhibitor	MDM2			Phase 1
serotonin	growth factor receptor activator	DRD1, DRD5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR3B, HTR4, HTR5A, HTR6, HTR7, SLC36A1	neurology/psychiatry	anxiety, depression, sleeplessness	Launched
sertaconazole	sterol demethylase inhibitor		infectious disease	tinea pedis	Launched
sertindole	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, KCNH2			Withdrawn
sertraline	selective serotonin reuptake inhibitor (SSRI)	SLC6A3, SLC6A4	neurology/psychiatry, obstetrics/gynecology	depression, obsessive compulsive disorder (OCD), panic disorders, posttraumatic stress disorder, premenstrual syndrome, social anxiety disorder	Launched
sesamin	NFkB pathway inhibitor				Preclinical
setipiprant	prostaglandin inhibitor	PTGDR2			Phase 3
setiptiline	adrenergic receptor antagonist	HRH1, HTR2A, HTR2C	neurology/psychiatry	depression	Launched
setmelanotide	melanocortin receptor agonist				Phase 3
sevoflurane	membrane integrity inhibitor	ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9, MT-ND1	neurology/psychiatry	anesthetic	Launched
SEW-2871	lysophospholipid receptor agonist	S1PR1			Preclinical
SF-11	neuropeptide receptor antagonist	MCOLN3, NPY2R			Preclinical
SGC-CBP30	bromodomain inhibitor	CREBBP, EP300			Preclinical
SGC-0946	histone lysine methyltransferase inhibitor				Preclinical
SGC-707	protein arginine N-methyltransferase inhibitor	PRMT3			Preclinical
SGI-1027	DNA methyltransferase inhibitor	DNMT1, DNMT3A, DNMT3B			Preclinical
SGI-1776	Pim kinase inhibitor	FLT3, PIM1, PIM2, PIM3			Phase 1
SGS-742	GABA receptor antagonist	GABBR1, GABBR2			Preclinical
SGX523	hepatocyte growth factor receptor inhibitor	MET			Phase 1
SHA-68	neuropeptide receptor antagonist	NPSR1			Preclinical
shikimic-acid					Preclinical
SHP099	protein tyrosine kinase inhibitor	PTPN11			Preclinical
SIB-1553A	acetylcholine receptor agonist	CHRNB4			Phase 2
SIB-1757	glutamate receptor antagonist	GRM5			Preclinical
SIB-1893	glutamate receptor antagonist	GRM4, GRM5			Preclinical
SID-7969543	steroidogenic factor antagonist	NR5A1			Preclinical
siguazodan	phosphodiesterase inhibitor	PDE3A			Phase 1
sildenafil	phosphodiesterase inhibitor	PDE5A, PDE6G, PDE6H, SLCO1B1, SLCO1B3	urology	erectile dysfunction	Launched
silibinin	cytochrome P450 inhibitor	ALOX5	gastroenterology	hepatic cirrhosis	Launched
silodosin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D	urology	benign prostatic hyperplasia (BPH)	Launched
silver-sulfadiazine	PABA antagonist		critical care	sepsis	Launched
silymarin					Launched
simeprevir	HCV inhibitor	CYP1A2, CYP3A4	infectious disease	hepatitis C	Launched
simurosertib	kinase inhibitor				Preclinical
simvastatin	HMGCR inhibitor	HMGCR, ITGB2	endocrinology, cardiology, neurology/psychiatry	hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia	Launched
sincalide	cholecystokinin agonist				Preclinical
sinefungin	DNA methyltransferase inhibitor, RNA synthesis inhibitor	CARM1			Preclinical
sinomenine	angiogenesis inhibitor				Preclinical
sipatrigine	voltage-gated sodium channel blocker	CACNA1D, SCN10A, SCN1A, SCN3A, SCN4A, SCN5A, SCN9A			Phase 2
siponimod	sphingosine 1-phosphate receptor modulator	S1PR1	neurology/psychiatry	multiple sclerosis	Launched
siramesine	sigma receptor antagonist	ADRA1A, ADRA1B, ADRA1D			Phase 2
siremadlin	MDM inhibitor				Preclinical
sirolimus	mTOR inhibitor	FKBP1A, MTOR	transplant, pulmonary	organ rejection, lymphangioleiomyomatosis	Launched
SirReal-2	SIRT inhibitor	SIRT2			Preclinical
sirtinol	SIRT inhibitor	SIRT1, SIRT2			Preclinical
sisomicin	protein synthesis inhibitor		ophthalmology	conjunctivitis, punctate keratitis	Launched
sisomicin-sulfate	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	Launched
SIS3	serine/threonine kinase inhibitor	SMAD3, TGFBR1			Preclinical
sitafloxacin	bacterial DNA gyrase inhibitor		infectious disease	buruli ulcer	Launched
sitagliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	Launched
sitaxentan	endothelin receptor antagonist	EDNRA, EDNRB			Withdrawn
sitosterol					Preclinical
sitravatinib	receptor tyrosine protein kinase inhibitor				Phase 3
sivelestat	elastase inhibitor	CELA1, ELANE	pulmonary	acute lung injury	Launched
SJ-172550	MDM inhibitor	MDM4			Preclinical
SJ-733	ATPase inhibitor				Phase 1
SJG-136	DNA intercalating agent				Phase 2
SK&F-10047-(+)	sigma receptor agonist	SIGMAR1			Phase 1
SKA-31	potassium channel activator	KCNN4			Preclinical
skepinone-L	p38 MAPK inhibitor	MAPK14			Preclinical
SKF-38393	dopamine receptor agonist	CALY, DRD1, DRD5			Preclinical
SKF-77434	dopamine receptor agonist	DRD1			Preclinical
SKF-81297	dopamine receptor agonist	DRD1, DRD5			Preclinical
SKF-83566	dopamine receptor antagonist	DRD1, DRD5			Preclinical
SKF-86002	p38 MAPK inhibitor	ALOX5, MAPK14			Preclinical
SKF-89976A	GABA uptake inhibitor	SLC6A1			Preclinical
SKF-91488	histamine N-methyltransferase inhibitor	HNMT			Preclinical
SKF-96365	calcium channel blocker	CYP3A4, PKD2, TRPC1, TRPC3, TRPC4, TRPC5, TRPV2			Preclinical
SKI-II	sphingosine kinase inhibitor	SPHK1			Preclinical
SKLB-1028	Abl kinase inhibitor, EGFR inhibitor, FLT3 inhibitor				Preclinical
SKLB1002	VEGFR inhibitor	KDR			Preclinical
SLV-319-(+/-)	cannabinoid receptor antagonist	CNR1, DRD2, HTR1A			Phase 2
SLV-320	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Phase 2
SM-108					Phase 2
SM-164	XIAP inhibitor	BIRC2, BIRC3, XIAP			Preclinical
SM-21	sigma receptor antagonist	PGRMC1			Preclinical
SMER-28	autophagy inducer	SNCA			Preclinical
SMI-4a	Pim kinase inhibitor	PIM1			Preclinical
SN-2	transient receptor potential channel agonist	MCOLN3			Preclinical
SN-38	topoisomerase inhibitor	TOP1	oncology	colorectal cancer	Launched
SN-6	sodium/calcium exchange inhibitor				Preclinical
SNAP	nitric oxide donor	PTPN1			Phase 2
SNAP-5089	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CACNA1C, CACNA1D			Preclinical
SNAP-94847		ADRA1A, DRD2			Preclinical
SNC-80		OPRD1			Preclinical
SNG-1153	selective estrogen receptor modulator (SERM)	ESR1			Preclinical
SNS-314	Aurora kinase inhibitor	AURKA, AURKB, AURKC			Phase 1
SNX-2112	HSP inhibitor				Phase 1
SNX-5422	HSP inhibitor	HSP90AA1, HSP90AB1			Phase 1/Phase 2
sobetirome	thyroid hormone receptor agonist	THRA, THRB			Phase 1/Phase 2
soblidotin	microtubule inhibitor				Phase 2
sobrepin	mucolytic agent		pulmonary	chest congestion	Launched
sobuzoxane	topoisomerase inhibitor		hematologic malignancy	peripheral T-cell lymphoma (PTCL)	Launched
sodium-ascorbate					Launched
sodium-butyrate	HDAC inhibitor	BCHE, FFAR2, FFAR3, HDAC1, HDAC2, HDAC3, HDAC8			Phase 2
sodium-danshensu					Preclinical
sodium-dodecyl-sulfate		ALB			Launched
sodium-gluconate					Launched
sodium-gualenate	antacid		gastroenterology, otolaryngology	peptic ulcer disease (PUD), pharyngitis	Launched
sodium-monofluorophosphate		PYGM	dental	cavities	Launched
sodium-nitrite	nitric oxide donor		critical care	poison antidote, cyanide poisoning	Launched
sodium-nitroprusside	nitric oxide donor		cardiology	hypertension, congestive heart failure	Launched
sodium-orthovanadate					Preclinical
sodium-picosulfate			gastroenterology	constipation	Launched
sodium-stibogluconate	tyrosine phosphatase inhibitor	PTPN6	infectious disease	leishmaniasis	Launched
sodium-tanshinone-II-A-sulfonate	potassium channel activator				Phase 2
sodium-tetradecyl-sulfate		PROC	dermatology	varicose veins	Launched
sofalcone	mucus protecting agent	CBR1	gastroenterology	peptic ulcer disease (PUD)	Launched
sofosbuvir	HCV inhibitor		infectious disease	hepatitis C, hepatitis C	Launched
sofosbuvir-impurity-m	antiviral				Preclinical
sograzepide	gastrin inhibitor				Phase 2
solamargine	apoptosis inhibitor				Phase 3
solcitinib	JAK inhibitor	JAK1			Phase 1
solifenacin-succinate	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence, urinary frequency	Launched
solithromycin	protein synthesis inhibitor				Phase 3
solriamfetol	dopamine reuptake inhibitor		neurology/psychiatry	narcolepsy	Launched
somantadine	antiviral				Phase 1
somatostatin	somatostatin receptor agonist	OPRD1, OPRM1, SSTR1, SSTR2, SSTR3, SSTR4, SSTR5	hematology	hemorrhage	Launched
sonepiprazole	dopamine receptor antagonist				Phase 2
sonidegib	smoothened receptor antagonist	SMO	oncology	basal cell carcinoma (BCC)	Launched
sophocarpine					Phase 3
sorafenib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET	oncology	renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)	Launched
soraprazan	proton pump inhibitor				Preclinical
sorbic-acid					Launched
sorbinil	aldose reductase inhibitor	AKR1B1			Phase 3
sorbitan-monostearate					Preclinical
sorbitol	mucolytic agent		gastroenterology	constipation	Launched
sotagliflozin	sodium/glucose cotransporter inhibitor	SLC5A1, SLC5A2			Phase 3
sotalol	adrenergic receptor antagonist	ADRB1, ADRB2, KCNH2	cardiology	atrial fibrillation (AF), ventricular arrhythmias	Launched
sotrastaurin	PKC inhibitor	PRKCA, PRKCB, PRKCD, PRKCE, PRKCH, PRKCQ			Phase 2
SP-100030	NFkB pathway inhibitor	JUN, NFKB1			Preclinical
SP-141	ubiquitin ligase inhibitor	MDM2			Preclinical
SP-420					Phase 1
spaglumic-acid	glutamate receptor antagonist	GRM3	allergy	allergic conjunctivitis, allergic rhinitis	Launched
sparfloxacin	bacterial DNA gyrase inhibitor	TOP2A			Withdrawn
sparfosate	aspartate carbamoyltransferase inhibitor	CA2, CA4			Phase 3
sparsentan	angiotensin receptor antagonist				Phase 3
sparteine-(+)					Launched
sparteine-(-)					Launched
sparteine-sulfate					Launched
spautin-1	deubiquitinase inhibitor	USP10, USP13			Preclinical
spectinomycin	bacterial 30S ribosomal subunit inhibitor		pulmonary	airsacculitis, chronic respiratory disease	Launched
spermidine	glutamate receptor modulator	KCNJ4, TXNRD1			Preclinical
spermine		CA14, CA4, CA6, CA9, CASR, GRIN1, GRIN2A, KCNJ4, ODC1, SMOX, SMS, TRPM4, TRPM5			Preclinical
sphingosylphosphorylcholine	gene expression stimulant	GPR12			Preclinical
spiperone	dopamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7	neurology/psychiatry	schizophrenia	Launched
spiradoline	opioid receptor agonist	OPRK1			Phase 2
spiramycin	bacterial 50S ribosomal subunit inhibitor		infectious disease	toxoplasmosis, soft tissue infection	Launched
spirobromin					Phase 1
spironolactone	mineralocorticoid receptor antagonist	AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG	endocrinology, cardiology, gastroenterology, rheumatology	hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia	Launched
spiroxatrine	serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR2B			Preclinical
spizofurone					Withdrawn
splitomycin	SIRT inhibitor	SIRT1			Preclinical
SPP301	endothelin receptor antagonist	EDNRA			Phase 3
SPP86	receptor tyrosine protein kinase inhibitor	RET			Preclinical
SQ-109	bacterial cell wall synthesis inhibitor	FDFT1			Phase 3
SQ-22536	adenylyl cyclase inhibitor	ADCY1			Preclinical
squalamine	antiviral				Phase 3
squaric-acid-dibutyl-ester	oxidative stress inducer				Preclinical
SR-1078	retinoid receptor agonist	RORA, RORC			Preclinical
SR-11302					Preclinical
SR-140333	neurokinin receptor antagonist	TACR1			Phase 2
SR-1664	PPAR receptor ligand	PPARG			Preclinical
SR-2211	retinoid receptor inverse agonist	RORC			Preclinical
SR-2640	leukotriene receptor antagonist	CYSLTR1			Phase 2
SR-27897	CCK receptor antagonist	CCKAR			Phase 2
SR-3306	JNK inhibitor	MAPK10, MAPK8, MAPK9			Preclinical
SR-33805	calcium channel blocker				Phase 1
SR-3576	JNK inhibitor	MAPK10			Preclinical
SR-3677	rho associated kinase inhibitor	ROCK2			Preclinical
SR-57227A	serotonin receptor agonist	HTR3A			Phase 2
SR-59230A	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3			Preclinical
SR-95639A	acetylcholine receptor agonist	CHRM1			Preclinical
SRC-kinase-inhibitor-I	SRC inhibitor	CSK, LCK, RIPK2			Preclinical
SRPIN340	serine arginine protein kinase inhibitor	SRPK1, SRPK2			Preclinical
SRT1720	SIRT activator	SIRT1			Preclinical
SRT2104	SIRT activator	SIRT1			Phase 2
SRT3190	CC chemokine receptor antagonist				Preclinical
SSR128129E					Preclinical
SSR180711	acetylcholine receptor agonist	CHRNA7			Phase 2
SSR240612	bradykinin receptor antagonist				Preclinical
ST-1535	adenosine receptor antagonist				Preclinical
ST-1859	antiamyloidogenic agent				Phase 1
ST-2825	myeloid differentiation primary response inhibitor	MYD88			Preclinical
ST-91	adrenergic receptor agonist				Preclinical
STA-5326	interleukin synthesis inhibitor	IL12A			Phase 2
statil	aldose reductase inhibitor				Preclinical
stattic					Preclinical
STAT3-inhibitor-VI	STAT inhibitor	STAT3			Preclinical
stavudine	DNA directed DNA polymerase inhibitor, nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	Launched
stemregenin-1	aryl hydrocarbon receptor antagonist	AHR			Preclinical
stepronin	mucolytic agent				Launched
stetaderm					Launched
STF-083010	serine/threonine kinase inhibitor	ERN1			Preclinical
STF-118804	NAMPT inhibitor	NAMPT			Preclinical
STF-31	NAMPT inhibitor	NAMPT, SLC2A1			Preclinical
STF-62247	autophagy inducer				Preclinical
stigmasterol					Preclinical
stiripentol	GABA uptake inhibitor	GABRA3	neurology/psychiatry	epilepsy	Launched
stobadine	adrenergic receptor antagonist	ADRA1A			Phase 2
streptomycin	bacterial 30S ribosomal subunit inhibitor		infectious disease	tuberculosis	Launched
streptozotocin	DNA alkylating agent		oncology	pancreatic cancer	Launched
strontium-ranelate	bone formation stimulant, bone resorption inhibitor	CASR	orthopedics, rheumatology	osteoporosis, osteoarthritis	Launched
strychnine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA10, CHRNA9, GLRA1, GLRA2, GLRA3, GLRB			Preclinical
substance-P	neurokinin receptor antagonist	TACR1, TACR2, TACR3			Phase 1
succinic-acid		ALDH5A1, ASPH, BBOX1, HSD17B6, OXCT1, OXCT2, P3H1, P3H2, P3H3, P4HA1, P4HA2, PLOD1, PLOD3, SDHA, SDHB, SDHC, SDHD, SLC13A1, SLC13A2, SLC13A3, SLC25A10, SUCLA2, SUCLG1, SUCLG2, SUCNR1, TMLHE			Launched
succinobucol	antioxidant	VCAM1			Phase 2/Phase 3
succinylcholine-chloride		CHRFAM7A, CHRM1, CHRM2, CHRM3, CHRNA1, CHRNA10	neurology/psychiatry	muscle relaxant	Launched
succinylsulfathiazole	dihydrofolate reductase inhibitor	DHFR			Phase 2
sucralfate	antacid		gastroenterology	duodenal ulcer disease	Launched
sucralose					Launched
sucrose		ACTA1, ATOX1, C22orf28, LYZ			Launched
sucrose-octaacetate					Preclinical
sudan-IV					Preclinical
sufugolix	gonadotropin releasing factor hormone receptor antagonist				Preclinical
sugammadex	neuromuscular blockade reversal agent				Launched
sulbactam	beta lactamase inhibitor		infectious disease	skin infections, intra-abdominal infections, gynecologic infections	Launched
sulbactam-pivoxil	beta lactamase inhibitor		infectious disease	skin infections	Launched
sulbentine	other antifungal				Preclinical
sulbutiamine	acetylcholine receptor antagonist		neurology/psychiatry	asthenia	Launched
sulconazole	sterol demethylase inhibitor		infectious disease	tinea pedis, tinea cruris, tinea corporis	Launched
sulfabenzamide	bacterial antifolate		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	Launched
sulfacarbamide					Withdrawn
sulfacetamide	PABA antagonist		ophthalmology	conjunctivitis	Launched
sulfachlorpyridazine	bacterial antifolate		infectious disease	urinary tract infections	Launched
sulfadiazine	bacterial antifolate		infectious disease, ophthalmology	malaria, meningitis, urinary tract infections, conjunctivitis, trachoma, chancroid	Launched
sulfadoxine	dihydropteroate synthase inhibitor		infectious disease	malaria	Launched
sulfafurazole	bacterial antifolate		infectious disease	urinary tract infections	Launched
sulfaguanidine	bacterial antifolate		infectious disease	urinary tract infections	Launched
sulfamerazine	bacterial antifolate		infectious disease	coccidiosis, cholera	Launched
sulfameter	dihydrofolate reductase inhibitor	DHFR	infectious disease	urinary tract infections	Launched
sulfamethazine	PABA antagonist		gastroenterology	enteritis	Launched
sulfamethizole	bacterial antifolate		infectious disease	urinary tract infections	Launched
sulfamethoxazole	PABA antagonist		infectious disease, gastroenterology	pneumonia, enteritis, urinary tract infections	Launched
sulfamethoxypyridazine	bacterial antifolate				Withdrawn
sulfametopyrazine	PABA antagonist		infectious disease	malaria, urinary tract infections, respiratory tract infections	Launched
sulfamonomethoxine	bacterial antifolate		infectious disease	urinary tract infections	Launched
sulfamoxole	PABA antagonist		infectious disease	urinary tract infections	Launched
sulfanilamide	carbonic anhydrase inhibitor	CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4	infectious disease	vulvovaginal candidiasis	Launched
sulfanilate-zinc					Preclinical
sulfanitran			infectious disease	coccidiosis	Launched
sulfaphenazole	dihydropteroate synthetase inhibitor	DHPS	infectious disease	urinary tract infections	Launched
sulfapyridine	PABA antagonist		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	Launched
sulfaquinoxaline	vitamin K antagonist		infectious disease	coccidiosis	Launched
sulfasalazine	cyclooxygenase inhibitor	ACAT1, ALOX5, CHUK, IKBKB, PLA2G1B, PPARG, PTGS1, PTGS2, SLC46A1, SLC7A11, TBXAS1	gastroenterology	ulcerative colitis	Launched
sulfathiazole	dihydropteroate synthase inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	Launched
sulfatinib	tyrosine kinase inhibitor				Phase 1
sulfinpyrazone	uricosuric blocker	ABCC1, FPR1, SLC22A12	rheumatology	gout	Launched
sulfisomidin	antibacterial				Preclinical
sulfisoxazole-acetyl	folic acid antagonist		infectious disease, otolaryngology	meningitis, urinary tract infections, otitis, trachoma	Launched
sulforaphane	anticancer agent, aryl hydrocarbon receptor antagonist	NFE2L2			Phase 2
sulindac	cyclooxygenase inhibitor	AKR1B1	rheumatology	osteoarthritis, rheumatoid arthritis, ankylosing spondylitis	Launched
sulisobenzone			dermatology	sunscreen lotion	Launched
sulmazole	adenosine receptor antagonist				Phase 1
sulmetozine	gastrin inhibitor	GAST	gastroenterology	peptic ulcer disease (PUD)	Launched
suloctidil	adrenergic receptor antagonist				Withdrawn
sulopenem	antibacterial				Phase 3
sulphadimethoxine	dihydropteroate synthetase inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	Launched
sulpiride	dopamine receptor antagonist		neurology/psychiatry	schizophrenia	Launched
sultamicillin	antibacterial 		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	Launched
sultiame	carbonic anhydrase inhibitor	CA2			Phase 3
sultopride	dopamine receptor antagonist				Preclinical
sumanirole	dopamine receptor agonist	DRD2			Phase 3
sumatriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR5A, HTR6, HTR7	neurology/psychiatry	migraine headache	Launched
SUN-B-8155	calcitonin agonist	CALCR			Preclinical
SUN-11602	fibroblast growth factor mimetic	FGFR1			Preclinical
sunitinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET	oncology	gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)	Launched
suplatast	histamine release inhibitor, immunoglobulin inhibitor		rheumatology	Kimura's disease	Launched
suprofen	cyclooxygenase inhibitor	PTGS1, PTGS2			Withdrawn
suramin	DNA synthesis inhibitor	F2, FSHR, P2RY1, P2RY11, P2RY13, P2RY2, PLA2G2A, RYR1, RYR2, SIRT5	infectious disease	African trypanosomiasis, onchocerciasis	Launched
suritozole	GABA receptor inverse agonist	GABBR1			Phase 2
sutezolid	protein synthesis inhibitor				Phase 2
suxibuzone	cyclooxygenase inhibitor		rheumatology, neurology/psychiatry	joint pain, muscle pain	Launched
SU014813	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	KDR			Phase 2
SU11274	hepatocyte growth factor receptor inhibitor, tyrosine kinase inhibitor	MET			Preclinical
SU16f	PDGFR tyrosine kinase receptor inhibitor	PDGFRB			Preclinical
SU3327	JNK inhibitor	MAPK8			Preclinical
SU4312	PDGFR tyrosine kinase receptor inhibitor, tyrosine kinase inhibitor, VEGFR inhibitor	KDR, PDGFRB			Preclinical
SU9516	CDK inhibitor	CDK1, CDK2, CDK4, CDK5			Preclinical
swainsonine	alpha mannosidase inhibitor	MAN2A1			Phase 2
SX-011	MAP kinase inhibitor	MAPK14			Preclinical
SY-640					Phase 2
SYM-2081	kainate receptor antagonist	GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, SLC1A2			Preclinical
SYM-2206	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4			Preclinical
symclosene					Preclinical
synephrine	adrenergic receptor agonist	ADRA1A	otolaryngology	sinusitis	Launched
S1P1-agonist-III	sphingosine kinase inhibitor	S1PR1			Preclinical
S15535	serotonin receptor agonist				Preclinical
S18986	glutamate receptor modulator	GRIA1, GRIA2, GRIA3, GRIA4			Phase 2
S26948	PPAR receptor agonist	PPARG			Preclinical
S4	carbonic anhydrase inhibitor	CA12, CA9			Preclinical
S49076	tyrosine kinase inhibitor				Preclinical
S63845	MCL1 inhibitor				Preclinical
T-0070907	PPAR receptor antagonist	PPARG			Preclinical
T-0156	phosphodiesterase inhibitor	PDE5A			Preclinical
T-025	CLK inhibitor				Preclinical
T-0901317	LXR agonist	NCOA1, NCOA2, NR1H2, NR1H3, NR1I2, RXRB			Preclinical
T-1095	sodium/glucose cotransporter inhibitor				Preclinical
T-5224	AP inhibitor	JUN			Phase 2
T-5601640	LIM kinase inhibitor	LIMK2			Preclinical
T-62	adenosine receptor modulator	ADORA2A			Phase 2
T-807	PET radiotracer				Phase 2
TA-01	casein kinase inhibitor, MAP kinase inhibitor	CSNK1D, CSNK1E, MAPK14			Preclinical
tabimorelin	growth hormone secretagogue receptor agonist	GHSR			Phase 2
tacalcitol	vitamin D receptor agonist	VDR	dermatology	psoriasis, chapped lips	Launched
tacedinaline	HDAC inhibitor	HDAC1			Phase 3
tacrine	acetylcholinesterase inhibitor	ACHE, BCHE	neurology/psychiatry	Alzheimer's disease	Launched
tacrolimus	calcineurin inhibitor	FKBP1A	transplant	organ rejection	Launched
tadalafil	phosphodiesterase inhibitor	PDE11A, PDE5A	urology	erectile dysfunction	Launched
tafamidis-meglumine	transthyretin amyloid inhibitor	TTR	neurology/psychiatry	familial amyloid polyneuropathy (FAP)	Launched
tafenoquine	antimalarial agent		infectious disease	malaria	Launched
tafluprost	prostaglandin inhibitor	PTGFR	ophthalmology	glaucoma, ocular hypertension	Launched
tagatose	phosphorylase inhibitor	PYGL			Launched
TAK-063	phosphodiesterase inhibitor	PDE10A			Phase 2
TAK-220	CC chemokine receptor antagonist	CCR5			Phase 1
TAK-243	ubiquitin activating enzyme inhibitor				Phase 1
TAK-285	EGFR inhibitor	ERBB2			Phase 1
TAK-593	VEGFR inhibitor	PDGFRA			Phase 1
TAK-632	RAF inhibitor	BRAF			Preclinical
TAK-659	spleen associated tyrosine kinase inhibitor				Phase 2
TAK-715	p38 MAPK inhibitor	MAPK14			Phase 2
TAK-733	MEK inhibitor	MAP2K1			Phase 1
TAK-779	CC chemokine receptor antagonist				Preclinical
TAK-875	insulin secretagogue	FFAR1			Phase 3
TAK-901	Aurora kinase inhibitor	AURKB			Phase 1
TAK-960	PLK inhibitor	PLK1			Phase 1
talabostat	dipeptidyl peptidase inhibitor, fibroblast activation protein inhibitor	DPP4			Phase 3
taladegib	smoothened receptor antagonist	DHH, IHH, SMO			Phase 2
talampanel	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4			Phase 2
talaporfin	photosensitizing agent				Phase 3
talarozole	cytochrome P450 inhibitor	CYP26A1			Phase 2
talazoparib	PARP inhibitor	PARP2	oncology	breast cancer	Launched
talinolol	adrenergic receptor antagonist	ADRB1	cardiology	hypertension	Launched
talipexole	adrenergic receptor agonist, dopamine receptor agonist	ADRA2A, DRD2, HTR3A	infectious disease	genitial herpes	Launched
talmapimod	p38 MAPK inhibitor	IL1B, MAPK11, MAPK14, MT-CO2, TNF			Phase 2
talnetant	tachykinin antagonist	TACR2, TACR3			Phase 2
talniflumate	cyclooxygenase inhibitor	CLCA1	neurology/psychiatry	pain relief	Launched
talopram	adrenergic inhibitor	SLC6A2			Phase 2
talsaclidine	acetylcholine receptor agonist				Phase 2/Phase 3
taltirelin	thyrotropin releasing hormone receptor agonist	TRHR	neurology/psychiatry	spinocerebellar ataxia	Launched
taltobulin	tubulin polymerization inhibitor				Phase 1
TAME					Preclinical
tamibarotene	retinoid receptor agonist	RARA, RARB	hematologic malignancy	acute promyelocytic leukemia (APL)	Launched
taminadenant	adenosine receptor antagonist				Phase 1/Phase 2
tamoxifen	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	EBP, ESR1, ESR2, GPER1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCI, PRKCQ, PRKCZ	oncology	breast cancer	Launched
tamsulosin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D	urology	benign prostatic hyperplasia (BPH)	Launched
tanaproget	progesterone receptor agonist	PGR			Phase 2
tandospirone	serotonin receptor agonist	HTR1A	neurology/psychiatry	generalized anxiety disorder (GAD), dysthymic disorder	Launched
tandutinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	CSF1R, FLT3, KIT, PDGFD, PDGFRB			Phase 2
tanespimycin	HSP inhibitor	HSP90AA1			Phase 3
tangeritin	cell cycle inhibitor				Preclinical
tannic-acid	PARG inhibitor	ANO1	gastroenterology	constipation	Launched
tanshinone-I	AP inhibitor	IFNG			Phase 2
tanshinone-IIA	anti-inflammatory agent, interleukin inhibitor	IL1B, NR1I2, TNF			Phase 2/Phase 3
tapinarof	aryl hydrocarbon receptor agonist				Phase 3
taprenepag	prostaglandin receptor agonist	PTGER2			Phase 2
tarafenacin	acetylcholine receptor antagonist	CHRM3			Phase 2
taranabant	cannabinoid receptor inverse agonist	CNR1			Phase 3
targinine	nitric oxide synthase inhibitor	NOS3			Phase 3
tariquidar	P glycoprotein inhibitor	ABCB1			Phase 3
tartaric-acid	antioxidant				Launched
TAS-103	topoisomerase inhibitor	TOP1			Phase 1
taselisib	PI3K inhibitor	PIK3CA			Phase 3
tasimelteon	melatonin receptor agonist	MTNR1A, MTNR1B	neurology/psychiatry	Non-24-Hour Sleep-Wake Disorder	Launched
tasisulam	apoptosis stimulant				Phase 3
tasquinimod	angiogenesis inhibitor, S100A9 inhibitor	HDAC4			Phase 3
tasuldine	mucolytic agent				Phase 3
taurine	antioxidant		neurology/psychiatry	anxiety, irritability, sleeplessness	Launched
taurocholate	G protein-coupled receptor agonist	CEL, FABP6, SLCO1C1			Phase 1
tauroglycocholate	membrane permeability enhancer				Preclinical
taurolidine	apoptosis stimulant		infectious disease	catheter-related bloodstream infection	Launched
tavaborole	leucyl-tRNA synthetase inhibitor		infectious disease	onychomycosis	Launched
tavilermide	tyrosine kinase partial agonist				Phase 3
taxifolin	opioid receptor antagonist	ADIPOR2			Phase 2
tazarotene	retinoid receptor agonist	RARA, RARB, RARG, RXRB	dermatology	cosmetic, sunscreen lotion	Launched
tazemetostat	histone lysine methyltransferase inhibitor	EZH2			Launched
tazobactam	beta lactamase inhibitor		infectious disease	pneumonia	Launched
TBA-354					Phase 1
TBOA-(DL)	excitatory amino acid transporter inhibitor	SLC1A1, SLC1A2, SLC1A3, SLC1A6, SLC1A7			Preclinical
TC-A-2317	Aurora kinase inhibitor	AURKA			Preclinical
TC-ASK-10	MAP kinase inhibitor	MAP3K5, MAP3K6			Preclinical
TC-E-5002	histone demethylase inhibitor	KDM2A, KDM4A, KDM4C, KDM5A, KDM6A, KDM7A, PHF8			Preclinical
TC-E-5006	gamma secretase modulator	APP			Preclinical
TC-F-2	FAAH inhibitor	FAAH			Preclinical
TC-FPR-43	formyl peptide receptor agonist	FPR2			Preclinical
TC-G-1000	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C			Preclinical
TC-G-1004	adenosine receptor antagonist	ADORA2A			Preclinical
TC-G-1005	G protein-coupled receptor agonist	GPBAR1			Preclinical
TC-G-1008	G protein-coupled receptor agonist	GPR39			Preclinical
TC-H-106	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC8			Preclinical
TC-I-15	integrin inhibitor	ITGA2, ITGB1			Preclinical
TC-I-2000	transient receptor potential channel antagonist	TRPM8			Preclinical
TC-I-2014	transient receptor potential channel antagonist	TRPM8			Preclinical
TC-LPA5-4	lysophosphatidic acid receptor antagonist	LPAR5			Preclinical
TC-Mps1-12	monopolar spindle 1 kinase inhibitor	TTK			Preclinical
TC-N-1752	sodium channel blocker	SCN9A			Preclinical
TC-NTR1-17	neurotensin agonist	NTSR1			Preclinical
TC-O-9311	G protein-coupled receptor agonist	GPR139			Preclinical
TC-OT-39	oxytocin receptor agonist, vasopressin receptor agonist	AVPR1A, OXT			Preclinical
TC-S-7003	SRC inhibitor	LCK			Preclinical
TC-S-7004	DYRK inhibitor	DYRK1A, DYRK1B			Preclinical
TC-S-7005	PLK inhibitor	PLK2			Preclinical
TC-S-7006	MAP kinase inhibitor	MAP3K8			Preclinical
TC-S-7009	hypoxia inducible factor inhibitor	EPAS1			Preclinical
TC-SP-14	sphingosine 1-phosphate receptor agonist	S1PR1			Preclinical
TCID					Preclinical
TCN201	glutamate receptor antagonist	GRIN2A			Preclinical
TCN238	glutamate receptor positive allosteric modulator	GRM4			Preclinical
TCS-HDAC6-20b	HDAC inhibitor	HDAC6			Preclinical
TCS-OX2-29	orexin receptor antagonist	HCRTR2			Preclinical
TCS-PIM-1-1	Pim kinase inhibitor	PIM1			Preclinical
TCS-2002	glycogen synthase kinase inhibitor	GSK3B			Preclinical
TCS-21311	JAK inhibitor	JAK3			Preclinical
TCS-2210	neural stem cell inducer				Preclinical
TCS-2314	integrin inhibitor	ITGA4, ITGB1			Preclinical
TCS-3035	G protein-coupled receptor agonist	GPR35			Preclinical
TCS-359	FLT3 inhibitor	FLT3			Preclinical
TCS-5861528	transient receptor potential channel antagonist	TRPA1			Preclinical
TCV-309	platelet activating factor receptor antagonist				Preclinical
TC1	beta-secretase inhibitor	BACE1			Preclinical
TC2559	acetylcholine receptor agonist	CHRNA4			Preclinical
TD139	anti-inflammatory agent				Phase 2
tebipenem	bacterial cell wall synthesis inhibitor	CNR1	infectious disease, otolaryngology	pneumonia, otitis	Launched
tecadenoson	adenosine receptor agonist	ADORA1			Phase 2
tecalcet	calcium-sensing receptor agonist	CASR			Phase 2
tecastemizole	histamine receptor antagonist	KCNH2			Phase 3
tecovirimat	orthopoxvirus egress inhibitor		infectious disease	smallpox	Launched
tedizolid	bacterial 50S ribosomal subunit inhibitor		infectious disease	skin infections	Launched
tedizolid-phosphate	protein synthesis inhibitor		infectious disease	skin infections	Launched
tegaserod	serotonin receptor partial agonist	HTR2A, HTR2B, HTR2C, HTR4			Withdrawn
tegobuvir	HCV inhibitor, protease inhibitor				Phase 3
teicoplanin	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	Launched
teicoplanin-A2-1	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	Launched
teicoplanin-A2-3	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	Launched
teijin-compound-1	CC chemokine receptor antagonist	CCR2			Preclinical
telaprevir	HCV inhibitor	CTSA, PGR	infectious disease	hepatitis C	Launched
telatinib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	KDR			Phase 2
telbivudine	DNA polymerase inhibitor		infectious disease	hepatitis B	Launched
telcagepant	calcitonin antagonist	CALCRL, RAMP1			Phase 3
telenzepine	acetylcholine receptor antagonist	CHRM1			Phase 3
telithromycin	bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor	CYP1A2, CYP2D6, CYP3A4, CYP3A5, CYP3A7	infectious disease	pneumonia	Launched
telmesteine	mucolytic agent		pulmonary	cough suppressant	Launched
telmisartan	angiotensin receptor antagonist	AGTR1, PPARG	cardiology	hypertension	Launched
telotristat	tryptophan hydroxylase inhibitor	TPH1	gastroenterology	diarrhea	Launched
telotristat-ethyl	tryptophan hydroxylase inhibitor	TPH1	gastroenterology	diarrhea	Launched
telratolimod	toll-like receptor agonist				Preclinical
temanogrel	serotonin receptor antagonist				Preclinical
temefos	cholinesterase inhibitor				Launched
temocapril	angiotensin converting enzyme inhibitor	ACE	cardiology, nephrology	hypertension, congestive heart failure, diabetic nephropathy, coronary artery disease (CAD)	Launched
temoporfin	radical formation stimulant		oncology	head and neck squamous cell carcinoma (HNSCC)	Launched
temozolomide	DNA alkylating agent	MGMT	oncology	glioblastoma, astrocytoma	Launched
tempol	free radical scavenger				Phase 2
temsirolimus	mTOR inhibitor	MTOR	oncology	renal cell carcinoma (RCC)	Launched
TEN-010	bromodomain inhibitor				Preclinical
tenalisib	PI3K inhibitor				Phase 2
tenapanor	sodium/hydrogen exchanger inhibitor				Launched
tenatoprazole	ATPase inhibitor	IDO1			Phase 2
teneligliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	Launched
tenidap	cyclooxygenase inhibitor	KCNJ4, PTGS1			Phase 3
tenilsetam	AGE inhibitor				Phase 3
teniposide	topoisomerase inhibitor	TOP2A, TOP2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	Launched
tenofovir	HIV integrase inhibitor, nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1), hepatitis B	Launched
tenofovir-alafenamide	nucleoside reverse transcriptase inhibitor		infectious disease	hepatitis B	Launched
tenofovir-disoproxil	nucleoside reverse transcriptase inhibitor	CYP1A2	infectious disease	human immunodeficiency virus (HIV-1), hepatitis B	Launched
tenovin-1	SIRT inhibitor, TP53 activator	SIRT1			Preclinical
tenovin-6	SIRT inhibitor	SIRT1, SIRT2, SIRT3			Preclinical
tenoxicam	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology, orthopedics	rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendinitis, bursitis, periarthritis	Launched
tenylidone					Preclinical
tepoxalin	cyclooxygenase inhibitor, lipoxygenase inhibitor	ALOX5	rheumatology, orthopedics	rheumatoid arthritis, hip dysplasia	Launched
TEPP-46	pyruvate kinase isozyme activator	PKM			Preclinical
teprenone	mucus protecting agent		dermatology	cosmetic	Launched
terameprocol	lipoxygenase inhibitor	BIRC5, CDK1			Phase 1/Phase 2
terazosin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D	urology, cardiology	benign prostatic hyperplasia (BPH), hypertension	Launched
terbinafine	fungal squalene epoxidase inhibitor	SQLE	infectious disease	tinea pedis, tinea cruris, tinea corporis	Launched
terbutaline	adrenergic receptor agonist	ADRB2	pulmonary	bronchospasm, bronchitis, emphysema	Launched
terciprazine					Phase 1
terconazole	sterol demethylase inhibitor		infectious disease	vulvovaginal candidiasis	Launched
terfenadine	histamine receptor antagonist	HRH1, KCNH1, KCNH2			Withdrawn
terguride	dopamine receptor agonist, serotonin receptor antagonist	ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD2, DRD3, DRD4, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C	neurology/psychiatry	Parkinson's Disease	Launched
teriflunomide	dihydroorotate dehydrogenase inhibitor	DHODH	neurology/psychiatry	multiple sclerosis	Launched
terlipressin	vasopressin receptor agonist	AVPR1A	cardiology	hypotension	Launched
terodiline	cholinergic receptor antagonist				Withdrawn
teroxirone	DNA inhibitor				Phase 1
terpene					Preclinical
terreic-acid-(-)	Bruton's tyrosine kinase (BTK) inhibitor	BTK			Preclinical
terutroban	prostanoid receptor antagonist	TBXA2R			Phase 3
tesaglitazar	insulin sensitizer, PPAR receptor agonist	PPARA, PPARG			Phase 3
tetomilast	phosphodiesterase inhibitor	PDE4D			Phase 2
tetrabenazine	vesicular monoamine transporter inhibitor	SLC18A1, SLC18A2	infectious disease, neurology/psychiatry	cholera, Huntington's disease	Launched
tetracaine	membrane integrity inhibitor	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	anesthetic	Launched
tetracycline	bacterial 30S ribosomal subunit inhibitor		infectious disease, dermatology	respiratory tract infections, pneumonia, skin infections, urinary tract infections, acne vulgaris (AV), plague, psittacosis	Launched
tetradecylthioacetic-acid	lipid peroxidase inhibitor				Phase 2
tetraethylenepentamine	superoxide dismutase inhibitor	SOD1, SOD2			Phase 2/Phase 3
tetrahydrofolic-acid		FOLR2			Launched
tetrahydropapaverine					Preclinical
tetrahydrouridine	cytidine deaminase inhibitor	CDA			Phase 2
tetrahydrozoline	adrenergic receptor agonist		ophthalmology	eye irritation	Launched
tetramethylthiuram-monosulfide					Preclinical
tetramisole	immunostimulant	ALPPL2, CHRNA3	infectious disease	gastrointestinal parasites	Launched
tetrandrine	calcium channel blocker	SLC6A3			Preclinical
tetrazol-5-yl-glycine-(RS)	glutamate receptor agonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			Preclinical
tetrindole	monoamine oxidase inhibitor	MAOA			Phase 3
tetroquinone					Preclinical
tezacaftor	CFTR channel agonist		pulmonary	cystic fibrosis	Launched
TFC-007	prostaglandin inhibitor	HPGDS			Preclinical
TG-003	CLK inhibitor	CLK1, CLK4, DYRK1A, DYRK1B			Preclinical
TG-02	CDK inhibitor, FLT3 inhibitor, JAK inhibitor	CDK1, CDK2, CDK7, CDK9, FLT3, JAK2			Phase 1/Phase 2
TG-100572	SRC inhibitor, VEGFR inhibitor	KDR, SRC			Preclinical
TG-100713	PI3K inhibitor				Preclinical
TG-100801	SRC inhibitor, VEGFR inhibitor	CSK, FGFR1, FLT1, FLT4, KDR, SRC			Phase 2
TG-101209	JAK inhibitor	JAK2, JAK3			Preclinical
TGR-1202	PI3K inhibitor				Phase 3
TGX-221	PI3K inhibitor	PIK3CB, PIK3CD			Preclinical
TG100-115	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			Phase 1/Phase 2
TH-302	DNA alkylating agent				Phase 3
TH-588	MTH1 inhibitor	NUDT1			Preclinical
thaliblastine	DNA inhibitor				Phase 2
thalidomide	tumor necrosis factor production inhibitor	TNF	oncology	myeloma	Launched
theaflavin	antiviral				Preclinical
theobromine	phosphodiesterase inhibitor	ADORA1, ADORA2A, PDE4B			Launched
thiamet-g	GLCNAC phosphotransferase inhibitor	MGEA5			Preclinical
thiamine	vitamin B	SLC19A2, SLC19A3, TPK1	metabolism	thiamine deficiency	Launched
thiamine-pyrophosphate			hematology	anemia	Launched
thiamphenicol	bacterial 50S ribosomal subunit inhibitor		infectious disease	pelvic inflammatory disease	Launched
thiamylal	glutamate receptor antagonist	GABRA1	neurology/psychiatry	sedative	Launched
thiazovivin	rho associated kinase inhibitor				Preclinical
thiethylperazine	dopamine receptor antagonist	DRD1, DRD2, DRD4	gastroenterology	nausea	Launched
thiocolchicoside	GABA receptor antagonist	GABRA1, GABRB2, GABRG2, GLRA1, GLRB	neurology/psychiatry	muscle relaxant	Launched
thioctic-acid	reducing agent	ACHE, PTGS2	nephrology	diabetic nephropathy	Launched
thiodiglycol					Preclinical
thioguanine	purine antagonist	IMPDH1, IMPDH2	hematologic malignancy	acute myeloid leukemia (AML)	Launched
thiomersal	other antibiotic	OXCT1	infectious disease	preservative	Launched
thiopental	GABA receptor antagonist	FAAH	neurology/psychiatry	anesthetic	Launched
thioperamide	histamine receptor antagonist	HRH3, HRH4			Preclinical
thiophanate					Preclinical
thioproperazine	dopamine receptor antagonist	ADRA1A, ADRA1B, DRD1, DRD2, HTR1A, HTR2A	neurology/psychiatry	schizophrenia	Launched
thioridazine	dopamine receptor antagonist	DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7			Withdrawn
thiorphan	membrane metalloendopeptidase inhibitor	MME			Phase 1
thiostrepton	FOXM1 inhibitor, protein synthesis inhibitor	FOXM1	obstetrics/gynecology	mastitis	Launched
thiotepa	cytochrome P450 inhibitor	CYP2B6, CYP3A4	oncology	breast cancer, ovarian cancer, bladder cancer	Launched
thiothixene	dopamine receptor antagonist	DRD1, DRD2, HRH1, HTR2A	neurology/psychiatry	schizophrenia	Launched
thiram		JAK2	ophthalmology	contact dermatitis	Launched
THK5351	PET radiotracer 				Phase 2
thonzonium	ATPase inhibitor		infectious disease	ear infections	Launched
thonzylamine	antihistamine		neurology/psychiatry	itching	Launched
threo-2-methylisocitrate-(DL)	isocitrate lyase substrate				Preclinical
thymalfasin	immune response modulator		infectious disease	hepatitis B, hepatitis C	Launched
thymol	GABA receptor positive allosteric modulator	TRPA1	infectious disease	ringworm, antiseptic	Launched
thymol-iodide					Preclinical
thymopentin	immune response stimulator				Launched
THZ1	CDK inhibitor	CDK7			Preclinical
THZ1-R	CDK inhibitor	CDK7			Preclinical
THZ2	CDK inhibitor	CDK7			Preclinical
tiabendazole	angiogenesis inhibitor		infectious disease	gastrointestinal roundworms, hookworm	Launched
tiagabine	GABA uptake inhibitor	SLC6A1	neurology/psychiatry	seizures	Launched
tianeptine	selective serotonin reuptake enhancer (SSRE)	OPRD1, OPRK1, OPRM1	neurology/psychiatry, pulmonary, gastroenterology	depression, asthma, irritable bowel syndrome	Launched
tiapride	dopamine receptor antagonist	DRD2, DRD3	neurology/psychiatry	dyskinesia, abstinence from alcohol, psychosis	Launched
tiaprofenic-acid	cyclooxygenase inhibitor	PTGS2	rheumatology	rheumatoid arthritis	Launched
tiaramide	anti-inflammatory agent		pulmonary	asthma	Launched
tibolone	androgen receptor agonist, estrogen receptor agonist, progesterone receptor agonist	ESR1	obstetrics/gynecology	endometriosis	Launched
ticagrelor	purinergic receptor antagonist	P2RY12	cardiology	acute coronary syndrome (ACS), myocardial infarction	Launched
ticarcillin	lactamase inhibitor		infectious disease	gram-negative bacterial infections	Launched
ticlopidine	purinergic receptor antagonist	P2RY12	hematology, neurology/psychiatry	thrombosis, stroke	Launched
TIC10	AKT inhibitor, TRAIL modulator	AKT1, MAPK1			Phase 2
tideglusib	glycogen synthase kinase inhibitor	GSK3B			Phase 2
tienilic-acid	cytochrome P450 inhibitor, sodium/potassium/chloride transporter inhibitor	CYP2C9, SLC12A1			Withdrawn
tie2-kinase-inhibitor	TIE tyrosine kinase inhibitor	KDR, MAPK14			Preclinical
tifenazoxide	ATP-sensitive potassium channel agonist	ABCC8, KCNJ11			Phase 1
tigecycline	bacterial 30S ribosomal subunit inhibitor		infectious disease	skin infections, pneumonia, intra-abdominal infections	Launched
tilmicosin	bacterial 50S ribosomal subunit inhibitor		pulmonary	bovine respiratory disease (BRD)	Launched
tilorone	interferon inducer		infectious disease, gastroenterology, neurology/psychiatry	influenza A virus infection, diarrhea, hepatitis B, multiple sclerosis, urinary tract infections, virus herpes simplex (HSV), hepatitis C	Launched
tiludronate	bone resorption inhibitor, osteoclast inhibitor	ATP6V1A, MMP2, PTPN1	orthopedics	navicular syndrome	Launched
timofibrate	cholesterol inhibitor, lipase clearing factor inhibitor	LPL			Phase 2
timolol	adrenergic receptor antagonist	ADRB1, ADRB2	ophthalmology	ocular hypertension, glaucoma	Launched
timonacic	antioxidant				Launched
tinazoline	adrenergic receptor agonist				Launched
tinidazole	antiprotozoal agent		infectious disease, obstetrics/gynecology	giardiasis, amebiasis, bacterial vaginosis, trichomoniasis	Launched
tinoridine	anti-inflammatory agent		neurology/psychiatry	pain relief	Launched
tioconazole	sterol demethylase inhibitor		infectious disease	yeast infection	Launched
tioguanine	purine antagonist		hematologic malignancy	acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML)	Launched
tiopronin	chelating agent, reducing agent		urology	kidney stones	Launched
tiotidine	histamine receptor antagonist	HRH2			Phase 2
tiotropium	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	pulmonary	chronic obstructive pulmonary disease (COPD), bronchitis, emphysema	Launched
tioxolone	carbonic anhydrase inhibitor	CA2			Preclinical
tipelukast	leukotriene receptor antagonist				Phase 2
tipifarnib	farnesyltransferase inhibitor	FNTA, FNTB			Phase 3
tipiracil	thymidine phosphorylase inhibitor		oncology	colorectal cancer	Launched
tiplaxtinin	plasminogen activator inhibitor	SERPINE1			Phase 1
tipranavir	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	Launched
tiprenolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3			Phase 2
tiquizium	acetylcholine receptor antagonist		neurology/psychiatry	spasms	Launched
tiracizine	sodium channel blocker	SCN5A			Withdrawn
tirapazamine	DNA inhibitor				Phase 3
tirasemtiv	troponin activator				Phase 2
tiratricol	thyroid hormone stimulant	THRA, THRB	endocrinology	Refetoff syndrome	Launched
tirofiban	platelet aggregation inhibitor, structural glycoprotein antagonist	ITGA2B, ITGB3	cardiology	myocardial infarction, refactory angina	Launched
titanocene-dichloride	apoptosis stimulant				Phase 2
tivantinib	tyrosine kinase inhibitor	MET			Phase 3
tivozanib	VEGFR inhibitor	FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB	oncology	renal cell carcinoma (RCC)	Launched
tizanidine	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C, NISCH	neurology/psychiatry	spasms	Launched
TMC-353121	RSV fusion inhibitor				Phase 2
TMC647055	RNA polymerase inhibitor				Phase 2
TMN-355	cyclophilin inhibitor	PPIA			Preclinical
TMPH					Preclinical
TMS					Preclinical
TNP-470	methionine aminopeptidase inhibitor	METAP2			Phase 2
tobramycin	bacterial 30S ribosomal subunit inhibitor		infectious disease	bacterial septicemia, respiratory tract infections, meningitis, skin infections, urinary tract infections	Launched
tocainide	sodium channel blocker	SCN5A	cardiology	cardiac arrythmia	Launched
toceranib	protein tyrosine kinase inhibitor	FLT1, FLT3, KDR, PDGFRA, PDGFRB	oncology	cutaneous mast cell tumors	Launched
tocofersolan	antioxidant		cardiology	cerebral cholesterosis	Launched
todralazine	antihypertensive agent		cardiology	hypertension	Launched
tofacitinib	JAK inhibitor	JAK1, JAK2, JAK3	rheumatology	rheumatoid arthritis	Launched
tofisopam	cytochrome P450 inhibitor, phosphodiesterase inhibitor	CYP3A4	neurology/psychiatry	anxiety, abstinence from alcohol	Launched
tofogliflozin	sodium/glucose cotransporter inhibitor	GCK	endocrinology	diabetes mellitus	Launched
tolamolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3			Phase 3
tolazamide	ATP channel blocker	ABCC8, KCNJ1, KCNJ10, KCNJ11	endocrinology	diabetes mellitus	Launched
tolazoline	adrenergic receptor antagonist	ADRA1A, ADRA2A, ADRA2B, ADRA2C, HRH1, HRH2	neurology/psychiatry	reverse sedative	Launched
tolbutamide	ATP channel blocker	ABCC8, KCNJ1, KCNJ11, KCNJ8	endocrinology	diabetes mellitus	Launched
tolcapone	catechol O methyltransferase inhibitor	COMT			Withdrawn
tolfenamic-acid	cyclooxygenase inhibitor, prostanoid receptor antagonist		neurology/psychiatry	migraine headache	Launched
tolimidone	SRC activator	LYN, SRC			Phase 2
tolmetin	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	rheumatoid arthritis, osteoarthritis	Launched
tolnaftate	fungal squalene epoxidase inhibitor		infectious disease	tinea pedis, tinea corporis	Launched
tolonidine	adrenergic receptor antagonist	ADRA2A			Launched
tolonium			hematology	methemoglobinemia	Launched
toloxatone	monoamine oxidase inhibitor	MAOA, MAOB	neurology/psychiatry	depression	Launched
tolperisone	voltage-gated sodium channel blocker	CYP2C19, CYP2D6	neurology/psychiatry, infectious disease, rheumatology, cardiology	muscle relaxant, multiple sclerosis, encephalomyelitis, ankylosing spondylitis, atherosclerosis, Raynaud's disease	Launched
tolrestat	aldose reductase inhibitor	AKR1A1, AKR1B1, AKR1B10			Withdrawn
tolterodine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence, urinary frequency	Launched
toltrazuril	antiprotozoal agent		infectious disease	coccidiosis	Launched
tolvaptan	vasopressin receptor antagonist	AVPR1A, AVPR2	endocrinology, cardiology, gastroenterology	hyponatremia, congestive heart failure, hepatic cirrhosis	Launched
tomeglovir	antiviral				Preclinical
tomelukast	leukotriene receptor antagonist	CYSLTR1			Phase 3
tomivosertib	MAPK-interacting kinase inhibitor				Phase 2
tonabersat	gap junction modulator, nitric oxide production inhibitor				Phase 2
topilutamide	androgen receptor antagonist				Preclinical
topiramate	carbonic anhydrase inhibitor, glutamate receptor antagonist, kainate receptor antagonist	CA1, CA12, CA2, CA4, CA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	epilepsy, migraine headache	Launched
topiroxostat	xanthine oxidase inhibitor	XDH	rheumatology, nephrology	gout, hyperuricemia	Launched
topotecan	topoisomerase inhibitor	TOP1, TOP1MT	oncology	small cell lung cancer, cervical cancer	Launched
torasemide	electrolyte reabsorption inhibitor, thromboxane receptor antagonist	SLC12A1	cardiology	edema, congestive heart failure, hypertension	Launched
torcetrapib	cholesteryl ester transfer protein inhibitor	CETP			Phase 3
torcitabine	DNA polymerase inhibitor	DCK, TK2			Phase 2
toremifene	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	ESR1	oncology	breast cancer	Launched
torin-1	mTOR inhibitor	MTOR			Preclinical
torin-2	mTOR inhibitor	MTOR			Preclinical
tosedostat	peptidase inhibitor	ANPEP, LAP3, NPEPPS			Phase 2
tosufloxacin	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	Launched
toyocamycin	serine/threonine kinase inhibitor	ERN1			Phase 1
tozadenant	adenosine receptor antagonist	ADORA2A			Phase 3
tozasertib	Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor	AURKA, AURKB, AURKC, LCK			Phase 2
TP-003	GABA receptor inverse agonist	GABRA1, GABRA2, GABRA3, GABRA5			Preclinical
TP-0903	AXL kinase inhibitor	AXL			Phase 1/Phase 2
TP-3654	1,4,5-trisphosphate inhibitor				Phase 1
TPCA-1	IKK inhibitor	IKBKB			Preclinical
TPPS4					Phase 1
trabectedin	antitumor agent				Phase 3
trabodenoson	adenosine receptor agonist				Phase 3
tracazolate	GABA receptor modulator	GABRA1			Phase 2
tradipitant	neurokinin receptor antagonist				Phase 3
TRAM-34	potassium channel antagonist	KCNN4			Preclinical
TRAM-39	calcium-activated potassium channel activator	KCNN4			Preclinical
trametinib	MEK inhibitor	MAP2K1, MAP2K2	oncology	melanoma	Launched
tramiprosate	beta amyloid protein neurotoxicity inhibitor	APP			Phase 3
trandolapril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, myocardial infarction	Launched
tranexamic-acid	antifibrinolytic, plasminogen activator inhibitor	PLG	hematology	hemophilia	Launched
tranilast	angiogenesis inhibitor	HPGDS, HRH1	pulmonary	asthma	Launched
trans-10,cis-12-conjugated-linoleic-acid					Launched
trans-2-undecenoic-acid					Preclinical
trans-4-[8-(3-fluorophenyl)-1,7-naphthyridin-6-yl]cyclohexanecarboxylic-acid					Preclinical
trans-4-hydroxycrotonic-acid	gamma hydroxybutyric acid ligand				Preclinical
trans-4-methoxycinnamic-acid					Preclinical
transcrocetinate	glutamate receptor antagonist				Preclinical
tranylcypromine	monoamine oxidase inhibitor	KDM1A, MAOA, MAOB	neurology/psychiatry	depression	Launched
trap-101	nociceptin/orphanin FQ receptor antagonist, opioid receptor antagonist	OPRL1			Preclinical
trapidil	PDGFR tyrosine kinase receptor inhibitor	PDGFRA	cardiology	coronary artery disease (CAD)	Launched
travoprost	prostanoid receptor agonist	PTGFR	ophthalmology	ocular hypertension, glaucoma	Launched
traxoprodil	glutamate receptor antagonist	GRIN2B			Phase 2
trazodone	adrenergic receptor antagonist, serotonin receptor antagonist, serotonin reuptake inhibitor	ADRA1A, ADRA2A, HRH1, HTR1A, HTR2A, HTR2B, HTR2C, SLC6A4	neurology/psychiatry	depression	Launched
trebenzomine					Phase 2
trelagliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	Launched
tremorine	acetylcholine receptor agonist				Preclinical
treosulfan	DNA synthesis inhibitor		oncology	ovarian cancer	Launched
trepibutone	cholinergic receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4	gastroenterology	irritable bowel syndrome	Launched
treprostinil	prostanoid receptor agonist	P2RY12, PPARD, PTGIR	pulmonary	pulmonary arterial hypertension (PAH)	Launched
trequinsin	phosphodiesterase inhibitor	PDE5A			Phase 1
tretazicar	DNA replication inhibitor	NQO2			Phase 2
tretinoin	retinoid receptor agonist, retinoid receptor ligand	ALDH1A1, ALDH1A2, GPRC5A, NR0B1, NR2C2, PPARD, RARA, RARB, RARG, RARRES1, RORB, RORC, RXRB, RXRG	hematologic malignancy	acute promyelocytic leukemia (APL)	Launched
triacetin					Launched
triamcinolone	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	Launched
triamcinolone-acetonide	glucocorticoid receptor agonist, immunosuppressant	NR3C1, SERPINA6	dermatology	corticosteroid-responsive dermatoses	Launched
triamcinolone-hexacetonide	anti-inflammatory agent				Launched
triamterene	sodium channel blocker	SCNN1A, SCNN1B, SCNN1D, SCNN1G	endocrinology, cardiology	hypokalemia, hypertension, edema	Launched
triapine	ribonucleotide reductase inhibitor	RRM1, RRM2			Phase 2
tribenoside	anti-inflammatory agent, capillary stabilizing agent				Launched
tribomsalan					Preclinical
tribromoethanol	analgesic agent				Preclinical
tributyrin	HDAC inhibitor				Phase 1
tricaprylin			dermatology	cosmetic	Launched
trichlormethiazide	chloride channel blocker	PTGS1, PTGS2, SLC12A1	cardiology	hypertension, edema	Launched
trichloroacetic-acid			dermatology	warts	Launched
trichloroethylene					Preclinical
trichostatin-a	HDAC inhibitor	HDAC1, HDAC10, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9			Phase 1
triciribine	AKT inhibitor	AKT1, AKT2, AKT3			Phase 1/Phase 2
triciribine-phosphate	AKT inhibitor				Phase 1/Phase 2
triclabendazole	microtubule inhibitor	DNMT1	infectious disease	tapeworm	Launched
triclocarban	other antibiotic		infectious disease	first-aid antiseptic	Launched
triclosan	antibacterial agent	DNMT1	infectious disease	first-aid antiseptic	Launched
tridihexethyl	acetylcholine receptor antagonist		gastroenterology, ophthalmology	peptic ulcer disease (PUD), nystagmus	Launched
trientine	chelating agent	CA14	metabolism	Wilson's disease	Launched
trifloxystrobin	mitochondrial electron transport inhibitor				Preclinical
trifluoperazine	dopamine receptor antagonist	ADRA1A, CALM1, CALY, DRD2, DRD4, HRH1, HTR2A, HTR2C, S100A4, TNNC1	neurology/psychiatry	schizophrenia	Launched
triflupromazine	dopamine receptor antagonist	CHRM1, CHRM2, DRD1, DRD2, HTR2B	neurology/psychiatry, gastroenterology	psychosis, nausea, vomiting	Launched
trifluridine	DNA directed DNA polymerase inhibitor, thymidylate synthase inhibitor	TYMS	infectious disease	virus herpes simplex (HSV)	Launched
triflusal	cyclooxygenase inhibitor, platelet aggregation inhibitor, thromboxane synthase inhibitor	NFKB1, NOS2, PDE10A, PTGS1	neurology/psychiatry, cardiology	stroke, myocardial infarction, atrial fibrillation (AF)	Launched
trigonelline					Phase 1
trihexyphenidyl	acetylcholine receptor antagonist	CHRM1	neurology/psychiatry	parkinsonism	Launched
trilaciclib	CDK inhibitor				Phase 2
trilostane	3beta-hydroxy-delta5-steroid dehydrogenase inhibitor		endocrinology	Cushing's syndrome	Launched
TRIM					Preclinical
trimebutine	opioid receptor agonist	OPRD1, OPRK1, OPRM1	gastroenterology	irritable bowel syndrome	Launched
trimetazidine	3-ketoacyl CoA thiolase inhibitor	ACAA2	cardiology	angina pectoris	Launched
trimethadione	oxazolidine antiepileptic	CACNA1G, CACNA1H, CACNA1I	neurology/psychiatry	seizures	Launched
trimethobenzamide	histamine receptor antagonist	DRD2	gastroenterology	vomiting, nausea, gastroenteritis	Launched
trimethoprim	dihydrofolate reductase inhibitor	DHFR, TYMS	infectious disease, gastroenterology	urinary tract infections, ear infections, diarrhea	Launched
trimethoquinol	adrenergic receptor antagonist	ADRB2, ADRB3	pulmonary	asthma	Launched
trimethylolpropane-triacrylate					Preclinical
trimetozine	sedative		neurology/psychiatry	sedative	Launched
trimetrexate	dihydrofolate reductase inhibitor	DHFR			Phase 3
trimipramine	norepinephrine reputake inhibitor, tricyclic antidepressant	SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	Launched
trioxsalen	DNA synthesis inhibitor		dermatology	vitiligo, eczema	Launched
tripelennamine	histamine receptor antagonist	HRH1	pulmonary, allergy	asthma, allergic rhinitis, urticaria	Launched
triprolidine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	Launched
triptan	serotonin receptor agonist	HTR1B, HTR1D			Phase 1
triptolide	RNA polymerase inhibitor	RELA			Phase 3
triptorelin	gonadotropin releasing factor hormone receptor agonist	GNRHR	oncology, endocrinology, obstetrics/gynecology	prostate cancer, breast cancer, precocious puberty, endometriosis, myoma, gender dysphoria	Launched
troclosene					Launched
trodusquemine	tyrosine phosphatase inhibitor				Phase 1
trofinetide	cytokine production inhibitor	IFNG, IL6, TNF			Phase 2
trofosfamide	DNA alkylating agent		oncology	medulloblastoma	Launched
troglitazone	insulin sensitizer, PPAR receptor agonist	CYP2C8, PPARG, TRPM3			Withdrawn
troleandomycin	protein synthesis inhibitor		infectious disease, pulmonary, otolaryngology	pneumonia, bronchitis, tonsillitis, sinusitis	Launched
trolox	antioxidant				Launched
tromaril	prostanoid receptor antagonist		ophthalmology	eye inflammation	Launched
trometamol		AMD1, CANT1, DCN, NEIL1, VEGFA			Launched
tropanyl-3,5-dimethylbenzoate	serotonin receptor antagonist	HTR3A, HTR3B			Preclinical
tropesin	cyclooxygenase inhibitor	PTGS1, PTGS2			Launched
tropicamide	acetylcholine receptor antagonist	CHRM3, CHRM4	ophthalmology	mydriasis diagnostic, cycloplegia diagnostic	Launched
tropifexor	FXR agonist				Phase 2
tropisetron	serotonin receptor antagonist	GLRA1, GLRA2, GLRB, HTR3A, HTR4	gastroenterology	nausea, vomiting	Launched
trospium	acetylcholine receptor antagonist	CHRM1	urology	urinary incontinence, urinary frequency	Launched
trovafloxacin	bacterial DNA gyrase inhibitor	TOP2A			Withdrawn
troventol					Phase 1
trovirdine	non-nucleoside reverse transcriptase inhibitor				Phase 1
troxerutin	antioxidant				Launched
troxipide	glucosamine synthetase stimulant		gastroenterology	gastroesophageal reflux disease (GERD)	Launched
TRV130	opioid receptor agonist	OPRM1			Phase 3
tryptanthrin	cyclooxygenase inhibitor	IDO1			Preclinical
tryptophan	serotonin receptor partial agonist	CASR, IDO1, SLC36A1, WARS, WARS2	neurology/psychiatry, gastroenterology	anxiety, bloating, constipation, fatigue, sleeplessness	Launched
TS-011	delayed vasospasm antagonist				Preclinical
TTNPB	retinoid receptor agonist	RARA, RARB, RARG			Phase 1
TTP-22	casein kinase inhibitor	CSNK2A1			Preclinical
TU-2100					Phase 2
tuaminoheptane			otolaryngology	nasal congestion	Launched
tubastatin-A	HDAC inhibitor	HDAC6			Preclinical
tubocurarine	acetylcholine receptor antagonist	ACHE, CHRNA2, HTR3A, HTR3B, KCNN1, KCNN2, KCNN3, ZACN	neurology/psychiatry	anesthetic	Launched
tucatinib	EGFR inhibitor	ERBB2			Phase 3
tucidinostat	HDAC inhibitor				Phase 3
tuftsin	macrophage activator				Preclinical
TUG-770	free fatty acid receptor agonist	FFAR1			Preclinical
TUG-891	free fatty acid receptor agonist	FFAR4			Preclinical
tulobuterol	adrenergic receptor agonist	ADRB2	pulmonary	asthma	Launched
tulrampator	antidepressant 				Phase 2
TW-37	BCL inhibitor	BCL2, BCL2L1, MCL1			Preclinical
TWS-119	glycogen synthase kinase inhibitor	GSK3B, JUN, MYC			Preclinical
TXA127	angiotensin receptor agonist				Phase 2
TY-52156	sphingosine 1-phosphate receptor antagonist	S1PR3			Preclinical
tylosin	protein synthesis inhibitor		infectious disease, gastroenterology	gram-positive bacterial infections, colitis	Launched
tymazoline			allergy	allergic rhinitis	Launched
tyrphostin-AG-1296	FLT3 inhibitor	FLT3			Preclinical
tyrphostin-AG-1478	EGFR inhibitor	EGFR, MAPK14			Preclinical
tyrphostin-AG-18	EGFR inhibitor, tyrosine kinase inhibitor	EGFR			Preclinical
tyrphostin-AG-494	EGFR inhibitor	EGFR			Preclinical
tyrphostin-AG-825	protein tyrosine kinase inhibitor	ERBB2			Preclinical
tyrphostin-AG-835	protein tyrosine kinase inhibitor	EGFR			Preclinical
tyrphostin-AG-879	tyrosine kinase inhibitor	ERBB2, KDR, NTRK1			Preclinical
tyrphostin-AG-99	tyrosine kinase inhibitor	EGFR			Preclinical
tyrphostin-A9	protein tyrosine kinase inhibitor, tyrosine kinase inhibitor				Preclinical
U-0124	MEK inhibitor				Preclinical
U-0126	MEK inhibitor	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1			Preclinical
U-0521	catechol O methyltransferase inhibitor	COMT			Preclinical
U-104	carbonic anhydrase inhibitor	CA1, CA12, CA2, CA9			Phase 1/Phase 2
U-18666A	oxidosqualene cyclase inhibitor				Preclinical
U-50488-(-)	opioid receptor agonist	OPRK1			Preclinical
U-54494A	opioid receptor agonist	OPRK1			Preclinical
U-75799E	growth hormone releasing factor agonist	GHSR			Phase 1
U-99194	dopamine receptor antagonist	DRD3			Preclinical
UAMC-00039	dipeptidyl peptidase inhibitor	DPP4, DPP7			Preclinical
UB-165	acetylcholine receptor agonist	CHRNA3, CHRNA4, CHRNB2			Preclinical
ubenimex	leukotriene synthesis inhibitor	LTA4H, RNPEP	hematologic malignancy	acute myeloid leukemia (AML)	Launched
UBP-296	glutamate receptor antagonist	GRIK1			Preclinical
UBP-302	glutamate receptor antagonist	GRIK1			Preclinical
UBP-310	glutamate receptor antagonist	GRIK1, GRIK5			Preclinical
UC-112	XIAP inhibitor	XIAP			Preclinical
UCL-2077	slow afterhyperpolarization channel blocker				Preclinical
udenafil	phosphodiesterase inhibitor		urology	erectile dysfunction	Launched
UF-010	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC8			Preclinical
ufenamate	cyclooxygenase inhibitor	PTGS1, PTGS2	dermatology	eczema, dermatitis	Launched
UH-232-(+)	dopamine receptor antagonist	DRD2, DRD3, DRD4, HTR1A			Preclinical
UK-356618	metalloproteinase inhibitor	MMP13, MMP14, MMP2, MMP3, MMP9			Preclinical
UK-383367	procollagen C-endopeptidase inhibitor	BMP1			Phase 1
UK-5099	monocarboxylate transporter inhibitor	SLC16A1			Preclinical
uki-1	urokinase inhibitor				Preclinical
ulifloxacin			infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	Launched
ulipristal	progesterone receptor antagonist	PGR	endocrinology	contraceptive	Launched
umeclidinium	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	pulmonary	chronic obstructive pulmonary disease (COPD), bronchitis, emphysema	Launched
unbs-5162	CC chemokine receptor antagonist				Phase 1
UNC0224	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			Preclinical
UNC0321	histone lysine methyltransferase inhibitor	EHMT2			Preclinical
UNC0631	histone lysine methyltransferase inhibitor	EHMT2			Preclinical
UNC0638	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			Preclinical
UNC0642	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			Preclinical
UNC0646	histone lysine methyltransferase inhibitor	EHMT2			Preclinical
UNC0737	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			Preclinical
UNC1215	L3MBTL antagonist	L3MBTL3			Preclinical
UNC1999	histone lysine methyltransferase inhibitor	EZH2			Preclinical
UNC2025	FLT3 inhibitor, MER tyrosine kinase inhibitor	FLT3, MERTK			Preclinical
UNC2250	MER tyrosine kinase inhibitor	MERTK			Preclinical
UNC2327	protein arginine N-methyltransferase inhibitor	PRMT3			Preclinical
UNC3230	phosphatidyl-inositol activator	PIP5K1C			Preclinical
UNC669	L3MBTL antagonist	L3MBTL1			Preclinical
UNC926	MBT inhibitor	L3MBTL1			Preclinical
undecylenic-acid	other antifungal		infectious disease	tinea pedis, tinea corporis	Launched
upadacitinib	JAK inhibitor				Launched
upamostat	serine protease inhibitor				Phase 2
UPF-1069	PARP inhibitor	PARP2			Preclinical
uprifosbuvir	antiviral				Preclinical
uprosertib	AKT inhibitor	AKT1, AKT2, AKT3			Phase 2
uracil		DPYD, UCKL1			Launched
uracil-mustard	DNA synthesis inhibitor		hematologic malignancy	non-Hodgkin lymphoma (NHL)	Launched
urapidil	adrenergic receptor antagonist	HTR1A	cardiology	hypertension	Launched
URB597	FAAH inhibitor	FAAH, FAAH2, TRPA1			Phase 1
urea	hydroxy radical formation stimulant	ARG1, CA2, CTNNB1	dermatology	psoriasis, xerosis cutis, ichthyosis vulgaris, eczema, keratosis, dermatitis	Launched
urethane	local anesthetic				Preclinical
uric-acid		PYGL			Phase 3
uridine	dopamine receptor agonist	LSM6, TYMP			Phase 2
uridine-triacetate			nephrology	orotic aciduria	Launched
uridine-5'-triphosphate	purinergic receptor activator	P2RY11, P2RY2, P2RY4, P2RY6, UCK2			Launched
URMC-099	mixed lineage kinase inhibitor	CDKL2, DAPK3, FLT3, LRRK2, MAP3K10, MAP3K11, MAP3K2, MAP3K9, SRPK2			Preclinical
urolithin-A	antioxidant				Phase 3
ursodeoxycholyltaurine	cholesterol inhibitor				Phase 3
ursodiol	nuclear factor erythroid derived, like (NRF2) activator	AKR1C2, NR1H4	gastroenterology	gallstones	Launched
ursolic-acid	ATPase inhibitor, NFkB pathway inhibitor, STAT inhibitor	HSD11B1, PLA2G1B, PTPN1, PYGM			Phase 2/Phase 3
usniacin-(+)	MAP kinase activator	PTPN1			Preclinical
V-51	adrenergic receptor antagonist				Phase 1
vaborbactam	beta lactamase inhibitor				Launched
vadadustat	hypoxia inducible factor prolyl hydroxylase inhibitor				Phase 3
val-tyr	angiotensin converting enzyme inhibitor				Preclinical
valaciclovir	DNA polymerase inhibitor		infectious disease	shingles, virus herpes simplex (HSV)	Launched
valbenazine	vesicular monoamine transporter inhibitor		neurology/psychiatry	dyskinesia	Launched
valdecoxib	cyclooxygenase inhibitor	CA12, PTGS2			Withdrawn
valethamate	acetylcholine receptor antagonist	CHRM1, CHRM4, CHRM5	obstetrics/gynecology	labor induction	Launched
valganciclovir	DNA synthesis inhibitor		infectious disease	cytomegalovirus (CMV)	Launched
valnemulin	bacterial 50S ribosomal subunit inhibitor		infectious disease, gastroenterology	dysentry, colitis, pneumonia	Launched
valnoctamide	arachidonic acid acylation inhibitor, benzodiazepine receptor agonist		neurology/psychiatry	sleeplessness	Launched
valproic-acid	benzodiazepine receptor agonist, HDAC inhibitor	ABAT, ACADSB, ALDH5A1, HDAC1, HDAC2, HDAC9, OGDH, SCN10A, SCN11A, SCN1A, SCN1B, SCN2A, SCN2B, SCN3A, SCN3B, SCN4A, SCN4B, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	epilepsy, seizures, seizures	Launched
valpromide	epoxide hydolase inhibitor		neurology/psychiatry	epilepsy	Launched
valrocemide					Phase 2
valrubicin	DNA inhibitor, topoisomerase inhibitor	TOP2A	oncology	bladder cancer	Launched
valsartan	angiotensin receptor antagonist	AGTR1	cardiology	hypertension, congestive heart failure, congestive heart failure	Launched
valspodar	P glycoprotein inhibitor	ABCB1			Phase 3
vancomycin	bacterial cell wall synthesis inhibitor		infectious disease	endocarditis	Launched
vandetanib	EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA	oncology	medullary thyroid cancer (MTC)	Launched
vanillin		ABAT, ALDH5A1			Preclinical
vanillylacetone					Preclinical
vaniprevir	serine protease inhibitor				Phase 3
vanitiolide					Preclinical
vanoxerine	dopamine reuptake inhibitor	SLC6A3			Phase 3
vapendavir	antiviral				Phase 2
vardenafil	phosphodiesterase inhibitor	PDE5A, PDE6G, PDE6H	urology	erectile dysfunction	Launched
varenicline	acetylcholine receptor agonist	CHRNA3, CHRNA4, CHRNA6, CHRNA7	neurology/psychiatry	smoking cessation	Launched
varespladib	secretory phospholipase inhibitor	PLA2G2A			Phase 3
vasopressin	vasopressin receptor agonist	AVPR1A, AVPR1B, AVPR2, OXTR	gastroenterology	abdominal distension	Launched
vatalanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	EGFR, FLT1, FLT4, KDR, PDGFRB			Phase 3
vatinoxan	adrenergic receptor antagonist				Preclinical
VBY-825	cathepsin inhibitor	CTSB, CTSL, CTSS			Preclinical
VCH-916	HCV inhibitor				Phase 1
VE-821	ATR kinase inhibitor	ATR			Preclinical
VE-822	ATR kinase inhibitor	ATM, ATR, MTOR, PIK3CG			Phase 2
vecabrutinib	Bruton's tyrosine kinase (BTK) inhibitor				Phase 1/Phase 2
vecuronium	acetylcholine receptor antagonist	CHRNA2	neurology/psychiatry	muscle relaxant	Launched
vedaprofen	anti-inflammatory agent	PTGS2	neurology/psychiatry, endocrinology	pain relief, fever	Launched
velaresol					Preclinical
veledimex	cytochrome P450 inhibitor				Phase 2
veliflapon	leukotriene synthesis inhibitor	ALOX5AP			Phase 3
veliparib	PARP inhibitor	PARP1, PARP2			Phase 3
velneperit	neuropeptide receptor antagonist	NPY5R			Phase 2
velpatasvir	antiviral		infectious disease	hepatitis C	Launched
vemurafenib	RAF inhibitor	BRAF, RAF1	oncology	melanoma	Launched
venetoclax	BCL inhibitor	BCL2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	Launched
venlafaxine	adrenergic inhibitor, norepinephrine reuptake inhibitor, serotonin–norepinephrine reuptake inhibitor (SNRI)	SLC6A2, SLC6A4	neurology/psychiatry	depression, generalized anxiety disorder (GAD), panic disorders, social anxiety disorder	Launched
VER-155008	HSP inhibitor	HSPA1A			Preclinical
VER-49009	HSP inhibitor	HSP90AA1			Preclinical
veralipride	dopamine receptor antagonist				Preclinical
verapamil	calcium channel blocker	CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CYP3A4, KCNA10, KCNA7, KCNH2, KCNJ11, NALCN, SCN5A, SLC29A4, SLC6A4	cardiology	hypertension	Launched
verbascoside	NFkB pathway inhibitor, PKC inhibitor				Phase 2/Phase 3
vercirnon	CC chemokine receptor antagonist	CCR9			Phase 3
verdinexor	exportin antagonist				Preclinical
verdiperstat	myeloperoxidase inhibitor				Phase 3
vericiguat	guanylate cyclase stimulant				Phase 3
verinurad	urate transporter inhibitor	SLC22A12			Phase 2
vernakalant	potassium channel blocker	KCNA5	cardiology	atrial fibrillation (AF)	Launched
verteporfin	photosensitizing agent		ophthalmology	macular degeneration	Launched
verubecestat	beta secretase inhibitor				Phase 3
verubulin	tubulin polymerization inhibitor	TUBB			Phase 2
verucerfont	corticotropin releasing factor receptor antagonist				Phase 2
vesamicol	acetylcholinesterase inhibitor	SLC18A3			Preclinical
vesnarinone	phosphodiesterase inhibitor	KCNH2, PDE3A	cardiology	congestive heart failure	Launched
VGX-1027	tumor necrosis factor receptor antagonist	TLR4			Phase 1
vicriviroc	CC chemokine receptor antagonist	CCR5			Phase 3
vidarabine	antiviral	ADA	infectious disease	virus herpes simplex (HSV), varicella-zoster virus (VZV)	Launched
vigabatrin	GABA aminotransferase inhibitor	ABAT, SLC32A1	neurology/psychiatry	seizures, spasms	Launched
vilanterol	adrenergic receptor agonist	ADRB2	pulmonary	chronic obstructive pulmonary disease (COPD)	Launched
vilazodone	serotonin reuptake inhibitor	DRD2, DRD3, HRH1, HTR1A, HTR4, SLC6A4	neurology/psychiatry	depression	Launched
vildagliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	Launched
viloxazine	norepinephrine reuptake inhibitor	SLC6A2	neurology/psychiatry	depression	Launched
vinblastine	microtubule inhibitor, tubulin polymerization inhibitor	JUN, TUBA1A, TUBB, TUBD1, TUBE1, TUBG1	hematologic malignancy, infectious disease, oncology	Hodgkin's lymphoma, true histiocytic lymphoma (THL), mycosis, small lymphocytic lymphoma (SLL), testicular carcinoma, Kaposi sarcoma	Launched
vinburnine	adrenergic receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4	neurology/psychiatry	stroke	Launched
vincamine	adrenergic receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4			Withdrawn
vincristine	tubulin polymerization inhibitor	TUBA4A, TUBB	hematologic malignancy	acute lymphoblastic leukemia (ALL)	Launched
vindesine	tubulin polymerization inhibitor	TUBB, TUBB1	oncology	breast cancer, non-small cell lung cancer (NSCLC), melanoma	Launched
vinflunine	microtubule inhibitor		oncology	bladder cancer	Launched
vinorelbine	tubulin polymerization inhibitor	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	non-small cell lung cancer (NSCLC)	Launched
vinpocetine	phosphodiesterase inhibitor, sodium channel blocker	PDE1A, PDE1C	neurology/psychiatry	stroke, senile dementia	Launched
viomycin	protein synthesis inhibitor		infectious disease	tuberculosis	Launched
vipadenant	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Phase 1
vismodegib	hedgehog pathway inhibitor, smoothened receptor antagonist	SMO	oncology	basal cell carcinoma (BCC)	Launched
visomitin	antioxidant				Preclinical
vitamin-B12			hematology	megaloblastic anemia	Launched
vitamin-E	LDL oxidation inhibitor, PKC inhibitor	ALOX5, DGKA, NR1I2, PPP2CA, PPP2CB, PRKCA, PRKCB, SEC14L2, SEC14L3, SEC14L4			Launched
vixotrigine	sodium channel blocker				Phase 2
VLX1570	deubiquitinase inhibitor				Phase 1/Phase 2
VLX600	antitumor agent, ubiquitin C-terminal hydrolase inhibitor	TP53, USP14			Phase 1
VL285	PROTAC				Preclinical
voclosporin	calcineurin inhibitor				Phase 3
voglibose	glucosidase inhibitor	MGAM	endocrinology	diabetes mellitus, hyperglycemia	Launched
volasertib	PLK inhibitor	PLK1			Phase 3
volinanserin	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C, KCNH2			Phase 3
vonoprazan	potassium-competitive acid antagonist	ATP4A	gastroenterology	peptic ulcer disease (PUD)	Launched
vorapaxar	thrombin inhibitor	F2R	cardiology	myocardial infarction, peripheral artery disease (PAD)	Launched
vorasidenib	isocitrate dehydrogenase inhibitor				Preclinical
voreloxin	topoisomerase inhibitor	TOP2A			Phase 3
voriconazole	cytochrome P450 inhibitor	CYP2C19, CYP2C9, CYP3A4, CYP3A5, PTGS1	infectious disease	esophageal candidiasis, aspergillosis, skin infections	Launched
vorinostat	HDAC inhibitor	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	Launched
vortioxetine	serotonin receptor agonist, serotonin receptor antagonist	HTR1A, HTR1B, HTR2A, HTR2C, HTR3A, HTR5A, HTR6, HTR7, SLC6A4	neurology/psychiatry	depression	Launched
voruciclib	CDK9 inhibitor				Phase 1
voxelotor	hemoglobin modulator				Launched
voxtalisib	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA			Phase 2
VP-20629	beta amyloid antagonist	PLA2G2E, SLC36A1			Phase 1
VS-4718	focal adhesion kinase inhibitor				Phase 1
VT-464	cytochrome P450 inhibitor	CYP17A1			Phase 2
VTP-27999	renin inhibitor	REN			Phase 1
VUF10166	serotonin receptor antagonist	HTR3A, HTR3B			Preclinical
VUF10460	histamine receptor agonist	HRH4			Preclinical
VUF11207	CC chemokine receptor agonist	ACKR3			Preclinical
VU0155069	phospholipase inhibitor	PLD1			Preclinical
VU0238429	acetylcholine receptor allosteric modulator	CHRM5			Preclinical
VU0240551	potassium/chloride cotransporter inhibitor	SLC12A5			Preclinical
VU0357121	glutamate receptor positive allosteric modulator	GRM5			Preclinical
VU0360172	glutamate receptor positive allosteric modulator	GRM5			Preclinical
VU0361737	glutamate receptor positive allosteric modulator	GRM4			Preclinical
VU0364439	glutamate receptor positive allosteric modulator	GRM4			Preclinical
VU0364739	phospholipase inhibitor	PLD2			Preclinical
VU0364770	glutamate receptor positive allosteric modulator	GRM4			Preclinical
VU0422288	glutamate receptor positive allosteric modulator	GRM3			Preclinical
VU10010	acetylcholine receptor allosteric modulator	CHRM4			Preclinical
VU152100	acetylcholine receptor allosteric modulator	CHRM4			Preclinical
VU1545	glutamate receptor positive allosteric modulator	GRM5			Preclinical
VU29	glutamate receptor potentiator	GRM5			Preclinical
VU591	potassium channel blocker	KCNJ1			Preclinical
VX-11e	MAP kinase inhibitor	MAPK1			Preclinical
VX-222	HCV inhibitor				Phase 2
VX-702	p38 MAPK inhibitor	IL1B, IL6, MAPK11, MAPK12, MAPK14, TNF			Phase 2
VX-745	p38 MAPK inhibitor	MAPK11, MAPK12, MAPK14			Phase 2
VX-765	caspase inhibitor	CASP1			Phase 2
W-54011	anaphylatoxin chemotactic receptor antagonist	C5AR1			Preclinical
walrycin-B	transcriptional regulatory protein WalR				Preclinical
warfarin	vitamin K antagonist	VKORC1	hematology, cardiology	deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation (AF), myocardial infarction	Launched
WAY-100635	serotonin receptor antagonist	HTR1A			Phase 1
WAY-161503	serotonin receptor agonist	HTR2C			Preclinical
WAY-170523	metalloproteinase inhibitor	MMP13			Preclinical
WAY-200070	estrogen receptor agonist	ERBB2, ERBB3, ERBB4, ESR2			Preclinical
WAY-207024	gonadotropin releasing factor hormone receptor antagonist	GNRHR, HRH2, TACR2			Preclinical
WAY-208466	serotonin receptor agonist	DRD2, HTR2A, HTR2C, HTR6, HTR7			Preclinical
WAY-213613	glutamate inhibitor	SLC1A2			Preclinical
WAY-255348	progesterone receptor antagonist				Preclinical
WAY-316606	secreted frizzled related protein inhibitor	SFRP1			Preclinical
WAY-362450	FXR agonist	NR1H4			Phase 1
WAY-600	mTOR inhibitor	MTOR			Preclinical
WAY-629	serotonin receptor agonist	HTR2C			Preclinical
WB-4101	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1A			Preclinical
WDR5-0103	histone lysine methyltransferase inhibitor	WDR5			Preclinical
WEHI-345-analog	SRC inhibitor				Preclinical
WH-4-023	SRC inhibitor	LCK, SRC			Preclinical
WHI-P154	JAK inhibitor	EGFR, JAK1, JAK2, JAK3			Preclinical
WIKI4	tankyrase inhibitor, WNT pathway inhibitor	TNKS2			Preclinical
WIN-18446	aldehyde dehydrogenase inhibitor	ALDH1A2			Preclinical
WIN-64338	bradykinin receptor antagonist	BDKRB2			Preclinical
wiskostatin	actin related protein inhibitor, neural Wiskott-Aldrich syndrome protein inhibitor	WASL			Preclinical
wnt-c59	porcupine inhibitor	PORCN			Preclinical
wortmannin	PI3K inhibitor	PI4KA, PI4KB, PIK3CA, PIK3CD, PIK3CG, PIK3R1, PLK1, PRKDC			Preclinical
WP1066	STAT inhibitor	STAT3			Phase 1
WP1130	deubiquitinase inhibitor	JAK2, UCHL5, USP14, USP9X			Preclinical
WP921					Preclinical
WR99210	dihydrofolate reductase inhibitor	TYMS	infectious disease	malaria	Preclinical
WWL-113	carboxylesterase inhibitor	CES3			Preclinical
WWL-123	monoacylglycerol lipase inhibitor	ABHD6			Preclinical
WY-16922	histamine release inhibitor				Phase 1
WYE-125132	mTOR inhibitor	MTOR			Preclinical
WYE-354	mTOR inhibitor	MTOR			Preclinical
WYE-687	mTOR inhibitor	MTOR			Preclinical
WZ-3146	EGFR inhibitor	EGFR			Preclinical
WZ-4002	EGFR inhibitor	EGFR, ERBB2			Preclinical
WZ4003	AMPK inhibitor	NUAK1, NUAK2			Preclinical
WZ8040	EGFR inhibitor	EGFR			Preclinical
WZ811	CC chemokine receptor antagonist	CXCR4			Preclinical
xaliproden	serotonin receptor agonist	HTR1A			Phase 3
xamoterol	adrenergic receptor agonist	ADRB1			Phase 3
xanomeline	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7			Phase 3
xanthone	antimalarial agent				Preclinical
XAV-939	tankyrase inhibitor	TNKS, TNKS2			Preclinical
XBD173	benzodiazepine receptor ligand	TSPO			Phase 2
XD-14	bromodomain inhibitor	BRD2, BRD3, BRD4, BRDT			Preclinical
XE-991	potassium channel blocker	KCNQ1, KCNQ2, KCNQ3, KCNQ4, KCNQ5			Preclinical
xenalipin					Phase 2
xibenolol	adrenergic receptor antagonist				Phase 3
xilobam					Phase 1
xipamide	carbonic anhydrase inhibitor	SLC12A3	cardiology	edema, hypertension	Launched
XL019	JAK inhibitor	JAK1, JAK2, JAK3			Phase 1
XL041	LXR agonist				Preclinical
XL147	PI3K inhibitor	PIK3CA, PIK3CD, PIK3CG			Phase 2
XL228	Abl kinase inhibitor, insulin growth factor receptor inhibitor, SRC inhibitor	IGF1R, SRC			Phase 1
XL388	mTOR inhibitor	MTOR			Preclinical
XL647	EGFR inhibitor, VEGFR inhibitor	EGFR, EPHB4, ERBB2, FLT4, KDR			Phase 3
XL888	HSP inhibitor				Phase 1
XMD17-109	MAP kinase inhibitor	MAPK7			Preclinical
XMD8-92	MAP kinase inhibitor	DCLK2, MAPK7, PLK4, TNK1			Preclinical
xylazine	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C	neurology/psychiatry	anesthetic	Launched
xylometazoline	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C	otolaryngology, allergy	nasal congestion, allergic rhinitis	Launched
xylose					Launched
Y-11	focal adhesion kinase inhibitor	PTK2			Preclinical
Y-134	estrogen receptor antagonist	ESR1, ESR2			Preclinical
Y-26763	potassium channel activator	KCNJ8			Phase 1
Y-27152	potassium channel activator	KCNJ8			Phase 1
Y-27632	rho associated kinase inhibitor	PKIA, PKN2, PRKACA, PRKCE, ROCK1, ROCK2			Preclinical
Y-29794	prolyl endopeptidase inhibitor	PREP			Preclinical
Y-320	interleukin inhibitor	IL17A			Preclinical
Y-39983	rho associated kinase inhibitor	ROCK1, ROCK2			Phase 2
YC-1	guanylyl cyclase activator	GUCY1A2, GUCY1A3, GUCY1B3, HIF1A			Preclinical
YIL-781	ghrelin receptor antagonist	GHSR			Preclinical
YK-4-279	apoptosis inhibitor	EWSR1, FLI1			Preclinical
YL0919	selective serotonin reuptake inhibitor (SSRI)				Preclinical
YM-022	CCK receptor antagonist	CCKBR			Phase 2
YM-155	survivin inhibitor	BIRC5			Phase 2
YM-201636	PI3K inhibitor				Preclinical
YM-244769	sodium/calcium exchange inhibitor				Preclinical
YM-298198	glutamate receptor antagonist	GRM1			Preclinical
YM-298198-desmethyl	glutamate receptor antagonist	GRM1			Preclinical
YM-511	aromatase inhibitor	CYP19A1			Phase 2
YM-58483	calcium channel blocker	TRPC3, TRPC5, TRPM4			Preclinical
YM-750	ACAT inhibitor	SOAT1			Phase 1
YM-90709	IL5 inhibitor	CSF2RB, IL5RA			Preclinical
YM-976	phosphodiesterase inhibitor	PDE4A			Phase 1
YO-01027	gamma secretase inhibitor				Preclinical
yoda-1	piezo channel activator	PIEZO1			Preclinical
yohimbine	adrenergic receptor antagonist	ADRA2A, ADRA2B, ADRA2C, DRD2, DRD3, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR7, KCNJ1, KCNJ10, KCNJ11, KCNJ12, KCNJ14, KCNJ15, KCNJ8	cardiology	cardiac arrythmia, bradycardia	Launched
YS-035	calcium channel blocker				Preclinical
YS-201	calcium receptor antagonist				Preclinical
YZ9	phosphofructokinase inhibitor	MIF, PFKFB3			Preclinical
Y16	rho associated kinase inhibitor	RHOA			Preclinical
zacopride	serotonin receptor antagonist	HTR3A, HTR3B, HTR4, HTR5A			Phase 2
zafirlukast	leukotriene receptor antagonist	CYSLTR1, CYSLTR2	pulmonary	asthma	Launched
zalcitabine	nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	Launched
zaldaride	calmodulin antagonist	CALM1			Phase 3
zaltidine	histamine receptor antagonist	HRH2			Phase 3
zaltoprofen	cyclooxygenase inhibitor		endocrinology, neurology/psychiatry	fever, pain relief	Launched
ZAMI-633	urease inhibitor				Phase 3
zamifenacin	acetylcholine receptor antagonist	CHRM3			Phase 3
zanamivir	neuraminidase inhibitor	NEU2	infectious disease	influenza A virus infection	Launched
zanubrutinib	Bruton's tyrosine kinase (BTK) inhibitor				Launched
ZAPA					Preclinical
zaprinast	phosphodiesterase inhibitor	GPR35, PDE1A, PDE4D, PDE5A, PDE9A			Phase 2
zardaverine	phosphodiesterase inhibitor	PDE4D			Phase 2
zatebradine	HCN channel blocker	HCN1, HCN2, HCN3, HCN4			Phase 3
ZCL-278	CDC inhibitor	CDC42			Preclinical
ZD-0947	potassium channel activator				Preclinical
ZD-2079	adrenergic receptor agonist	ADRB3			Phase 2
ZD-7114	adrenergic receptor agonist	ADRB3			Phase 1
ZD-7155	angiotensin receptor antagonist	AGTR1			Preclinical
ZD-7288	HCN channel blocker	HCN1, HCN2, HCN3, HCN4			Phase 2
zeatin					Phase 1
zebularine	DNA methyltransferase inhibitor	CDA, DNMT1			Preclinical
zibotentan	endothelin receptor antagonist	EDNRA			Phase 3
zidovudine	nucleoside reverse transcriptase inhibitor	TERT	infectious disease	human immunodeficiency virus (HIV-1), acquired immunodeficiency syndrome (AIDS)	Launched
zileuton	leukotriene synthesis inhibitor, lipoxygenase inhibitor	ALOX5	pulmonary	asthma	Launched
zilpaterol	adrenergic receptor agonist	ADRB2	endocrinology	weight-gain aid	Launched
zimelidine	selective serotonin reuptake inhibitor (SSRI)	MAOA, MAOB, SLC6A4			Withdrawn
zinc-undecylenate	other antifungal		infectious disease	tinea pedis	Launched
zindotrine	phosphodiesterase inhibitor				Phase 2
ziprasidone	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A4	neurology/psychiatry	schizophrenia, bipolar disorder	Launched
ziritaxestat	autotaxin inhibitor				Phase 3
ZK-164015	estrogen receptor antagonist	ESR1, ESR2			Preclinical
ZK-200775	kainate receptor antagonist				Phase 2
ZK-811752	CC chemokine receptor antagonist	CCR1			Phase 2
ZK-93423	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2			Phase 3
ZK-93426	benzodiazepine receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA5			Phase 1
ZLN005					Preclinical
ZLN024	AMPK activator	PRKAA1, PRKAB1, PRKAG1			Preclinical
ZM-226600	Kir6 channel (KATP) activator				Preclinical
ZM-241385	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Preclinical
ZM-306416	Abl kinase inhibitor, SRC inhibitor, VEGFR inhibitor	EGFR, FLT1, FLT4, KDR			Preclinical
ZM-323881	VEGFR inhibitor	KDR			Preclinical
ZM-336372	RAF inhibitor	BRAF, LCK, MAPK14, RAF1			Preclinical
ZM-39923	JAK inhibitor	JAK1, JAK3			Preclinical
ZM-447439	Aurora kinase inhibitor	AURKA, AURKB			Preclinical
zofenopril-calcium	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	Launched
zolantidine	histamine receptor antagonist				Preclinical
zoledronic-acid	bone resorption inhibitor	FDPS, GGPS1	endocrinology	Paget's disease	Launched
zoliflodacin	antibacterial 				Phase 3
zolimidine	mucus protecting agent		gastroenterology	peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD)	Launched
zolmitriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F	neurology/psychiatry	migraine headache	Launched
zomepirac	prostaglandin synthesis inhibitor	PTGDR2			Withdrawn
zometapine					Phase 2
zoniporide	sodium/hydrogen exchanger inhibitor	SLC9A1			Phase 3
zonisamide	sodium channel blocker, T-type calcium channel blocker	CA1, CA10, CA11, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA8, CA9, CACNA1G, CACNA1H, CACNA1I, MAOA, MAOB, SCN10A, SCN11A, SCN1A, SCN1B, SCN2A, SCN2B, SCN3A, SCN3B, SCN4A, SCN4B, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures, epilepsy	Launched
zopolrestat		AKR1B1, AKR1B10			Phase 2
zosuquidar	P glycoprotein inhibitor	ABCB1, ABCB4			Phase 3
zotarolimus	mTOR inhibitor	FKBP1A	cardiology	coronary artery restenosis	Launched
zotepine	dopamine receptor antagonist, serotonin receptor antagonist	ADRA2B, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR6, HTR7, SLC6A2, SLC6A4	neurology/psychiatry	schizophrenia	Launched
zoxazolamine	myorelaxant				Phase 2
ZSET1446	nicotinic receptor agonist				Preclinical
ZSTK-474	PI3K inhibitor	PIK3CB, PIK3CD, PIK3CG			Phase 1/Phase 2
zuclopenthixol	dopamine receptor antagonist	ADRA1A, ADRA2A, DRD1, DRD2, DRD5, HRH1, HTR2A	neurology/psychiatry	schizophrenia, bipolar disorder	Launched
zuranolone	GABA receptor agonist				Phase 3
Z160	N-type calcium channel blocker	CACNA2D1			Phase 2
1,12-Besm	polyamine biosynthesis inhibitor				Phase 2
1,2,3,4,5,6-hexabromocyclohexane	JAK inhibitor	JAK2			Preclinical
1,3-dipropyl-8-phenylxanthine	adenosine receptor antagonist				Preclinical
1,4-butanediol	benzodiazepine receptor agonist, gamma hydroxybutyric acid agonist	MAN1B1, PLA2G2A, PLA2G2E			Phase 1
1,5-dicaffeoylquinic-acid					Phase 1
1-((Z)-3-chloroallyl)-1,3,5,7-tetraazaadamantan-1-ium					Preclinical
1-(1,2-diphenylethyl)piperidine-(+/-)	glutamate receptor antagonist				Preclinical
1-(2-chloro-5-methylphenoxy)-3-(isopropylamino)-2-propanol					Preclinical
1-acetyl-4-methylpiperazine	acetylcholine receptor agonist				Preclinical
1-azakenpaullone	glycogen synthase kinase inhibitor	CCNB1, CDK1, CDK5, GSK3B			Preclinical
1-deoxymannojirimycin	alpha mannosidase inhibitor	MAN2A1			Preclinical
1-EBIO	potassium channel activator	KCNN1, KCNN2, KCNN3, KCNN4			Preclinical
1-ethyl-2-pyrrolidone	transdermal absorption-enhancing compound				Preclinical
1-hexadecanal	sphingosine 1-phosphate receptor substrate	DBI, RHO			Preclinical
1-hexadecanol			dermatology	cosmetic	Launched
1-naphthyl-PP1	SRC inhibitor	SRC			Preclinical
1-octacosanol					Phase 2
1-octanol		GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1			Phase 2
1-phenylbiguanide	serotonin receptor agonist	HTR3A, HTR3B			Preclinical
1E-1-(2-hydroxy-5-methylphenyl)-1-dodecanone-oxime					Preclinical
1S,2R-phenylpropanolamine	adrenergic receptor agonist				Withdrawn
10-deacetylbaccatin	antitumor agent				Preclinical
10-DEBC	AKT inhibitor	PIM1			Preclinical
10-hydroxycamptothecin	topoisomerase inhibitor	TOP1			Preclinical
10058-F4	c-Myc inhibitor				Preclinical
12-O-tetradecanoylphorbol-13-acetate	PKC activator	KCNT2, TRPV4			Phase 2
1400W	nitric oxide synthase inhibitor	NOS1, NOS2, NOS3			Preclinical
16,16-dimethylprostaglandin-e2	prostanoid receptor agonist	HPGD			Phase 2
17-hydroxyprogesterone-caproate	progesterone receptor agonist	AR, ESR1, ESR2, NR1H4, NR1I2, NR3C1, PGR	obstetrics/gynecology	spontaneous preterm birth	Launched
17-PA	glucocorticoid receptor agonist				Preclinical
2'-C-methylguanosine	HCV inhibitor				Preclinical
2'-MeCCPA	adenosine receptor agonist	ADORA1			Preclinical
2,3-cis/exo-camphanediol					Phase 1
2,3-cis/exo-pinanediol					Phase 1
2,3-DCPE	BCL-XL downregulator	BCL2L1			Preclinical
2,4-dinitrochlorobenzene	thioredoxin inhibitor	TXN			Phase 2
2,4-dinitrophenol	ATP synthase inhibitor	APP			Preclinical
2,5-furandimethanol	hemoglobin modulator	HBB			Phase 2
2,6-dimethylpiperidine					Preclinical
2-(chloromethyl)-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4(3H)-one					Preclinical
2-(1-adamantylamino)benzoic-acid					Preclinical
2-(3-mercaptopropyl)pentanedioic-acid	glutamate carboxypeptidase inhibitor	FOLH1			Phase 1
2-[1-(4-piperonyl)piperazinyl]benzothiazole	serotonin receptor agonist	HTR4			Preclinical
2-aminobenzenesulfonamide	carbonic anhydrase inhibitor	CA12, CA14, CA2, CA6, CA9			Preclinical
2-APB	1,4,5-trisphosphate inhibitor	TRPC1, TRPC3, TRPC4, TRPC5, TRPC6, TRPC7, TRPM2, TRPM3, TRPM6, TRPV1, TRPV6			Preclinical
2-BFI	imidazoline receptor ligand	ADRA2A, ADRA2B, ADRA2C, MAOA, MAOB			Preclinical
2-chloro-N6-cyclopentyladenosine	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Preclinical
2-chloroadenosine	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B			Preclinical
2-chloropyrazine					Preclinical
2-CMDO	dopamine receptor antagonist	DRD2, DRD4			Preclinical
2-deoxy-2-([methyl(nitroso)carbamoyl]amino)hexose			oncology, endocrinology	pancreatic cancer, hypoglycemia	Preclinical
2-deoxyglucose	glycolysis inhibitor	SLC2A1, SLC2A2, SLC2A3, SLC2A4			Phase 2
2-ethoxybenzoic-acid	analgesic agent				Phase 1
2-ethyl-1,3-hexanediol					Preclinical
2-fluoro-2-deoxy-D-galactose		LCT			Phase 1
2-fluorofucose					Phase 1
2-hydroxy-4-((E)-3-(4-hydroxyphenyl)acryloyl)-2-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-6-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)cyclohexane-1,3,5-trione					Preclinical
2-hydroxyethyl-salicylate			neurology/psychiatry	pain relief	Launched
2-hydroxyflutamide	androgen receptor antagonist	AR			Phase 2
2-hydroxysaclofen	GABA receptor antagonist	GABBR1, GABBR2			Preclinical
2-iminobiotin	nitric oxide synthase inhibitor	NOS1, NOS2			Phase 2
2-iodohippuric-acid					Preclinical
2-iodomelatonin	melatonin receptor agonist	MTNR1A, MTNR1B, NQO2			Preclinical
2-methoxyestradiol	hypoxia inducible factor inhibitor	COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB			Phase 2
2-methyl-5-hydroxytryptamine	serotonin receptor agonist	HTR1B, HTR1D, HTR1E, HTR1F, HTR3A, HTR3B, HTR6			Preclinical
2-methyl-5-nitrophenol					Preclinical
2-methylimidazole	cholesterol inhibitor				Preclinical
2-octyldodecan-1-ol					Preclinical
2-oleoylglycerol	glucose dependent insulinotropic receptor ligand	GPR119			Phase 1
2-oxoglutaric-acid		OXGR1			Preclinical
2-oxopropanoate	pyruvate dehydrogenase kinase inhibitor	ABAT			Preclinical
2-phenylmelatonin	melatonin receptor agonist	MTNR1A, MTNR1B			Preclinical
2-PMDQ	adrenergic receptor antagonist	ADRA1A			Preclinical
2-pyridylethylamine	histamine receptor agonist	HRH1			Preclinical
2-TEDC	lipoxygenase inhibitor	ALOX12			Preclinical
2-thiouracil					Preclinical
20-HETE	ion channel antagonist				Preclinical
20-hydroxyecdysone	ecdysone receptor modulator				Phase 2
3'-fluorobenzylspiperone	dopamine receptor ligand	DRD2			Preclinical
3,3'-dichlorobenzaldazine	glutamate receptor modulator	GRM5			Preclinical
3,3'-diindolylmethane	CHK inhibitor, cytochrome P450 activator, indoleamine 2,3-dioxygenase inhibitor	AR, HIF1A, IFNG, PI3			Phase 3
3,4-DCPG-(+/-)	glutamate receptor agonist	GRM8			Preclinical
3,4-DCPG-(R)	glutamate receptor antagonist				Preclinical
3,4-DCPG-(S)	glutamate receptor agonist	GRM8			Preclinical
3,4-methylenedioxy-beta-nitrostyrene	SRC inhibitor, SYK inhibitor	SRC, SYK			Preclinical
3,5-DHPG-(S)	glutamate receptor agonist	GRM1			Preclinical
3-(4-methylbenzylidene)camphor	endocrine disruptor		dermatology	sunscreen lotion	Launched
3-alpha-bis-(4-fluorophenyl)-methoxytropane	dopamine uptake inhibitor	CHRM1, SLC6A2, SLC6A3, SLC6A4			Preclinical
3-alpha-hydroxy-5-beta-androstan-17-one		HSD17B11, IGHG2, SULT2A1			Preclinical
3-amino-benzamide	PARP inhibitor	PARP1			Phase 2
3-anilinopropan-1-ol					Preclinical
3-AQC	serotonin receptor agonist	HTR3A			Preclinical
3-bromo-7-nitroindazole	nitric oxide synthase inhibitor	NOS1, NOS2, NOS3			Preclinical
3-bromocamphor					Launched
3-bromopyruvate	hexokinase inhibitor	HK2			Preclinical
3-carboxy-4-hydroxyphenylglycine-(R)	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C			Preclinical
3-carboxy-4-hydroxyphenylglycine-(S)	glutamate receptor antagonist	GRM1, GRM5			Preclinical
3-CPMT	dopamine reuptake inhibitor				Preclinical
3-deazaadenosine	adenosylhomocysteinase inhibitor	AHCY			Phase 2
3-deazaneplanocin-A	histone lysine methyltransferase inhibitor	EZH2			Preclinical
3-deazauridine	cytidine deaminase inhibitor				Preclinical
3-hydroxy-3-phenylpentanamide	GABA receptor modulator				Phase 1
3-indolebutyric-acid		B2M, HLA-A, TRAC, TRBC1			Preclinical
3-MATIDA	glutamate receptor antagonist	GRM1			Preclinical
3-methyl-GABA	GABA aminotransferase activator	ABAT			Preclinical
3-methyladenine	PI3K inhibitor	PI3			Preclinical
3-MPPI	adrenergic receptor ligand	ADRA1A			Preclinical
3PO	phosphofructokinase inhibitor	PFKFB3			Preclinical
4,4'-DDT					Preclinical
4,4-pentamethylenepiperidine	M2 channel blocker				Preclinical
4,5,6,7-tetrabromobenzotriazole	casein kinase inhibitor	AKT1, CHEK1, CSNK2A1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SGK1			Preclinical
4-(aminomethyl)benzoic-acid	hemostatic agent				Preclinical
4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine	serotonin receptor antagonist	HTR2A			Preclinical
4-acetyl-1,1-dimethylpiperazinium	acetylcholine receptor agonist				Preclinical
4-aminohippuric-acid		SLC22A6	nephrology	renal diagnostic agent	Launched
4-carboxy-3-hydroxyphenylglycine-(RS)	glutamate receptor agonist, glutamate receptor antagonist	GRM1			Preclinical
4-carboxy-3-hydroxyphenylglycine-(S)	glutamate receptor agonist, glutamate receptor antagonist	GRM1, GRM2			Preclinical
4-chlorophenylguanidine	urokinase inhibitor	PLAUR			Preclinical
4-CMTB	free fatty acid receptor agonist	FFAR2			Preclinical
4-DAMP	cholinergic receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5			Preclinical
4-galactosyllactose					Preclinical
4-HQN	PARP inhibitor	PARP1			Preclinical
4-hydroxy-phenazone					Preclinical
4-IBP	sigma receptor agonist	SIGMAR1			Preclinical
4-iodo-L-phenylalanine		DPP4			Preclinical
4-iodo-6-phenylpyrimidine	macrophage migration inhibiting factor inhibitor	MIF			Preclinical
4-methylgenistein	protein tyrosine kinase inhibitor	CYP19A1, ESRRA, ESRRB, ESRRG, FASN			Preclinical
4-methylhistamine	histamine receptor agonist	HRH4			Preclinical
4-mu-8C	IRE1 inhibitor	ERN1			Preclinical
4-P-PDOT	melatonin receptor antagonist	MTNR1A, MTNR1B			Preclinical
4-phenolsulfonic-acid					Preclinical
4-phenyl-1,2,3,4-tetrahydroisoquinoline	dopamine release inhibitor				Preclinical
4-PPBP	sigma receptor ligand	SIGMAR1			Preclinical
4-propylbenzoic-acid					Preclinical
4-pyrimidinecarbonitrile					Preclinical
4-tert-butylphenol					Preclinical
4BP-TQS	nicotinic receptor agonist	CHRNA7			Preclinical
4EGI-1	protein synthesis inhibitor	EIF4E			Preclinical
4E1RCat	protein synthesis inhibitor	EIF4E, EIF4G1			Preclinical
4SC-202	HDAC inhibitor	HDAC1			Phase 1
5'-chloro-5'-deoxy-ENBA-(+/-)	adenosine receptor agonist	ADORA1			Preclinical
5,7-dichlorokynurenic-acid	glutamate receptor antagonist	GLRA2, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			Preclinical
5-(4chlorophenyl)-4-ethyl-2,4-dihydro-3H-1,2,4-triazol-3-one					Preclinical
5-amino-3-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione		TLR7			Preclinical
5-aminolevulinic-acid	oxidizing agent	ALAD	oncology, dermatology	glioma, actinic keratosis (AK)	Launched
5-BDBD	purinergic receptor antagonist	P2RX4			Preclinical
5-carboxamidotryptamine	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7			Preclinical
5-fluoro-3-pyridyl-methanol					Preclinical
5-fluoropyrimidine	kinase inhibitor				Phase 3
5-fluorouracil	thymidylate synthase inhibitor	DPYD, TYMS	oncology	colorectal cancer, breast cancer, pancreatic cancer, gastric adenocarcinoma	Launched
5-FP	thymidylate synthase inhibitor	TYMS			Phase 1
5-HMF					Phase 2
5-hydroxydecanoic-acid					Preclinical
5-hydroxyectoine					Preclinical
5-hydroxymethyl-tolterodine	acetylcholine receptor antagonist	CHRM3			Phase 1
5-hydroxytryptophan	neurotransmitter	SLC36A1, SLC36A2	neurology/psychiatry	insomnia	Launched
5-iodo-A-85380	acetylcholine receptor agonist				Phase 2
5-methylfurmethiodide	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4			Preclinical
5-methylhydantoin-(D)					Preclinical
5-methylhydantoin-(L)					Preclinical
5-octanoylsalicylic-acid	protein kinase activator				Preclinical
6,7-dehydro-17-acetoxy-progesterone	steroidal progestin				Preclinical
6-aminochrysene	transferase inhibitor				Phase 2
6-aminopenicillanic-acid					Preclinical
6-benzylaminopurine	purinergic receptor activator				Preclinical
6-chloromelatonin	melatonin receptor agonist	MTNR1A, MTNR1B			Preclinical
6-diazo-5-oxo-L-norleucine	glutamate receptor antagonist, glutaminase inhibitor				Preclinical
6-iodo-nordihydrocapsaicin	TRPV antagonist	TRPV1			Preclinical
7,8,9,10-tetrahydroazepino[2,1-b]quinazolin-12(6H)-one					Preclinical
7-aminocephalosporanic-acid	beta lactamase inhibitor				Preclinical
7-chlorokynurenic-acid	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C			Preclinical
7-hydroxy-DPAT	dopamine receptor agonist	DRD2, DRD3			Preclinical
7-hydroxy-PIPAT	dopamine receptor ligand	DRD3			Preclinical
7-hydroxystaurosporine	CDK inhibitor, CHK inhibitor, PKC inhibitor	CDK1, CHEK1, CHEK2, GSK3B, LCK, MAPK14, MARK1, MARK3, PDPK1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG			Phase 2
7-keto-DHEA	steroid				Launched
7-methoxytacrine	acetylcholinesterase inhibitor	ACHE			Phase 2
7-methylxanthine	adenosine receptor antagonist				Phase 2
7-nitroindazole	nitric oxide synthase inhibitor	NOS1, NOS2, NOS3			Preclinical
8-bromo-cAMP	PKA activator				Preclinical
8-bromo-cGMP	PKA activator	PRKG1			Preclinical
8-hydroxy-DPAT	serotonin receptor agonist	HTR5A, HTR7			Preclinical
8-hydroxy-PIPAT	dopamine receptor ligand	DRD2, DRD3			Preclinical
8-M-PDOT	melatonin receptor agonist	MTNR1A, MTNR1B			Preclinical
80841-78-7					Preclinical
9-aminoacridine					Preclinical
9-aminocamptothecin	topoisomerase inhibitor	TOP1			Phase 2
9-anthracenecarboxylic-acid		ANO1, CLCN1			Preclinical
